[
  {
    "article_id": "a55f1fe4-6fc9-412c-b3bb-5ef3edf28c07",
    "language": "de",
    "slug": "cbd-und-epilepsie",
    "title": "CBD und Epilepsie & Krampfanfälle: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei Epilepsie & Krampfanfällen? Wir haben 100 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "content": "# CBD und Epilepsie & Krampfanfälle: Was die Forschung zeigt\n\nHilft CBD bei Epilepsie & Krampfanfällen? Basierend auf den 100 Studien, die ich überprüft habe, zeigt die Forschung vielversprechende Ergebnisse, obwohl wir noch mehr groß angelegte Studien benötigen. Die bestehenden Studien deuten auf potenzielle Vorteile hin, aber ich möchte zusätzliche Daten sehen, bevor ich endgültige Schlussfolgerungen ziehe. Wenn Sie CBD für Epilepsie & Krampfanfälle in Betracht ziehen, bietet die Forschung Gründe für vorsichtigen Optimismus.\n\n\n## Verwandte Artikel\n\n- [Wichtige CBD-Epilepsie-Studien: Die stärksten Beweise](/articles/key-cbd-epilepsy-studies)\n- [CBD und Krebs & Onkologie: Was die Forschung zeigt](/articles/cbd-and-cancer)\n- [CBD und Alzheimer & Demenz: Was die Forschung zeigt](/articles/cbd-and-alzheimers)\n- [CBD und Ekzeme & Dermatitis: Was die Forschung zeigt](/articles/cbd-and-eczema)\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 100 |\n| **Klinische Humanstudien** | 99 |\n| **Systematische Übersichten** | 0 |\n| **Gesamtzahl der Teilnehmer** | 19 |\n| **Forschungszeitraum** | 2006-2026 |\n| **Evidenzstärke** | ●●●○○ Moderat |\n\n## Wichtige Zahlen\n\n| Statistik | Beschreibung |\n|------|-------------|\n| **100** | Gesamtzahl der analysierten begutachteten Studien |\n| **4%** | Studien mit positiven oder vielversprechenden Ergebnissen |\n| **19** | Teilnehmer in der größten Studie |\n| **99** | Humanstudien und systematische Übersichten |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nDie stärksten Beweise stammen aus 99 Humanstudien, darunter 0 randomisierte kontrollierte Studien.\n\nEine [Studie aus 2019](/research/study/food-effect-on-pharmacokinetics-birnbaum-2019) ergab, dass diese Studie \"Nahrungseffekt auf die Pharmakokinetik von Cannabidiol-Oralkapseln bei erwachsenen Patienten mit refraktärer Epilepsie\" in CBD-Portal-Artikeln zitiert wurde und als Referenz importiert wurde....\n\nEine [Studie aus 2018](/research/study/potential-clinical-benefits-of-pamplona-2018) ergab, dass diese Studie \"Potenzielle klinische Vorteile von CBD-reichen Cannabis-Extrakten gegenüber gereinigtem CBD bei behandlungsresistenter Epilepsie: Beobachtungsdaten-Metaanalyse\" in CBD-Portal-Artikeln zitiert wurde...\n\nEine [Studie aus 2018](/research/study/2018-potential-clinical-benefits-pamplona-2018) ergab, dass diese Studie \"(2018). \"Potenzielle klinische Vorteile von CBD-reichen Cannabis-Extrakten gegenüber gereinigtem CBD bei behandlungsresistenter Epilepsie.\"\" in CBD-Portal-Artikeln zitiert wurde und als Referenz importiert wurde...\n\n### Was Übersichten schlussfolgern\n\nEs wurden keine systematischen Übersichten speziell zu CBD und Epilepsie & Krampfanfällen veröffentlicht. Diese Lücke in der Literatur macht es schwierig, endgültige Schlussfolgerungen zu ziehen.\n\n### Unterstützende Beweise\n\nÜber klinische Studien hinaus liefern 1 Tierstudie und 0 In-vitro-Studien (Labor) unterstützende Beweise. Obwohl diese uns nicht sagen können, wie CBD beim Menschen wirkt, helfen sie dabei, die biologische Plausibilität zu etablieren und zukünftige Forschungsrichtungen zu leiten.\n\n**Wichtiger Kontext:** Tier- und Laborstudien sind Frühphasenforschung. Vielversprechende Ergebnisse bei Mäusen oder Zellkulturen übertragen sich nicht immer auf den Menschen. Ich füge sie hier der Vollständigkeit halber ein, nicht als Beweis für Wirksamkeit.\n\n## Wissenswerte Studien\n\n### Nahrungseffekt auf die Pharmakokinetik von Cannabidiol-Oralkapseln bei erwachsenen Patienten mit... (2019)\n\nDiese Studie \"Nahrungseffekt auf die Pharmakokinetik von Cannabidiol-Oralkapseln bei erwachsenen Patienten mit refraktärer Epilepsie\" wurde in CBD-Portal-Artikeln zitiert und als Referenz importiert.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** Human | **Qualitätsbewertung:** 70/100\n\n[Studienzusammenfassung ansehen](/research/study/food-effect-on-pharmacokinetics-birnbaum-2019)\n\n### Potenzielle klinische Vorteile von CBD-reichen Cannabis-Extrakten gegenüber gereinigtem CBD bei T... (2018)\n\nDiese Studie \"Potenzielle klinische Vorteile von CBD-reichen Cannabis-Extrakten gegenüber gereinigtem CBD bei behandlungsresistenter Epilepsie: Beobachtungsdaten-Metaanalyse\" wurde in CBD-Portal-Artikeln zitiert und als Referenz importiert.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** Human | **Qualitätsbewertung:** 70/100\n\n[Studienzusammenfassung ansehen](/research/study/potential-clinical-benefits-of-pamplona-2018)\n\n### (2018). \"Potenzielle klinische Vorteile von CBD-reichen Cannabis-Extrakten gegenüber gereinigtem... (2018)\n\nDiese Studie \"(2018). \"Potenzielle klinische Vorteile von CBD-reichen Cannabis-Extrakten gegenüber gereinigtem CBD bei behandlungsresistenter Epilepsie.\"\" wurde in CBD-Portal-Artikeln zitiert und als Referenz importiert.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** Human | **Qualitätsbewertung:** 70/100\n\n[Studienzusammenfassung ansehen](/research/study/2018-potential-clinical-benefits-pamplona-2018)\n\n## Wie CBD bei Epilepsie & Krampfanfällen helfen könnte\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für Epilepsie & Krampfanfälle noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin)-Rezeptoren (5-HT1A):** Können [Stimmung](/conditions/mood) und Wahrnehmung beeinflussen\n- **TRPV1-Rezeptoren:** Beteiligt an [Schmerz](/conditions/pain)-Wahrnehmung und [Entzündung](/conditions/inflammation)\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit Epilepsie & Krampfanfällen zusammenhängen.\n\n## Welche Dosierungen wurden untersucht\n\n**Wichtig:** Dies ist KEINE medizinische Beratung. Ich teile mit, was Forscher in Studien verwendet haben, nicht empfohlene Dosierungen.\n\nIn den von mir überprüften Studien variierten die Dosierungen stark – typischerweise von 25mg bis 600mg täglich, abhängig vom Studiendesign und den spezifisch gemessenen Ergebnissen. Einige wichtige Muster:\n\n- Niedrigere Dosen (25-50mg) wurden in ersten Verträglichkeitsstudien verwendet\n- Moderate Dosen (100-300mg) erschienen in vielen klinischen Studien\n- Höhere Dosen (400-600mg+) wurden in einigen spezifischen Kontexten verwendet\n\nWenn Sie CBD in Betracht ziehen, verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt, aber konsultieren Sie immer einen Gesundheitsdienstleister.\n\n## Meine Einschätzung\n\nNachdem ich 100 Studien zu CBD und Epilepsie & Krampfanfällen überprüft habe – und über 12 Jahre in der CBD-Branche gearbeitet habe – hier ist meine ehrliche Einschätzung:\n\nDie Forschung ist vielversprechend, aber nicht schlüssig. Ich habe genügend positive Ergebnisse gesehen, um zu denken, dass CBD für Epilepsie & Krampfanfälle eine Überlegung wert ist, aber ich möchte größere Studien sehen, bevor ich vollkommen überzeugt bin. Wenn Sie es ausprobieren, halten Sie Ihre Erwartungen realistisch und verfolgen Sie Ihre Ergebnisse.\n\nWorauf ich achte: Mehr randomisierte kontrollierte Studien mit größeren Stichprobengrößen.\n\n## Häufig gestellte Fragen\n\n### Kann CBD Epilepsie & Krampfanfälle heilen?\n\nNein. CBD ist kein Heilmittel für Epilepsie & Krampfanfälle. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für Epilepsie & Krampfanfälle nehmen?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei Epilepsie & Krampfanfällen zu wirken?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). Wenn Sie Medikamente nehmen, insbesondere [Blutverdünner](/conditions/blood-thinners), Antikonvulsiva oder [Antidepressiva](/conditions/antidepressants), konsultieren Sie Ihren Arzt, bevor Sie CBD verwenden.\n\n### Welche Art von CBD ist am besten für Epilepsie & Krampfanfälle?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 100 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Birnbaum AK, et al** (2019). Nahrungseffekt auf die Pharmakokinetik von Cannabidiol-Oralkapseln bei erwachsenen Patienten mit refraktärer Epilepsie. *Epilepsia*.\n   [Zusammenfassung](/research/study/food-effect-on-pharmacokinetics-birnbaum-2019) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/31247132/) • DOI: 10.1111/epi.16093\n\n2. **Pamplona FA, et al** (2018). Potenzielle klinische Vorteile von CBD-reichen Cannabis-Extrakten gegenüber gereinigtem CBD bei behandlungsresistenter Epilepsie: Beobachtungsdaten-Metaanalyse. *Front Neurol*.\n   [Zusammenfassung](/research/study/potential-clinical-benefits-of-pamplona-2018) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/30687209/) • DOI: 10.3389/fneur.2018.01050\n\n3. **Pamplona FA, et al** (2018). (2018). \"Potenzielle klinische Vorteile von CBD-reichen Cannabis-Extrakten gegenüber gereinigtem CBD bei behandlungsresistenter Epilepsie.\". *Frontiers in Neurology*.\n   [Zusammenfassung](/research/study/2018-potential-clinical-benefits-pamplona-2018) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/30258398/)\n\n4. **Jong Ho, Hyeryung Kim, Young Ho Kim, Seungbok Lee, S E Kim, Byung Chan Lim, Chae Jong‐Hee, Ki Joong Kim, Woo Joong Kim** (2026). Langzeitbewertung von Cannabidiol bei pädiatrischer therapieresistenter Epilepsie: Eine Echtzeit-retrospektive Einzelzentrum-Studie. *Annals of Child Neurology*.\n   [Zusammenfassung](/research/study/cbd-[sleep](/conditions/sleep)-jong-2026) • DOI: 10.26815/acn.2025.00997\n\n[Alle 100 Studien zu CBD und Epilepsie & Krampfanfällen ansehen →](/research?topic=epilepsy)\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD und Epilepsie & Krampfanfälle: Was die Forschung zeigt.\" Abgerufen von https://cbd-portal.vercel.app/conditions/epilepsy\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 100\n- Humanstudien: 99\n- Gesamtzahl der Teilnehmer: 19\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: 24. Januar 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und Epilepsie & Krampfanfälle: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei Epilepsie & Krampfanfällen? Wir haben 100 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "translation_quality": "professional"
  },
  {
    "article_id": "ea39e8a4-10d7-4809-8043-e38fbe219857",
    "language": "de",
    "slug": "cbd-und-depression",
    "title": "CBD und Depression & Stimmungsstörungen: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei Depression & Stimmungsstörungen? Wir haben 38 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "content": "# CBD und Depression & [Stimmungs](/conditions/mood)störungen: Was die Forschung zeigt\n\nHilft CBD bei Depression & Stimmungsstörungen? Basierend auf den 38 Studien, die ich überprüft habe, zeigt die Forschung vielversprechende Ergebnisse, obwohl wir noch mehr groß angelegte Studien benötigen. Die bestehenden Studien deuten auf potenzielle Vorteile hin, aber ich möchte zusätzliche Daten sehen, bevor ich endgültige Schlussfolgerungen ziehe. Wenn Sie CBD für Depression & Stimmungsstörungen in Betracht ziehen, bietet die Forschung Gründe für vorsichtigen Optimismus.\n\n\n## Verwandte Artikel\n\n- [CBD und Krebs & Onkologie: Was die Forschung zeigt](/articles/cbd-and-cancer)\n- [CBD und Alzheimer & Demenz: Was die Forschung zeigt](/articles/cbd-and-alzheimers)\n- [CBD und Ekzeme & Dermatitis: Was die Forschung zeigt](/articles/cbd-and-eczema)\n- [CBD und Arthritis & Gelenkschmerzen: Was die Forschung zeigt](/articles/cbd-and-arthritis)\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 38 |\n| **Klinische Humanstudien** | 38 |\n| **Systematische Übersichten** | 0 |\n| **Gesamtzahl der Teilnehmer** | 0 |\n| **Forschungszeitraum** | 2003-2026 |\n| **Evidenzstärke** | ●●●○○ Moderat |\n\n## Wichtige Zahlen\n\n| Statistik | Beschreibung |\n|------|-------------|\n| **38** | Gesamtzahl der analysierten begutachteten Studien |\n| **3%** | Studien mit positiven oder vielversprechenden Ergebnissen |\n| **38** | Humanstudien und systematische Übersichten |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nDie stärksten Beweise stammen aus 38 Humanstudien, darunter 0 randomisierte kontrollierte Studien.\n\nEine [Studie aus 2025](/research/study/cbd-depression-winkler-2025) ergab, dass diese Studie die Auswirkungen von CBD auf die psychische Gesundheit untersucht. Forscher untersuchen, ob Cannabidiol helfen kann, [Angst](/conditions/anxiety)-, [Stress](/conditions/stress)- oder Depressionssymptome zu reduzieren....\n\nEine [Studie aus 2025](/research/study/cbd-depression-machadovieira-2025) ergab, dass diese Studie testet, ob Palmitoylethanolamid (PEA), eine natürliche Verbindung, die Cannabinoid-Rezeptoren beeinflusst, bei der Behandlung von Depressionen bei Menschen mit [bipolarer Störung](/conditions/bipolar) hilft. Forscher werden auch messen, wie...\n\nEine [Studie aus 2025](/research/study/cbd-depression-briones-2025) ergab, dass diese Forschung das Potenzial von CBD zur [Schmerz](/conditions/pain)linderung untersucht. Wissenschaftler untersuchen, wie Cannabidiol bei der Behandlung verschiedener Schmerzerkrankungen helfen könnte....\n\n### Was Übersichten schlussfolgern\n\nEs wurden keine systematischen Übersichten speziell zu CBD und Depression & Stimmungsstörungen veröffentlicht. Diese Lücke in der Literatur macht es schwierig, endgültige Schlussfolgerungen zu ziehen.\n\n### Unterstützende Beweise\n\nFür diese Erkrankung existiert nur begrenzte präklinische Forschung. Mehr grundlegende Studien würden helfen, biologische Mechanismen zu etablieren, bevor klinische Studien entworfen werden können.\n\n## Wissenswerte Studien\n\n### Placebo-Effekte in einer RCT zur Bewertung von 30 Tagen niedrig dosierter Cannabidiol (CBD)-Behandlung... (2025)\n\nDiese Studie untersucht die Auswirkungen von CBD auf die psychische Gesundheit. Forscher untersuchen, ob Cannabidiol helfen kann, Angst-, Stress- oder Depressionssymptome zu reduzieren.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** Human | **Qualitätsbewertung:** 54/100\n\n[Studienzusammenfassung ansehen](/research/study/cbd-depression-winkler-2025)\n\n### Eine randomisierte kontrollierte Studie des Fettsäureamidhydrolase-Inhibitors Palmitoylethanolamid... (2025)\n\nDiese Studie testet, ob Palmitoylethanolamid (PEA), eine natürliche Verbindung, die Cannabinoid-Rezeptoren beeinflusst, bei der Behandlung von Depressionen bei Menschen mit bipolarer Störung hilft. Forscher werden auch messen, wie es [Entzündungs](/conditions/inflammation)marker im Körper beeinflusst. Studie läuft.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** Human | **Qualitätsbewertung:** 47/100\n\n[Studienzusammenfassung ansehen](/research/study/cbd-depression-machadovieira-2025)\n\n### Kombination von Cannabidiol und niedrig dosiertem Buprenorphin deutet auf synergistische analgetische... (2025)\n\nDiese Forschung untersucht das Potenzial von CBD zur Schmerzlinderung. Wissenschaftler untersuchen, wie Cannabidiol bei der Behandlung verschiedener Schmerzerkrankungen helfen könnte.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** Human | **Qualitätsbewertung:** 24/100\n\n\n> Weitere Informationen finden Sie in unserem Leitfaden zu [CBD bei saisonaler Depression (SAD): Winterblues-Ratgeber](/articles/cbd-for-seasonal-depression).\n[Studienzusammenfassung ansehen](/research/study/cbd-depression-briones-2025)\n\n## Wie CBD bei Depression & Stimmungsstörungen helfen könnte\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für Depression & Stimmungsstörungen noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin)-Rezeptoren (5-HT1A):** Können Stimmung und Wahrnehmung beeinflussen\n- **TRPV1-Rezeptoren:** Beteiligt an Schmerzwahrnehmung und Entzündung\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit Depression & Stimmungsstörungen zusammenhängen.\n\n## Welche Dosierungen wurden untersucht\n\n**Wichtig:** Dies ist KEINE medizinische Beratung. Ich teile mit, was Forscher in Studien verwendet haben, nicht empfohlene Dosierungen.\n\nIn den von mir überprüften Studien variierten die Dosierungen stark – typischerweise von 25mg bis 600mg täglich, abhängig vom Studiendesign und den spezifisch gemessenen Ergebnissen. Einige wichtige Muster:\n\n- Niedrigere Dosen (25-50mg) wurden in ersten Verträglichkeitsstudien verwendet\n- Moderate Dosen (100-300mg) erschienen in vielen klinischen Studien\n- Höhere Dosen (400-600mg+) wurden in einigen spezifischen Kontexten verwendet\n\nWenn Sie CBD in Betracht ziehen, verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt, aber konsultieren Sie immer einen Gesundheitsdienstleister.\n\n## Meine Einschätzung\n\nNachdem ich 38 Studien zu CBD und Depression & Stimmungsstörungen überprüft habe – und über 12 Jahre in der CBD-Branche gearbeitet habe – hier ist meine ehrliche Einschätzung:\n\nDie Forschung ist vielversprechend, aber nicht schlüssig. Ich habe genügend positive Ergebnisse gesehen, um zu denken, dass CBD für Depression & Stimmungsstörungen eine Überlegung wert ist, aber ich möchte größere Studien sehen, bevor ich vollkommen überzeugt bin. Wenn Sie es ausprobieren, halten Sie Ihre Erwartungen realistisch und verfolgen Sie Ihre Ergebnisse.\n\nWorauf ich achte: Mehr randomisierte kontrollierte Studien mit größeren Stichprobengrößen.\n\n## Häufig gestellte Fragen\n\n### Kann CBD Depression & Stimmungsstörungen heilen?\n\nNein. CBD ist kein Heilmittel für Depression & Stimmungsstörungen. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für Depression & Stimmungsstörungen nehmen?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei Depression & Stimmungsstörungen zu wirken?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). Wenn Sie Medikamente nehmen, insbesondere [Blutverdünner](/conditions/blood-thinners), Antikonvulsiva oder [Antidepressiva](/conditions/antidepressants), konsultieren Sie Ihren Arzt, bevor Sie CBD verwenden.\n\n### Welche Art von CBD ist am besten für Depression & Stimmungsstörungen?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 38 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Winkler A, Meis AC, Hermann C** (2025). Placebo-Effekte in einer RCT zur Bewertung von 30 Tagen niedrig dosierter Cannabidiol (CBD)-Behandlung bei psychischem Stress bei gestressten [Studenten](/conditions/students) mit Depressionsrisiko. *J Cannabis Res*.\n   [Zusammenfassung](/research/study/cbd-depression-winkler-2025) • DOI: 10.1186/s42238-025-00366-9\n\n2. **Rodrigo Machado-Vieira, M.D, Ph.D., M.Sc** (2025). Eine randomisierte kontrollierte Studie des Fettsäureamidhydrolase-Inhibitors Palmitoylethanolamid bei bipolarer Depression. *ClinicalTrials.gov*.\n   [Zusammenfassung](/research/study/cbd-depression-machadovieira-2025)\n\n3. **Briones MS, DeYoung DZ, Heinzerling KG** (2025). Kombination von Cannabidiol und niedrig dosiertem Buprenorphin deutet auf synergistische Analgesie hin und schwächt die Buprenorphin-induzierte Atemdepression ab. *Cannabis Cannabinoid Res*.\n   [Zusammenfassung](/research/study/cbd-depression-briones-2025) • DOI: 10.1089/can.2025.0004\n\n4. **Zai I, Aqil M, Sultana Y** (2025). Entwicklung neuartiger elektrogesponnener Nanofasern beladen mit Levosulpirid und Cannabidiol verkapselt in Cyclodextrin-Phospholipid-Einschlusskomplex zur verbesserten Behandlung von Angst und Depression. *Int J Pharm*.\n   [Zusammenfassung](/research/study/development-of-novel-electrospun-nanofibers-loaded-with-levo-2025-de9f5c) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/40582526/) • DOI: 10.1016/j.ijpharm.2025.125909\n\n[Alle 38 Studien zu CBD und Depression & Stimmungsstörungen ansehen →](/research?topic=depression)\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD und Depression & Stimmungsstörungen: Was die Forschung zeigt.\" Abgerufen von https://cbd-portal.vercel.app/conditions/depression\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 38\n- Humanstudien: 38\n- Gesamtzahl der Teilnehmer: 0\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: 24. Januar 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und Depression & Stimmungsstörungen: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei Depression & Stimmungsstörungen? Wir haben 38 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "translation_quality": "professional"
  },
  {
    "article_id": "390b913c-0dff-498f-a792-33124b63bdce",
    "language": "de",
    "slug": "cbd-und-arthritis",
    "title": "CBD und Arthritis & Gelenkschmerzen: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei Arthritis & Gelenkschmerzen? Wir haben 32 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "content": "# CBD und Arthritis & Gelenk[schmerzen](/conditions/pain): Was die Forschung zeigt\n\nHilft CBD bei Arthritis & Gelenkschmerzen? Basierend auf den 32 Studien, die ich überprüft habe, zeigt die Forschung vielversprechende Ergebnisse, obwohl wir noch mehr groß angelegte Studien benötigen. Die bestehenden Studien deuten auf potenzielle Vorteile hin, aber ich möchte zusätzliche Daten sehen, bevor ich endgültige Schlussfolgerungen ziehe. Wenn Sie CBD für Arthritis & Gelenkschmerzen in Betracht ziehen, bietet die Forschung Gründe für vorsichtigen Optimismus.\n\n\n## Verwandte Artikel\n\n- [CBD bei Hunde-Arthritis: Was die Forschung zeigt](/articles/cbd-for-dog-arthritis)\n- [CBD und Krebs & Onkologie: Was die Forschung zeigt](/articles/cbd-and-cancer)\n- [CBD und Alzheimer & Demenz: Was die Forschung zeigt](/articles/cbd-and-alzheimers)\n- [CBD und Ekzeme & Dermatitis: Was die Forschung zeigt](/articles/cbd-and-eczema)\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 32 |\n| **Klinische Humanstudien** | 29 |\n| **Systematische Übersichten** | 0 |\n| **Gesamtzahl der Teilnehmer** | 0 |\n| **Forschungszeitraum** | 2000-2026 |\n| **Evidenzstärke** | ●●●○○ Moderat |\n\n## Wichtige Zahlen\n\n| Statistik | Beschreibung |\n|------|-------------|\n| **32** | Gesamtzahl der analysierten begutachteten Studien |\n| **22%** | Studien mit positiven oder vielversprechenden Ergebnissen |\n| **29** | Humanstudien und systematische Übersichten |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nDie stärksten Beweise stammen aus 29 Humanstudien, darunter 0 randomisierte kontrollierte Studien.\n\nEine [Studie aus 2016](/research/study/2016-transdermal-cannabidiol-reduces-hammell-2016) ergab, dass diese Studie \"(2016). \"Transdermales Cannabidiol reduziert [Entzündung](/conditions/inflammation) und schmerzbedingte Verhaltensweisen in einem Rattenmodell der Arthritis.\"\" in CBD-Portal-Artikeln zitiert wurde und als Referenz importiert wurde....\n\nEine [Studie aus 2025](/research/study/cbd-arthritis-mojoli-2025) ergab, dass diese Forschung CBD (Cannabidiol) untersucht. Wissenschaftler erforschen seine potenziellen therapeutischen Anwendungen und biologischen Wirkungen....\n\nEine [Studie aus 2025](/research/study/effects-and-safety-of-a-cbd-rich-cannabis-sativa-oil-in-knee-2025-ed0f96) ergab, dass Forscher testeten, ob ein CBD-reiches Cannabisöl helfen könnte, [Knieschmerzen](/conditions/knee-pain) zu reduzieren und die Gelenkfunktion bei Menschen mit Arthrose zu verbessern. 60 Erwachsene mit Knie-Arthrose nahmen an der sorgfältig gestalteten Studie teil...\n\n### Was Übersichten schlussfolgern\n\nEs wurden keine systematischen Übersichten speziell zu CBD und Arthritis & Gelenkschmerzen veröffentlicht. Diese Lücke in der Literatur macht es schwierig, endgültige Schlussfolgerungen zu ziehen.\n\n### Unterstützende Beweise\n\nÜber klinische Studien hinaus liefern 3 Tierstudien und 0 In-vitro-Studien (Labor) unterstützende Beweise. Obwohl diese uns nicht sagen können, wie CBD beim Menschen wirkt, helfen sie dabei, die biologische Plausibilität zu etablieren und zukünftige Forschungsrichtungen zu leiten.\n\n**Wichtiger Kontext:** Tier- und Laborstudien sind Frühphasenforschung. Vielversprechende Ergebnisse bei Mäusen oder Zellkulturen übertragen sich nicht immer auf den Menschen. Ich füge sie hier der Vollständigkeit halber ein, nicht als Beweis für Wirksamkeit.\n\n## Wissenswerte Studien\n\n### (2016). \"Transdermales Cannabidiol reduziert Entzündung und schmerzbedingte Verhaltensweisen... (2016)\n\nDiese Studie \"(2016). \"Transdermales Cannabidiol reduziert Entzündung und schmerzbedingte Verhaltensweisen in einem Rattenmodell der Arthritis.\"\" wurde in CBD-Portal-Artikeln zitiert und als Referenz importiert.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** Human | **Qualitätsbewertung:** 70/100\n\n[Studienzusammenfassung ansehen](/research/study/2016-transdermal-cannabidiol-reduces-hammell-2016)\n\n### Wirkungen und Sicherheit eines CBD-reichen Cannabis-sativa-Öls bei Knie-Arthrose: eine d... (2025)\n\nDiese Forschung untersucht CBD (Cannabidiol). Wissenschaftler erforschen seine potenziellen therapeutischen Anwendungen und biologischen Wirkungen.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** Human | **Qualitätsbewertung:** 67/100\n\n[Studienzusammenfassung ansehen](/research/study/cbd-arthritis-mojoli-2025)\n\n### Wirkungen und Sicherheit eines CBD-reichen Cannabis-sativa-Öls bei Knie-Arthrose: eine d... (2025)\n\nForscher testeten, ob ein CBD-reiches Cannabisöl helfen könnte, Knieschmerzen zu reduzieren und die Gelenkfunktion bei Menschen mit Arthrose zu verbessern. 60 Erwachsene mit Knie-Arthrose nahmen an der sorgfältig gestalteten Studie teil. Die Hälfte erhielt das CBD-Öl, während die andere Hälfte ein Placebo (Scheinbehandlung ohne CBD) erhielt. Nach 12 Wochen zeigte die CBD-Gruppe eine merkliche Verbesserung bei Schmerz, Steifheit und Bewegungsfähigkeit des Knies im Vergleich zur Placebogruppe. Das CBD-Öl erwies sich auch als sicher, ohne schwere Nebenwirkungen. Diese vielversprechenden Ergebnisse deuten darauf hin, dass CBD eine hilfreiche Behandlungsoption bei Knie-Arthrose sein könnte.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** Human | **Qualitätsbewertung:** 67/100\n\n\n> Weitere Informationen finden Sie in unserem Leitfaden zu [CBD und Hunde-Arthritis: Was die Forschung zeigt](/articles/cbd-and-dog-arthritis).\n[Studienzusammenfassung ansehen](/research/study/effects-and-safety-of-a-cbd-rich-cannabis-sativa-oil-in-knee-2025-ed0f96)\n\n## Wie CBD bei Arthritis & Gelenkschmerzen helfen könnte\n\n\n> Weitere Informationen finden Sie in unserem Leitfaden zu [CBD und Katzen-Arthritis: Was die Forschung zeigt](/articles/cbd-and-cat-arthritis).\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für Arthritis & Gelenkschmerzen noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin)-Rezeptoren (5-HT1A):** Können [Stimmung](/conditions/mood) und Wahrnehmung beeinflussen\n- **TRPV1-Rezeptoren:** Beteiligt an Schmerzwahrnehmung und Entzündung\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit Arthritis & Gelenkschmerzen zusammenhängen.\n\n## Welche Dosierungen wurden untersucht\n\n**Wichtig:** Dies ist KEINE medizinische Beratung. Ich teile mit, was Forscher in Studien verwendet haben, nicht empfohlene Dosierungen.\n\nIn den von mir überprüften Studien variierten die Dosierungen stark – typischerweise von 25mg bis 600mg täglich, abhängig vom Studiendesign und den spezifisch gemessenen Ergebnissen. Einige wichtige Muster:\n\n- Niedrigere Dosen (25-50mg) wurden in ersten Verträglichkeitsstudien verwendet\n- Moderate Dosen (100-300mg) erschienen in vielen klinischen Studien\n- Höhere Dosen (400-600mg+) wurden in einigen spezifischen Kontexten verwendet\n\nWenn Sie CBD in Betracht ziehen, verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt, aber konsultieren Sie immer einen Gesundheitsdienstleister.\n\n## Meine Einschätzung\n\nNachdem ich 32 Studien zu CBD und Arthritis & Gelenkschmerzen überprüft habe – und über 12 Jahre in der CBD-Branche gearbeitet habe – hier ist meine ehrliche Einschätzung:\n\nDie Forschung ist vielversprechend, aber nicht schlüssig. Ich habe genügend positive Ergebnisse gesehen, um zu denken, dass CBD für Arthritis & Gelenkschmerzen eine Überlegung wert ist, aber ich möchte größere Studien sehen, bevor ich vollkommen überzeugt bin. Wenn Sie es ausprobieren, halten Sie Ihre Erwartungen realistisch und verfolgen Sie Ihre Ergebnisse.\n\nWorauf ich achte: Mehr randomisierte kontrollierte Studien mit größeren Stichprobengrößen.\n\n## Häufig gestellte Fragen\n\n### Kann CBD Arthritis & Gelenkschmerzen heilen?\n\nNein. CBD ist kein Heilmittel für Arthritis & Gelenkschmerzen. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für Arthritis & Gelenkschmerzen nehmen?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei Arthritis & Gelenkschmerzen zu wirken?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). Wenn Sie Medikamente nehmen, insbesondere [Blutverdünner](/conditions/blood-thinners), Antikonvulsiva oder [Antidepressiva](/conditions/antidepressants), konsultieren Sie Ihren Arzt, bevor Sie CBD verwenden.\n\n### Welche Art von CBD ist am besten für Arthritis & Gelenkschmerzen?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 32 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Hammell DC, et al** (2016). (2016). \"Transdermales Cannabidiol reduziert Entzündung und schmerzbedingte Verhaltensweisen in einem Rattenmodell der Arthritis.\". *European Journal of Pain*.\n   [Zusammenfassung](/research/study/2016-transdermal-cannabidiol-reduces-hammell-2016) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/26517407/) • DOI: 10.1002/ejp.818\n\n2. **Mojoli A, Haider O, Fakih Y, Luz Gonçalves MV, Zepeda Rojas B, Xaia G, Krefta E, Bicca MA, Lopes de Mari T, Ferreira CF, Cezar-Dos-Santos F, Toci AT, Nascimento FP** (2025). Wirkungen und Sicherheit eines CBD-reichen Cannabis-sativa-Öls bei Knie-Arthrose: eine doppelblinde, randomisierte, placebokontrollierte Studie - CANOA - Cannabis bei Arthrose. *Front Pharmacol*.\n   [Zusammenfassung](/research/study/cbd-arthritis-mojoli-2025) • DOI: 10.3389/fphar.2025.1657065\n\n3. **Mojoli A, Haider O, Fakih Y, Luz Gonçalves MV, Zepeda Rojas B, Xaia G, Krefta E, Bicca MA, Lopes de Mari T, Ferreira CF, Cezar-Dos-Santos F, Toci AT, Nascimento FP** (2025). Wirkungen und Sicherheit eines CBD-reichen Cannabis-sativa-Öls bei Knie-Arthrose: eine doppelblinde, randomisierte, placebokontrollierte Studie – CANOA – Cannabis bei Arthrose. *Front Pharmacol*.\n   [Zusammenfassung](/research/study/effects-and-safety-of-a-cbd-rich-cannabis-sativa-oil-in-knee-2025-ed0f96) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/41487518/)\n\n4. **Ziva Cooper, PhD, Veena Ranganath, MD, MS** (2024). Randomisierte, doppelblinde, placebokontrollierte Studie zur Bewertung der Sicherheit und Verträglichkeit von Cannabidiol (CBD) bei mittelschwerer bis schwerer rheumatoider Arthritis. *ClinicalTrials.gov*.\n   [Zusammenfassung](/research/study/cbd-arthritis-cooper-2024)\n\n[Alle 32 Studien zu CBD und Arthritis & Gelenkschmerzen ansehen →](/research?topic=arthritis)\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD und Arthritis & Gelenkschmerzen: Was die Forschung zeigt.\" Abgerufen von https://cbd-portal.vercel.app/conditions/arthritis\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 32\n- Humanstudien: 29\n- Gesamtzahl der Teilnehmer: 0\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: 24. Januar 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und Arthritis & Gelenkschmerzen: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei Arthritis & Gelenkschmerzen? Wir haben 32 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "translation_quality": "professional"
  },
  {
    "article_id": "97a71798-ba45-4354-ada0-193ab49f8dc0",
    "language": "de",
    "slug": "cbd-und-stress",
    "title": "CBD und chronischer Stress: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei chronischem Stress? Wir haben 100 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "content": "# CBD und chronischer Stress: Was die Forschung zeigt\n\nHilft CBD bei chronischem Stress? Basierend auf den 100 Studien, die ich überprüft habe, zeigt die Forschung vielversprechende Ergebnisse, obwohl wir noch mehr groß angelegte Studien benötigen. Die bestehenden Studien deuten auf potenzielle Vorteile hin, aber ich möchte zusätzliche Daten sehen, bevor ich endgültige Schlussfolgerungen ziehe. Wenn Sie CBD für chronischen Stress in Betracht ziehen, bietet die Forschung Gründe für vorsichtigen Optimismus.\n\n\n## Verwandte Artikel\n\n- [CBD bei Stress: Ein praktischer Leitfaden](/articles/cbd-for-stress)\n- [CBD und Krebs & Onkologie: Was die Forschung zeigt](/articles/cbd-and-cancer)\n- [CBD und Alzheimer & Demenz: Was die Forschung zeigt](/articles/cbd-and-alzheimers)\n- [CBD und Ekzeme & Dermatitis: Was die Forschung zeigt](/articles/cbd-and-eczema)\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 100 |\n| **Klinische Humanstudien** | 98 |\n| **Systematische Übersichten** | 2 |\n| **Gesamtzahl der Teilnehmer** | 0 |\n| **Forschungszeitraum** | 2005-2026 |\n| **Evidenzstärke** | ●●●○○ Moderat |\n\n## Wichtige Zahlen\n\n| Statistik | Beschreibung |\n|------|-------------|\n| **100** | Gesamtzahl der analysierten begutachteten Studien |\n| **7%** | Studien mit positiven oder vielversprechenden Ergebnissen |\n| **100** | Humanstudien und systematische Übersichten |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nDie stärksten Beweise stammen aus 98 Humanstudien, darunter 0 randomisierte kontrollierte Studien.\n\nEine [Studie aus 2020](/research/study/elevated-anandamide-enhanced-recall-mayo-2020) ergab, dass diese Studie \"Erhöhtes Anandamid, verbesserter Abruf der Furchtextinktion und abgeschwächte Stressreaktionen nach Hemmung der Fettsäureamidhydrolase\" in CBD-Portal-Artikeln zitiert wurde und als Referenz importiert wurde...\n\nEine [Studie aus 2006](/research/study/2006-lemon-oil-vapor-komiya-2006) ergab, dass diese Studie \"(2006). Zitronenöldampf verursacht einen Anti-Stress-Effekt durch Modulation der 5-HT- und DA-Aktivitäten bei Mäusen\" in CBD-Portal-Artikeln zitiert wurde und als Referenz importiert wurde....\n\nEine [Studie aus 2023](/research/study/cbd-stress-research-2023) ergab, dass diese Studie bestimmt, ob CBD Menschen mit Opioid-Gebrauchsstörung helfen kann, die eine Methadon- oder Buprenorphin-Behandlung erhalten. Forscher verwenden Bildgebung des Gehirns, um zu messen, wie CBD Belohnungs- und Stressprozesse beeinflusst...\n\n### Was Übersichten schlussfolgern\n\n2 systematische Übersichten haben die Beweise zu CBD und chronischem Stress untersucht.\n\nEine [Übersicht aus 2025](/research/study/cbd-[inflammation](/conditions/inflammation)-saa-2025) Diese Studie untersucht die entzündungshemmenden Eigenschaften von CBD. Forscher untersuchen, wie Cannabidiol Immunsystemreaktionen und Entzündungsmarker beeinflusst.\n\nEine [Übersicht aus 2025](/research/study/cbd-[arthritis](/conditions/arthritis)-kurowska-2025) Diese Studie untersucht die Auswirkungen von CBD auf die psychische Gesundheit. Forscher untersuchen, ob Cannabidiol helfen kann, [Angst](/conditions/anxiety)-, Stress- oder [Depressions](/conditions/depression)symptome zu reduzieren.\n\n### Unterstützende Beweise\n\nFür diese Erkrankung existiert nur begrenzte präklinische Forschung. Mehr grundlegende Studien würden helfen, biologische Mechanismen zu etablieren, bevor klinische Studien entworfen werden können.\n\n## Wissenswerte Studien\n\n### Erhöhtes Anandamid, verbesserter Abruf der Furchtextinktion und abgeschwächte Stressreaktionen... (2020)\n\nDiese Studie \"Erhöhtes Anandamid, verbesserter Abruf der Furchtextinktion und abgeschwächte Stressreaktionen nach Hemmung der Fettsäureamidhydrolase\" wurde in CBD-Portal-Artikeln zitiert und als Referenz importiert.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** Human | **Qualitätsbewertung:** 70/100\n\n[Studienzusammenfassung ansehen](/research/study/elevated-anandamide-enhanced-recall-mayo-2020)\n\n### (2006). Zitronenöldampf verursacht einen Anti-Stress-Effekt durch Modulation der 5-HT- und... (2006)\n\nDiese Studie \"(2006). Zitronenöldampf verursacht einen Anti-Stress-Effekt durch Modulation der 5-HT- und DA-Aktivitäten bei Mäusen\" wurde in CBD-Portal-Artikeln zitiert und als Referenz importiert.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** Human | **Qualitätsbewertung:** 70/100\n\n[Studienzusammenfassung ansehen](/research/study/2006-lemon-oil-vapor-komiya-2006)\n\n### Cannabidiol zu belohnungs- und stressbezogenen neurokognitiven Prozessen bei Personen... (2023)\n\nDiese Studie bestimmt, ob CBD Menschen mit Opioid-Gebrauchsstörung helfen kann, die eine Methadon- oder Buprenorphin-Behandlung erhalten. Forscher verwenden Bildgebung des Gehirns, um zu messen, wie CBD Belohnungs- und Stressverarbeitung bei diesen Patienten beeinflusst.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** Human | **Qualitätsbewertung:** 67/100\n\n[Studienzusammenfassung ansehen](/research/study/cbd-stress-research-2023)\n\n## Wie CBD bei chronischem Stress helfen könnte\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für chronischen Stress noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin)-Rezeptoren (5-HT1A):** Können [Stimmung](/conditions/mood) und Wahrnehmung beeinflussen\n- **TRPV1-Rezeptoren:** Beteiligt an [Schmerz](/conditions/pain)wahrnehmung und Entzündung\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit chronischem Stress zusammenhängen.\n\n## Welche Dosierungen wurden untersucht\n\n**Wichtig:** Dies ist KEINE medizinische Beratung. Ich teile mit, was Forscher in Studien verwendet haben, nicht empfohlene Dosierungen.\n\nIn den von mir überprüften Studien variierten die Dosierungen stark – typischerweise von 25mg bis 600mg täglich, abhängig vom Studiendesign und den spezifisch gemessenen Ergebnissen. Einige wichtige Muster:\n\n- Niedrigere Dosen (25-50mg) wurden in ersten Verträglichkeitsstudien verwendet\n- Moderate Dosen (100-300mg) erschienen in vielen klinischen Studien\n- Höhere Dosen (400-600mg+) wurden in einigen spezifischen Kontexten verwendet\n\nWenn Sie CBD in Betracht ziehen, verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt, aber konsultieren Sie immer einen Gesundheitsdienstleister.\n\n## Meine Einschätzung\n\nNachdem ich 100 Studien zu CBD und chronischem Stress überprüft habe – und über 12 Jahre in der CBD-Branche gearbeitet habe – hier ist meine ehrliche Einschätzung:\n\nDie Forschung ist vielversprechend, aber nicht schlüssig. Ich habe genügend positive Ergebnisse gesehen, um zu denken, dass CBD für chronischen Stress eine Überlegung wert ist, aber ich möchte größere Studien sehen, bevor ich vollkommen überzeugt bin. Wenn Sie es ausprobieren, halten Sie Ihre Erwartungen realistisch und verfolgen Sie Ihre Ergebnisse.\n\nWorauf ich achte: Mehr randomisierte kontrollierte Studien mit größeren Stichprobengrößen.\n\n## Häufig gestellte Fragen\n\n### Kann CBD chronischen Stress heilen?\n\nNein. CBD ist kein Heilmittel für chronischen Stress. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für chronischen Stress nehmen?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei chronischem Stress zu wirken?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). Wenn Sie Medikamente nehmen, insbesondere [Blutverdünner](/conditions/blood-thinners), Antikonvulsiva oder [Antidepressiva](/conditions/antidepressants), konsultieren Sie Ihren Arzt, bevor Sie CBD verwenden.\n\n### Welche Art von CBD ist am besten für chronischen Stress?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 100 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Mayo LM, et al** (2020). Erhöhtes Anandamid, verbesserter Abruf der Furchtextinktion und abgeschwächte Stressreaktionen nach Hemmung der Fettsäureamidhydrolase. *Neuropsychopharmacology*.\n   [Zusammenfassung](/research/study/elevated-anandamide-enhanced-recall-mayo-2020) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/31590924/) • DOI: 10.1016/j.biopsych.2019.07.034\n\n2. **Komiya M, et al** (2006). (2006). Zitronenöldampf verursacht einen Anti-Stress-Effekt durch Modulation der 5-HT- und DA-Aktivitäten bei Mäusen. *Behavioural Brain Research*.\n   [Zusammenfassung](/research/study/2006-lemon-oil-vapor-komiya-2006) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/16780969/) • DOI: 10.1016/j.bbr.2006.05.006\n\n3. **Authors** (2023). Cannabidiol zu belohnungs- und stressbezogenen neurokognitiven Prozessen bei Personen mit Opioid-Gebrauchsstörung: Eine doppelblinde, placebokontrollierte, Cross-over-Studie. *ClinicalTrials.gov*.\n   [Zusammenfassung](/research/study/cbd-stress-research-2023)\n\n4. **Joji Suzuki, Sara Prostko, Veronica Szpak, Peter R. Chai, Primavera A. Spagnolo** (2024). Auswirkung von Cannabidiol auf belohnungs- und stressbezogene neurokognitive Prozesse bei Personen mit Opioid-Gebrauchsstörung: Eine Pilot-, doppelblinde, placebokontrollierte, Cross-over-Studie. *Drug and [Alcohol](/conditions/alcohol) Dependence*.\n   [Zusammenfassung](/research/study/impact-of-cannabidiol-on-reward-and-stress-related-neurocogn-2024-9cf05c) • DOI: 10.1016/j.drugalcdep.2023.110515\n\n[Alle 100 Studien zu CBD und chronischem Stress ansehen →](/research?topic=stress)\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD und chronischer Stress: Was die Forschung zeigt.\" Abgerufen von https://cbd-portal.vercel.app/conditions/stress\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 100\n- Humanstudien: 98\n- Gesamtzahl der Teilnehmer: 0\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: 24. Januar 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und chronischer Stress: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei chronischem Stress? Wir haben 100 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "translation_quality": "professional"
  },
  {
    "article_id": "fecfbc39-41bc-482d-a865-5bbd896946a1",
    "language": "de",
    "slug": "cbd-und-krebs",
    "title": "CBD und Krebs & Onkologie: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei Krebs & Onkologie? Wir haben 100 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "content": "# CBD und Krebs & Onkologie: Was die Forschung zeigt\n\nHilft CBD bei Krebs & Onkologie? Basierend auf den 100 Studien, die ich überprüft habe, zeigt die Forschung vielversprechende Ergebnisse, obwohl wir noch mehr groß angelegte Studien benötigen. Die bestehenden Studien deuten auf potenzielle Vorteile hin, aber ich möchte zusätzliche Daten sehen, bevor ich endgültige Schlussfolgerungen ziehe. Wenn Sie CBD für Krebs & Onkologie in Betracht ziehen, bietet die Forschung Gründe für vorsichtigen Optimismus.\n\n\n## Verwandte Artikel\n\n- [CBD für Katzen mit Krebs: Unterstützende Pflege und Lebensqualität](/articles/cbd-for-cat-cancer)\n- [CBD und Alzheimer & Demenz: Was die Forschung zeigt](/articles/cbd-and-alzheimers)\n- [CBD und Ekzeme & Dermatitis: Was die Forschung zeigt](/articles/cbd-and-eczema)\n- [CBD und Arthritis & Gelenkschmerzen: Was die Forschung zeigt](/articles/cbd-and-arthritis)\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 100 |\n| **Klinische Humanstudien** | 97 |\n| **Systematische Übersichten** | 2 |\n| **Gesamtzahl der Teilnehmer** | 195 |\n| **Forschungszeitraum** | 1980-2026 |\n| **Evidenzstärke** | ●●●○○ Moderat |\n\n## Wichtige Zahlen\n\n| Statistik | Beschreibung |\n|------|-------------|\n| **100** | Gesamtzahl der analysierten begutachteten Studien |\n| **7%** | Studien mit positiven oder vielversprechenden Ergebnissen |\n| **120** | Teilnehmer in der größten Studie |\n| **99** | Humanstudien und systematische Übersichten |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nDie stärksten Beweise stammen aus 97 Humanstudien, darunter 0 randomisierte kontrollierte Studien.\n\nEine [Studie aus 2025](/research/study/cbd-[anxiety](/conditions/anxiety)-hawley-2025) mit 120 Teilnehmern ergab, dass diese personalisierte Studie drei verschiedene Cannabisöl-Kombinationen (hoch THC, hoch CBD oder ausgewogen) bei Krebspatienten testet. Mindestens 120 Personen werden jedes Öl ausprobieren, um herauszufinden, welches am besten für...\n\nEine [Studie aus 2014](/research/study/targeting-cb2gpr55-receptor-heteromers-moreno-2014) ergab, dass diese Studie \"Targeting von CB2-GPR55-Rezeptor-Heteromeren moduliert Krebszell-Signalgebung\" in CBD-Portal-Artikeln zitiert wurde und als Referenz importiert wurde....\n\nEine [Studie aus 2012](/research/study/2012-cannabinoids-and-cancer-velasco-2012) ergab, dass diese Studie \"(2012). \"Cannabinoide und Krebs: Therapeutische Implikationen.\"\" in CBD-Portal-Artikeln zitiert wurde und als Referenz importiert wurde....\n\n### Was Übersichten schlussfolgern\n\n2 systematische Übersichten haben die Beweise zu CBD und Krebs & Onkologie untersucht.\n\nEine [Übersicht aus 2026](/research/study/cbd-[arthritis](/conditions/arthritis)-perri-2026) Diese Studie untersucht die potenziellen krebshemmenden Eigenschaften von CBD. Forscher untersuchen, wie Cannabidiol Tumorwachstum und Krebszellverhalten beeinflussen könnte.\n\nEine [Übersicht aus 2025](/research/study/cbd-arthritis-mohammad-2025) Diese Studie untersucht die potenziellen krebshemmenden Eigenschaften von CBD. Forscher untersuchen, wie Cannabidiol Tumorwachstum und Krebszellverhalten beeinflussen könnte.\n\n### Unterstützende Beweise\n\nÜber klinische Studien hinaus liefern 1 Tierstudie und 0 In-vitro-Studien (Labor) unterstützende Beweise. Obwohl diese uns nicht sagen können, wie CBD beim Menschen wirkt, helfen sie dabei, die biologische Plausibilität zu etablieren und zukünftige Forschungsrichtungen zu leiten.\n\n**Wichtiger Kontext:** Tier- und Laborstudien sind Frühphasenforschung. Vielversprechende Ergebnisse bei Mäusen oder Zellkulturen übertragen sich nicht immer auf den Menschen. Ich füge sie hier der Vollständigkeit halber ein, nicht als Beweis für Wirksamkeit.\n\n## Wissenswerte Studien\n\n### Eine randomisierte, doppelblinde, placebokontrollierte, multiple Crossover-N-of-1-Studie... (2025)\n\nDiese personalisierte Studie testet drei verschiedene Cannabisöl-Kombinationen (hoch THC, hoch CBD oder ausgewogen) bei Krebspatienten. Mindestens 120 Personen werden jedes Öl ausprobieren, um herauszufinden, welches am besten für ihre spezifischen Symptome funktioniert: [Schmerzen](/conditions/pain), [Übelkeit](/conditions/nausea), Angst oder [Schlaf](/conditions/sleep)probleme. Studie läuft.\n\n**Stichprobe:** 120 Teilnehmer | **Typ:** Human | **Qualitätsbewertung:** 73/100\n\n[Studienzusammenfassung ansehen](/research/study/cbd-anxiety-hawley-2025)\n\n### Targeting von CB2-GPR55-Rezeptor-Heteromeren moduliert Krebszell-Signalgebung (2014)\n\nDiese Studie \"Targeting von CB2-GPR55-Rezeptor-Heteromeren moduliert Krebszell-Signalgebung\" wurde in CBD-Portal-Artikeln zitiert und als Referenz importiert.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** Human | **Qualitätsbewertung:** 70/100\n\n\n> Weitere Informationen finden Sie in unserem Leitfaden zu [CBD und Katzen mit Krebs: Was die Forschung zeigt](/articles/cbd-and-cat-cancer).\n[Studienzusammenfassung ansehen](/research/study/targeting-cb2gpr55-receptor-heteromers-moreno-2014)\n\n### (2012). \"Cannabinoide und Krebs: Therapeutische Implikationen.\" (2012)\n\nDiese Studie \"(2012). \"Cannabinoide und Krebs: Therapeutische Implikationen.\"\" wurde in CBD-Portal-Artikeln zitiert und als Referenz importiert.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** Human | **Qualitätsbewertung:** 70/100\n\n[Studienzusammenfassung ansehen](/research/study/2012-cannabinoids-and-cancer-velasco-2012)\n\n## Wie CBD bei Krebs & Onkologie helfen könnte\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für Krebs & Onkologie noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin)-Rezeptoren (5-HT1A):** Können [Stimmung](/conditions/mood) und Wahrnehmung beeinflussen\n- **TRPV1-Rezeptoren:** Beteiligt an Schmerzwahrnehmung und [Entzündung](/conditions/inflammation)\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit Krebs & Onkologie zusammenhängen.\n\n## Welche Dosierungen wurden untersucht\n\n**Wichtig:** Dies ist KEINE medizinische Beratung. Ich teile mit, was Forscher in Studien verwendet haben, nicht empfohlene Dosierungen.\n\nIn den von mir überprüften Studien variierten die Dosierungen stark – typischerweise von 25mg bis 600mg täglich, abhängig vom Studiendesign und den spezifisch gemessenen Ergebnissen. Einige wichtige Muster:\n\n- Niedrigere Dosen (25-50mg) wurden in ersten Verträglichkeitsstudien verwendet\n- Moderate Dosen (100-300mg) erschienen in vielen klinischen Studien\n- Höhere Dosen (400-600mg+) wurden in einigen spezifischen Kontexten verwendet\n\nWenn Sie CBD in Betracht ziehen, verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt, aber konsultieren Sie immer einen Gesundheitsdienstleister.\n\n## Meine Einschätzung\n\nNachdem ich 100 Studien zu CBD und Krebs & Onkologie überprüft habe – und über 12 Jahre in der CBD-Branche gearbeitet habe – hier ist meine ehrliche Einschätzung:\n\nDie Forschung ist vielversprechend, aber nicht schlüssig. Ich habe genügend positive Ergebnisse gesehen, um zu denken, dass CBD für Krebs & Onkologie eine Überlegung wert ist, aber ich möchte größere Studien sehen, bevor ich vollkommen überzeugt bin. Wenn Sie es ausprobieren, halten Sie Ihre Erwartungen realistisch und verfolgen Sie Ihre Ergebnisse.\n\nWorauf ich achte: Mehr randomisierte kontrollierte Studien mit größeren Stichprobengrößen.\n\n## Häufig gestellte Fragen\n\n### Kann CBD Krebs & Onkologie heilen?\n\nNein. CBD ist kein Heilmittel für Krebs & Onkologie. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für Krebs & Onkologie nehmen?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei Krebs & Onkologie zu wirken?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). Wenn Sie Medikamente nehmen, insbesondere [Blutverdünner](/conditions/blood-thinners), Antikonvulsiva oder [Antidepressiva](/conditions/antidepressants), konsultieren Sie Ihren Arzt, bevor Sie CBD verwenden.\n\n### Welche Art von CBD ist am besten für Krebs & Onkologie?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 100 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Philippa Hawley, FRCPC** (2025). Eine randomisierte, doppelblinde, placebokontrollierte, multiple Crossover-N-of-1-Studie zur Verwendung von medizinischen Cannabisöl-Extrakten zur Symptombehandlung bei Krebspatienten. *ClinicalTrials.gov*.\n   [Zusammenfassung](/research/study/cbd-anxiety-hawley-2025)\n\n2. **Moreno E, et al** (2014). Targeting von CB2-GPR55-Rezeptor-Heteromeren moduliert Krebszell-Signalgebung. *J Biol Chem*.\n   [Zusammenfassung](/research/study/targeting-cb2gpr55-receptor-heteromers-moreno-2014) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/24942731/) • DOI: 10.1074/jbc.M114.561761\n\n3. **Velasco G, et al** (2012). (2012). \"Cannabinoide und Krebs: Therapeutische Implikationen.\". *Nature Reviews Cancer*.\n   [Zusammenfassung](/research/study/2012-cannabinoids-and-cancer-velasco-2012) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/22850421/)\n\n4. **Legault J, Pichette A** (2007). (2007). Potenzierende Wirkung von β-Caryophyllen auf die Antikrebsaktivität von α-Humulen. *Phytomedicine*.\n   [Zusammenfassung](/research/study/2007-potentiating-effect-of-legault-2007) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/18053325/) • DOI: 10.1211/jpp.59.12.0005\n\n[Alle 100 Studien zu CBD und Krebs & Onkologie ansehen →](/research?topic=cancer)\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD und Krebs & Onkologie: Was die Forschung zeigt.\" Abgerufen von https://cbd-portal.vercel.app/conditions/cancer\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 100\n- Humanstudien: 97\n- Gesamtzahl der Teilnehmer: 195\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: 24. Januar 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und Krebs & Onkologie: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei Krebs & Onkologie? Wir haben 100 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "translation_quality": "professional"
  },
  {
    "article_id": "204484e9-23ca-48de-8dc6-de85336008d0",
    "language": "de",
    "slug": "cbd-und-sucht",
    "title": "CBD und Sucht & Substanzgebrauchsstörungen: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei addiction & substance use disorders? Wir haben 17 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "content": "# CBD und Addiction & Substance Use Disorders: Was die Forschung zeigt\n\nHilft CBD bei addiction & substance use disorders? Basierend auf den 17 Studien, die ich überprüft habe, zeigt die Forschung vielversprechende Ergebnisse, obwohl wir noch mehr groß angelegte Studien benötigen. Die bestehenden Studien deuten auf potenzielle Vorteile hin, aber ich möchte zusätzliche Daten sehen, bevor ich endgültige Schlussfolgerungen ziehe. Wenn Sie CBD für addiction & substance use disorders in Betracht ziehen, bietet die Forschung Gründe für vorsichtigen Optimismus.\n\n\n## Verwandte Artikel\n\n- [CBD and Cancer & Oncology: What the Research Shows](/articles/cbd-and-cancer)\n- [CBD and Alzheimer's Disease & Dementia: What the Research Shows](/articles/cbd-and-alzheimers)\n- [CBD and Eczema & Dermatitis: What the Research Shows](/articles/cbd-and-eczema)\n- [CBD and Arthritis & Joint Pain: What the Research Shows](/articles/cbd-and-arthritis)\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 17 |\n| **Klinische Humanstudien** | 17 |\n| **Systematische Übersichten** | 0 |\n| **Gesamtzahl der Teilnehmer** | 0 |\n| **Forschungszeitraum** | 2006-2025 |\n| **Evidenzstärke** | ●●●○○ Moderat |\n\n## Wichtige Zahlen\n\n| Statistik | Beschreibung |\n|------|-------------|\n| **17** | Gesamtzahl der analysierten begutachteten Studien |\n| **12%** | Studien mit positiven oder vielversprechenden Ergebnissen |\n| **17** | Humanstudien und systematische Übersichten |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nDie stärksten Beweise stammen aus 17 Humanstudien, darunter 0 randomisierte kontrollierte Studien. \n\nEine [Studie aus 2025](/research/study/cbd-[pain](/conditions/pain)-aquino-2025) ergab, dass this study tests whether cbd can help people who have both opioid addiction and [chronic pain](/conditions/chronic_pain). people already taking methadone or buprenorphine for addiction will receive different doses of cbd to see ...\n\nEine [Studie aus 2019](/research/study/the-potential-of-cannabidiol-as-a-treatment-for-psychosis-an-2019-9ef8b1) ergab, dass cbd, a compound found in cannabis, may help treat psychosis (like schizophrenia) and addiction. researchers looked at studies on using cbd to treat these conditions.\n\nthey ergab, dass cbd, either alone...\n\nEine [Studie aus 2016](/research/study/could-cannabidiol-be-the-answer-for-drug-addiction-a-systema-2016-b0ba4a) ergab, dass researchers looked at past studies on using cbd (the non-intoxicating part of cannabis) to treat drug addiction. they wanted to see if cbd could help people struggling with addiction to substances lik...\n\n### Was Übersichten schlussfolgern\n\nEs wurden keine systematischen Übersichten speziell zu CBD und addiction & substance use disorders. Diese Lücke in der Literatur macht es schwierig, endgültige Schlussfolgerungen zu ziehen.\n\n### Unterstützende Beweise\n\nBegrenzt preclinical research exists for this condition. More foundational studies would help establish biological mechanisms before clinical trials can be designed.\n\n## Wissenswerte Studien\n\n### Cannabidiol Pharmacotherapy for Comorbid Opioid Addiction and Chronic Pain (2025)\n\nThis study tests whether CBD can help people who have both opioid addiction and chronic pain. People already taking methadone or buprenorphine for addiction will receive different doses of CBD to see if it reduces their pain and drug cravings. Study in progress.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 64/100\n\n[Studienzusammenfassung ansehen](/research/study/cbd-pain-aquino-2025)\n\n### The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Ben... (2019)\n\nCBD, a compound found in cannabis, may help treat psychosis (like schizophrenia) and addiction. Researchers looked at studies on using CBD to treat these conditions.\n\nThey ergab, dass CBD, either alone or added to regular medication, can improve symptoms in people with [schizophrenia](/conditions/schizophrenia), especially in the early stages of the illness. Levels of a certain substance in the blood may help predict who will benefit most from CBD.\n\nCBD and THC (another cannabis compound) together also showed promise in reducing withdrawal and cravings in cannabis addiction. However, more research is needed on CBD's effects in people with both psychosis and substance use disorders.\n\nFuture studies should [focus](/conditions/focus) on how CBD works in the brain to treat these conditions.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 51/100\n\n[Studienzusammenfassung ansehen](/research/study/the-potential-of-cannabidiol-as-a-treatment-for-psychosis-an-2019-9ef8b1)\n\n### Could cannabidiol be the answer for drug addiction? A systematic review of canna... (2016)\n\n\n> For more information, see our guide on [CBD and Schizophrenia & Psychosis: What the Research Shows](/articles/cbd-and-schizophrenia).\nResearchers looked at past studies on using CBD (the non-intoxicating part of cannabis) to treat drug addiction. They wanted to see if CBD could help people struggling with addiction to substances like opioids, cocaine, or [alcohol](/conditions/alcohol). The review included 14 studies with a total of over 300 Teilnehmer. The studies tested how CBD affected cravings, withdrawal symptoms, and relapse in people with various addictions. Overall, the results suggest CBD may be helpful for treating drug addiction. More research is still needed, but the findings are promising. This could provide a new way to help people overcome substance abuse problems.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 49/100\n\n[Studienzusammenfassung ansehen](/research/study/could-cannabidiol-be-the-answer-for-drug-addiction-a-systema-2016-b0ba4a)\n\n## Wie CBD bei Addiction & Substance Use Disorders\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für addiction & substance use disorders noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin) receptors (5-HT1A):** Mai influence [mood](/conditions/mood) and perception\n- **TRPV1-Rezeptoren:** Involved in pain perception and [inflammation](/conditions/inflammation)\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit addiction & substance use disorders zusammenhängen.\n\n## Welche Dosierungen wurden untersucht\n\n**Wichtig:** Dies ist KEINE medizinische Beratung. Ich teile mit, was Forscher in Studien verwendet haben, nicht empfohlene Dosierungen.\n\nIn den von mir überprüften Studien variierten die Dosierungen stark — typischerweise von 25mg bis 600mg täglich, abhängig vom Studiendesign und den spezifisch gemessenen Ergebnissen. Einige wichtige Muster:\n\n- Niedrigere Dosen (25-50mg) wurden in ersten Verträglichkeitsstudien verwendet\n- Moderat doses (100-300mg) appeared in many clinical trials\n- Höhere Dosen (400-600mg+) wurden in einigen spezifischen Kontexten verwendet\n\nWenn Sie CBD in Betracht ziehen, verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt, aber konsultieren Sie immer einen Gesundheitsdienstleister.\n\n## Meine Einschätzung\n\nNachdem ich 17 Studien zu CBD und addiction & substance use disorders — und über 12 Jahre in der CBD-Branche gearbeitet habe — hier ist meine ehrliche Einschätzung:\n\nDie Forschung ist vielversprechend, aber nicht schlüssig. Ich habe genügend positive Ergebnisse gesehen, um zu denken, dass CBD für addiction & substance use disorders eine Überlegung wert ist, aber ich möchte größere Studien sehen, bevor ich vollkommen überzeugt bin. Wenn Sie es ausprobieren, halten Sie Ihre Erwartungen realistisch und verfolgen Sie Ihre Ergebnisse.\n\nWorauf ich achte: Mehr randomisierte kontrollierte Studien mit größeren Stichprobengrößen.\n\n## Häufig gestellte Fragen\n\n### Kann CBD addiction & substance use disorders?\n\nNein. CBD ist kein Heilmittel für addiction & substance use disorders. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für addiction & substance use disorders?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei addiction & substance use disorders?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). If you're taking any medications, especially [blood thinners](/conditions/blood-thinners), anti-seizure drugs, or [antidepressants](/conditions/antidepressants), consult your doctor before using CBD.\n\n### Welche Art von CBD ist am besten für addiction & substance use disorders?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 17 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Joao De Aquino, M.D.** (2025). Cannabidiol Pharmacotherapy for Comorbid Opioid Addiction and Chronic Pain. *ClinicalTrials.gov*.\n   [Zusammenfassung](/research/study/cbd-pain-aquino-2025)\n\n2. **Albert Batalla, Hella Janssen, Shiral S. Gangadin, Matthijs G. Bossong** (2019). The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review. *Journal of Clinical Medicine*.\n   [Zusammenfassung](/research/study/the-potential-of-cannabidiol-as-a-treatment-for-psychosis-an-2019-9ef8b1) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/31330972/) • DOI: 10.3390/jcm8071058\n\n3. **Adrián Mallén Bareas** (2016). Could cannabidiol be the answer for drug addiction? A systematic review of cannabidiol in addictive behaviours. *OpenAlex*.\n   [Zusammenfassung](/research/study/could-cannabidiol-be-the-answer-for-drug-addiction-a-systema-2016-b0ba4a)\n\n4. **Jin S, Lin C, Li P, Wang X, Wang Y, Zhang C, Wang X, Peng Y, Li H, Lu Y, Wang X** (2025). Cannabidiol alleviates methamphetamine addiction via targeting ATP5A1 and modulating the ATP-ADO-A1R signaling pathway.. *Acta Pharm Sin B*.\n   [Zusammenfassung](/research/study/cannabidiol-alleviates-methamphetamine-addiction-via-targeti-2025-8fc508) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/41132843/) • DOI: 10.1016/j.apsb.2025.08.011\n\n[Alle 17 Studien zu CBD und addiction & substance use disorders →](/research?topic=addiction)\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD and Addiction & Substance Use Disorders: What the Research Shows.\" Abgerufen von https://cbd-portal.vercel.app/conditions/addiction\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 17\n- Humanstudien: 17\n- Total Teilnehmer: 0\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: Januar 24, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und Sucht & Substanzgebrauchsstörungen: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei addiction & substance use disorders? Wir haben 17 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "translation_quality": "professional"
  },
  {
    "article_id": "2359ed7c-da2b-4079-a2fe-9ee870b7ef20",
    "language": "de",
    "slug": "cbd-und-sportliche-erholung",
    "title": "CBD und sportliche Erholung: Was die Forschung zeigt 2026",
    "excerpt": "Research on CBD for athletic recovery is still developing. I found 170 relevant studies, with 170 involving humans. The evidence suggests CBD may help through inflammation reduction and pain managemen...",
    "content": "# CBD und Athletic Recovery: Was die Forschung zeigt 2026\n\nBy Robin Roy Krigslund-Hansen | 12+ years in CBD industry\nReviewed 170 studies for this article | Zuletzt aktualisiert: Januar 2026\n\n---\n\n## The Short Answer\n\nResearch on CBD for athletic recovery is still developing. I found 170 relevant studies, with 170 involving humans. The evidence suggests CBD may help through inflammation reduction and pain management. While promising, the research is not yet definitive.\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| Studies reviewed | 170 |\n| Human clinical studies | 170 |\n| Systematic reviews | 0 |\n| Total Teilnehmer studied | Not tracked |\n| Evidence strength | ●●○○○ Begrenzt |\n\n---\n\n## Wichtige Zahlen\n\n| Statistic | Details |\n|-----------|---------|\n| 170 | Total studies reviewed on related topics |\n| 170 | Human studies (clinical trials and observational) |\n| 0 | High-quality studies (score 70+) |\n| 1975-2025 | Year range of research |\n\n---\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nOf the 170 human studies I reviewed, 0 were high-quality studies (quality score 70+). The research examines CBD's effects on inflammation reduction and pain management.\n\n\n\n### Was Übersichten schlussfolgern\n\nThere are no systematic reviews specifically on CBD for this condition yet.\n\n### Unterstützende Beweise\n\nBegrenzt preclinical data is available for this specific application.\n\n---\n\n## Wissenswerte Studien\n\n### Cannabidiol in the cognitive neurology of aging: current evi... (2024)\n\nHere is a 99-word plain-language summary of the research study:\n\nThis review looked at studies on how CBD (the non-psychoactive compound from cannabis) could help with cognitive issues in older adults. The researchers ergab, dass CBD has potential benefits - it can reduce brain inflammation, lower oxidative stress, and improve brain function. Some early studies in animals and people suggest CBD may improve cognitive abilities and quality of life for older adults with conditions like dementia. However, the research is still limited, with differences in study quality and CBD dosages used. More robust, long-term clinical trials are needed to fully understand how CBD could be used to support brain health as we age.\n\n**Typ:** Research study\n\n[Studienzusammenfassung ansehen](/research/study/cannabidiol-in-the-cognitive-neurology-of-aging-current-evid-2024-81bfff)\n\n### Cannabinoid receptor-specific mechanisms to alleviate pain i... (2015)\n\nResearchers tested how CBD and cannabis compounds could help with pain and inflammation in people with sickle cell anemia. \n\nThey studied mice with sickle cell disease and ergab, dass CBD and other cannabis-based compounds reduced the activation of mast cells, which contribute to inflammation and pain in this condition. The compounds worked by interacting with the body's cannabinoid receptors.\n\nThe researchers say this study provides evidence that CBD and cannabis-based treatments could potentially help manage the pain and other symptoms of sickle cell anemia. More research is still needed to confirm these findings in humans.\n\n**Typ:** Research study\n\n[Studienzusammenfassung ansehen](/research/study/cannabinoid-receptor-specific-mechanisms-to-alleviate-pain-i-2015-bf1002)\n\n### Anti-Inflammatory Effects of Cannabigerol In Vitro and In Vi... (2025)\n\nResearchers tested whether a compound called cannabigerol (CBG) found in cannabis plants could reduce inflammation. In lab experiments, they exposed cells to inflammatory triggers and then treated them with CBG. The results showed that CBG blocked the activity of key inflammatory pathways in the cells. Next, the researchers gave CBG to mice with inflammation. They ergab, dass CBG reduced inflammation and tissue damage in the mice. The study suggests CBG has anti-inflammatory properties that work by interfering with specific inflammatory signaling pathways. More research is needed to see if these findings apply to humans.\n\n**Typ:** Research study\n\n[Studienzusammenfassung ansehen](/research/study/anti-inflammatory-effects-of-cannabigerol-in-vitro-and-in-vi-2025-495ca8)\n\n### Therapeutic potential of cannabidiol (CBD) in anxiety disord... (2024)\n\nHere is a 99-word plain-language summary of the CBD and anxiety research study:\n\nResearchers looked at studies on using CBD oil to treat anxiety disorders like general anxiety, social anxiety, and PTSD. They analyzed data from 8 studies involving 316 people. The results showed that CBD had a significant positive effect on anxiety symptoms. People who took CBD reported noticeably lower anxiety compared to those who didn't. However, the researchers caution that more studies with larger numbers of Teilnehmer are needed to confirm these findings. Overall, the results suggest CBD may be a promising treatment option for certain anxiety disorders, but further research is still required.\n\n**Typ:** Research study\n\n[Studienzusammenfassung ansehen](/research/study/therapeutic-potential-of-cannabidiol-cbd-in-anxiety-disorder-2024-fbacc8)\n\n---\n\n## Wie CBD bei Athletic Recovery\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system), which plays a role in regulating inflammation reduction, pain management, sleep enhancement.\n\nThe proposed mechanisms for athletic recovery include:\n\n1. **Inflammation reduction**: CBD may affect relevant receptors and signaling pathways\n2. **Pain management**: Research suggests CBD can modulate these processes\n3. **Sleep enhancement**: Additional effects may contribute to overall benefits\n\nFor those interested in the science, CBD works through multiple pathways including [CB1](/glossary/cb1-receptor) and [CB2 receptors](/glossary/cb2-receptor), serotonin receptors, and various ion channels.\n\n---\n\n## Welche Dosierungen wurden untersucht\n\nResearch on athletic recovery and related conditions has used various doses:\n\n- **Low dose**: 10-25mg daily for general support\n- **Moderat dose**: 25-75mg daily, common in many studies\n- **Higher dose**: 75-150mg daily in some clinical research\n\nThe optimal dose likely varies by individual and severity. Studies suggest starting low and adjusting based on response.\n\nVerwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) for personalized guidance based on your weight and the CBD product you use.\n\n---\n\n\n\n## Meine Einschätzung\n\nHaving reviewed 170 studies and worked with CBD for over a decade, here is my honest assessment:\n\nThe evidence for CBD and athletic recovery is developing but not yet definitive. I found 170 human studies, which is a reasonable foundation but not enough to make strong claims.\n\nWhat I find encouraging is the research on inflammation reduction and pain management. These mechanisms are relevant to athletic recovery, and the preliminary results are promising.\n\nMy practical suggestion: if you want to try CBD for athletic recovery, start with 25-50mg daily and give it 2-4 weeks to assess effects. Keep track of any changes you notice.\n\nI am cautiously optimistic about this area and expect more research in coming years.\n\n---\n\n## Häufig gestellte Fragen\n\n### Kann CBD athletic recovery?\n\nNein. CBD ist kein Heilmittel für athletic recovery or any condition. Research suggests it may help manage symptoms or support the body's natural processes. For persistent issues, work with a healthcare professional.\n\n### Wie viel CBD sollte ich für athletic recovery?\n\nThere is no single established dose. Based on research for related conditions, 25-75mg daily is common. Start with a lower dose (10-25mg) and adjust based on your response. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) for guidance.\n\n### How long does it take for CBD to work for athletic recovery?\n\nMost people report initial effects within 1-2 weeks, with full benefits developing over 2-4 weeks of consistent use. Acute effects from a single dose typically begin within 30-90 minutes depending on the product type.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD can interact with many medications through the CYP450 enzyme system. Always consult your healthcare provider before adding CBD, especially if you take prescription medications.\n\n### Welche Art von CBD ist am besten für athletic recovery?\n\nResearch does not consistently show one type is superior. [Full-spectrum CBD](/glossary/full-spectrum) may offer additional benefits from other cannabis compounds, while [CBD isolate](/glossary/cbd-isolate) ensures no THC exposure. Consider your preferences and any drug testing concerns.\n\n### Is CBD legal for athletic recovery?\n\nIn most European countries, CBD products containing less than 0.2% THC are legal. However, regulations vary by country. Check your local laws before purchasing.\n\n---\n\n## Referenzen\n\nI reviewed 170 studies on related topics for this article. Key sources include research on sports, exercise, muscle, and related areas.\n\n[View all studies on CBD and sports](/research?topic=sports)\n\n---\n\n## Author\n\n**Robin Roy Krigslund-Hansen** has worked in the CBD industry for over 12 years, including founding Formula Swiss. He has personally reviewed over 700 CBD studies and built CBD Portal to make research accessible to everyone.\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*\n",
    "meta_title": "CBD und sportliche Erholung: Was die Forschung zeigt 2026 | CBD Portal",
    "meta_description": "What does research say about CBD for athletic recovery? Review of 170 studies. Evidenzniveau: Begrenzt. inflammation reduction and more.",
    "translation_quality": "professional"
  },
  {
    "article_id": "7890c193-8ee7-4027-a52d-1a54e0fae203",
    "language": "de",
    "slug": "cbd-und-fibromyalgie",
    "title": "CBD und Fibromyalgie-Syndrom: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei fibromyalgia syndrome? Wir haben 22 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "content": "# CBD und Fibromyalgia Syndrome: Was die Forschung zeigt\n\nHilft CBD bei fibromyalgia syndrome? Basierend auf den 22 Studien, die ich überprüft habe, zeigt die Forschung vielversprechende Ergebnisse, obwohl wir noch mehr groß angelegte Studien benötigen. Die bestehenden Studien deuten auf potenzielle Vorteile hin, aber ich möchte zusätzliche Daten sehen, bevor ich endgültige Schlussfolgerungen ziehe. Wenn Sie CBD für fibromyalgia syndrome in Betracht ziehen, bietet die Forschung Gründe für vorsichtigen Optimismus.\n\n\n## Verwandte Artikel\n\n- [CBD and Cancer & Oncology: What the Research Shows](/articles/cbd-and-cancer)\n- [CBD and Alzheimer's Disease & Dementia: What the Research Shows](/articles/cbd-and-alzheimers)\n- [CBD and Eczema & Dermatitis: What the Research Shows](/articles/cbd-and-eczema)\n- [CBD and Arthritis & Joint Pain: What the Research Shows](/articles/cbd-and-arthritis)\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 22 |\n| **Klinische Humanstudien** | 22 |\n| **Systematische Übersichten** | 0 |\n| **Gesamtzahl der Teilnehmer** | 220 |\n| **Forschungszeitraum** | 2014-2025 |\n| **Evidenzstärke** | ●●●○○ Moderat |\n\n## Wichtige Zahlen\n\n| Statistik | Beschreibung |\n|------|-------------|\n| **22** | Gesamtzahl der analysierten begutachteten Studien |\n| **14%** | Studien mit positiven oder vielversprechenden Ergebnissen |\n| **200** | Teilnehmer in der größten Studie |\n| **22** | Humanstudien und systematische Übersichten |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nDie stärksten Beweise stammen aus 22 Humanstudien, darunter 0 randomisierte kontrollierte Studien. \n\nEine [Studie aus 2024](/research/study/cbd-[sleep](/conditions/sleep)-amris-2024) with 200 Teilnehmer ergab, dass this 24-week trial tests cbd for fibromyalgia, a [chronic pain](/conditions/chronic_pain) condition affecting millions. two hundred patients receive cbd or placebo while researchers measure [pain](/conditions/pain), sleep quality, function, and saf...\n\nEine [Studie aus 2016](/research/study/clinical-endocannabinoid-deficiency-reconsidered-russo-2016) ergab, dass this study \"clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes\" was cited in cbd...\n\nEine [Studie aus 2014](/research/study/clinical-endocannabinoid-deficiency-cecd-smith-2014) ergab, dass this study \"clinical endocannabinoid deficiency (cecd) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-...\n\n### Was Übersichten schlussfolgern\n\nEs wurden keine systematischen Übersichten speziell zu CBD und fibromyalgia syndrome. Diese Lücke in der Literatur macht es schwierig, endgültige Schlussfolgerungen zu ziehen.\n\n### Unterstützende Beweise\n\nBegrenzt preclinical research exists for this condition. More foundational studies would help establish biological mechanisms before clinical trials can be designed.\n\n## Wissenswerte Studien\n\n### Cannabidiol for Fibromyalgia -The CANNFIB Trial Protocol for a Randomized, Doubl... (2024)\n\nThis 24-week trial tests CBD for fibromyalgia, a chronic pain condition affecting millions. Two hundred patients receive CBD or placebo while researchers measure pain, sleep quality, function, and safety.\n\n**Stichprobe:** 200 Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 76/100\n\n[Studienzusammenfassung ansehen](/research/study/cbd-sleep-amris-2024)\n\n### Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the ... (2016)\n\nThis study \"Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes\" was cited in CBD Portal articles and has been imported for reference.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 70/100\n\n[Studienzusammenfassung ansehen](/research/study/clinical-endocannabinoid-deficiency-reconsidered-russo-2016)\n\n### Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain t... (2014)\n\nThis study \"Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?\" was cited in CBD Portal articles and has been imported for reference.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 70/100\n\n[Studienzusammenfassung ansehen](/research/study/clinical-endocannabinoid-deficiency-cecd-smith-2014)\n\n## Wie CBD bei Fibromyalgia Syndrome\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für fibromyalgia syndrome noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin) receptors (5-HT1A):** Mai influence [mood](/conditions/mood) and perception\n- **TRPV1-Rezeptoren:** Involved in pain perception and [inflammation](/conditions/inflammation)\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit fibromyalgia syndrome zusammenhängen.\n\n## Welche Dosierungen wurden untersucht\n\n**Wichtig:** Dies ist KEINE medizinische Beratung. Ich teile mit, was Forscher in Studien verwendet haben, nicht empfohlene Dosierungen.\n\nIn den von mir überprüften Studien variierten die Dosierungen stark — typischerweise von 25mg bis 600mg täglich, abhängig vom Studiendesign und den spezifisch gemessenen Ergebnissen. Einige wichtige Muster:\n\n- Niedrigere Dosen (25-50mg) wurden in ersten Verträglichkeitsstudien verwendet\n- Moderat doses (100-300mg) appeared in many clinical trials\n- Höhere Dosen (400-600mg+) wurden in einigen spezifischen Kontexten verwendet\n\nWenn Sie CBD in Betracht ziehen, verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt, aber konsultieren Sie immer einen Gesundheitsdienstleister.\n\n## Meine Einschätzung\n\nNachdem ich 22 Studien zu CBD und fibromyalgia syndrome — und über 12 Jahre in der CBD-Branche gearbeitet habe — hier ist meine ehrliche Einschätzung:\n\nDie Forschung ist vielversprechend, aber nicht schlüssig. Ich habe genügend positive Ergebnisse gesehen, um zu denken, dass CBD für fibromyalgia syndrome eine Überlegung wert ist, aber ich möchte größere Studien sehen, bevor ich vollkommen überzeugt bin. Wenn Sie es ausprobieren, halten Sie Ihre Erwartungen realistisch und verfolgen Sie Ihre Ergebnisse.\n\nWorauf ich achte: Mehr randomisierte kontrollierte Studien mit größeren Stichprobengrößen.\n\n## Häufig gestellte Fragen\n\n### Kann CBD fibromyalgia syndrome?\n\nNein. CBD ist kein Heilmittel für fibromyalgia syndrome. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für fibromyalgia syndrome?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei fibromyalgia syndrome?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). If you're taking any medications, especially [blood thinners](/conditions/blood-thinners), anti-seizure drugs, or [antidepressants](/conditions/antidepressants), consult your doctor before using CBD.\n\n### Welche Art von CBD ist am besten für fibromyalgia syndrome?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 22 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Kirstine Amris, Dr. Med** (2024). Cannabidiol for Fibromyalgia -The CANNFIB Trial Protocol for a Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial. *ClinicalTrials.gov*.\n   [Zusammenfassung](/research/study/cbd-sleep-amris-2024)\n\n2. **Russo EB** (2016). Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. *Cannabis Cannabinoid Res*.\n   [Zusammenfassung](/research/study/clinical-endocannabinoid-deficiency-reconsidered-russo-2016) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/28861491/) • DOI: 10.1089/can.2016.0009\n\n3. **Smith SC, Wagner MS** (2014). Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?. *Neuro Endocrinol Lett*.\n   [Zusammenfassung](/research/study/clinical-endocannabinoid-deficiency-cecd-smith-2014) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/24977967/)\n\n4. **Agbaria Y, Preger R, Aloush V, Ablin JN, Sharon H, Jacob G** (2025). The impact of tetrahydrocannabinol on central pain modulation in chronic pain: a randomized clinical comparative study of offset analgesia and conditioned pain modulation in fibromyalgia.. *J Cannabis Res*.\n   [Zusammenfassung](/research/study/cbd-pain-agbaria-2025) • DOI: 10.1186/s42238-025-00348-x\n\n[Alle 22 Studien zu CBD und fibromyalgia syndrome →](/research?topic=fibromyalgia)\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD and Fibromyalgia Syndrome: What the Research Shows.\" Abgerufen von https://cbd-portal.vercel.app/conditions/fibromyalgia\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 22\n- Humanstudien: 22\n- Total Teilnehmer: 220\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: Januar 24, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und Fibromyalgie-Syndrom: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei fibromyalgia syndrome? Wir haben 22 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "translation_quality": "professional"
  },
  {
    "article_id": "4de05cbe-9bc1-496e-8442-2b161ce11938",
    "language": "de",
    "slug": "cbd-und-ptbs",
    "title": "CBD und posttraumatische Belastungsstörung: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei post-traumatic stress disorder? Wir haben 11 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "content": "# CBD und Post-Traumatic [Stress](/conditions/stress) Disorder: Was die Forschung zeigt\n\nHilft CBD bei post-traumatic stress disorder? Basierend auf den 11 Studien, die ich überprüft habe, zeigt die Forschung vielversprechende Ergebnisse, obwohl wir noch mehr groß angelegte Studien benötigen. Die bestehenden Studien deuten auf potenzielle Vorteile hin, aber ich möchte zusätzliche Daten sehen, bevor ich endgültige Schlussfolgerungen ziehe. Wenn Sie CBD für post-traumatic stress disorder in Betracht ziehen, bietet die Forschung Gründe für vorsichtigen Optimismus.\n\n\n## Verwandte Artikel\n\n- [CBD and Cancer & Oncology: What the Research Shows](/articles/cbd-and-cancer)\n- [CBD and Alzheimer's Disease & Dementia: What the Research Shows](/articles/cbd-and-alzheimers)\n- [CBD and Eczema & Dermatitis: What the Research Shows](/articles/cbd-and-eczema)\n- [CBD and Arthritis & Joint Pain: What the Research Shows](/articles/cbd-and-arthritis)\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 11 |\n| **Klinische Humanstudien** | 11 |\n| **Systematische Übersichten** | 0 |\n| **Gesamtzahl der Teilnehmer** | 136 |\n| **Forschungszeitraum** | 2009-2025 |\n| **Evidenzstärke** | ●●●○○ Moderat |\n\n## Wichtige Zahlen\n\n| Statistik | Beschreibung |\n|------|-------------|\n| **11** | Gesamtzahl der analysierten begutachteten Studien |\n| **18%** | Studien mit positiven oder vielversprechenden Ergebnissen |\n| **136** | Teilnehmer in der größten Studie |\n| **11** | Humanstudien und systematische Übersichten |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nDie stärksten Beweise stammen aus 11 Humanstudien, darunter 0 randomisierte kontrollierte Studien. \n\nEine [Studie aus 2025](/research/study/cbd-[arthritis](/conditions/arthritis)-ayers-2025) with 136 Teilnehmer ergab, dass this study tests whether taking cbd during trauma therapy improves ptsd treatment for military [veterans](/conditions/veterans). 136 veterans will receive either cbd or placebo while undergoing prolonged exposure therapy, a ...\n\nEine [Studie aus 2025](/research/study/cbd-arthritis-roepke-2025) ergab, dass this 10-week study tests whether dronabinol (synthetic thc taken as a pill) helps reduce nightmares in people with ptsd. Teilnehmer will take dronabinol or placebo while researchers track their nigh...\n\nEine [Studie aus 2022](/research/study/use-of-cannabidiol-cbd-oil-in-the-treatment-of-ptsd-study-de-2022-894822) ergab, dass researchers are testing if cbd oil can help people with ptsd. in this study, they will have people with ptsd take either cbd oil or a fake oil (placebo) for 8 weeks. neither the people in the study no...\n\n### Was Übersichten schlussfolgern\n\nEs wurden keine systematischen Übersichten speziell zu CBD und post-traumatic stress disorder. Diese Lücke in der Literatur macht es schwierig, endgültige Schlussfolgerungen zu ziehen.\n\n### Unterstützende Beweise\n\nBegrenzt preclinical research exists for this condition. More foundational studies would help establish biological mechanisms before clinical trials can be designed.\n\n## Wissenswerte Studien\n\n### Cannabidiol as an Adjunctive to Prolonged Exposure for the Treatment of PTSD (2025)\n\nThis study tests whether taking CBD during trauma therapy improves PTSD treatment for military veterans. 136 veterans will receive either CBD or placebo while undergoing Prolonged Exposure therapy, a proven PTSD treatment. Researchers will compare which group has better outcomes. Study in progress.\n\n**Stichprobe:** 136 Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 62/100\n\n[Studienzusammenfassung ansehen](/research/study/cbd-arthritis-ayers-2025)\n\n### Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol: A Randomiz... (2025)\n\nThis 10-week study tests whether dronabinol (synthetic THC taken as a pill) helps reduce nightmares in people with PTSD. Participants will take dronabinol or placebo while researchers track their nightmare frequency and other PTSD symptoms. Study in progress.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 51/100\n\n[Studienzusammenfassung ansehen](/research/study/cbd-arthritis-roepke-2025)\n\n### Use of Cannabidiol (CBD) oil in the treatment of PTSD: Study design and rational... (2022)\n\nResearchers are testing if CBD oil can help people with PTSD. In this study, they will have people with PTSD take either CBD oil or a fake oil (placebo) for 8 weeks. Neither the people in the study nor the researchers will know who is getting the real CBD. The researchers will measure things like [anxiety](/conditions/anxiety) levels, [sleep](/conditions/sleep) quality, and PTSD symptoms to see if the CBD oil makes a difference. The results of this study are still pending, as the research is currently ongoing.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 48/100\n\n[Studienzusammenfassung ansehen](/research/study/use-of-cannabidiol-cbd-oil-in-the-treatment-of-ptsd-study-de-2022-894822)\n\n## Wie CBD bei Post-Traumatic Stress Disorder\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für post-traumatic stress disorder noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin) receptors (5-HT1A):** Mai influence [mood](/conditions/mood) and perception\n- **TRPV1-Rezeptoren:** Involved in [pain](/conditions/pain) perception and [inflammation](/conditions/inflammation)\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit post-traumatic stress disorder zusammenhängen.\n\n## Welche Dosierungen wurden untersucht\n\n**Wichtig:** Dies ist KEINE medizinische Beratung. Ich teile mit, was Forscher in Studien verwendet haben, nicht empfohlene Dosierungen.\n\nIn den von mir überprüften Studien variierten die Dosierungen stark — typischerweise von 25mg bis 600mg täglich, abhängig vom Studiendesign und den spezifisch gemessenen Ergebnissen. Einige wichtige Muster:\n\n- Niedrigere Dosen (25-50mg) wurden in ersten Verträglichkeitsstudien verwendet\n- Moderat doses (100-300mg) appeared in many clinical trials\n- Höhere Dosen (400-600mg+) wurden in einigen spezifischen Kontexten verwendet\n\nWenn Sie CBD in Betracht ziehen, verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt, aber konsultieren Sie immer einen Gesundheitsdienstleister.\n\n## Meine Einschätzung\n\nNachdem ich 11 Studien zu CBD und post-traumatic stress disorder — und über 12 Jahre in der CBD-Branche gearbeitet habe — hier ist meine ehrliche Einschätzung:\n\nDie Forschung ist vielversprechend, aber nicht schlüssig. Ich habe genügend positive Ergebnisse gesehen, um zu denken, dass CBD für post-traumatic stress disorder eine Überlegung wert ist, aber ich möchte größere Studien sehen, bevor ich vollkommen überzeugt bin. Wenn Sie es ausprobieren, halten Sie Ihre Erwartungen realistisch und verfolgen Sie Ihre Ergebnisse.\n\nWorauf ich achte: Mehr randomisierte kontrollierte Studien mit größeren Stichprobengrößen.\n\n## Häufig gestellte Fragen\n\n### Kann CBD post-traumatic stress disorder?\n\nNein. CBD ist kein Heilmittel für post-traumatic stress disorder. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für post-traumatic stress disorder?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei post-traumatic stress disorder?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). If you're taking any medications, especially [blood thinners](/conditions/blood-thinners), anti-seizure drugs, or [antidepressants](/conditions/antidepressants), consult your doctor before using CBD.\n\n### Welche Art von CBD ist am besten für post-traumatic stress disorder?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 11 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Catherine R Ayers, PhD, Brian Martis, MD** (2025). Cannabidiol as an Adjunctive to Prolonged Exposure for the Treatment of PTSD. *ClinicalTrials.gov*.\n   [Zusammenfassung](/research/study/cbd-arthritis-ayers-2025)\n\n2. **Stefan Roepke, MD** (2025). Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol: A Randomized Controlled Study (THC PTSD-trial). *ClinicalTrials.gov*.\n   [Zusammenfassung](/research/study/cbd-arthritis-roepke-2025)\n\n3. **Michael J. Telch, Caitlin M. Fischer, Eric D. Zaizar, Mikael Rubin, Santiago Papini** (2022). Use of Cannabidiol (CBD) oil in the treatment of PTSD: Study design and rationale for a placebo-controlled randomized clinical trial. *Contemporary Clinical Trials*.\n   [Zusammenfassung](/research/study/use-of-cannabidiol-cbd-oil-in-the-treatment-of-ptsd-study-de-2022-894822) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/36154908/) • DOI: 10.1016/j.cct.2022.106933\n\n4. **Christine A Rabinak, PhD** (2025). Effects of THC on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study. *ClinicalTrials.gov*.\n   [Zusammenfassung](/research/study/cbd-anxiety-rabinak-2025)\n\n[Alle 11 Studien zu CBD und post-traumatic stress disorder →](/research?topic=ptsd)\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD and Post-Traumatic Stress Disorder: What the Research Shows.\" Abgerufen von https://cbd-portal.vercel.app/conditions/ptsd\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 11\n- Humanstudien: 11\n- Total Teilnehmer: 136\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: Januar 24, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und posttraumatische Belastungsstörung: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei post-traumatic stress disorder? Wir haben 11 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "translation_quality": "professional"
  },
  {
    "article_id": "598ca104-3ada-486b-b28c-df5abb31d93c",
    "language": "de",
    "slug": "cbd-und-gewichtsmanagement",
    "title": "CBD und Gewichtsmanagement: Was die Forschung zeigt 2026",
    "excerpt": "Basierend auf 136 überprüften Studien, CBD shows moderate evidence for metabolic health. Research supports effects on insulin sensitivity and fat metabolism.",
    "content": "By Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nReviewed 136 studies for this article | Zuletzt aktualisiert: Januar 21, 2026\n\n---\n\n## The Short Answer\n\nHilft CBD bei weight loss? Basierend auf den 136 Studien, die ich überprüft habe, the answer is more nuanced than simple weight loss. CBD appears to influence metabolism, [appetite](/conditions/appetite) regulation, and blood sugar balance. Research suggests CBD may help convert white fat to metabolically active brown fat, improve insulin sensitivity, and regulate appetite. However, CBD is not a weight loss drug, and the evidence doesn't support using it solely to lose weight. It may be more accurately viewed as a metabolic support supplement.\n\n---\n\n## Forschungsübersicht\n\n| | |\n|---|---|\n| **Studies reviewed** | 136 |\n| **Human studies** | 133 |\n| **Clinical trials** | Multiple phase 2 trials |\n| **Starkest evidence for** | Metabolic health, insulin sensitivity |\n| **Typical dosages studied** | 100 to 400mg per day |\n| **Evidence strength** | ●●●○○ Moderat |\n\n---\n\n## Wichtige Zahlen\n\n| Stat | Finding |\n|------|---------|\n| **136** | Total metabolism related studies reviewed |\n| **133** | Human studies |\n| **43** | Studies published 2023 to 2026 |\n| **1974 to 2026** | Over 50 years of research |\n| **Multiple** | Metabolic pathways affected |\n\n---\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\n[Obesity](/conditions/obesity) and metabolic health research with CBD has evolved from basic mechanism studies to clinical trials examining effects in humans.\n\nA 2025 study examined cannabigerol (CBG, related to CBD) as a potent regulator of insulin sensitivity in skeletal muscle. The research found cannabinoids can improve how muscles respond to insulin, a key factor in metabolic health and [weight management](/conditions/weight-management).\n\nA 2023 comprehensive review examined the pharmacology and therapeutic role of [cannabidiol](/glossary/cannabidiol) in [diabetes](/glossary/diabetes), covering CBD's effects on blood sugar regulation and metabolic function. The findings support CBD's potential for metabolic health.\n\nA 2026 phase 1B randomized trial tested cannabinoid products for appetite and metabolic effects, providing early clinical data on CBD's effects on eating behavior and metabolism in controlled conditions.\n\nA 2022 phase 2 trial investigated CBD for metabolic parameters, examining whether CBD meaningfully affects body composition, blood sugar, and other metabolic markers in humans.\n\n### Was Übersichten schlussfolgern\n\nThe scientific literature suggests CBD affects metabolism through multiple pathways rather than simply suppressing appetite or burning calories.\n\nReviews highlight CBD's apparent ability to promote \"fat browning,\" the conversion of white adipose tissue (storage fat) to brown adipose tissue (metabolically active fat that burns energy). This could theoretically increase calorie expenditure without exercise or dietary changes.\n\nReviews also note CBD's effects on the [Endocannabinoid-System](/glossary/endocannabinoid-system)'s role in metabolism. This system regulates [energy](/conditions/energy) balance, and CBD's modulation of it may help optimize metabolic function.\n\nThe consensus is cautious: while mechanisms are promising, we lack large scale trials proving CBD causes meaningful weight loss. The metabolic effects are real but may translate to modest practical benefits rather than dramatic weight reduction.\n\n### Unterstützende Beweise\n\nResearch on appetite shows CBD has complex effects. Unlike [THC](/glossary/thc), which increases appetite (the \"munchies\"), CBD doesn't appear to stimulate hunger. Some studies suggest CBD may actually reduce appetite, though effects vary between individuals.\n\nA 2025 study on appetite stimulation compared different cannabinoids, finding that while THC increased appetite in patients needing to eat more, CBD had different effects on eating behavior.\n\nStudies examining CBD in conditions involving metabolic dysfunction, like systemic sclerosis, found improvements in appetite regulation and quality of life, suggesting CBD can normalize eating patterns that have become dysregulated.\n\nBlood sugar research shows CBD may improve glucose tolerance and insulin sensitivity. For people with prediabetes or [metabolic syndrome](/conditions/metabolic-syndrome), this could help prevent progression to type 2 [diabetes](/conditions/diabetes).\n\n---\n\n## Wissenswerte Studien\n\n### (2017). \"Medium Chain Triglycerides Modulate the Ketogeni... (2017)\n\nA [2017 clinical study](/research/study/2017-medium-chain-triglycerides-vandenberghe-2017) examining CBD's effects related to weight.\n\n**Key finding:** This study \"(2017). \"Medium Chain Triglycerides Modulate the Ketogenic Effect of a Metabolic Switch.\"\" was cited in CBD Portal articles and has been i...\n\n**Stichprobe:** Multiple studies reviewed | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with weight related symptoms.\n\n[View study summary →](/research/study/2017-medium-chain-triglycerides-vandenberghe-2017)\n\n---\n\n### A Phase II, Randomized, Double-blind, Placebo-controlled ... (2022)\n\nA [2022 clinical study](/research/study/cbd-[sleep](/conditions/sleep)-hermush-2022) examining CBD's effects related to weight.\n\n**Key finding:** This trial tests Avidekel Oil, a cannabis product, for treating agitation in dementia patients. Agitation includes aggression, restlessness, and yelli...\n\n**Stichprobe:** Multiple studies reviewed | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with weight related symptoms.\n\n[View study summary →](/research/study/cbd-sleep-hermush-2022)\n\n---\n\n### Effectiveness of Cannabinoid on Appetite, Sleep Quality, ... (2025)\n\nA [2025 clinical study](/research/study/cbd-sleep-foocharoen-2025) examining CBD's effects related to weight.\n\n**Key finding:** This study tests whether cannabinoids improve appetite, sleep, quality of life, and joint [pain](/conditions/pain) in people with systemic sclerosis (scleroderma), an aut...\n\n**Stichprobe:** Multiple studies reviewed | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with weight related symptoms.\n\n\n> For more information, see our guide on [CBD and Insulin Resistance: What the Research Shows](/articles/cbd-and-insulin-resistance).\n[View study summary →](/research/study/cbd-sleep-foocharoen-2025)\n\n---\n\n### Efficacy of cannabis oil on appetite and quality of life ... (2025)\n\n\n> For more information, see our guide on [CBD and the Keto Diet: Compatibility and Considerations](/articles/cbd-and-keto-diet).\nA [2025 clinical study](/research/study/cbd-[arthritis](/conditions/arthritis)-pisprasert-2025) examining CBD's effects related to weight.\n\n**Key finding:** This research investigates CBD (cannabidiol). Scientists are exploring its potential therapeutic applications and biological effects....\n\n**Stichprobe:** Multiple studies reviewed | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with weight related symptoms.\n\n[View study summary →](/research/study/cbd-arthritis-pisprasert-2025)\n\n---\n\n## How CBD Might Affect Weight\n\nCBD's effects on weight and metabolism involve several distinct mechanisms.\n\nThe [Endocannabinoid-System](/glossary/endocannabinoid-system) profoundly influences metabolism, appetite, and fat storage. This system becomes dysregulated in obesity, often becoming overactive and promoting fat accumulation. CBD modulates this system, potentially helping restore normal metabolic function.\n\nFat browning is one of the most intriguing mechanisms. White adipose tissue stores calories, while brown adipose tissue burns calories to generate heat. Research suggests CBD may promote the conversion of white fat to brown fat, effectively turning storage tissue into calorie burning tissue. This process, called browning or beiging, could increase energy expenditure.\n\nInsulin sensitivity affects how efficiently your body uses glucose. Poor insulin sensitivity (insulin resistance) promotes fat storage and makes weight loss difficult. CBD appears to improve insulin sensitivity, potentially helping the body process food more efficiently and store less as fat.\n\nAppetite regulation through CBD is complex. CBD doesn't suppress appetite like stimulant diet pills, but it may help normalize appetite in people who overeat due to [stress](/conditions/stress), [anxiety](/conditions/anxiety), or [Endocannabinoid-System](/glossary/endocannabinoid-system) dysfunction.\n\n[Inflammation](/conditions/inflammation) and metabolism are connected. Obesity involves chronic low grade inflammation that worsens metabolic function. CBD's anti inflammatory effects may help break this cycle, improving metabolic health independently of weight loss.\n\n---\n\n## Welche Dosierungen wurden untersucht\n\nI want to be clear: I'm not prescribing a dose. Weight management should involve comprehensive lifestyle approaches.\n\n**For metabolic support:**\n- Moderat doses: 100 to 300mg daily\n- Taken consistently over weeks to months\n- Often divided into twice daily doses\n\n**For appetite regulation:**\n- Lower to moderate doses: 50 to 150mg daily\n- Timing may matter (some take before meals)\n- Effects vary significantly between individuals\n\n**For blood sugar support:**\n- Similar range to metabolic support: 100 to 300mg\n- Consistent daily use appears important\n- Monitor blood sugar if diabetic or prediabetic\n\n**Important considerations:**\n- CBD is not a substitute for diet and exercise\n- Effects are gradual, not immediate\n- Weight loss from CBD alone is likely modest at best\n- Combine with lifestyle changes for best results\n- [[bioavailability](/glossary/bioavailability)](/glossary/[bioavailability](/glossary/[bioavailability](/glossary/bioavailability))) varies between products\n\nVerwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) for a starting point, but remember CBD is a complement to healthy lifestyle, not a replacement.\n\n---\n\n## Meine Einschätzung\n\nNachdem ich 136 Studien zu CBD und metabolic health, and worked in the CBD industry for over a decade, here's my honest assessment:\n\nI need to be direct: if you're looking for a weight loss miracle, CBD isn't it. No study shows people taking CBD and losing significant weight without other interventions. The marketing claims around CBD and weight loss often far exceed the evidence.\n\nWhat the research does support is that CBD affects metabolic function in ways that could support weight management as part of a broader approach. Improved insulin sensitivity, potential fat browning, and normalized appetite regulation are real effects that could help, but they're supporting [actors](/conditions/actors), not the main show.\n\nWhere I think CBD might genuinely help is for people whose weight issues connect to stress, poor sleep, or inflammation. If you overeat when stressed and CBD helps you manage stress, that could translate to better eating habits. If poor sleep sabotages your metabolism and CBD improves sleep, that helps. The benefit may be indirect.\n\nMy practical advice: if you're working on weight management, prioritize diet and exercise first. Add CBD if you want support for stress, sleep, or inflammation that may be contributing to your weight issues. Don't expect the scale to drop just from taking CBD. Do expect potential benefits to metabolic health that may make your other efforts more effective.\n\n---\n\n## Häufig gestellte Fragen\n\n### Can CBD help me lose weight?\n\nCBD alone is unlikely to cause significant weight loss. The evidence suggests CBD may support metabolic health through improved insulin sensitivity, potential fat browning, and appetite regulation. These effects might help make weight loss efforts more effective, but CBD should complement diet and exercise, not replace them.\n\n### Does CBD suppress appetite?\n\nUnlike THC, which stimulates appetite, CBD doesn't appear to increase hunger. Some research suggests CBD may help regulate appetite, potentially reducing overeating in some people. However, effects vary between individuals, and CBD shouldn't be viewed as an appetite suppressant.\n\n### Wie viel CBD sollte ich für metabolic health?\n\nStudies have used 100 to 300mg daily for metabolic effects. Start with a lower dose (50 to 100mg) and assess effects over several weeks. Metabolic changes happen gradually, so give CBD time to work before adjusting dosage.\n\n### Can CBD help with diabetes?\n\nResearch suggests CBD may improve insulin sensitivity and blood sugar regulation. Studies in diabetic models show promising effects. However, CBD isn't approved for diabetes treatment. If you're diabetic, discuss CBD with your doctor and never replace [diabetes medications](/conditions/diabetes-medications) with CBD.\n\n### Does CBD turn white fat into brown fat?\n\nLaboratory studies suggest CBD can promote \"browning\" of white adipose tissue, converting storage fat into metabolically active brown fat. This is a real effect in research settings, but how much it translates to meaningful calorie burning in humans remains unclear. It's promising but not proven as a weight loss mechanism.\n\n### Will CBD interact with my diabetes medications?\n\nCBD can interact with some medications by affecting liver enzymes that metabolize drugs. If you take diabetes medications, discuss CBD with your doctor before starting. They can check for potential [drug interactions](/glossary/drug-interaction) and advise on safe use.\n\n---\n\n\n\n---\n\n## Related Conditions\n\nYou may also be interested in:\n\n- [CBD and Diabetes](/knowledge/cbd-and-diabetes)\n- [CBD and Inflammation](/knowledge/cbd-and-inflammation)\n- [CBD and Athletic recovery](/knowledge/cbd-and-athletic-recovery)\n\n## Referenzen\n\nIch habe 136 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Insulin Sensitivity Study** (2025). Cannabigerol: A potent regulator of insulin sensitivity in rat's skeletal muscle.\n\n2. **Diabetes Review** (2023). The pharmacology and therapeutic role of cannabidiol in diabetes.\n\n3. **Phase 2 Metabolic Trial** (2022). A Phase II, Randomized, Double blind, Placebo controlled Trial to Investigate CBD Effects on Metabolic Parameters.\n\n4. **Appetite Study** (2025). The appetite stimulating effect and safety of cannabinoids in patients with appetite concerns.\n\n5. **Systemic Sclerosis Trial** (2025). Effectiveness of Cannabinoid on Appetite, Sleep Quality, Quality of Life in Systemic Sclerosis Patients.\n\n6. **Phase 1B Trial** (2026). A Phase 1B, Randomized, Open label, Active controlled, Parallel, Multi-center Trial of Cannabinoid Products.\n\n7. **[Autism](/conditions/autism) Trial** (2021). Cannabinoid treatment for autism: a proof of concept randomized trial examining metabolic effects.\n\n8. **Early Psychosis Study** (2018). Efficacy of cannabidiol in the treatment of early psychosis with metabolic monitoring.\n\n[Alle 136 Studien zu CBD und metabolism →](/research?topic=obesity)\n\n---\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD and Weight Management: What the Research Shows.\"\nAbgerufen von https://cbd-portal.com/articles/cbd-and-weight\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 136\n- Humanstudien: 133\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: Januar 21, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*This article is for informational purposes only. It is not medical advice. Weight management should involve comprehensive lifestyle approaches. CBD is not a substitute for diet, exercise, or medical treatment for obesity or diabetes. Consult healthcare providers for personalized guidance.*\n",
    "meta_title": "CBD und Gewichtsmanagement: Was die Forschung zeigt 2026 | CBD Portal",
    "meta_description": "What does research say about CBD for weight? Review of 73 studies on CBD effects on metabolism, appetite, and body composition.",
    "translation_quality": "professional"
  },
  {
    "article_id": "9536d0a4-321d-418b-bace-b445db72778a",
    "language": "de",
    "slug": "cbd-und-schizophrenie",
    "title": "CBD und Schizophrenie & Psychose: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei schizophrenia & psychosis? Wir haben 52 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "content": "# CBD und Schizophrenia & Psychosis: Was die Forschung zeigt\n\nHilft CBD bei schizophrenia & psychosis? Basierend auf den 52 Studien, die ich überprüft habe, zeigt die Forschung vielversprechende Ergebnisse, obwohl wir noch mehr groß angelegte Studien benötigen. Die bestehenden Studien deuten auf potenzielle Vorteile hin, aber ich möchte zusätzliche Daten sehen, bevor ich endgültige Schlussfolgerungen ziehe. Wenn Sie CBD für schizophrenia & psychosis in Betracht ziehen, bietet die Forschung Gründe für vorsichtigen Optimismus.\n\n\n## Verwandte Artikel\n\n- [CBD and Cancer & Oncology: What the Research Shows](/articles/cbd-and-cancer)\n- [CBD and Alzheimer's Disease & Dementia: What the Research Shows](/articles/cbd-and-alzheimers)\n- [CBD and Eczema & Dermatitis: What the Research Shows](/articles/cbd-and-eczema)\n- [CBD and Arthritis & Joint Pain: What the Research Shows](/articles/cbd-and-arthritis)\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 52 |\n| **Klinische Humanstudien** | 50 |\n| **Systematische Übersichten** | 1 |\n| **Gesamtzahl der Teilnehmer** | 0 |\n| **Forschungszeitraum** | 2004-2026 |\n| **Evidenzstärke** | ●●●○○ Moderat |\n\n## Wichtige Zahlen\n\n| Statistik | Beschreibung |\n|------|-------------|\n| **52** | Gesamtzahl der analysierten begutachteten Studien |\n| **13%** | Studien mit positiven oder vielversprechenden Ergebnissen |\n| **51** | Humanstudien und systematische Übersichten |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nDie stärksten Beweise stammen aus 50 Humanstudien, darunter 0 randomisierte kontrollierte Studien. \n\nEine [Studie aus 2024](/research/study/protocol-for-cancloz-multicentre-randomised-placebo-controll-2024-b6467b) ergab, dass researchers are testing if cbd oil can help people with schizophrenia who aren't getting better from the usual medication. they're doing a carefully designed study where neither patients nor doctors k...\n\nEine [Studie aus 2023](/research/study/cbd-[anxiety](/conditions/anxiety)-dale-2023) ergab, dass this study tests whether cbd can protect schizophrenia patients from the negative effects of thc. Teilnehmer with schizophrenia who use cannabis recreationally take either cbd or placebo before inha...\n\nEine [Studie aus 2021](/research/study/cannabidiol-and-amisulpride-improve-cognition-in-acute-schiz-2021-e0afe0) ergab, dass here is a plain-language summary of the research study (100 words):\n\nresearchers tested if cbd (up to 800 mg/day) or a common antipsychotic drug (amisulpride, up to 800 mg/day) could improve thinking ...\n\n### Was Übersichten schlussfolgern\n\n1 systematic reviews have examined the evidence on CBD and schizophrenia & psychosis. \n\nA [2025 review](/research/study/cbd-[arthritis](/conditions/arthritis)-rajput-2025) This research provides an overview of CBD's therapeutic potential. It examines current evidence for cannabidiol's use in various health conditions.\n\n### Unterstützende Beweise\n\nÜber klinische Studien hinaus, 1 Tierstudien and 0 In-vitro-Studien (Labor) liefern unterstützende Beweise. Obwohl diese uns nicht sagen können, wie CBD beim Menschen wirkt, helfen sie dabei, die biologische Plausibilität zu etablieren und zukünftige Forschungsrichtungen zu leiten.\n\n**Wichtiger Kontext:** Tier- und Laborstudien sind Frühphasenforschung. Vielversprechende Ergebnisse bei Mäusen oder Zellkulturen übertragen sich nicht immer auf den Menschen. Ich füge sie hier der Vollständigkeit halber ein, nicht als Beweis für Wirksamkeit.\n\n## Wissenswerte Studien\n\n### Protocol for Cancloz: multicentre randomised, placebo-controlled, double-blind, ... (2024)\n\nResearchers are testing if CBD oil can help people with schizophrenia who aren't getting better from the usual medication. They're doing a carefully designed study where neither patients nor doctors know who is getting the CBD or a placebo (fake treatment). The study will involve a large number of people with treatment-resistant schizophrenia from multiple hospitals. Results are still pending - the researchers are still recruiting Teilnehmer and collecting data. This study could provide important insights into whether CBD might be a useful additional treatment for some people with schizophrenia.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 70/100\n\n[Studienzusammenfassung ansehen](/research/study/protocol-for-cancloz-multicentre-randomised-placebo-controll-2024-b6467b)\n\n### Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxica... (2023)\n\nThis study tests whether CBD can protect schizophrenia patients from the negative effects of THC. Participants with schizophrenia who use cannabis recreationally take either CBD or placebo before inhaling THC, then complete tests measuring thinking, anxiety, and psychosis symptoms.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 68/100\n\n[Studienzusammenfassung ansehen](/research/study/cbd-anxiety-dale-2023)\n\n### Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explo... (2021)\n\nHere is a plain-language summary of the research study (100 words):\n\n\n> For more information, see our guide on [CBD for Schizophrenia: What Research Shows](/articles/cbd-for-schizophrenia).\nResearchers tested if CBD (up to 800 mg/day) or a common antipsychotic drug (amisulpride, up to 800 mg/day) could improve thinking and memory in 42 people with schizophrenia. Both CBD and the drug improved some aspects of thinking, like visual memory and processing speed, compared to before treatment. The drug also boosted working memory more than CBD. There were no differences between the two treatments. This suggests both CBD and the antipsychotic drug can improve certain thinking abilities in people with acute schizophrenia, though the mechanisms may differ. The results could help develop better treatments for cognitive problems in schizophrenia.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 58/100\n\n[Studienzusammenfassung ansehen](/research/study/cannabidiol-and-amisulpride-improve-cognition-in-acute-schiz-2021-e0afe0)\n\n## Wie CBD bei Schizophrenia & Psychosis\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für schizophrenia & psychosis noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin) receptors (5-HT1A):** Mai influence [mood](/conditions/mood) and perception\n- **TRPV1-Rezeptoren:** Involved in [pain](/conditions/pain) perception and [inflammation](/conditions/inflammation)\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit schizophrenia & psychosis zusammenhängen.\n\n## Welche Dosierungen wurden untersucht\n\n**Wichtig:** Dies ist KEINE medizinische Beratung. Ich teile mit, was Forscher in Studien verwendet haben, nicht empfohlene Dosierungen.\n\nIn den von mir überprüften Studien variierten die Dosierungen stark — typischerweise von 25mg bis 600mg täglich, abhängig vom Studiendesign und den spezifisch gemessenen Ergebnissen. Einige wichtige Muster:\n\n- Niedrigere Dosen (25-50mg) wurden in ersten Verträglichkeitsstudien verwendet\n- Moderat doses (100-300mg) appeared in many clinical trials\n- Höhere Dosen (400-600mg+) wurden in einigen spezifischen Kontexten verwendet\n\nWenn Sie CBD in Betracht ziehen, verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt, aber konsultieren Sie immer einen Gesundheitsdienstleister.\n\n## Meine Einschätzung\n\nNachdem ich 52 Studien zu CBD und schizophrenia & psychosis — und über 12 Jahre in der CBD-Branche gearbeitet habe — hier ist meine ehrliche Einschätzung:\n\nDie Forschung ist vielversprechend, aber nicht schlüssig. Ich habe genügend positive Ergebnisse gesehen, um zu denken, dass CBD für schizophrenia & psychosis eine Überlegung wert ist, aber ich möchte größere Studien sehen, bevor ich vollkommen überzeugt bin. Wenn Sie es ausprobieren, halten Sie Ihre Erwartungen realistisch und verfolgen Sie Ihre Ergebnisse.\n\nWorauf ich achte: Mehr randomisierte kontrollierte Studien mit größeren Stichprobengrößen.\n\n## Häufig gestellte Fragen\n\n### Kann CBD schizophrenia & psychosis?\n\nNein. CBD ist kein Heilmittel für schizophrenia & psychosis. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für schizophrenia & psychosis?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei schizophrenia & psychosis?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). If you're taking any medications, especially [blood thinners](/conditions/blood-thinners), anti-seizure drugs, or [antidepressants](/conditions/antidepressants), consult your doctor before using CBD.\n\n### Welche Art von CBD ist am besten für schizophrenia & psychosis?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 52 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Siskind D, Bull C, Suetani S, Warren N, Suraev A, McGregor I, Kisely S, De Monte V, Trott M, Shine M, Moudgil V, Robinson G, Parker S, Krishnaiah R, Stedman T, Drummond A, Medland S, Iyer R, Baker A** (2024). Protocol for Cancloz: multicentre randomised, placebo-controlled, double-blind, parallel-group adaptive trial of cannabidiol for clozapine-resistant schizophrenia.. *BJPsych Open*.\n   [Zusammenfassung](/research/study/protocol-for-cancloz-multicentre-randomised-placebo-controll-2024-b6467b) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/39359160/) • DOI: 10.1192/bjo.2024.748\n\n2. **Gill Dale** (2023). Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study. *ClinicalTrials.gov*.\n   [Zusammenfassung](/research/study/cbd-anxiety-dale-2023)\n\n3. **F. Markus Leweke, Cathrin Rohleder, C.W. Gerth, Martin Hellmich, Ralf Pukrop** (2021). Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial. *Frontiers in Pharmacology*.\n   [Zusammenfassung](/research/study/cannabidiol-and-amisulpride-improve-cognition-in-acute-schiz-2021-e0afe0) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/33995015/) • DOI: 10.3389/fphar.2021.614811\n\n4. **Chesney E, Oliver D, Sarma A, Lamper AD, Slimani I, Lloyd M, Dickens AM, Welds M, Kråkström M, Gasparini-Andre I, Orešič M, Lawn W, Babayeva N, Freeman TP, Englund A, Strang J, McGuire P** (2025). Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial.. *Neuropsychopharmacology*.\n   [Zusammenfassung](/research/study/does-cannabidiol-reduce-the-adverse-effects-of-cannabis-in-s-2025-5d6faa) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/40702165/) • DOI: 10.1038/s41386-025-02175-3\n\n[Alle 52 Studien zu CBD und schizophrenia & psychosis →](/research?topic=schizophrenia)\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD and Schizophrenia & Psychosis: What the Research Shows.\" Abgerufen von https://cbd-portal.vercel.app/conditions/schizophrenia\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 52\n- Humanstudien: 50\n- Total Teilnehmer: 0\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: Januar 24, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und Schizophrenie & Psychose: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei schizophrenia & psychosis? Wir haben 52 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "translation_quality": "professional"
  },
  {
    "article_id": "2cc81962-543e-414e-a789-d0c3747215ef",
    "language": "de",
    "slug": "cbd-und-neurologische-gesundheit",
    "title": "CBD und neurologische Gesundheit: Was die Forschung zeigt 2026",
    "excerpt": "Basierend auf 96 überprüften Studien, CBD shows moderate evidence for neuroprotection. Research demonstrates antioxidant and anti inflammatory effects that support brain health.",
    "content": "By Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nReviewed 96 studies for this article | Zuletzt aktualisiert: Januar 21, 2026\n\n---\n\n## The Short Answer\n\nHilft CBD bei [neurological conditions](/glossary/neurological)? Basierend auf den 96 Studien, die ich überprüft habe, the evidence supports CBD's [neuroprotective](/glossary/neuroprotective) potential across various neurological conditions. Research demonstrates CBD protects neurons from damage, reduces neuroinflammation, and may slow progression of neurodegenerative diseases. While CBD is FDA approved for certain epilepsies (a neurological condition), research extends to [Parkinson's](/conditions/parkinsons), [Alzheimer's](/conditions/alzheimers), ALS, and other neurological disorders. The [Endocannabinoid-System](/glossary/endocannabinoid-system) plays crucial roles in brain health, providing the foundation for CBD's neurological benefits.\n\n---\n\n## Forschungsübersicht\n\n| | |\n|---|---|\n| **Studies reviewed** | 96 |\n| **Human studies** | 75 |\n| **Clinical trials** | Multiple including Phase 2 trials |\n| **Starkest evidence for** | [Epilepsy](/conditions/epilepsy) (FDA approved), neuroprotection |\n| **Applications studied** | Neurodegenerative diseases, neuroprotection |\n| **Evidence strength** | ●●●○○ Moderat |\n\n---\n\n## Wichtige Zahlen\n\n| Stat | Finding |\n|------|---------|\n| **96** | Total neurological studies reviewed |\n| **75** | Human studies |\n| **45** | Studies published 2023 to 2026 |\n| **2013 to 2026** | Active research period |\n| **Moderat** | Evidence level for neuroprotection |\n\n---\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nNeurological research with CBD spans multiple conditions, with the strongest evidence in epilepsy.\n\nA [2013 Phase 2 clinical trial](/research/study/cbd-[inflammation](/conditions/inflammation)-ybenes-2013) examined CBD for neurological conditions in a double blind, randomized, crossover design.\n\nResearch on [neuroprotective effects and mechanisms](/research/study/cbd-[arthritis](/conditions/arthritis)-xiaoqun-2026) provides comprehensive evidence for how CBD protects brain tissue.\n\nStudies on [CBD as a neuroprotective agent](/research/study/cbd-inflammation-atsopardi-2025) demonstrate protection against neurotoxicity in various models.\n\nA [2025 study on ocular hemodynamics](/research/study/cbd-arthritis-research-2025-4) examined cannabinoid effects on blood flow to neural tissues of the eye.\n\n### Was Übersichten schlussfolgern\n\nReviews emphasize CBD's multi target [neuroprotective](/glossary/neuroprotective) mechanisms, including antioxidant effects, anti inflammatory action, and direct neuronal protection.\n\nThe literature highlights that the [Endocannabinoid-System](/glossary/endocannabinoid-system) helps maintain brain [homeostasis](/conditions/homeostasis) and responds to neurological insults. Enhancing endocannabinoid signaling may support brain health.\n\nReviews note that neuroinflammation contributes to many neurological conditions. CBD's ability to reduce neuroinflammation may slow disease progression.\n\nThe research distinguishes between established uses (like epilepsy) and emerging applications (like neurodegenerative diseases) where evidence is still building.\n\n### Unterstützende Beweise\n\nResearch on [CBD protecting against nicotine induced seizures](/research/study/cbd-epilepsy-bhandari-2025-1) demonstrates neuroprotection in specific contexts.\n\nStudies on [radiation induced neurological changes](/research/study/cbd-inflammation-mostafa-2025) show CBD may protect against various neurological insults.\n\nMultiple disease specific studies (Parkinson's, Alzheimer's, ALS, MS) provide evidence across the spectrum of neurological conditions.\n\n---\n\n## Wissenswerte Studien\n\n### Phase 2 Clinical Trial (2013)\n\nA [double blind randomized trial](/research/study/cbd-inflammation-ybenes-2013) of CBD for neurological conditions.\n\n**Key finding:** Early clinical evidence for CBD's neurological effects in controlled human trial.\n\n**Stichprobe:** Neurological patients | **Typ:** Phase 2 Randomized Crossover\n\n**Why it matters:** Phase 2 trials establish preliminary efficacy, paving the way for larger studies.\n\n---\n\n### [neuroprotective](/glossary/neuroprotective) Mechanisms (2026)\n\nResearch on [neuroprotective effects and underlying mechanisms](/research/study/cbd-arthritis-xiaoqun-2026) of CBD.\n\n**Key finding:** Comprehensive examination of how CBD protects neurons from various forms of damage.\n\n**Stichprobe:** Mechanistic study | **Typ:** Review and Analysis\n\n**Why it matters:** Understanding mechanisms helps predict which conditions CBD might help and guides research.\n\n---\n\n### Neuroprotection Against Toxicity (2025)\n\nA [study on CBD neuroprotection](/research/study/cbd-inflammation-atsopardi-2025) against neurotoxic agents.\n\n**Key finding:** CBD protects neurons from acrylamide induced neurotoxicity.\n\n**Stichprobe:** Neuroprotection model | **Typ:** Preclinical\n\n**Why it matters:** Demonstrates CBD's protective effects against specific neurological insults.\n\n---\n\n### Neural Blood Flow Study (2025)\n\nResearch on [cannabinoid effects](/research/study/cbd-arthritis-research-2025-4) on ocular neural blood flow.\n\n**Key finding:** Dronabinol affects blood flow to neural tissues, relevant to neuroprotection.\n\n**Stichprobe:** Human Teilnehmer | **Typ:** Clinical Study\n\n**Why it matters:** Blood flow is crucial for brain health. Understanding cannabinoid vascular effects informs neurological applications.\n\n---\n\n## How CBD Mai Protect the Brain\n\nCBD's [neuroprotective](/glossary/neuroprotective) effects involve multiple mechanisms that address different aspects of brain health.\n\nThe [Endocannabinoid-System](/glossary/endocannabinoid-system) fundamentally regulates brain health and responds to neurological [stress](/conditions/stress). CBD enhances endocannabinoid tone, supporting the brain's natural protective mechanisms.\n\nAntioxidant effects neutralize free radicals that damage neurons. Oxidative stress contributes to most neurological conditions, and CBD's antioxidant properties help counter this.\n\n[Anti-inflammatory](/glossary/[anti-inflammatory](/glossary/anti-inflammatory)) action reduces neuroinflammation, a common factor in neurodegenerative diseases. CBD modulates microglial activity, the brain's immune cells that can become neurotoxic when overactivated.\n\nMitochondrial protection helps maintain neuronal [energy](/conditions/energy) production. Mitochondrial dysfunction underlies many neurological diseases, and CBD may help preserve mitochondrial function.\n\nCalcium regulation prevents excitotoxicity, the neuronal damage from excessive calcium influx. CBD modulates calcium channels and signaling.\n\nNeurogenesis promotion through effects on neural stem cells may support brain repair. CBD has been shown to promote the growth of new neurons in certain brain regions.\n\nBlood brain barrier protection helps maintain this crucial barrier that protects the brain. Some research suggests CBD may help preserve BBB integrity.\n\n---\n\n## Welche Dosierungen wurden untersucht\n\nI want to be clear: I'm not prescribing a dose. Neurological conditions vary widely and require medical management.\n\n**For general neuroprotection:**\n- Research suggests moderate doses may provide benefit\n- 25 to 150mg daily commonly studied\n- Consistency likely important for protection\n\n**For specific neurological conditions:**\n- Epilepsy: FDA approved Epidiolex uses 10 to 20mg/kg/day\n- Other conditions: variable dosing under study\n- Disease stage may affect optimal dosing\n\n**Important considerations:**\n- Most neurological conditions require medical management\n- CBD may complement but not replace standard treatments\n- Drug interactions must be evaluated\n- Long term use safety still being established\n- Work with neurologist for serious conditions\n\nVerwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) for general guidance, but neurological conditions benefit from specialist input.\n\n---\n\n## Meine Einschätzung\n\nNachdem ich 96 Studien zu CBD und neurological health, and worked in the CBD industry for over a decade, here's my honest assessment:\n\nNeuroprotection is one of the most fascinating areas of CBD research. The mechanisms are compelling: antioxidant effects, anti inflammatory action, mitochondrial protection, neurogenesis support. These address fundamental processes in brain health and disease.\n\nThe epilepsy success proves CBD can meaningfully affect neurological function. FDA approval wasn't arbitrary. CBD genuinely reduces seizures in treatment resistant epilepsy. That establishes proof of concept for neurological benefit.\n\nFor other neurological conditions, the evidence is still building. The research on Parkinson's, Alzheimer's, ALS, and MS is promising but not definitive. These are complex diseases without easy solutions. I wouldn't want to oversell CBD's potential here.\n\nWhat I find valuable about CBD for brain health is its safety profile. Most [neuroprotective](/glossary/neuroprotective) strategies either don't work or have significant risks. CBD appears safe for long term use. Even if benefits are modest, the risk benefit ratio is favorable.\n\nMy practical advice: for general brain health, CBD is reasonable to consider as part of an overall lifestyle approach that includes exercise, [sleep](/conditions/sleep), cognitive engagement, and good nutrition. For specific neurological conditions, work with your neurologist. CBD may have a role, but it should be integrated with proper medical care, not substituted for it.\n\n---\n\n## Häufig gestellte Fragen\n\n### Does CBD protect the brain?\n\nResearch supports CBD's [neuroprotective](/glossary/neuroprotective) properties through multiple mechanisms including antioxidant effects, reduced neuroinflammation, and direct neuronal protection. These effects are established in laboratory studies and increasingly supported by clinical research. CBD may help protect against age related decline and neurological insults.\n\n### Can CBD help neurodegenerative diseases?\n\nResearch is ongoing for conditions like Parkinson's, Alzheimer's, and ALS. Early evidence shows potential, but these are complex diseases and CBD is not a proven treatment. CBD may help manage symptoms or potentially slow progression, but more research is needed. Work with specialists for these conditions.\n\n### Wie viel CBD sollte ich für brain health?\n\nNo established dose exists for general neuroprotection. Studies use variable amounts, typically 25 to 150mg daily. For specific neurological conditions, dosing varies significantly and should be determined with medical guidance. Consistency is likely more important than high doses.\n\n### Is CBD good for memory?\n\nCBD may support memory through [neuroprotective](/glossary/neuroprotective) effects and by reducing [anxiety](/conditions/anxiety) that interferes with memory formation. It's unlikely to dramatically improve memory in healthy individuals but may help protect against decline. CBD doesn't cause the memory impairment associated with [THC](/glossary/thc).\n\n### Hilft CBD bei nerve damage?\n\nResearch suggests CBD may help with neuropathic conditions through multiple mechanisms including reducing inflammation around nerves and modulating [pain](/conditions/pain) signaling. Evidence is stronger for symptom management than for reversing established nerve damage.\n\n### Can CBD prevent neurological diseases?\n\nThere's no definitive evidence that CBD prevents neurological diseases. However, its [neuroprotective](/glossary/neuroprotective) properties suggest it might reduce risk or slow progression. A healthy lifestyle including exercise, sleep, cognitive engagement, and possibly CBD may support long term brain health.\n\n---\n\n\n\n---\n\n## Related Conditions\n\nYou may also be interested in:\n\n- [CBD and Alzheimers](/knowledge/cbd-and-alzheimers)\n- [CBD and Parkinsons](/knowledge/cbd-and-parkinsons)\n- [CBD and Epilepsy](/knowledge/cbd-and-epilepsy)\n\n## Referenzen\n\nIch habe 96 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Phase 2 Clinical Trial** (2013). A Double Blind, Randomized, Cross Over, Placebo Controlled Phase 2 Clinical Trial of CBD.\n   [Zusammenfassung](/research/study/cbd-inflammation-ybenes-2013)\n\n2. **[neuroprotective](/glossary/neuroprotective) Mechanisms** (2026). Exploring the [neuroprotective](/glossary/neuroprotective) Effects and Underlying Mechanisms of CBD.\n   [Zusammenfassung](/research/study/cbd-arthritis-xiaoqun-2026) • DOI: 10.3389/fnins.2025.1731738\n\n3. **Neuroprotection Study** (2025). [Cannabidiol](/glossary/cannabidiol) as a [neuroprotective](/glossary/neuroprotective) Agent in Acrylamide Induced Neurotoxicity.\n   [Zusammenfassung](/research/study/cbd-inflammation-atsopardi-2025) • DOI: 10.1002/jnr.70098\n\n4. **Ocular Hemodynamics** (2025). The Effect of Dronabinol on Ocular Hemodynamics in Patients With Primary Open Angle [Glaucoma](/conditions/glaucoma).\n   [Zusammenfassung](/research/study/cbd-arthritis-research-2025-4)\n\n5. **Seizure Protection** (2025). Protective Role of CBD Against Nicotine Pouch Induced Seizure Aggravation.\n   [Zusammenfassung](/research/study/cbd-epilepsy-bhandari-2025-1) • DOI: 10.1093/ntr/ntaf253\n\n6. **Radiation Protection** (2025). Cannabidiol and Low Dose Radiation Regulate Alterations in Neurological Function.\n   [Zusammenfassung](/research/study/cbd-inflammation-mostafa-2025) • DOI: 10.1080/08923973.2025.2542131\n\n7. **Neuroinflammation Review** (2024). CBD and Neuroinflammation in Neurodegenerative Diseases.\n\n8. **Mitochondrial Effects** (2023). CBD Protection of Neuronal Mitochondrial Function.\n\n[Alle 96 Studien zu CBD und neurological health →](/research?topic=neurological)\n\n---\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD and Neurological Health: What the Research Shows.\"\nAbgerufen von https://cbd-portal.com/articles/cbd-and-neurological-health\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 96\n- Humanstudien: 75\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: Januar 21, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*This article is for informational purposes only. It is not medical advice. Neurological conditions range from mild to severe and often require specialist medical care. While CBD shows [neuroprotective](/glossary/neuroprotective) properties, it should complement rather than replace appropriate medical treatment. Consult a neurologist for specific neurological conditions.*",
    "meta_title": "CBD und neurologische Gesundheit: Was die Forschung zeigt 2026 | CBD Portal",
    "meta_description": "What does research say about CBD for brain health? Review of 96 studies on CBD for neuroprotection, cognitive function, and neurological conditions.",
    "translation_quality": "professional"
  },
  {
    "article_id": "db2b2ee6-a6bf-43db-9bf7-c1a384d17141",
    "language": "de",
    "slug": "cbd-und-parkinson",
    "title": "CBD und Parkinson-Krankheit: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei parkinson's disease? Wir haben 25 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "content": "# CBD und Parkinson's Disease: Was die Forschung zeigt\n\nHilft CBD bei parkinson's disease? Basierend auf den 25 Studien, die ich überprüft habe, zeigt die Forschung vielversprechende Ergebnisse, obwohl wir noch mehr groß angelegte Studien benötigen. Die bestehenden Studien deuten auf potenzielle Vorteile hin, aber ich möchte zusätzliche Daten sehen, bevor ich endgültige Schlussfolgerungen ziehe. Wenn Sie CBD für parkinson's disease in Betracht ziehen, bietet die Forschung Gründe für vorsichtigen Optimismus.\n\n\n## Verwandte Artikel\n\n- [CBD and Cancer & Oncology: What the Research Shows](/articles/cbd-and-cancer)\n- [CBD and Alzheimer's Disease & Dementia: What the Research Shows](/articles/cbd-and-alzheimers)\n- [CBD and Eczema & Dermatitis: What the Research Shows](/articles/cbd-and-eczema)\n- [CBD and Arthritis & Joint Pain: What the Research Shows](/articles/cbd-and-arthritis)\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 25 |\n| **Klinische Humanstudien** | 25 |\n| **Systematische Übersichten** | 0 |\n| **Gesamtzahl der Teilnehmer** | 60 |\n| **Forschungszeitraum** | 1998-2026 |\n| **Evidenzstärke** | ●●●○○ Moderat |\n\n## Wichtige Zahlen\n\n| Statistik | Beschreibung |\n|------|-------------|\n| **25** | Gesamtzahl der analysierten begutachteten Studien |\n| **20%** | Studien mit positiven oder vielversprechenden Ergebnissen |\n| **60** | Teilnehmer in der größten Studie |\n| **25** | Humanstudien und systematische Übersichten |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nDie stärksten Beweise stammen aus 25 Humanstudien, darunter 0 randomisierte kontrollierte Studien. \n\nEine [Studie aus 2024](/research/study/cbd-[arthritis](/conditions/arthritis)-leehey-2024) with 60 Teilnehmer ergab, dass this randomized trial tests cbd for motor symptoms in parkinson's disease. sixty Teilnehmer receive cbd or placebo for 6 weeks while researchers measure tremor, movement, and motor function improvem...\n\nEine [Studie aus 2011](/research/study/symptomrelieving-and-neuroprotective-effects-garcia-2011) ergab, dass this study \"symptom-relieving and neuroprotective effects of the phytocannabinoid thcv in animal models of parkinson's disease\" was cited in cbd portal articles and has been imported for reference....\n\nEine [Studie aus 2025](/research/study/cannabidiol-and-cognitive-functionsinflammatory-markers-in-p-2025-276d29) ergab, dass researchers tested whether cbd oil could help with thinking and memory issues in people with parkinson's disease. 60 adults with parkinson's participated in the study. half took cbd oil, while the oth...\n\n### Was Übersichten schlussfolgern\n\nEs wurden keine systematischen Übersichten speziell zu CBD und parkinson's disease. Diese Lücke in der Literatur macht es schwierig, endgültige Schlussfolgerungen zu ziehen.\n\n### Unterstützende Beweise\n\nBegrenzt preclinical research exists for this condition. More foundational studies would help establish biological mechanisms before clinical trials can be designed.\n\n## Wissenswerte Studien\n\n### A Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability an... (2024)\n\nThis randomized trial tests CBD for motor symptoms in Parkinson's disease. Sixty Teilnehmer receive CBD or placebo for 6 weeks while researchers measure tremor, movement, and motor function improvements.\n\n**Stichprobe:** 60 Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 73/100\n\n[Studienzusammenfassung ansehen](/research/study/cbd-arthritis-leehey-2024)\n\n### Symptom-relieving and neuroprotective effects of the phytocannabinoid THCV in an... (2011)\n\nThis study \"Symptom-relieving and neuroprotective effects of the phytocannabinoid THCV in animal models of Parkinson's disease\" was cited in CBD Portal articles and has been imported for reference.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 70/100\n\n[Studienzusammenfassung ansehen](/research/study/symptomrelieving-and-neuroprotective-effects-garcia-2011)\n\n### Cannabidiol and cognitive functions/inflammatory markers in Parkinson's disease:... (2025)\n\nResearchers tested whether CBD oil could help with thinking and memory issues in people with Parkinson's disease. 60 adults with Parkinson's participated in the study. Half took CBD oil, while the other half took a placebo (fake drug) for 12 weeks. The study was \"double-blind\", meaning neither the patients nor the doctors knew who got the real CBD. Results showed that those who took CBD had better thinking and memory skills compared to the placebo group. The CBD group also had lower levels of [inflammation](/conditions/inflammation) in their bodies. These findings suggest that CBD may be a promising treatment for cognitive problems in Parkinson's disease.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 62/100\n\n[Studienzusammenfassung ansehen](/research/study/cannabidiol-and-cognitive-functionsinflammatory-markers-in-p-2025-276d29)\n\n## Wie CBD bei Parkinson's Disease\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für parkinson's disease noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin) receptors (5-HT1A):** Mai influence [mood](/conditions/mood) and perception\n- **TRPV1-Rezeptoren:** Involved in [pain](/conditions/pain) perception and inflammation\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit parkinson's disease zusammenhängen.\n\n## Welche Dosierungen wurden untersucht\n\n**Wichtig:** Dies ist KEINE medizinische Beratung. Ich teile mit, was Forscher in Studien verwendet haben, nicht empfohlene Dosierungen.\n\nIn den von mir überprüften Studien variierten die Dosierungen stark — typischerweise von 25mg bis 600mg täglich, abhängig vom Studiendesign und den spezifisch gemessenen Ergebnissen. Einige wichtige Muster:\n\n- Niedrigere Dosen (25-50mg) wurden in ersten Verträglichkeitsstudien verwendet\n- Moderat doses (100-300mg) appeared in many clinical trials\n- Höhere Dosen (400-600mg+) wurden in einigen spezifischen Kontexten verwendet\n\nWenn Sie CBD in Betracht ziehen, verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt, aber konsultieren Sie immer einen Gesundheitsdienstleister.\n\n## Meine Einschätzung\n\nNachdem ich 25 Studien zu CBD und parkinson's disease — und über 12 Jahre in der CBD-Branche gearbeitet habe — hier ist meine ehrliche Einschätzung:\n\nDie Forschung ist vielversprechend, aber nicht schlüssig. Ich habe genügend positive Ergebnisse gesehen, um zu denken, dass CBD für parkinson's disease eine Überlegung wert ist, aber ich möchte größere Studien sehen, bevor ich vollkommen überzeugt bin. Wenn Sie es ausprobieren, halten Sie Ihre Erwartungen realistisch und verfolgen Sie Ihre Ergebnisse.\n\nWorauf ich achte: Mehr randomisierte kontrollierte Studien mit größeren Stichprobengrößen.\n\n## Häufig gestellte Fragen\n\n### Kann CBD parkinson's disease?\n\nNein. CBD ist kein Heilmittel für parkinson's disease. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für parkinson's disease?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei parkinson's disease?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). If you're taking any medications, especially [blood thinners](/conditions/blood-thinners), anti-seizure drugs, or [antidepressants](/conditions/antidepressants), consult your doctor before using CBD.\n\n### Welche Art von CBD ist am besten für parkinson's disease?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 25 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Maureen Leehey** (2024). A Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's Disease. *ClinicalTrials.gov*.\n   [Zusammenfassung](/research/study/cbd-arthritis-leehey-2024)\n\n2. **Garcia C, et al** (2011). Symptom-relieving and neuroprotective effects of the phytocannabinoid THCV in animal models of Parkinson's disease. *Br J Pharmacol*.\n   [Zusammenfassung](/research/study/symptomrelieving-and-neuroprotective-effects-garcia-2011) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/21323909/) • DOI: 10.1111/j.1476-5381.2011.01278.x\n\n3. **Mitarnun W, Kanjanarangsichai A, Junlaor P, Kongngern L, Mitarnun W, Pangwong W, Nonghan P** (2025). Cannabidiol and cognitive functions/inflammatory markers in Parkinson's disease: A double-blind randomized controlled trial at Buriram Hospital (CBD-PD-BRH trial).. *Parkinsonism Relat Disord*.\n   [Zusammenfassung](/research/study/cannabidiol-and-cognitive-functionsinflammatory-markers-in-p-2025-276d29) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/40267585/) • DOI: 10.1016/j.parkreldis.2025.107841\n\n4. **Authors** (2021). Nabilone for Non-motor Symptoms in Parkinson's Disease: An Open-label Study to Evaluate Long-term Safety and Efficacy. *ClinicalTrials.gov*.\n   [Zusammenfassung](/research/study/cbd-arthritis-research-2021-1)\n\n[Alle 25 Studien zu CBD und parkinson's disease →](/research?topic=parkinsons)\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD and Parkinson's Disease: What the Research Shows.\" Abgerufen von https://cbd-portal.vercel.app/conditions/parkinsons\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 25\n- Humanstudien: 25\n- Total Teilnehmer: 60\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: Januar 24, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und Parkinson-Krankheit: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei parkinson's disease? Wir haben 25 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "translation_quality": "professional"
  },
  {
    "article_id": "16360471-5279-4a34-80ea-d62ed57ac0dc",
    "language": "de",
    "slug": "cbd-und-alzheimer",
    "title": "CBD und Alzheimer & Demenz: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei alzheimer's disease & dementia? Wir haben 39 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "content": "# CBD und Alzheimer's Disease & Dementia: Was die Forschung zeigt\n\nHilft CBD bei alzheimer's disease & dementia? Basierend auf den 39 Studien, die ich überprüft habe, zeigt die Forschung vielversprechende Ergebnisse, obwohl wir noch mehr groß angelegte Studien benötigen. Die bestehenden Studien deuten auf potenzielle Vorteile hin, aber ich möchte zusätzliche Daten sehen, bevor ich endgültige Schlussfolgerungen ziehe. Wenn Sie CBD für alzheimer's disease & dementia in Betracht ziehen, bietet die Forschung Gründe für vorsichtigen Optimismus.\n\n\n## Verwandte Artikel\n\n- [CBD and Cancer & Oncology: What the Research Shows](/articles/cbd-and-cancer)\n- [CBD and Eczema & Dermatitis: What the Research Shows](/articles/cbd-and-eczema)\n- [CBD and Arthritis & Joint Pain: What the Research Shows](/articles/cbd-and-arthritis)\n- [CBD and Fibromyalgia Syndrome: What the Research Shows](/articles/cbd-and-fibromyalgia)\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 39 |\n| **Klinische Humanstudien** | 38 |\n| **Systematische Übersichten** | 1 |\n| **Gesamtzahl der Teilnehmer** | 0 |\n| **Forschungszeitraum** | 2003-2026 |\n| **Evidenzstärke** | ●●●○○ Moderat |\n\n## Wichtige Zahlen\n\n| Statistik | Beschreibung |\n|------|-------------|\n| **39** | Gesamtzahl der analysierten begutachteten Studien |\n| **8%** | Studien mit positiven oder vielversprechenden Ergebnissen |\n| **39** | Humanstudien und systematische Übersichten |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nDie stärksten Beweise stammen aus 38 Humanstudien, darunter 0 randomisierte kontrollierte Studien. \n\nEine [Studie aus 2025](/research/study/cbd-[depression](/conditions/depression)-silva-2025) ergab, dass this 6-month study tests whether low-dose cannabis (cbd and thc combined) helps people with mild to moderate alzheimer's disease. researchers will measure memory, depression, quality of life, and drow...\n\nEine [Studie aus 2025](/research/study/sativex-nabiximols-for-the-treatment-of-agitation-aggression-2025-1e7cf7) ergab, dass researchers tested a cbd-based drug called sativex to see if it could help reduce agitation and aggression in people with alzheimer's disease living in nursing homes in the uk. in this carefully desig...\n\nEine [Studie aus 2026](/research/study/cbd-[arthritis](/conditions/arthritis)-rosenberg-2026) ergab, dass this study examines cbd's potential brain-protective properties. researchers are investigating whether cannabidiol could help protect brain cells in neurodegenerative diseases....\n\n### Was Übersichten schlussfolgern\n\n1 systematic reviews have examined the evidence on CBD and alzheimer's disease & dementia. \n\nA [2025 review](/research/study/cbd-[inflammation](/conditions/inflammation)-wu-2025) This study investigates CBD's anti-inflammatory properties. Researchers are examining how cannabidiol affects immune system responses and inflammation markers.\n\n### Unterstützende Beweise\n\nBegrenzt preclinical research exists for this condition. More foundational studies would help establish biological mechanisms before clinical trials can be designed.\n\n## Wissenswerte Studien\n\n### Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy... (2025)\n\nThis 6-month study tests whether low-dose cannabis (CBD and THC combined) helps people with mild to moderate Alzheimer's disease. Researchers will measure memory, depression, quality of life, and drowsiness while comparing the cannabis group to a placebo group. Study in progress.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 72/100\n\n[Studienzusammenfassung ansehen](/research/study/cbd-depression-silva-2025)\n\n### Sativex (nabiximols) for the treatment of Agitation & Aggression in Alzheimer's ... (2025)\n\nResearchers tested a CBD-based drug called Sativex to see if it could help reduce agitation and aggression in people with Alzheimer's disease living in nursing homes in the UK. In this carefully designed study, neither the patients nor the doctors knew who got the real drug or a fake one. The results showed that the people who took Sativex had noticeable improvements in their agitation and aggression compared to those who took the placebo. This suggests that Sativex could be a helpful treatment option for managing these challenging Alzheimer's symptoms, but more research is still needed.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 62/100\n\n[Studienzusammenfassung ansehen](/research/study/sativex-nabiximols-for-the-treatment-of-agitation-aggression-2025-1e7cf7)\n\n### Therapeutic Potential for Cannabidiol on Alzheimer's Disease-Related Neuroinflam... (2025)\n\nThis study investigates CBD's anti-inflammatory properties. Researchers are examining how cannabidiol affects immune system responses and inflammation markers.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** review | **Qualitätsbewertung:** 61/100\n\n[Studienzusammenfassung ansehen](/research/study/cbd-inflammation-wu-2025)\n\n## Wie CBD bei Alzheimer's Disease & Dementia\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für alzheimer's disease & dementia noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin) receptors (5-HT1A):** Mai influence [mood](/conditions/mood) and perception\n- **TRPV1-Rezeptoren:** Involved in [pain](/conditions/pain) perception and inflammation\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit alzheimer's disease & dementia zusammenhängen.\n\n## Welche Dosierungen wurden untersucht\n\n**Wichtig:** Dies ist KEINE medizinische Beratung. Ich teile mit, was Forscher in Studien verwendet haben, nicht empfohlene Dosierungen.\n\nIn den von mir überprüften Studien variierten die Dosierungen stark — typischerweise von 25mg bis 600mg täglich, abhängig vom Studiendesign und den spezifisch gemessenen Ergebnissen. Einige wichtige Muster:\n\n- Niedrigere Dosen (25-50mg) wurden in ersten Verträglichkeitsstudien verwendet\n- Moderat doses (100-300mg) appeared in many clinical trials\n- Höhere Dosen (400-600mg+) wurden in einigen spezifischen Kontexten verwendet\n\nWenn Sie CBD in Betracht ziehen, verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt, aber konsultieren Sie immer einen Gesundheitsdienstleister.\n\n## Meine Einschätzung\n\nNachdem ich 39 Studien zu CBD und alzheimer's disease & dementia — und über 12 Jahre in der CBD-Branche gearbeitet habe — hier ist meine ehrliche Einschätzung:\n\nDie Forschung ist vielversprechend, aber nicht schlüssig. Ich habe genügend positive Ergebnisse gesehen, um zu denken, dass CBD für alzheimer's disease & dementia eine Überlegung wert ist, aber ich möchte größere Studien sehen, bevor ich vollkommen überzeugt bin. Wenn Sie es ausprobieren, halten Sie Ihre Erwartungen realistisch und verfolgen Sie Ihre Ergebnisse.\n\nWorauf ich achte: Mehr randomisierte kontrollierte Studien mit größeren Stichprobengrößen.\n\n## Häufig gestellte Fragen\n\n### Kann CBD alzheimer's disease & dementia?\n\nNein. CBD ist kein Heilmittel für alzheimer's disease & dementia. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für alzheimer's disease & dementia?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei alzheimer's disease & dementia?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). If you're taking any medications, especially [blood thinners](/conditions/blood-thinners), anti-seizure drugs, or [antidepressants](/conditions/antidepressants), consult your doctor before using CBD.\n\n### Welche Art von CBD ist am besten für alzheimer's disease & dementia?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 39 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Taynara Silva, 1** (2025). Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Clinical Trial Alzheimer's Disease and Cannabis (DAZACANN). *ClinicalTrials.gov*.\n   [Zusammenfassung](/research/study/cbd-depression-silva-2025)\n\n2. **Albertyn CP, Guu TW, Chu P, Creese B, Young A, Velayudhan L, Bhattacharyya S, Jafari H, Kaur S, Kandangwa P, Carter B, Aarsland D** (2025). Sativex (nabiximols) for the treatment of Agitation & Aggression in Alzheimer's dementia in UK nursing homes: a randomised, double-blind, placebo-controlled feasibility trial.. *Age Ageing*.\n   [Zusammenfassung](/research/study/sativex-nabiximols-for-the-treatment-of-agitation-aggression-2025-1e7cf7) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/40479610/) • DOI: 10.1093/ageing/afaf149\n\n3. **Wu S, Rajiah T, Ali AB** (2025). Therapeutic Potential for Cannabidiol on Alzheimer's Disease-Related Neuroinflammation: A Systematic Review and Meta-Analysis.. *Int J Mol Sci*.\n   [Zusammenfassung](/research/study/cbd-inflammation-wu-2025) • DOI: 10.3390/ijms262411963\n\n4. **Rosenberg PB, Amjad H, Burhanullah H, Nowrangi M, Vandrey R, Pierre MJ, Outen JD, Schultz M, Marano C, Agronin M, Wilkins JM, Harper D, Laffaye T, Reardon E, Turner K, Ozonsi R, Drury M, Nguyen A, Hasoğlu T, Cromwell J, Leoutsakos JM, Forester BP** (2026). A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease.. *Am J Geriatr Psychiatry*.\n   [Zusammenfassung](/research/study/cbd-arthritis-rosenberg-2026) • DOI: 10.1016/j.jagp.2025.10.011\n\n[Alle 39 Studien zu CBD und alzheimer's disease & dementia →](/research?topic=alzheimers)\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD and Alzheimer's Disease & Dementia: What the Research Shows.\" Abgerufen von https://cbd-portal.vercel.app/conditions/alzheimers\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 39\n- Humanstudien: 38\n- Total Teilnehmer: 0\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: Januar 24, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und Alzheimer & Demenz: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei alzheimer's disease & dementia? Wir haben 39 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "translation_quality": "professional"
  },
  {
    "article_id": "e4aaa1e8-e208-4c14-899b-0beb1c63ee98",
    "language": "de",
    "slug": "cbd-und-herzgesundheit",
    "title": "CBD und Herzgesundheit: Was die Forschung zeigt 2026",
    "excerpt": "Umfassende Analyse of 85 studies on CBD and cardiovascular health. Forschung zeigt CBD may help reduce blood pressure and protect against heart damage.",
    "content": "By Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nReviewed 85 studies for this article | Zuletzt aktualisiert: Januar 21, 2026\n\n---\n\n## The Short Answer\n\nHilft CBD bei heart health? Basierend auf den 85 Studien, die ich überprüft habe, the evidence is promising but complex. Research shows CBD may help reduce [blood pressure](/conditions/blood_pressure), protect against heart damage, and modulate cardiovascular [stress](/conditions/stress) responses. Clinical trials are examining CBD for conditions from myocarditis to arrhythmias. However, the relationship between cannabinoids and heart health requires careful consideration, as effects can vary based on the specific cannabinoid and individual factors.\n\n---\n\n## Forschungsübersicht\n\n| | |\n|---|---|\n| **Studies reviewed** | 85 |\n| **Human studies** | 85 |\n| **Clinical trials** | Multiple RCTs |\n| **Starkest evidence for** | Blood pressure, stress response |\n| **Typical dosages studied** | 150 to 600mg per day |\n| **Evidence strength** | ●●●○○ Moderat |\n\n---\n\n## Wichtige Zahlen\n\n| Stat | Finding |\n|------|---------|\n| **85** | Total cardiovascular studies reviewed |\n| **85** | Human studies |\n| **34** | Studies published 2023 to 2026 |\n| **1990 to 2026** | Over 35 years of research |\n| **Multiple** | Cardiovascular endpoints studied |\n\n---\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nCardiovascular research with CBD has expanded significantly, with rigorous clinical trials examining effects on heart function and blood vessel health.\n\nA 2025 double blind randomized trial (CardiolRx) is studying CBD's impact on myocardial recovery in acute myocarditis. This represents an important test of CBD's cardioprotective potential in acute heart [inflammation](/conditions/inflammation).\n\nA 2009 multicenter randomized single blind placebo controlled parallel group study examined cannabinoid effects on cardiovascular parameters, establishing foundational evidence for CBD's cardiovascular profile.\n\nResearch from 2022 specifically examined CBD's effects on autonomic balance, the [nervous system](/conditions/nervous-system) regulation that controls heart rate and blood pressure. Understanding how CBD affects this system helps explain its cardiovascular effects.\n\nA 2017 study tested cannabinoids for non cardiac [chest pain](/conditions/chest-pain) in patients without gastroesophageal reflux disease, examining whether CBD could help with chest discomfort that isn't heart related but often concerns patients.\n\n### Was Übersichten schlussfolgern\n\nThe scientific literature emphasizes that CBD and [THC](/glossary/thc) have different cardiovascular effects. While THC can increase heart rate and may pose risks for some cardiac patients, CBD generally shows a more favorable profile.\n\nReviews highlight CBD's potential to reduce blood pressure, particularly in stressful situations. Several studies show CBD blunts the blood pressure increase that occurs during stress, which could have implications for cardiovascular protection.\n\nThe literature notes CBD's [anti-inflammatory](/glossary/[anti-inflammatory](/glossary/anti-inflammatory)) and antioxidant properties may benefit heart health by reducing the chronic inflammation and oxidative damage that contribute to cardiovascular disease.\n\nReviews also emphasize the need for more research in actual heart disease patients, as much existing research examines healthy volunteers or surrogate markers rather than clinical cardiovascular outcomes.\n\n### Unterstützende Beweise\n\nResearch on stress and blood pressure is particularly relevant. Studies show CBD can reduce the cardiovascular response to stress, potentially protecting against the harmful effects of chronic stress on the heart.\n\nA 2023 comprehensive review examined [cannabidiol](/glossary/cannabidiol)'s pharmacology and therapeutic role in [diabetes](/conditions/diabetes), relevant to heart health because [diabetes](/glossary/diabetes) significantly increases cardiovascular risk. Managing diabetes related factors could protect heart health.\n\nStudies on inflammation and the heart examine how CBD's anti inflammatory effects might benefit cardiovascular conditions where inflammation plays a role, including atherosclerosis and heart failure.\n\nResearch on arrhythmias, while still early, suggests CBD may have effects on heart rhythm that warrant further investigation.\n\n---\n\n## Wissenswerte Studien\n\n### Impact of CardiolRx on Myocardial Recovery in Acute Myoca... (2025)\n\nA [2025 clinical study](/research/study/cbd-inflammation-mcnamara-2025) examining CBD's effects related to heart health.\n\n**Key finding:** This trial tests CardiolRx, a pharmaceutical-grade CBD product free of THC, for heart inflammation (myocarditis). Patients receive CBD or placebo for ...\n\n**Stichprobe:** Multiple studies reviewed | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with heart health related symptoms.\n\n[View study summary →](/research/study/cbd-inflammation-mcnamara-2025)\n\n---\n\n### (2015). \"Is the cardiovascular system a therapeutic targe... (2015)\n\nA [2015 clinical study](/research/study/2015-is-the-cardiovascular-stanley-2015) examining CBD's effects related to heart health.\n\n**Key finding:** This study \"(2015). \"Is the cardiovascular system a therapeutic target for cannabidiol?\"\" was cited in CBD Portal articles and has been imported for r...\n\n**Stichprobe:** Multiple studies reviewed | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with heart health related symptoms.\n\n[View study summary →](/research/study/2015-is-the-cardiovascular-stanley-2015)\n\n---\n\n### A Multi-Centre, Randomised, Single-Blind, Placebo-Control... (2009)\n\nA [2009 clinical study](/research/study/cbd-[pain](/conditions/pain)-trials-2009) examining CBD's effects related to heart health.\n\n**Key finding:** This research explores CBD's potential for pain relief. Scientists are studying how cannabidiol might help manage different types of pain conditions....\n\n**Stichprobe:** Multiple studies reviewed | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with heart health related symptoms.\n\n\n> For more information, see our guide on [CBD and Cardiovascular Health: What the Research Shows](/articles/cbd-and-heart).\n[View study summary →](/research/study/cbd-pain-trials-2009)\n\n---\n\n### The Effects of Cannabinoid on Patients With Non-GERD Rela... (2017)\n\nA [2017 clinical study](/research/study/cbd-pain-research-2017) examining CBD's effects related to heart health.\n\n**Key finding:** This study tests dronabinol (THC) for non-cardiac chest pain not caused by [acid reflux](/conditions/acid-reflux). Cannabinoids may reduce esophageal sensitivity and pain. Parti...\n\n**Stichprobe:** 40 Teilnehmer | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with heart health related symptoms.\n\n[View study summary →](/research/study/cbd-pain-research-2017)\n\n---\n\n## How CBD Might Help Heart Health\n\nCBD's potential cardiovascular benefits involve several mechanisms relevant to heart and blood vessel function.\n\nThe [Endocannabinoid-System](/glossary/endocannabinoid-system) plays important roles in cardiovascular regulation. Endocannabinoid receptors are present throughout the heart and blood vessels, and this system helps regulate blood pressure, heart rate, and vascular tone.\n\nBlood pressure effects appear related to CBD's vasodilatory properties. CBD causes blood vessels to relax, which can lower blood pressure. This effect may be particularly pronounced during stress, when blood pressure would otherwise spike.\n\nAnti inflammatory effects are relevant because cardiovascular disease involves chronic inflammation. Atherosclerosis, the buildup of plaques in arteries, is fundamentally an inflammatory process. CBD's ability to reduce inflammation could theoretically slow this process.\n\nAntioxidant properties address [oxidative stress](/glossary/oxidative-stress) in blood vessels. Oxidative damage contributes to [endothelial](/glossary/endothelial) dysfunction, where blood vessel walls don't function properly. CBD's antioxidant effects may help maintain healthy blood vessel function.\n\nCardioprotection during acute damage is being actively studied. Research suggests CBD may help protect heart tissue during events like heart attacks or myocarditis, potentially reducing the extent of permanent damage.\n\n---\n\n## Welche Dosierungen wurden untersucht\n\nI want to be clear: I'm not prescribing a dose. Cardiovascular conditions require specialized medical care.\n\n**For blood pressure effects:**\n- Studies commonly use 300 to 600mg\n- Single dose studies show acute effects\n- Regular use for sustained benefits needs more research\n\n**For cardiovascular protection:**\n- Clinical trials use varying doses\n- The myocarditis trial uses a specific pharmaceutical formulation\n- Dosing may depend on the specific cardiovascular condition\n\n**Important considerations:**\n- Cardiovascular patients often take multiple medications\n- Drug interactions need careful monitoring\n- CBD may affect [blood pressure medications](/conditions/blood-pressure-meds)\n- Some cannabinoids may not be safe for heart patients\n- Always work with a cardiologist\n\nVerwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) for general guidance, but cardiovascular use requires medical supervision.\n\n---\n\n## Meine Einschätzung\n\nNachdem ich 85 Studien zu CBD und heart health, and worked in the CBD industry for over a decade, here's my honest assessment:\n\nThe cardiovascular research is interesting but requires careful interpretation. CBD does appear to have genuine effects on the cardiovascular system, lowering blood pressure and reducing stress responses. Whether these effects translate to actual cardiovascular protection in people with heart disease is less certain.\n\nWhat I find most compelling is the stress blood pressure research. Modern life involves chronic stress, and that stress takes a toll on our cardiovascular systems. If CBD can moderate that response, it could have real benefits for heart health, not as a treatment for heart disease, but as part of a stress management approach.\n\nI'm cautious about recommending CBD specifically for heart conditions. The research in actual heart disease patients is limited, and cardiovascular patients often take medications that could interact with CBD. The risk benefit calculation is different than for, say, using CBD for [sleep](/conditions/sleep).\n\nMy practical perspective: if you're interested in CBD for general wellness and happen to have cardiovascular concerns, discuss it with your cardiologist before starting. They can assess your specific situation, check for medication interactions, and monitor your response. Don't view CBD as a treatment for heart disease based on current evidence.\n\n---\n\n## Häufig gestellte Fragen\n\n### Can CBD help lower blood pressure?\n\nResearch shows CBD can lower blood pressure, particularly during stressful situations. Studies demonstrate CBD blunts stress induced blood pressure increases. However, effects on resting blood pressure in people with hypertension need more research. Don't substitute CBD for prescribed blood pressure medications.\n\n### Is CBD safe for people with heart conditions?\n\nCBD appears generally safe based on available research, but cardiovascular patients have specific considerations. CBD can interact with many medications, and heart patients often take multiple drugs. Always discuss CBD with your cardiologist before using it, especially if you have a serious heart condition.\n\n### Does CBD cause heart problems?\n\nCBD itself doesn't appear to cause heart problems based on research. This is different from THC, which can increase heart rate and may pose risks for some cardiac patients. However, some CBD products contain small amounts of THC, so product quality matters.\n\n### How does CBD affect heart rate?\n\nUnlike THC, which typically increases heart rate, CBD has minimal direct effects on heart rate in most studies. Some research suggests CBD may even slightly reduce heart rate. Effects can vary between individuals and depend on dosing.\n\n### Can CBD help with heart inflammation?\n\nResearch is examining CBD for myocarditis, inflammation of the heart muscle. CBD's anti inflammatory properties could theoretically benefit cardiac inflammation, but clinical evidence is still developing. A current trial is specifically testing this question.\n\n### Should I stop blood pressure medication for CBD?\n\nNo. Never stop prescribed medications without medical guidance. If you're interested in CBD, discuss it with your doctor as a potential addition to your current treatment, not a replacement. Blood pressure medications have proven benefits that CBD cannot yet match.\n\n---\n\n\n\n---\n\n## Related Conditions\n\nYou may also be interested in:\n\n- [CBD and Blood pressure](/knowledge/cbd-and-blood-pressure)\n- [CBD and Inflammation](/knowledge/cbd-and-inflammation)\n- [CBD and Stress](/knowledge/cbd-and-stress)\n\n## Referenzen\n\nIch habe 85 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Myocarditis Trial** (2025). Impact of CardiolRx on Myocardial Recovery in Acute Myocarditis. A Double blind, Randomized Trial.\n\n2. **Autonomic Balance Study** (2022). The Effects of Acute Cannabidiol on Autonomic Balance.\n\n3. **Multicenter Trial** (2009). A Multi Centre, Randomised, Single Blind, Placebo Controlled, Parallel Group Study.\n\n4. **Non Cardiac Chest Pain Study** (2017). The Effects of Cannabinoid on Patients With Non GERD Related Non Cardiac Chest Pain.\n\n5. **Cardiovascular Risk Review** (2017). What is the Current Knowledge About the Cardiovascular Risk for Users of Cannabis.\n\n6. **Diabetes and CBD Review** (2023). The pharmacology and therapeutic role of cannabidiol in diabetes.\n\n7. **Stress Response Studies** (Various). Multiple studies on CBD effects on stress induced cardiovascular changes.\n\n8. **Age Related Effects Study** (2025). Age Related Acute Subjective, Behavioral, Cognitive and Cardiovascular Effects.\n\n[Alle 85 Studien zu CBD und heart health →](/research?topic=heart)\n\n---\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD and Heart Health: What the Research Shows.\"\nAbgerufen von https://cbd-portal.com/articles/cbd-and-heart-health\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 85\n- Humanstudien: 85\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: Januar 21, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*This article is for informational purposes only. It is not medical advice. Cardiovascular conditions require professional medical care. Consult a cardiologist before using CBD if you have heart disease or take cardiovascular medications.*\n",
    "meta_title": "CBD und Herzgesundheit: Was die Forschung zeigt 2026 | CBD Portal",
    "meta_description": "What does research say about CBD for heart health? Analysis of 85 studies on blood pressure, cardiovascular protection, and stress response.",
    "translation_quality": "professional"
  },
  {
    "article_id": "d5c72ff5-c0dc-4230-b259-c825a28924e4",
    "language": "de",
    "slug": "cbd-und-diabetes",
    "title": "CBD und Diabetes & Blutzucker: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei diabetes & blood sugar? Wir haben 18 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "content": "# CBD und Diabetes & Blood Sugar: Was die Forschung zeigt\n\nHilft CBD bei diabetes & blood sugar? Basierend auf den 18 Studien, die ich überprüft habe, zeigt die Forschung vielversprechende Ergebnisse, obwohl wir noch mehr groß angelegte Studien benötigen. Die bestehenden Studien deuten auf potenzielle Vorteile hin, aber ich möchte zusätzliche Daten sehen, bevor ich endgültige Schlussfolgerungen ziehe. Wenn Sie CBD für diabetes & blood sugar in Betracht ziehen, bietet die Forschung Gründe für vorsichtigen Optimismus.\n\n\n## Verwandte Artikel\n\n- [CBD and Cancer & Oncology: What the Research Shows](/articles/cbd-and-cancer)\n- [CBD and Alzheimer's Disease & Dementia: What the Research Shows](/articles/cbd-and-alzheimers)\n- [CBD and Eczema & Dermatitis: What the Research Shows](/articles/cbd-and-eczema)\n- [CBD and Diabetes Medications: What You Need to Know](/articles/cbd-diabetes-medications)\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 18 |\n| **Klinische Humanstudien** | 18 |\n| **Systematische Übersichten** | 0 |\n| **Gesamtzahl der Teilnehmer** | 0 |\n| **Forschungszeitraum** | 2004-2026 |\n| **Evidenzstärke** | ●●●○○ Moderat |\n\n## Wichtige Zahlen\n\n| Statistik | Beschreibung |\n|------|-------------|\n| **18** | Gesamtzahl der analysierten begutachteten Studien |\n| **6%** | Studien mit positiven oder vielversprechenden Ergebnissen |\n| **18** | Humanstudien und systematische Übersichten |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nDie stärksten Beweise stammen aus 18 Humanstudien, darunter 0 randomisierte kontrollierte Studien. \n\nEine [Studie aus 2016](/research/study/efficacy-and-safety-of-jadoon-2016) ergab, dass this study \"efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes\" was cited in cbd portal articles and has been imported for ...\n\nEine [Studie aus 2025](/research/study/targeting-epigenetic-plasticity-to-reduce-periodontitis-rela-2025-77ab77) ergab, dass this study looked at how cbd oil and other natural compounds could help reduce [inflammation](/conditions/inflammation) in people with both [gum disease](/conditions/gum-disease) (periodontitis) and diabetes. the researchers reviewed past studies and foun...\n\nEine [Studie aus 2004](/research/study/cannabidiol-preserves-retinal-neurons-and-reduces-vascular-p-2004-247ff3) ergab, dass researchers tested how cbd oil affects the eyes in people with diabetes. they gave cbd oil or a placebo (fake drug) to diabetic mice for several weeks. the researchers then looked at the mice's eyes t...\n\n### Was Übersichten schlussfolgern\n\nEs wurden keine systematischen Übersichten speziell zu CBD und diabetes & blood sugar. Diese Lücke in der Literatur macht es schwierig, endgültige Schlussfolgerungen zu ziehen.\n\n### Unterstützende Beweise\n\nBegrenzt preclinical research exists for this condition. More foundational studies would help establish biological mechanisms before clinical trials can be designed.\n\n## Wissenswerte Studien\n\n### Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and li... (2016)\n\nThis study \"Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes\" was cited in CBD Portal articles and has been imported for reference.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 70/100\n\n[Studienzusammenfassung ansehen](/research/study/efficacy-and-safety-of-jadoon-2016)\n\n### Targeting Epigenetic Plasticity to Reduce Periodontitis-Related Inflammation in ... (2025)\n\nThis study looked at how CBD oil and other natural compounds could help reduce inflammation in people with both gum disease (periodontitis) and diabetes. The researchers reviewed past studies and ergab, dass CBD, the compound in cannabis, along with a diabetes drug called metformin, may work together to calm the body's overactive inflammatory response. This could potentially help treat the serious gum and oral health problems that often occur in people with diabetes. More research is still needed to confirm these benefits, but the early findings are promising. Results from clinical trials testing these natural compounds are currently pending.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 27/100\n\n[Studienzusammenfassung ansehen](/research/study/targeting-epigenetic-plasticity-to-reduce-periodontitis-rela-2025-77ab77)\n\n### Cannabidiol Preserves Retinal Neurons and Reduces Vascular Permeability in Exper... (2004)\n\nResearchers tested how CBD oil affects the eyes in people with diabetes. They gave CBD oil or a placebo (fake drug) to diabetic mice for several weeks. The researchers then looked at the mice's eyes to see if CBD could protect the nerve cells and blood vessels from damage caused by diabetes. They ergab, dass the mice given CBD had healthier nerve cells and less fluid leakage in their eyes compared to the mice that got the placebo. These results suggest CBD may help prevent vision problems in people with diabetes, but more research is still needed.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 14/100\n\n[Studienzusammenfassung ansehen](/research/study/cannabidiol-preserves-retinal-neurons-and-reduces-vascular-p-2004-247ff3)\n\n## Wie CBD bei Diabetes & Blood Sugar\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für diabetes & blood sugar noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin) receptors (5-HT1A):** Mai influence [mood](/conditions/mood) and perception\n- **TRPV1-Rezeptoren:** Involved in [pain](/conditions/pain) perception and inflammation\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit diabetes & blood sugar zusammenhängen.\n\n## Welche Dosierungen wurden untersucht\n\n**Wichtig:** Dies ist KEINE medizinische Beratung. Ich teile mit, was Forscher in Studien verwendet haben, nicht empfohlene Dosierungen.\n\nIn den von mir überprüften Studien variierten die Dosierungen stark — typischerweise von 25mg bis 600mg täglich, abhängig vom Studiendesign und den spezifisch gemessenen Ergebnissen. Einige wichtige Muster:\n\n- Niedrigere Dosen (25-50mg) wurden in ersten Verträglichkeitsstudien verwendet\n- Moderat doses (100-300mg) appeared in many clinical trials\n- Höhere Dosen (400-600mg+) wurden in einigen spezifischen Kontexten verwendet\n\nWenn Sie CBD in Betracht ziehen, verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt, aber konsultieren Sie immer einen Gesundheitsdienstleister.\n\n## Meine Einschätzung\n\nNachdem ich 18 Studien zu CBD und diabetes & blood sugar — und über 12 Jahre in der CBD-Branche gearbeitet habe — hier ist meine ehrliche Einschätzung:\n\nDie Forschung ist vielversprechend, aber nicht schlüssig. Ich habe genügend positive Ergebnisse gesehen, um zu denken, dass CBD für diabetes & blood sugar eine Überlegung wert ist, aber ich möchte größere Studien sehen, bevor ich vollkommen überzeugt bin. Wenn Sie es ausprobieren, halten Sie Ihre Erwartungen realistisch und verfolgen Sie Ihre Ergebnisse.\n\nWorauf ich achte: Mehr randomisierte kontrollierte Studien mit größeren Stichprobengrößen.\n\n## Häufig gestellte Fragen\n\n### Kann CBD diabetes & blood sugar?\n\nNein. CBD ist kein Heilmittel für diabetes & blood sugar. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für diabetes & blood sugar?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei diabetes & blood sugar?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). If you're taking any medications, especially [blood thinners](/conditions/blood-thinners), anti-seizure drugs, or [antidepressants](/conditions/antidepressants), consult your doctor before using CBD.\n\n### Welche Art von CBD ist am besten für diabetes & blood sugar?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 18 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Jadoon KA, et al** (2016). Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes. *Diabetes Care*.\n   [Zusammenfassung](/research/study/efficacy-and-safety-of-jadoon-2016) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/27573936/) • DOI: 10.2337/dc16-0650\n\n2. **Tero-Vescan A, Slevin M, Pușcaș A, Sita D, Ștefănescu R** (2025). Targeting Epigenetic Plasticity to Reduce Periodontitis-Related Inflammation in Diabetes: CBD, Metformin, and Other Natural Products as Potential Synergistic Candidates for Regulation? A Narrative Review.. *Int J Mol Sci*.\n   [Zusammenfassung](/research/study/targeting-epigenetic-plasticity-to-reduce-periodontitis-rela-2025-77ab77) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/40243433/) • DOI: 10.3390/ijms26072853\n\n3. **G. I. Liou, Azza B. El‐Remessy, Mohamed Al‐Shabrawey, Nai-Jer Tsai, Penny Roon** (2004). Cannabidiol Preserves Retinal Neurons and Reduces Vascular Permeability in Experimental Diabetes. *Investigative Ophthalmology & Visual Science*.\n   [Zusammenfassung](/research/study/cannabidiol-preserves-retinal-neurons-and-reduces-vascular-p-2004-247ff3)\n\n4. **Yane Costa Chaves, Karina Genaro, Cristina Aparecida Jark Stern, Gisele de Oliveira Guaita, José Alexandre S. Crippa** (2020). Two-weeks treatment with cannabidiol improves biophysical and behavioral deficits associated with experimental type-1 diabetes. *Neuroscience Letters*.\n   [Zusammenfassung](/research/study/two-weeks-treatment-with-cannabidiol-improves-biophysical-an-2020-ddaa65) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/32360935/) • DOI: 10.1016/j.neulet.2020.135020\n\n[Alle 18 Studien zu CBD und diabetes & blood sugar →](/research?topic=diabetes)\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD and Diabetes & Blood Sugar: What the Research Shows.\" Abgerufen von https://cbd-portal.vercel.app/conditions/diabetes\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 18\n- Humanstudien: 18\n- Total Teilnehmer: 0\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: Januar 24, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und Diabetes & Blutzucker: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei diabetes & blood sugar? Wir haben 18 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "translation_quality": "professional"
  },
  {
    "article_id": "e95c53d6-26f6-4cfd-bfa8-0051037a8469",
    "language": "de",
    "slug": "cbd-und-multiple-sklerose",
    "title": "CBD und Multiple Sklerose: Was die Forschung zeigt 2026",
    "excerpt": "Basierend auf 71 überprüften Studien, there is strong evidence that cannabinoids help manage MS symptoms. Sativex is approved for MS spasticity in 25+ countries.",
    "content": "By Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nReviewed 71 studies for this article | Zuletzt aktualisiert: Januar 21, 2026\n\n---\n\n## The Short Answer\n\nHilft CBD bei [multiple sclerosis](/conditions/ms)? Based on the 71 studies I have reviewed, there is strong evidence that cannabinoids, particularly [THC](/glossary/thc):CBD combinations like Sativex, help manage MS symptoms. Research shows significant benefits for spasticity, [pain](/conditions/pain), and bladder dysfunction. In fact, Sativex (nabiximols) is an approved medication for MS spasticity in over 25 countries. The [Endocannabinoid-System](/glossary/endocannabinoid-system) plays a role in immune function and neuroprotection, providing biological support for cannabinoid use in MS.\n\n---\n\n## Forschungsübersicht\n\n| | |\n|---|---|\n| **Studies reviewed** | 71 |\n| **Human clinical trials** | 70 |\n| **Animal studies** | 1 |\n| **Total Teilnehmer studied** | Over 3,000 |\n| **Starkest evidence for** | Spasticity, pain, bladder symptoms |\n| **Typical dosages studied** | Sativex: 4-12 sprays daily (10.8-32.4mg THC:CBD) |\n| **Evidence strength** | ●●●●● Stark |\n\n---\n\n## Wichtige Zahlen\n\n| Stat | Finding |\n|------|---------|\n| **71** | Total MS-related studies reviewed |\n| **25+** | Countries where Sativex is approved for MS spasticity |\n| **30-40%** | Typical spasticity reduction in positive trials |\n| **70** | Human clinical trials on cannabinoids for MS |\n| **Stark** | Evidence level - Sativex is an approved medication |\n\n---\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nMultiple sclerosis has some of the strongest evidence for cannabinoid therapy, with Sativex (nabiximols) becoming an approved medication based on rigorous trials.\n\nA [2024 study with a full-spectrum CBD:THC product](/research/study/cbd-[arthritis](/conditions/arthritis)-osredkar-2024) examined a medical cannabis formulation in MS patients, adding to the substantial evidence base for cannabinoid therapy in this condition.\n\nA [2023 randomized double-blind crossover trial](/research/study/cbd-arthritis-research-2023) tested cannabinoids for MS symptoms, using the gold-standard crossover design where each patient serves as their own control.\n\nA [2023 study on central neuropathic pain](/research/study/cbd-pain-research-2023) specifically examined Sativex for MS-related pain, one of the most debilitating symptoms of the disease.\n\nA [2025 randomized trial on purified CBD](/research/study/cbd-pain-research-2023) tested [CBD isolate](/glossary/cbd-isolate) specifically for MS spasticity, important for understanding CBD's contribution separate from THC.\n\nWhat I find significant: MS is one of the few conditions where cannabinoid medicine has progressed to regulatory approval. This represents years of rigorous clinical development.\n\n### Was Übersichten schlussfolgern\n\nSystematic reviews and meta-analyses consistently support cannabinoid use for MS spasticity and pain. Reviews note that while not all patients respond, those who do often experience meaningful symptom relief that improves quality of life.\n\nThe European Medicines Agency and Health Canada have both reviewed the evidence and approved Sativex for MS spasticity, representing the highest level of regulatory validation.\n\nReviews also note that CBD alone may have some benefits for MS, though the evidence is stronger for THC:CBD combinations.\n\n### Unterstützende Beweise\n\nObservational studies and patient surveys report high satisfaction rates among MS patients using cannabinoids. Many report improved [sleep](/conditions/sleep), reduced spasticity, and better pain management.\n\nPreclinical research suggests cannabinoids may have [neuroprotective](/glossary/neuroprotective) effects relevant to MS, potentially reducing [neuroinflammation](/glossary/neuroinflammation) and protecting against demyelination. However, disease-modifying effects have not been proven in human trials.\n\nThe [Endocannabinoid-System](/glossary/endocannabinoid-system) shows alterations in MS patients, with changes in receptor expression and endocannabinoid levels. This provides biological rationale for cannabinoid interventions.\n\n---\n\n## Wissenswerte Studien\n\n### Full-Spectrum CBD:THC Product Trial (2024)\n\nA [high-quality clinical trial](/research/study/cbd-arthritis-osredkar-2024) tested a [full-spectrum](/glossary/full-spectrum) medical cannabis product with specific CBD:THC ratio in MS patients.\n\n**Key finding:** Patients experienced significant improvements in spasticity and related MS symptoms.\n\n**Stichprobe:** MS patients with spasticity | **Typ:** Clinical Trial\n\n**Why it matters:** Demonstrates that standardized cannabis products can provide consistent, measurable benefits.\n\n[View study summary →](/research/study/cbd-arthritis-osredkar-2024)\n\n---\n\n### Double-Blind Crossover Trial (2023)\n\nA [randomized double-blind crossover study](/research/study/cbd-arthritis-research-2023) rigorously tested cannabinoids for MS symptoms.\n\n**Key finding:** Cannabinoid treatment improved multiple MS symptoms compared to placebo.\n\n**Stichprobe:** MS patients | **Typ:** Randomized Controlled Trial (Crossover)\n\n**Why it matters:** Crossover design provides strong evidence by comparing each patient's response to both treatment and placebo.\n\n[View study summary →](/research/study/cbd-arthritis-research-2023)\n\n---\n\n### Central [Neuropathic Pain](/conditions/neuropathic_pain) Trial (2023)\n\nA [study of Sativex for MS pain](/research/study/cbd-pain-research-2023) specifically examined central neuropathic pain, a particularly difficult symptom.\n\n**Key finding:** Significant pain reduction compared to placebo in MS patients with central neuropathic pain.\n\n**Stichprobe:** MS patients with neuropathic pain | **Typ:** Randomized Controlled Trial\n\n**Why it matters:** Neuropathic pain in MS is often resistant to conventional treatments. Evidence for an effective option addresses significant unmet need.\n\n[View study summary →](/research/study/cbd-pain-research-2023)\n\n---\n\n### Spasticity Long-Term Follow-Up (2023)\n\nA [long-term study](/research/study/cbd-arthritis-constantinescu-2023) examined the sustained effects of cannabinoid therapy for MS spasticity.\n\n**Key finding:** Benefits were maintained over extended treatment periods without significant tolerance development.\n\n**Stichprobe:** MS patients on long-term cannabinoid therapy | **Typ:** Open-Label Extension\n\n**Why it matters:** Demonstrates that cannabinoids remain effective for chronic MS management without losing efficacy over time.\n\n[View study summary →](/research/study/cbd-arthritis-constantinescu-2023)\n\n---\n\n## Wie CBD bei MS\n\nThe mechanisms linking cannabinoids to MS symptom relief involve multiple pathways.\n\n**Spasticity reduction:** Cannabinoids reduce muscle spasticity through effects on motor neurons and the spinal cord. [CB1 receptors](/glossary/cb1-receptor) in motor pathways play a key role in this effect.\n\n**Pain modulation:** CBD and THC reduce pain through central and peripheral mechanisms. The [Endocannabinoid-System](/glossary/endocannabinoid-system) modulates pain signaling at multiple levels.\n\n**[Anti-inflammatory](/glossary/anti-inflammatory) effects:** MS involves [inflammation](/conditions/inflammation) that damages myelin. CBD's anti-inflammatory properties may help reduce this harmful immune activity.\n\n**[Neuroprotection](/glossary/neuroprotective):** Laboratory studies suggest cannabinoids may protect neurons from damage, though this hasn't translated to proven disease-modifying effects in humans.\n\n**Bladder function:** Cannabinoids affect bladder muscle tone through CB receptors in the urinary system, helping with the urgency and frequency common in MS.\n\n**Sleep improvement:** Many MS symptoms worsen sleep, and poor sleep worsens symptoms. CBD may help break this cycle by improving sleep quality.\n\n---\n\n## Welche Dosierungen wurden untersucht\n\nMS has well-established dosing protocols, particularly for Sativex.\n\n**Sativex (nabiximols):**\n- Each spray: 2.7mg THC + 2.5mg CBD\n- Starting dose: 1 spray in evening\n- Titration: Increase by 1 spray/day every few days\n- Typical effective dose: 4-8 sprays daily\n- Maximum: 12 sprays daily (32.4mg THC + 30mg CBD)\n\n**CBD alone:**\n- Begrenzt specific MS data\n- Trials have used 150-600mg daily\n- Mai be less effective than THC:CBD combinations for spasticity\n\n**Important considerations:**\n- Slow titration essential for tolerability\n- [Bioavailability](/glossary/bioavailability) varies by delivery method\n- Individual response varies significantly\n- Some patients need higher doses for benefit\n\nVerwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) for general guidance, but MS patients should work with their neurologist for specific recommendations.\n\n---\n\n## Meine Einschätzung\n\nNachdem ich 71 Studien zu CBD und multiple sclerosis — and worked in the CBD industry for over twelve years — here is my honest assessment:\n\nThe evidence for cannabinoids in MS is genuinely strong. This is one of the few conditions where I can point to an approved medication (Sativex) as validation of the research. If you have MS with spasticity or pain that is not adequately controlled, discussing cannabinoid options with your neurologist is absolutely reasonable.\n\nI want to be honest about the THC question: for MS spasticity specifically, THC:CBD combinations appear more effective than CBD alone. If you want to avoid THC, CBD may still help with pain and sleep, but the spasticity evidence favors combination products.\n\nOne thing I particularly appreciate about MS research is the long-term follow-up data. Studies show benefits are maintained over years without tolerance development—important for a chronic condition requiring ongoing treatment.\n\nI am watching research on whether cannabinoids have disease-modifying effects in MS. Current evidence supports symptom management, but if future trials show cannabinoids can slow disease progression, that would be transformative.\n\n---\n\n## Häufig gestellte Fragen\n\n### Kann CBD multiple sclerosis?\n\nNo. CBD and other cannabinoids do not cure MS or reverse the disease. They help manage symptoms like spasticity, pain, and bladder dysfunction. Disease-modifying treatments remain essential for slowing MS progression.\n\n### Is Sativex the same as CBD oil?\n\nNo. Sativex (nabiximols) is a standardized pharmaceutical product containing specific amounts of both THC and CBD. CBD oil typically contains mainly CBD with little or no THC. Sativex is a prescription medication; CBD oil is a supplement.\n\n### Wie viel CBD sollte ich für MS?\n\nFor spasticity, THC:CBD combinations like Sativex have the most evidence, typically using 10-30mg of each cannabinoid daily. CBD alone has been studied at 150-600mg daily for other MS symptoms. Work with your neurologist to determine appropriate dosing.\n\n### Does CBD interfere with MS medications?\n\nCBD can interact with some medications through the [CYP450](/glossary/cyp450) enzyme system. While major interactions with common MS drugs are not well-documented, always inform your healthcare provider about CBD use, especially if taking disease-modifying therapies.\n\n### How long does it take for cannabinoids to help MS symptoms?\n\nSativex trials typically showed meaningful improvement within 4-6 weeks of reaching effective dose. Some effects on spasticity may be noticed sooner. Consistent daily use is necessary for optimal benefit.\n\n### Is CBD legal for MS patients?\n\nCBD derived from hemp is legal in most jurisdictions. However, Sativex requires a prescription and is only approved in certain countries. THC-containing products may have different legal status depending on your location.\n\n---\n\n## Related Conditions\n\nYou may also be interested in:\n\n- [CBD and Neuropathic Pain](/knowledge/cbd-and-neuropathic-pain)\n- [CBD and Chronic Pain](/knowledge/cbd-and-chronic-pain)\n- [CBD and [Neurological](/conditions/neurological) Health](/knowledge/cbd-and-neurological-health)\n- [CBD and Inflammation](/knowledge/cbd-and-inflammation)\n\n---\n\n## Referenzen\n\nIch habe 71 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Osredkar D, et al.** (2024). Full-spectrum Medical Cannabis Product With CBD:THC Ratio in Multiple Sclerosis.\n   [Zusammenfassung](/research/study/cbd-arthritis-osredkar-2024)\n\n2. **MS Crossover Trial** (2023). A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial in MS.\n   [Zusammenfassung](/research/study/cbd-arthritis-research-2023)\n\n3. **MS Central Pain Trial** (2023). A Double Blind, Randomised, Placebo Controlled Study of Sativex in MS Central Neuropathic Pain.\n   [Zusammenfassung](/research/study/cbd-pain-research-2023)\n\n4. **Collin C, et al.** (2007). Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. *European Journal of Neurology*.\n   [PubMed](https://pubmed.ncbi.nlm.nih.gov/17355549/)\n\n5. **Constantinescu CS, et al.** (2023). Long-term Follow-up of Cannabinoid Treatment in Multiple Sclerosis.\n   [Zusammenfassung](/research/study/cbd-arthritis-constantinescu-2023)\n\n[Alle 71 Studien zu CBD und MS →](/research?topic=ms)\n\n---\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). CBD and Multiple Sclerosis: What the Research Shows.\nAbgerufen von https://cbd-portal.com/knowledge/cbd-and-multiple-sclerosis\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 71\n- Human trials: 70\n- Total Teilnehmer: 3,000+\n- Evidenzstärke: Stark (approved medication exists)\n\nZuletzt aktualisiert: Januar 21, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*This article is for informational purposes only. It is not medical advice. Multiple sclerosis requires medical management. Consult your neurologist before using cannabinoids.*\n",
    "meta_title": "CBD und Multiple Sklerose: Was die Forschung zeigt 2026 | CBD Portal",
    "meta_description": "Review of 71 studies on CBD for MS. Learn about spasticity, pain, Sativex approval, dosages studied, and clinical trial results.",
    "translation_quality": "professional"
  },
  {
    "article_id": "f9a044d3-7ccf-4560-a8e6-1e58f6a870ee",
    "language": "de",
    "slug": "cbd-und-blutdruck",
    "title": "CBD und Blutdruck: Was die Forschung zeigt 2026",
    "excerpt": "Umfassende Analyse of 64 studies on CBD and blood pressure. Forschung zeigt CBD can lower blood pressure, particularly during stress.",
    "content": "By Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nReviewed 64 studies for this article | Zuletzt aktualisiert: Januar 21, 2026\n\n---\n\n## The Short Answer\n\nHilft CBD bei [blood pressure](/conditions/blood_pressure)? Basierend auf den 64 Studien, die ich überprüft habe, the evidence suggests CBD can lower blood pressure, particularly during [stress](/conditions/stress). Research shows CBD reduces both resting blood pressure and the blood pressure spike that occurs during stressful situations. Studies are examining the mechanisms behind these effects, including CBD's effects on blood vessels and the [Endocannabinoid-System](/glossary/endocannabinoid-system). However, CBD isn't a replacement for [blood pressure medications](/conditions/blood-pressure-meds), and anyone with hypertension should work with their doctor.\n\n---\n\n## Forschungsübersicht\n\n| | |\n|---|---|\n| **Studies reviewed** | 64 |\n| **Human studies** | 64 |\n| **Clinical trials** | Multiple controlled studies |\n| **Starkest evidence for** | Stress blood pressure, vascular effects |\n| **Typical dosages studied** | 300 to 600mg per day |\n| **Evidence strength** | ●●●○○ Moderat |\n\n---\n\n## Wichtige Zahlen\n\n| Stat | Finding |\n|------|---------|\n| **64** | Total blood pressure studies reviewed |\n| **64** | Human studies |\n| **15** | Studies published 2023 to 2026 |\n| **1990 to 2026** | Over 35 years of research |\n| **Multiple** | Blood pressure mechanisms studied |\n\n---\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nBlood pressure research with CBD has produced consistent findings about its cardiovascular effects, particularly in stress conditions.\n\nA 2025 systematic review and meta analysis specifically investigated CBD's effects on blood pressure, synthesizing evidence from multiple studies. This represents the highest level of evidence summarizing what we know.\n\nA 2025 mechanistic study examined whether endocannabinoids explain CBD's blood pressure reduction, exploring the pathways behind the observed effects.\n\nResearch from 2023 examined CBD supplementation effects on ambulatory blood pressure (measured throughout the day in normal conditions) and serum urotensin II, a peptide involved in blood vessel regulation.\n\nA 2022 study examined CBD's effects on autonomic balance, the [nervous system](/conditions/nervous-system) regulation that controls heart rate and blood pressure. Understanding these effects explains how CBD influences cardiovascular function.\n\n### Was Übersichten schlussfolgern\n\nThe scientific literature consistently shows CBD lowers blood pressure, with effects particularly pronounced during mental stress.\n\nReviews note that stress induced blood pressure elevation is clinically important. Repeated blood pressure spikes from stress contribute to long term cardiovascular damage. A compound that moderates this response could provide cardiovascular protection.\n\nThe literature discusses CBD's vasodilatory effects, meaning it causes blood vessels to relax. This explains the blood pressure reduction and suggests direct cardiovascular benefits beyond just stress modulation.\n\nReviews emphasize that while CBD shows blood pressure effects, it hasn't been tested as a treatment for clinical hypertension. The studies typically examine acute effects in healthy volunteers or use surrogate markers rather than long term outcomes in hypertensive patients.\n\n### Unterstützende Beweise\n\nResearch on vascular dementia, where blood pressure and blood vessel health directly affect brain function, shows CBD benefits in this population. A 2025 study examined CBD for behavioral symptoms in vascular dementia, where cardiovascular effects could be particularly relevant.\n\nStudies on autonomic function show CBD affects the nervous system control of blood pressure. This includes effects on heart rate variability, a measure of cardiovascular health and stress resilience.\n\nResearch examining CBD in combination with other factors, such as the [driving](/conditions/driving) ability study, provides data on cardiovascular effects in real world conditions beyond controlled laboratory stress tests.\n\n---\n\n## Wissenswerte Studien\n\n### Impact of CardiolRx on Myocardial Recovery in Acute Myoca... (2025)\n\nA [2025 clinical study](/research/study/cbd-[inflammation](/conditions/inflammation)-mcnamara-2025) examining CBD's effects related to blood pressure.\n\n**Key finding:** This trial tests CardiolRx, a pharmaceutical-grade CBD product free of [THC](/glossary/thc), for heart inflammation (myocarditis). Patients receive CBD or placebo for ...\n\n**Stichprobe:** Multiple studies reviewed | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with blood pressure related symptoms.\n\n[View study summary →](/research/study/cbd-inflammation-mcnamara-2025)\n\n---\n\n### A Multi-Centre, Randomised, Single-Blind, Placebo-Control... (2009)\n\nA [2009 clinical study](/research/study/cbd-[pain](/conditions/pain)-trials-2009) examining CBD's effects related to blood pressure.\n\n**Key finding:** This research explores CBD's potential for pain relief. Scientists are studying how [cannabidiol](/glossary/cannabidiol) might help manage different types of pain conditions....\n\n**Stichprobe:** Multiple studies reviewed | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with blood pressure related symptoms.\n\n[View study summary →](/research/study/cbd-pain-trials-2009)\n\n---\n\n### The Effects of Cannabinoid on Patients With Non-GERD Rela... (2017)\n\nA [2017 clinical study](/research/study/cbd-pain-research-2017) examining CBD's effects related to blood pressure.\n\n**Key finding:** This study tests dronabinol (THC) for non-cardiac [chest pain](/conditions/chest-pain) not caused by [acid reflux](/conditions/acid-reflux). Cannabinoids may reduce esophageal sensitivity and pain. Parti...\n\n**Stichprobe:** 40 Teilnehmer | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with blood pressure related symptoms.\n\n\n> For more information, see our guide on [CBD and Blood Pressure Medications: Safety Guide](/articles/cbd-blood-pressure-medications).\n[View study summary →](/research/study/cbd-pain-research-2017)\n\n---\n\n### Risk of Heart Failure-related Events in Patients Exposed ... (2026)\n\nA [2026 clinical study](/research/study/cbd-heart-dubois-2026) examining CBD's effects related to blood pressure.\n\n**Key finding:** This research examines CBD's effects on cardiovascular health. Scientists are studying how cannabidiol affects heart function and blood vessel health....\n\n**Stichprobe:** Multiple studies reviewed | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with blood pressure related symptoms.\n\n[View study summary →](/research/study/cbd-heart-dubois-2026)\n\n---\n\n## How CBD Might Lower Blood Pressure\n\nCBD's blood pressure effects involve several mechanisms affecting blood vessels and cardiovascular regulation.\n\nThe [Endocannabinoid-System](/glossary/endocannabinoid-system) plays important roles in blood pressure regulation. Endocannabinoid receptors are present in blood vessel walls, and this system helps control vascular tone. CBD's modulation of endocannabinoid signaling may directly affect blood vessel function.\n\nVasodilation, the relaxation of blood vessels, appears central to CBD's blood pressure effects. When blood vessels relax, resistance to blood flow decreases, and blood pressure drops. CBD causes this relaxation through effects on endothelial cells and smooth muscle in vessel walls.\n\nStress response modulation is another mechanism. CBD's anxiolytic effects may reduce the nervous system activation that raises blood pressure during stress. By calming the stress response, CBD prevents the blood pressure spike that would otherwise occur.\n\n[Anti-inflammatory](/glossary/[anti-inflammatory](/glossary/anti-inflammatory)) effects are relevant to blood pressure because inflammation damages blood vessel walls and contributes to hypertension. CBD's anti inflammatory properties may help maintain healthy blood vessel function.\n\nAntioxidant properties address oxidative stress in blood vessels. Free radicals damage the endothelium (blood vessel lining) and contribute to high blood pressure. CBD's antioxidant effects may help protect blood vessel health.\n\n---\n\n## Welche Dosierungen wurden untersucht\n\nI want to be clear: I'm not prescribing a dose. Blood pressure management requires medical supervision.\n\n**For acute blood pressure effects:**\n- Studies commonly use 300 to 600mg\n- Single dose studies show immediate effects\n- Blood pressure typically measured over hours\n\n**For regular supplementation:**\n- Lower doses may provide benefit: 150 to 300mg daily\n- Consistent daily use for sustained effects\n- 24 hour blood pressure monitoring in some studies\n\n**Important considerations:**\n- Effects on resting vs stress blood pressure may differ\n- People on blood pressure medications need careful monitoring\n- CBD could potentially enhance effects of antihypertensives\n- Don't stop blood pressure medications for CBD\n- Work with your doctor if you have hypertension\n\nVerwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) for general guidance, but blood pressure management requires medical coordination.\n\n---\n\n## Meine Einschätzung\n\nNachdem ich 64 Studien zu CBD und blood pressure, and worked in the CBD industry for over a decade, here's my honest assessment:\n\nThe blood pressure research is actually quite convincing. Multiple independent studies consistently show CBD lowers blood pressure, particularly during stress. The meta analysis confirms this isn't random. CBD really does affect blood pressure.\n\nWhat I find most interesting is the stress blood pressure effect. We know chronic stress contributes to cardiovascular disease. If CBD can moderate the blood pressure response to stress, that could have real cardiovascular benefits over time. This isn't about treating hypertension. It's about potentially reducing the cardiovascular damage from daily stress.\n\nHowever, I want to be careful here. CBD hasn't been tested as a treatment for clinical hypertension. If you have high blood pressure, you need proper medical treatment. Blood pressure medications save lives. CBD might be a reasonable complement to stress management, but it's not a substitute for antihypertensive therapy.\n\nMy practical perspective: if you're generally healthy and interested in CBD for wellness, the blood pressure effects are a reasonable bonus, not a primary reason to use it. If you have hypertension, talk to your doctor before trying CBD. They can advise on whether it makes sense alongside your current treatment and help monitor for any interactions with your medications.\n\n---\n\n## Häufig gestellte Fragen\n\n### Kann CBD high blood pressure?\n\nNo. CBD is not a treatment for hypertension. While studies show CBD can lower blood pressure, it hasn't been tested as a long term treatment for high blood pressure. If you have hypertension, continue your prescribed treatment and discuss CBD as a potential complement with your doctor.\n\n### How much does CBD lower blood pressure?\n\nStudies show varying effects, but typical reductions are in the range of 5 to 10 mmHg for systolic blood pressure after acute doses of 300 to 600mg. Effects during stress may be larger. Individual responses vary, and long term effects from regular use aren't well established.\n\n### Is CBD safe with blood pressure medications?\n\nCBD may potentially enhance the effects of blood pressure lowering medications. If you take antihypertensives, discuss CBD use with your doctor before starting. They can monitor your blood pressure and adjust medications if needed.\n\n### Does CBD cause low blood pressure?\n\nIn some people, CBD can cause a noticeable blood pressure drop, which might cause lightheadedness, especially when standing up quickly. This is more likely with higher doses. If you're sensitive to blood pressure changes, start with lower doses.\n\n### How quickly does CBD affect blood pressure?\n\nAcute effects on blood pressure typically occur within one to two hours after taking CBD, depending on the delivery method. Effects may last several hours. For stress blood pressure reduction, effects are observed during the stress event.\n\n### Should I stop blood pressure medication and use CBD instead?\n\nNo. Never stop prescribed blood pressure medications without medical guidance. Uncontrolled hypertension causes serious health problems including stroke and heart disease. If you're interested in CBD, discuss it with your doctor as a potential addition to your treatment, not a replacement.\n\n---\n\n\n\n---\n\n## Related Conditions\n\nYou may also be interested in:\n\n- [CBD and Heart health](/knowledge/cbd-and-heart-health)\n- [CBD and Stress](/knowledge/cbd-and-stress)\n- [CBD and Anxiety](/knowledge/cbd-and-anxiety)\n\n## Referenzen\n\nIch habe 64 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Blood Pressure Meta Analysis** (2025). Systematic Review and Meta analysis to Investigate the Effects of Cannabidiol on Blood Pressure.\n\n2. **Mechanism Study** (2025). Can Endocannabinoids Explain CBD Mediated Reduction in Blood Pressure? Insights from Research.\n\n3. **Ambulatory BP Study** (2023). Effects of CBD supplementation on ambulatory blood pressure and serum urotensin II.\n\n4. **Autonomic Balance Study** (2022). The Effects of Acute Cannabidiol on Autonomic Balance.\n\n5. **Vascular Dementia Study** (2025). Effects of cannabidiol on behavioral and psychological symptoms of vascular dementia.\n\n6. **Safety Study** (2022). Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD).\n\n7. **Multiple acute dosing studies examining blood pressure responses to CBD.**\n\n8. **Cardiovascular physiology research on [Endocannabinoid-System](/glossary/endocannabinoid-system) and vascular function.**\n\n[Alle 64 Studien zu CBD und blood pressure →](/research?topic=blood_pressure)\n\n---\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD and Blood Pressure: What the Research Shows.\"\nAbgerufen von https://cbd-portal.com/articles/cbd-and-blood-pressure\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 64\n- Humanstudien: 64\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: Januar 21, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*This article is for informational purposes only. It is not medical advice. High blood pressure requires professional medical treatment. Never substitute CBD for prescribed blood pressure medications. Consult your doctor before using CBD if you have hypertension or take cardiovascular medications.*\n",
    "meta_title": "CBD und Blutdruck: Was die Forschung zeigt 2026 | CBD Portal",
    "meta_description": "What does research say about CBD for blood pressure? Analysis of 64 studies on hypertension, stress response, and cardiovascular effects.",
    "translation_quality": "professional"
  },
  {
    "article_id": "f553ed71-55f4-4f3e-ac56-0cba93e7137a",
    "language": "de",
    "slug": "cbd-und-ekzeme",
    "title": "CBD und Ekzeme & Dermatitis: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei eczema & dermatitis? Wir haben 0 begutachtete Studien analysiert, um das herauszufinden. Evidence level: Insufficient.",
    "content": "# CBD und Eczema & Dermatitis: Was die Forschung zeigt\n\nHilft CBD bei eczema & dermatitis? Basierend auf den 0 Studien, die ich überprüft habe, I have to be direct: there's very little research specifically on CBD and eczema & dermatitis. The few studies that exist are preliminary, and I can't draw meaningful conclusions from such limited data.\n\n\n## Verwandte Artikel\n\n- [CBD and Cancer & Oncology: What the Research Shows](/articles/cbd-and-cancer)\n- [CBD and Alzheimer's Disease & Dementia: What the Research Shows](/articles/cbd-and-alzheimers)\n- [CBD and Arthritis & Joint Pain: What the Research Shows](/articles/cbd-and-arthritis)\n- [CBD and Fibromyalgia Syndrome: What the Research Shows](/articles/cbd-and-fibromyalgia)\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 0 |\n| **Klinische Humanstudien** | 0 |\n| **Systematische Übersichten** | 0 |\n| **Gesamtzahl der Teilnehmer** | 0 |\n| **Forschungszeitraum** | 2000-2026 |\n| **Evidenzstärke** | ●○○○○ Insufficient |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nCurrently, there are no completed clinical trials specifically testing CBD for eczema & dermatitis. The existing research is primarily preclinical.\n\n### Was Übersichten schlussfolgern\n\nEs wurden keine systematischen Übersichten speziell zu CBD und eczema & dermatitis. Diese Lücke in der Literatur macht es schwierig, endgültige Schlussfolgerungen zu ziehen.\n\n### Unterstützende Beweise\n\nBegrenzt preclinical research exists for this condition. More foundational studies would help establish biological mechanisms before clinical trials can be designed.\n\n## Wie CBD bei Eczema & Dermatitis\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für eczema & dermatitis noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin) receptors (5-HT1A):** Mai influence [mood](/conditions/mood) and perception\n- **TRPV1-Rezeptoren:** Involved in [pain](/conditions/pain) perception and [inflammation](/conditions/inflammation)\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit eczema & dermatitis zusammenhängen.\n\n## Meine Einschätzung\n\nNachdem ich 0 Studien zu CBD und eczema & dermatitis — und über 12 Jahre in der CBD-Branche gearbeitet habe — hier ist meine ehrliche Einschätzung:\n\nI have to be direct: there's almost no research on CBD for eczema & dermatitis. I can't recommend it based on evidence because the evidence doesn't exist yet. Some people try it based on CBD's general effects, but you'd be experimenting, not following science.\n\nWhat I'm watching for: Any foundational research that could justify clinical studies.\n\n## Häufig gestellte Fragen\n\n### Kann CBD eczema & dermatitis?\n\nNein. CBD ist kein Heilmittel für eczema & dermatitis. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für eczema & dermatitis?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei eczema & dermatitis?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). If you're taking any medications, especially [blood thinners](/conditions/blood-thinners), anti-seizure drugs, or [antidepressants](/conditions/antidepressants), consult your doctor before using CBD.\n\n### Welche Art von CBD ist am besten für eczema & dermatitis?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 0 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n[Alle 0 Studien zu CBD und eczema & dermatitis →](/research?topic=eczema)\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und Ekzeme & Dermatitis: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei eczema & dermatitis? Wir haben 0 begutachtete Studien analysiert, um das herauszufinden. Evidence level: Insufficient.",
    "translation_quality": "professional"
  },
  {
    "article_id": "dadbb5c7-f512-4f20-af5f-0b4c5ad0d5e8",
    "language": "de",
    "slug": "cbd-und-frauengesundheit",
    "title": "CBD und Frauengesundheit: Was die Forschung zeigt 2026",
    "excerpt": "Umfassende Analyse of 54 studies on CBD and womens health. Forschung zeigt promise for menstrual symptoms and menopause, with important pregnancy safety concerns.",
    "content": "By Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nReviewed 54 studies for this article | Zuletzt aktualisiert: Januar 21, 2026\n\n---\n\n## The Short Answer\n\nHilft CBD bei women's health issues? Basierend auf den 54 Studien, die ich überprüft habe, the evidence shows promise for several concerns specific to women. Research is examining CBD for menstrual symptoms, menopausal complaints, and conditions like aromatase inhibitor associated joint [pain](/conditions/pain) in breast [cancer](/conditions/cancer) survivors. Clinical trials are testing CBD vaginal suppositories for [menopause](/conditions/menopause) and oral CBD for period pain. However, important safety concerns exist around [pregnancy](/conditions/pregnancy) and [breastfeeding](/conditions/breastfeeding) where CBD should be avoided.\n\n---\n\n## Forschungsübersicht\n\n| | |\n|---|---|\n| **Studies reviewed** | 54 |\n| **Human studies** | 54 |\n| **Clinical trials** | Multiple RCTs |\n| **Starkest evidence for** | Menstrual symptoms, menopause |\n| **Typical dosages studied** | 50 to 300mg per day |\n| **Evidence strength** | ●●●○○ Moderat |\n\n---\n\n## Wichtige Zahlen\n\n| Stat | Finding |\n|------|---------|\n| **54** | Total women's health studies reviewed |\n| **54** | Human studies |\n| **38** | Studies published 2023 to 2026 |\n| **1981 to 2026** | Over 45 years of research |\n| **Critical** | Pregnancy safety concerns identified |\n\n---\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nWomen's health research with CBD has expanded significantly, with trials targeting conditions that disproportionately affect women.\n\nA 2025 randomized controlled trial tested CBD based vaginal suppositories specifically for menopausal symptoms, examining a novel delivery method for this common concern.\n\nA 2023 randomized open label trial examined [CBD isolate](/glossary/cbd-isolate) effects on menstrual related symptoms, directly testing CBD for period pain and related issues.\n\nA 2025 phase 2 trial tested CBD for aromatase inhibitor associated arthralgia, the joint pain that affects many breast cancer survivors taking hormone blocking medications.\n\nResearch from 2025 examined [full-spectrum](/glossary/full-spectrum) cannabis extracts specifically for women with [chronic pain](/conditions/chronic_pain) syndromes, recognizing that women experience and respond to pain differently than men.\n\n### Was Übersichten schlussfolgern\n\nThe scientific literature recognizes that women may respond differently to cannabinoids than men due to hormonal interactions and physiological differences.\n\nReviews highlight that the [Endocannabinoid-System](/glossary/endocannabinoid-system) interacts with female hormones including estrogen. This interaction may explain why some women report CBD helps with hormone related symptoms.\n\nThe literature strongly emphasizes safety concerns during pregnancy and breastfeeding. Multiple studies and regulatory agencies warn against CBD use during these periods due to potential developmental effects.\n\nReviews also note that women make up a significant portion of CBD users, often seeking relief for conditions like [anxiety](/conditions/anxiety), pain, and [sleep](/conditions/sleep) issues that affect women at higher rates than men.\n\n### Unterstützende Beweise\n\nMenopause research is developing rapidly. A 2026 study examined CBD as a non hormonal treatment option for menopausal symptoms, relevant for women who cannot or prefer not to use hormone replacement therapy.\n\nResearch on cannabis suppositories combined with mindfulness for pelvic symptoms suggests multimodal approaches may help conditions like [endometriosis](/conditions/endometriosis) and chronic [pelvic pain](/conditions/pelvic-pain).\n\nStudies examining sex differences in cannabis treatment outcomes found women may respond differently to cannabinoids, highlighting the importance of women specific research.\n\nPregnancy and breastfeeding research consistently raises safety concerns. Multiple animal and human studies suggest potential risks to fetal and infant development.\n\n---\n\n## Wissenswerte Studien\n\n### Effect of Cannabidiol-Based Vaginal Suppositories on Meno... (2025)\n\nA [2025 clinical study](/research/study/cbd-[arthritis](/conditions/arthritis)-research-2025-1) examining CBD's effects related to womens health.\n\n**Key finding:** This trial tests CBD/hyaluronic acid vaginal suppositories for menopausal symptoms. Researchers evaluate whether this combination relieves symptoms li...\n\n**Stichprobe:** Multiple studies reviewed | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with womens health related symptoms.\n\n[View study summary →](/research/study/cbd-arthritis-research-2025-1)\n\n---\n\n### Effects of Repeated Cannabis Administration on Experiment... (2025)\n\nA [2025 clinical study](/research/study/cbd-sleep-research-2025-2) examining CBD's effects related to womens health.\n\n**Key finding:** This inpatient study tests repeated daily cannabis use for pain, measuring whether tolerance develops and if hyperalgesia (increased pain sensitivity)...\n\n**Stichprobe:** 16 Teilnehmer | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with womens health related symptoms.\n\n[View study summary →](/research/study/cbd-sleep-research-2025-2)\n\n---\n\n### A Feasibility Study of Topical Cannabinoids for Treatment... (2025)\n\nA [2025 clinical study](/research/study/cbd-pain-blaes-2025) examining CBD's effects related to womens health.\n\n**Key finding:** This pilot study tests whether cannabinoid creams help with joint pain caused by aromatase inhibitors, a common breast cancer treatment. Women will tr...\n\n**Stichprobe:** 3 Teilnehmer | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with womens health related symptoms.\n\n\n> For more information, see our guide on [CBD and Endometriosis: What the Research Shows](/articles/cbd-and-endometriosis).\n[View study summary →](/research/study/cbd-pain-blaes-2025)\n\n---\n\n### A Randomized, Open-Label Trial on the Effects of Cannabid... (2023)\n\nA [2023 clinical study](/research/study/cbd-arthritis-irons-2023) examining CBD's effects related to womens health.\n\n**Key finding:** This trial compares two CBD doses for menstrual-related symptoms. Participants take 160mg or 320mg of CBD daily for five days during three menstrual c...\n\n**Stichprobe:** Multiple studies reviewed | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with womens health related symptoms.\n\n[View study summary →](/research/study/cbd-arthritis-irons-2023)\n\n---\n\n## How CBD Might Help Women's Health\n\nCBD's potential benefits for women's health involve mechanisms relevant to hormonal and reproductive function.\n\nThe [Endocannabinoid-System](/glossary/endocannabinoid-system) interacts extensively with the female reproductive system. Endocannabinoid receptors are present in the uterus, ovaries, and throughout reproductive tissues. CBD's modulation of this system could affect menstrual and reproductive function.\n\nPain modulation through CBD's [anti-inflammatory](/glossary/[anti-inflammatory](/glossary/anti-inflammatory)) effects addresses the [inflammation](/conditions/inflammation) underlying [menstrual cramps](/conditions/menstrual-cramps), endometriosis pain, and other gynecological pain conditions.\n\nHormone interaction is complex. Some research suggests CBD may affect hormone metabolism, though the clinical significance isn't fully understood. This interaction might explain reported effects on menstrual symptoms and menopause.\n\nAnxiety and [mood](/conditions/mood) effects benefit women who experience premenstrual mood changes, perimenopausal anxiety, or [stress](/conditions/stress) related to women's health conditions.\n\nSleep improvement could help women dealing with perimenopausal insomnia or sleep disruption from [hot flashes](/conditions/hot-flashes).\n\nVasomotor symptoms (hot flashes) might respond to CBD through effects on temperature regulation and the autonomic [nervous system](/conditions/nervous-system), though research is still early.\n\n---\n\n## Welche Dosierungen wurden untersucht\n\nI want to be clear: I'm not prescribing a dose. Women's health needs vary widely, and some situations require avoiding CBD entirely.\n\n**For menstrual symptoms:**\n- Oral CBD: 50 to 150mg during symptomatic days\n- Some studies use CBD throughout the cycle\n- Timing around symptoms may be important\n\n**For menopausal symptoms:**\n- Oral: 50 to 200mg daily\n- Vaginal suppositories being studied for local effects\n- Consistent use may be more effective than as needed\n\n**For chronic pain conditions:**\n- Higher doses may be needed: 100 to 300mg\n- Often used alongside other treatments\n- Long term use common for chronic conditions\n\n**Critical safety information:**\n- AVOID during pregnancy\n- AVOID during breastfeeding\n- Discuss with healthcare provider if trying to conceive\n- Mai interact with hormonal contraceptives\n- Mai interact with other medications\n\nVerwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) for general guidance, but always discuss women's health concerns with your healthcare provider.\n\n---\n\n## Meine Einschätzung\n\nNachdem ich 54 Studien zu CBD und women's health, and worked in the CBD industry for over a decade, here's my honest assessment:\n\nWomen's health is an area where CBD shows genuine promise but requires careful consideration. The menstrual and menopausal research is encouraging. Many women struggle with these issues and have limited options, especially women who can't use hormonal treatments.\n\nI'm particularly interested in the aromatase inhibitor research. Breast cancer survivors face a cruel choice: endure severe joint pain from medications that reduce their cancer recurrence risk, or stop the medication. If CBD can help them tolerate these treatments, that's potentially life saving.\n\nHowever, I need to be very clear about pregnancy and breastfeeding: the research consistently raises concerns. This isn't overcaution. Multiple studies show potential effects on fetal development. The FDA explicitly advises against CBD during pregnancy and breastfeeding. Until we know more, CBD should be avoided during these periods.\n\nMy practical advice: for menstrual symptoms or menopause, CBD may be worth trying under appropriate guidance. For chronic conditions like endometriosis, discuss CBD as part of a comprehensive treatment plan. If you're pregnant, breastfeeding, or trying to conceive, wait until more safety data is available.\n\n---\n\n## Häufig gestellte Fragen\n\n### Can CBD help with period pain?\n\nResearch suggests CBD may help with menstrual cramps through its anti inflammatory and pain relieving effects. Some studies directly test CBD for menstrual symptoms with promising results. Many women report benefit, though individual responses vary.\n\n### Is CBD safe during pregnancy?\n\nBased on current evidence, CBD should be avoided during pregnancy. Multiple studies show potential risks to fetal development, and the FDA advises against CBD use during pregnancy. The potential risks outweigh any potential benefits.\n\n### Can CBD help with menopause symptoms?\n\nEarly research is promising. Clinical trials are testing CBD for hot flashes, sleep problems, and other menopausal symptoms. CBD may offer a non hormonal option for women who cannot or prefer not to use hormone replacement therapy.\n\n### Does CBD interact with birth control?\n\nCBD may potentially interact with hormonal contraceptives through liver enzyme effects. While significant interactions haven't been proven, discuss CBD use with your healthcare provider if you rely on hormonal contraception.\n\n### Can I use CBD while breastfeeding?\n\nNo. CBD should be avoided while breastfeeding. CBD can transfer to breast milk, and potential effects on infant development aren't fully understood. Wait until you've finished breastfeeding before using CBD.\n\n### Hilft CBD bei endometriosis?\n\nResearch is limited but suggests CBD's anti inflammatory and pain relieving properties could benefit endometriosis symptoms. Some studies examine cannabis suppositories for pelvic pain. Discuss CBD as part of comprehensive endometriosis management with your gynecologist.\n\n---\n\n\n\n---\n\n## Related Conditions\n\nYou may also be interested in:\n\n- [CBD and Pain](/knowledge/cbd-and-pain)\n- [CBD and Anxiety](/knowledge/cbd-and-anxiety)\n- [CBD and Sleep](/knowledge/cbd-and-sleep)\n\n## Referenzen\n\nIch habe 54 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Menopausal Suppository Trial** (2025). Effect of [Cannabidiol](/glossary/cannabidiol) Based Vaginal Suppositories on Menopausal Symptoms: a Randomized Trial.\n\n2. **Menstrual Symptoms Study** (2023). A Randomized, Open Label Trial on the Effects of Cannabidiol [Isolate](/glossary/cbd-isolate) on Menstrual Related Symptoms.\n\n3. **Aromatase Inhibitor Study** (2025). Phase 2 Trial of Cannabidiol (CBD) for Treatment of Aromatase Inhibitor Associated Arthralgia.\n\n4. **Chronic Pain Study** (2025). [full-spectrum](/glossary/full-spectrum) cannabis extracts for women with chronic pain syndromes: a real life report.\n\n5. **Non Hormonal Treatment** (2026). Cannabidiol (CBD): An acceptable non hormonal treatment option for women suffering with menopausal symptoms.\n\n6. **Pregnancy Pharmacokinetics** (2021). Maternal and Fetal Pharmacokinetic Analysis of Cannabidiol during Pregnancy in Mice.\n\n7. **Sex Differences Review** (2020). Sex and Gender Based Analysis in Cannabis Treatment Outcomes: A Systematic Review.\n\n8. **FDA Guidance** (2020). FDA advises against CBD, [THC](/glossary/thc), and marijuana during pregnancy and breastfeeding.\n\n[Alle 54 Studien zu CBD und women's health →](/research?topic=womens)\n\n---\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD and Women's Health: What the Research Shows.\"\nAbgerufen von https://cbd-portal.com/articles/cbd-and-womens-health\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 54\n- Humanstudien: 54\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: Januar 21, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*This article is for informational purposes only. It is not medical advice. Women's health concerns often require professional medical guidance. Consult your healthcare provider before using CBD, especially if pregnant, breastfeeding, trying to conceive, or taking hormonal medications.*\n",
    "meta_title": "CBD und Frauengesundheit: Was die Forschung zeigt 2026 | CBD Portal",
    "meta_description": "What does research say about CBD for womens health? Analysis of 54 studies on menstrual pain, menopause, and pregnancy safety.",
    "translation_quality": "professional"
  },
  {
    "article_id": "7fe70587-8af1-4f1f-8ac5-2d7cb305ff27",
    "language": "de",
    "slug": "cbd-und-uebelkeit",
    "title": "CBD und Übelkeit & Erbrechen: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei nausea & vomiting? Wir haben 20 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "content": "# CBD und Nausea & Vomiting: Was die Forschung zeigt\n\nHilft CBD bei nausea & vomiting? Basierend auf den 20 Studien, die ich überprüft habe, zeigt die Forschung vielversprechende Ergebnisse, obwohl wir noch mehr groß angelegte Studien benötigen. Die bestehenden Studien deuten auf potenzielle Vorteile hin, aber ich möchte zusätzliche Daten sehen, bevor ich endgültige Schlussfolgerungen ziehe. Wenn Sie CBD für nausea & vomiting in Betracht ziehen, bietet die Forschung Gründe für vorsichtigen Optimismus.\n\n\n## Verwandte Artikel\n\n- [CBD for Dog Nausea: Natural Relief for Upset Stomachs](/articles/cbd-for-dog-nausea)\n- [CBD and Cancer & Oncology: What the Research Shows](/articles/cbd-and-cancer)\n- [CBD and Alzheimer's Disease & Dementia: What the Research Shows](/articles/cbd-and-alzheimers)\n- [CBD and Eczema & Dermatitis: What the Research Shows](/articles/cbd-and-eczema)\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 20 |\n| **Klinische Humanstudien** | 20 |\n| **Systematische Übersichten** | 0 |\n| **Gesamtzahl der Teilnehmer** | 0 |\n| **Forschungszeitraum** | 2001-2025 |\n| **Evidenzstärke** | ●●●○○ Moderat |\n\n## Wichtige Zahlen\n\n| Statistik | Beschreibung |\n|------|-------------|\n| **20** | Gesamtzahl der analysierten begutachteten Studien |\n| **15%** | Studien mit positiven oder vielversprechenden Ergebnissen |\n| **20** | Humanstudien und systematische Übersichten |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nDie stärksten Beweise stammen aus 20 Humanstudien, darunter 0 randomisierte kontrollierte Studien. \n\nEine [Studie aus 2013](/research/study/tetrahydrocannabinolic-acid-reduces-nauseainduced-rock-2013) ergab, dass this study \"tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats\" was cited in cbd portal articles and has been imported for reference....\n\nEine [Studie aus 2012](/research/study/cannabidiol-a-nonpsychotropic-component-rock-2012) ergab, dass this study \"cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-ht1a somatodendritic autoreceptors in the dorsal raphe nucleu...\n\nEine [Studie aus 2013](/research/study/cannabidiolic-acid-prevents-vomiting-bolognini-2013) ergab, dass this study \"cannabidiolic acid prevents vomiting in suncus murinus and nausea-induced behaviour in rats\" was cited in cbd portal articles and has been imported for reference....\n\n### Was Übersichten schlussfolgern\n\nEs wurden keine systematischen Übersichten speziell zu CBD und nausea & vomiting. Diese Lücke in der Literatur macht es schwierig, endgültige Schlussfolgerungen zu ziehen.\n\n### Unterstützende Beweise\n\nBegrenzt preclinical research exists for this condition. More foundational studies would help establish biological mechanisms before clinical trials can be designed.\n\n## Wissenswerte Studien\n\n### Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats (2013)\n\nThis study \"Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats\" was cited in CBD Portal articles and has been imported for reference.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 70/100\n\n[Studienzusammenfassung ansehen](/research/study/tetrahydrocannabinolic-acid-reduces-nauseainduced-rock-2013)\n\n### Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and n... (2012)\n\nThis study \"Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus\" was cited in CBD Portal articles and has been imported for reference.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 70/100\n\n[Studienzusammenfassung ansehen](/research/study/cannabidiol-a-nonpsychotropic-component-rock-2012)\n\n### Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behavi... (2013)\n\nThis study \"Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats\" was cited in CBD Portal articles and has been imported for reference.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 70/100\n\n\n> For more information, see our guide on [CBD and Dog Nausea & Motion Sickness: What the Research Shows](/articles/cbd-and-dog-nausea).\n[Studienzusammenfassung ansehen](/research/study/cannabidiolic-acid-prevents-vomiting-bolognini-2013)\n\n## Wie CBD bei Nausea & Vomiting\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für nausea & vomiting noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin) receptors (5-HT1A):** Mai influence [mood](/conditions/mood) and perception\n- **TRPV1-Rezeptoren:** Involved in [pain](/conditions/pain) perception and [inflammation](/conditions/inflammation)\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit nausea & vomiting zusammenhängen.\n\n## Welche Dosierungen wurden untersucht\n\n**Wichtig:** Dies ist KEINE medizinische Beratung. Ich teile mit, was Forscher in Studien verwendet haben, nicht empfohlene Dosierungen.\n\nIn den von mir überprüften Studien variierten die Dosierungen stark — typischerweise von 25mg bis 600mg täglich, abhängig vom Studiendesign und den spezifisch gemessenen Ergebnissen. Einige wichtige Muster:\n\n- Niedrigere Dosen (25-50mg) wurden in ersten Verträglichkeitsstudien verwendet\n- Moderat doses (100-300mg) appeared in many clinical trials\n- Höhere Dosen (400-600mg+) wurden in einigen spezifischen Kontexten verwendet\n\nWenn Sie CBD in Betracht ziehen, verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt, aber konsultieren Sie immer einen Gesundheitsdienstleister.\n\n## Meine Einschätzung\n\nNachdem ich 20 Studien zu CBD und nausea & vomiting — und über 12 Jahre in der CBD-Branche gearbeitet habe — hier ist meine ehrliche Einschätzung:\n\nDie Forschung ist vielversprechend, aber nicht schlüssig. Ich habe genügend positive Ergebnisse gesehen, um zu denken, dass CBD für nausea & vomiting eine Überlegung wert ist, aber ich möchte größere Studien sehen, bevor ich vollkommen überzeugt bin. Wenn Sie es ausprobieren, halten Sie Ihre Erwartungen realistisch und verfolgen Sie Ihre Ergebnisse.\n\nWorauf ich achte: Mehr randomisierte kontrollierte Studien mit größeren Stichprobengrößen.\n\n## Häufig gestellte Fragen\n\n### Kann CBD nausea & vomiting?\n\nNein. CBD ist kein Heilmittel für nausea & vomiting. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für nausea & vomiting?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei nausea & vomiting?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). If you're taking any medications, especially [blood thinners](/conditions/blood-thinners), anti-seizure drugs, or [antidepressants](/conditions/antidepressants), consult your doctor before using CBD.\n\n### Welche Art von CBD ist am besten für nausea & vomiting?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 20 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Rock EM, et al** (2013). Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats. *Psychopharmacology*.\n   [Zusammenfassung](/research/study/tetrahydrocannabinolic-acid-reduces-nauseainduced-rock-2013) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/23889598/) • DOI: 10.1111/bph.12316\n\n2. **Rock EM, et al** (2012). Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus. *Br J Pharmacol*.\n   [Zusammenfassung](/research/study/cannabidiol-a-nonpsychotropic-component-rock-2012) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/21827451/) • DOI: 10.1111/j.1476-5381.2011.01621.x\n\n3. **Bolognini D, et al** (2013). Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats. *Br J Pharmacol*.\n   [Zusammenfassung](/research/study/cannabidiolic-acid-prevents-vomiting-bolognini-2013) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/23121618/) • DOI: 10.1111/bph.12043\n\n4. **Sun X, Nie F, Sun J, Zhang J, Wang Y** (2025). Medicinal Plants for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Antiemetic, Chemosensitizing, and Immunomodulatory Mechanisms.. *Ther Clin Risk Manag*.\n   [Zusammenfassung](/research/study/medicinal-plants-for-chemotherapy-induced-nausea-and-vomitin-2025-f3e804) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/40771488/) • DOI: 10.2147/tcrm.s531645\n\n[Alle 20 Studien zu CBD und nausea & vomiting →](/research?topic=nausea)\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD and Nausea & Vomiting: What the Research Shows.\" Abgerufen von https://cbd-portal.vercel.app/conditions/nausea\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 20\n- Humanstudien: 20\n- Total Teilnehmer: 0\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: Januar 24, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und Übelkeit & Erbrechen: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei nausea & vomiting? Wir haben 20 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "translation_quality": "professional"
  },
  {
    "article_id": "40af40c8-0cd8-4672-9f19-66c66c4ab46d",
    "language": "de",
    "slug": "cbd-und-augengesundheit",
    "title": "CBD und Augengesundheit: Was die Forschung zeigt 2026",
    "excerpt": "Analysis of 25 studies on CBD and eye health. Important finding: CBD may not help glaucoma and could potentially increase eye pressure, contrary to popular belief.",
    "content": "By Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nReviewed 25 studies for this article | Zuletzt aktualisiert: Januar 21, 2026\n\n---\n\n## The Short Answer\n\nHilft CBD bei eye health and [glaucoma](/glossary/glaucoma)? Basierend auf den 25 Studien, die ich überprüft habe, the answer is nuanced. While [THC](/glossary/thc) has been shown to lower [intraocular pressure](/glossary/intraocular-pressure) (IOP), CBD's effects are more complex. Some research suggests CBD may actually increase IOP or interfere with THC's pressure lowering effects. The [Endocannabinoid-System](/glossary/endocannabinoid-system) does play a role in eye function, but CBD specifically may not be beneficial for [glaucoma](/conditions/glaucoma). This is an area where the evidence goes against popular assumptions.\n\n---\n\n## Forschungsübersicht\n\n| | |\n|---|---|\n| **Studies reviewed** | 25 |\n| **Human studies** | 25 |\n| **Clinical trials** | Multiple controlled studies |\n| **Key finding** | CBD may increase IOP |\n| **Typical context** | Glaucoma, ocular pressure |\n| **Evidence strength** | ●●○○○ Begrenzt (with caution) |\n\n---\n\n## Wichtige Zahlen\n\n| Stat | Finding |\n|------|---------|\n| **25** | Total eye health studies reviewed |\n| **25** | Human and clinical studies |\n| **5** | Studies published 2023 to 2026 |\n| **1984 to 2026** | Over 40 years of research |\n| **Important** | CBD and THC have different effects |\n\n---\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nEye health research with cannabinoids has revealed that different cannabinoids have different, sometimes opposite, effects on the eye.\n\nA 2025 study examined the effect of dronabinol (synthetic THC) on ocular hemodynamics, finding effects on blood flow in the eye. This addresses vascular aspects of glaucoma.\n\nA 2018 study specifically compared THC and CBD effects on intraocular pressure, finding they work differently. THC lowered pressure while CBD did not, and CBD may even interfere with THC's beneficial effects.\n\nA 2006 pilot study examined [sublingual](/glossary/sublingual) cannabinoid application effects on intraocular pressure, providing early evidence on how different cannabinoids affect IOP.\n\nResearch from 2022 examined CBD's effects on aqueous humor outflow and trabecular meshwork cell signaling, the specific mechanisms that regulate eye pressure.\n\n### Was Übersichten schlussfolgern\n\nThe scientific literature reveals an important distinction: while cannabis has historically been associated with lowering eye pressure, this effect appears primarily due to THC, not CBD.\n\nA 2019 review specifically addressed what is currently known about CBD and ocular pressure, concluding that CBD's effects are different from and potentially antagonistic to THC's beneficial effects on IOP.\n\nReviews note that the [Endocannabinoid-System](/glossary/endocannabinoid-system) is present throughout the eye, including in the structures that regulate intraocular pressure. However, CBD's interactions with this system don't appear to lower pressure as THC does.\n\nThe literature emphasizes that patients using CBD for glaucoma based on cannabis's reputation may not be getting the pressure lowering benefits they expect, and could potentially be harming their eye health.\n\n### Unterstützende Beweise\n\nOcular blood flow research shows cannabinoids affect [circulation](/conditions/circulation) in the eye. A 2025 single oral dose study of dronabinol increased ocular blood flow in glaucoma patients, which could be [neuroprotective](/glossary/neuroprotective).\n\nResearch on the [Endocannabinoid-System](/glossary/endocannabinoid-system) in the eye has expanded understanding of how cannabinoids might affect various eye conditions beyond just pressure.\n\nNeuroprotection studies examine whether cannabinoids might protect the optic nerve independently of pressure effects, relevant because glaucoma damages the optic nerve.\n\n---\n\n\nRelevant research includes:\n- [The Effect of Dronabinol on Ocular Hemodynamics in... (2025)](/research/study/cbd-[arthritis](/conditions/arthritis)-research-2025-4)\n\n## Wissenswerte Studien\n\n### THC vs CBD Comparison (2018)\n\nDirect comparison of how THC and CBD affect intraocular pressure differently.\n\n**Key finding:** THC lowered IOP while CBD did not have this effect and may counteract THC's pressure lowering effects.\n\n**Stichprobe:** Controlled comparison | **Typ:** Mechanistic Study\n\n**Why it matters:** This directly challenges the assumption that CBD helps glaucoma. Patients need to understand that CBD and THC have different, potentially opposite effects on eye pressure.\n\n---\n\n### Ocular Blood Flow Study (2025)\n\nResearch on synthetic THC (dronabinol) effects on eye circulation.\n\n**Key finding:** Oral dronabinol increased blood flow in the eyes of glaucoma patients.\n\n**Stichprobe:** Glaucoma patients | **Typ:** Clinical Study\n\n**Why it matters:** Glaucoma involves both pressure and blood flow issues. Understanding how cannabinoids affect ocular circulation helps evaluate their potential role in treatment.\n\n---\n\n### CBD and Ocular Pressure Review (2019)\n\nReview of current knowledge about CBD specifically and eye pressure.\n\n**Key finding:** Concluded that CBD does not lower IOP and may even raise it, contrary to popular belief about cannabis and glaucoma.\n\n**Stichprobe:** Literature review | **Typ:** Review\n\n**Why it matters:** This authoritative review corrects misconceptions and warns against assuming CBD helps glaucoma.\n\n---\n\n### Sublingual Cannabinoid Study (2006)\n\n\n> For more information, see our guide on [CBD and Liver Health: What Research Shows About Liver Enzymes](/articles/cbd-and-liver-health).\nEarly clinical research on sublingual cannabinoid effects on eye pressure.\n\n**Key finding:** Examined how different cannabinoid preparations affect IOP when delivered sublingually.\n\n**Stichprobe:** Pilot study Teilnehmer | **Typ:** Pilot Study\n\n**Why it matters:** Provided early evidence distinguishing between different cannabinoids' effects on the eye.\n\n---\n\n## How Cannabinoids Affect the Eye\n\n\n> For more information, see our guide on [CBD and Womens Health: What the Research Shows 2026](/articles/cbd-and-womens-health).\nThe relationship between cannabinoids and eye health involves complex mechanisms that differ between CBD and THC.\n\n\n> For more information, see our guide on [CBD and Neurological Health: What the Research Shows 2026](/articles/cbd-and-neurological-health).\nThe [Endocannabinoid-System](/glossary/endocannabinoid-system) in the eye includes [CB1 receptor](/glossary/cb1-receptor)s in the ciliary body (which produces aqueous humor) and trabecular meshwork (which drains it). This system helps regulate intraocular pressure.\n\n\n> For more information, see our guide on [CBD and Glaucoma & Eye Pressure: What the Research Shows](/articles/cbd-and-glaucoma).\nTHC lowers eye pressure through [CB1 receptor](/glossary/cb1-receptor) activation, increasing aqueous humor outflow. This is the basis for historical interest in cannabis for glaucoma.\n\n\n> For more information, see our guide on [CBD for Eye Health: What We Know](/articles/cbd-for-eye-health).\nCBD's effects are different and potentially problematic for glaucoma. Research suggests CBD may:\n- Not lower IOP significantly\n- Potentially increase IOP\n- Interfere with THC's pressure lowering effects when used together\n\nThe mechanism behind CBD's different effects is being studied. CBD doesn't directly activate [CB1 receptor](/glossary/cb1-receptor) and may modulate them in ways that oppose THC's beneficial effects on eye pressure.\n\nNeuroprotection through cannabinoids might still benefit glaucoma independently of pressure effects. Glaucoma damages the optic nerve, and cannabinoids' [neuroprotective](/glossary/neuroprotective) properties could theoretically help, though this needs more research.\n\n---\n\n## What This Means for Eye Health\n\nI want to be clear: this is one area where I need to present concerning rather than encouraging evidence.\n\n**For glaucoma patients:**\n- CBD alone likely does not lower eye pressure\n- CBD may actually increase IOP\n- CBD may interfere with THC's pressure lowering effects\n- Don't substitute CBD for glaucoma treatment\n\n**For general eye health:**\n- The [Endocannabinoid-System](/glossary/endocannabinoid-system) plays a role in eye function\n- Research continues on cannabinoids for various eye conditions\n- CBD's effects on eye health beyond pressure need more research\n\n**Important considerations:**\n- Glaucoma is a serious condition causing irreversible vision loss\n- Eye pressure must be managed with proven treatments\n- Relying on CBD for glaucoma could result in vision damage\n- Discuss any cannabinoid use with your ophthalmologist\n\nVerwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) for general CBD guidance, but do not use CBD as a glaucoma treatment.\n\n---\n\n## Meine Einschätzung\n\nNachdem ich 25 Studien zu CBD und eye health, and worked in the CBD industry for over a decade, here's my honest assessment:\n\nThis is one area where I need to be clear that CBD may not help and could potentially harm. The popular belief that \"cannabis helps glaucoma\" comes from THC's effects, not CBD's. The research suggests CBD doesn't lower eye pressure and might actually raise it.\n\nI take this seriously because glaucoma causes irreversible vision loss. Someone managing their glaucoma with CBD instead of appropriate treatment could go blind. That's not an exaggeration. Glaucoma progresses silently, and by the time you notice vision loss, permanent damage has occurred.\n\nThe endocannabinoid research in the eye is fascinating from a scientific perspective. There's genuine interest in how this system regulates eye function. But current evidence doesn't support using CBD for glaucoma.\n\nMy practical advice: if you have glaucoma, do not rely on CBD for treatment. Continue your prescribed medications and follow your ophthalmologist's recommendations. If you're interested in cannabinoid approaches, discuss THC based options with your eye doctor, understanding that even these aren't first line treatments. For general eye health without glaucoma, there's no strong reason to use CBD zusammenhängen.\n\n---\n\n## Häufig gestellte Fragen\n\n### Does CBD help glaucoma?\n\nBased on current evidence, CBD does not appear to help glaucoma and may actually be harmful. Research shows CBD does not lower intraocular pressure like THC does, and some studies suggest CBD may increase eye pressure. Do not use CBD as a glaucoma treatment.\n\n### Doesn't cannabis lower eye pressure?\n\nTHC, the psychoactive component of cannabis, can lower intraocular pressure temporarily. However, CBD appears to have different effects and may not lower pressure or could even raise it. The beneficial effects attributed to \"cannabis\" for glaucoma are primarily from THC.\n\n### Can I use CBD with my glaucoma medication?\n\nDiscuss any CBD use with your ophthalmologist. Given that CBD may increase eye pressure, it could potentially interfere with your glaucoma treatment. Do not add CBD to your regimen without medical guidance.\n\n### Is CBD safe for eye health in general?\n\nFor people without glaucoma or elevated eye pressure, there's no specific evidence that CBD harms the eyes. However, there's also no strong evidence it benefits eye health. The concern is specifically for people who need to manage their eye pressure.\n\n### What about CBD eye drops?\n\nResearch on topical CBD for the eye is limited. The systemic effects discussed in studies use oral or sublingual delivery. Topical CBD eye products haven't been proven safe or effective for any eye condition.\n\n### Should I avoid CBD entirely if I have glaucoma?\n\nDiscuss with your ophthalmologist. Given the concerning evidence that CBD may increase eye pressure, caution is warranted. At minimum, don't use CBD hoping it will help your glaucoma, as evidence suggests otherwise.\n\n---\n\n\n\n---\n\n## Related Conditions\n\nYou may also be interested in:\n\n- [CBD and [Neurological](/conditions/neurological) health](/knowledge/cbd-and-neurological-health)\n- [CBD and Healthy aging](/knowledge/cbd-and-healthy-aging)\n\n## Referenzen\n\nIch habe 25 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **THC vs CBD Study** (2018). THC AND CBD DIFFERENTIALLY REGULATE INTRAOCULAR PRESSURE.\n\n2. **Ocular Blood Flow Study** (2025). Single oral administration of dronabinol increases ocular blood flow in patients with glaucoma.\n\n3. **Ocular Hemodynamics Study** (2025). The Effect of Dronabinol on Ocular Hemodynamics in Patients With Primary Glaucoma.\n\n4. **CBD and Ocular Pressure Review** (2019). What is currently known about [cannabidiol](/glossary/cannabidiol) and ocular pressure.\n\n5. **Sublingual Study** (2006). Effect of Sublingual Application of Cannabinoids on Intraocular Pressure: A Pilot Study.\n\n6. **Endocannabinoid Review** (2025). Role of Endocannabinoids in Glaucoma: A Review.\n\n7. **Glaucoma Treatment Review** (2016). Cannabinoids for treatment of glaucoma.\n\n8. **Aqueous Humor Study** (2022). The Effects of Cannabidiol on Aqueous Humor Outflow and Trabecular Meshwork Cell Signaling.\n\n[Alle 25 Studien zu CBD und eye health →](/research?topic=glaucoma)\n\n---\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD and Eye Health: What the Research Shows.\"\nAbgerufen von https://cbd-portal.com/articles/cbd-and-eye-health\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 25\n- Humanstudien: 25\n- Evidenzstärke: Begrenzt (with caution for glaucoma)\n\nZuletzt aktualisiert: Januar 21, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*This article is for informational purposes only. It is not medical advice. Glaucoma is a serious condition requiring professional ophthalmological care. Do not substitute CBD for glaucoma treatment. Consult your eye doctor before using any cannabinoid products if you have glaucoma or ocular hypertension.*\n",
    "meta_title": "CBD und Augengesundheit: Was die Forschung zeigt 2026 | CBD Portal",
    "meta_description": "What does research say about CBD for glaucoma and eye health? Analysis of 25 studies with important findings about CBD and eye pressure.",
    "translation_quality": "professional"
  },
  {
    "article_id": "70a122c1-5404-4fa4-9129-f7fc20f13c57",
    "language": "de",
    "slug": "cbd-und-morbus-crohn",
    "title": "CBD und Morbus Crohn & CED: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei crohn's disease & ibd? Wir haben 101 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "content": "# CBD und Crohn's Disease & IBD: Was die Forschung zeigt\n\nHilft CBD bei crohn's disease & ibd? Basierend auf den 101 Studien, die ich überprüft habe, zeigt die Forschung vielversprechende Ergebnisse, obwohl wir noch mehr groß angelegte Studien benötigen. Die bestehenden Studien deuten auf potenzielle Vorteile hin, aber ich möchte zusätzliche Daten sehen, bevor ich endgültige Schlussfolgerungen ziehe. Wenn Sie CBD für crohn's disease & ibd in Betracht ziehen, bietet die Forschung Gründe für vorsichtigen Optimismus.\n\n\n## Verwandte Artikel\n\n- [CBD and Cancer & Oncology: What the Research Shows](/articles/cbd-and-cancer)\n- [CBD and Alzheimer's Disease & Dementia: What the Research Shows](/articles/cbd-and-alzheimers)\n- [CBD and Eczema & Dermatitis: What the Research Shows](/articles/cbd-and-eczema)\n- [CBD and Arthritis & Joint Pain: What the Research Shows](/articles/cbd-and-arthritis)\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 101 |\n| **Klinische Humanstudien** | 98 |\n| **Systematische Übersichten** | 2 |\n| **Gesamtzahl der Teilnehmer** | 60 |\n| **Forschungszeitraum** | 1998-2026 |\n| **Evidenzstärke** | ●●●○○ Moderat |\n\n## Wichtige Zahlen\n\n| Statistik | Beschreibung |\n|------|-------------|\n| **101** | Gesamtzahl der analysierten begutachteten Studien |\n| **8%** | Studien mit positiven oder vielversprechenden Ergebnissen |\n| **60** | Teilnehmer in der größten Studie |\n| **100** | Humanstudien und systematische Übersichten |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nDie stärksten Beweise stammen aus 98 Humanstudien, darunter 0 randomisierte kontrollierte Studien. \n\nEine [Studie aus 2024](/research/study/cbd-[arthritis](/conditions/arthritis)-research-2024) ergab, dass this trial tests whether cbd can help crohn's disease patients reduce their steroid medications. patients add cbd to their current treatment, then researchers gradually lower steroid doses while monit...\n\nEine [Studie aus 2024](/research/study/cbd-arthritis-leehey-2024) with 60 Teilnehmer ergab, dass this randomized trial tests cbd for motor symptoms in [parkinson's](/conditions/parkinsons) disease. sixty Teilnehmer receive cbd or placebo for 6 weeks while researchers measure tremor, movement, and motor function improvem...\n\nEine [Studie aus 2009](/research/study/2009-the-endocannabinoid-system-bíró-2009) ergab, dass this study \"(2009). \"the Endocannabinoid-System of the skin in health and disease.\"\" was cited in cbd portal articles and has been imported for reference....\n\n### Was Übersichten schlussfolgern\n\n2 systematic reviews have examined the evidence on CBD and crohn's disease & ibd. \n\nA [2025 review](/research/study/cbd-[inflammation](/conditions/inflammation)-wu-2025) This study investigates CBD's anti-inflammatory properties. Researchers are examining how cannabidiol affects immune system responses and inflammation markers.\n\nA [2025 review](/research/study/cbd-inflammation-saa-2025) This study investigates CBD's anti-inflammatory properties. Researchers are examining how cannabidiol affects immune system responses and inflammation markers.\n\n### Unterstützende Beweise\n\nÜber klinische Studien hinaus, 1 Tierstudien and 0 In-vitro-Studien (Labor) liefern unterstützende Beweise. Obwohl diese uns nicht sagen können, wie CBD beim Menschen wirkt, helfen sie dabei, die biologische Plausibilität zu etablieren und zukünftige Forschungsrichtungen zu leiten.\n\n**Wichtiger Kontext:** Tier- und Laborstudien sind Frühphasenforschung. Vielversprechende Ergebnisse bei Mäusen oder Zellkulturen übertragen sich nicht immer auf den Menschen. Ich füge sie hier der Vollständigkeit halber ein, nicht als Beweis für Wirksamkeit.\n\n## Wissenswerte Studien\n\n### A Phase 2a, Randomized, Double-blind, Placebo-controlled, Crossover, Multicenter... (2024)\n\nThis trial tests whether CBD can help Crohn's disease patients reduce their steroid medications. Patients add CBD to their current treatment, then researchers gradually lower steroid doses while monitoring disease activity.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 79/100\n\n[Studienzusammenfassung ansehen](/research/study/cbd-arthritis-research-2024)\n\n### A Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability an... (2024)\n\nThis randomized trial tests CBD for motor symptoms in Parkinson's disease. Sixty Teilnehmer receive CBD or placebo for 6 weeks while researchers measure tremor, movement, and motor function improvements.\n\n**Stichprobe:** 60 Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 73/100\n\n\n> For more information, see our guide on [CBD and Parkinson's Disease: What the Research Shows](/articles/cbd-and-parkinsons).\n[Studienzusammenfassung ansehen](/research/study/cbd-arthritis-leehey-2024)\n\n### (2009). \"The Endocannabinoid-System of the skin in health and disease.\" (2009)\n\n\n> For more information, see our guide on [CBD for Crohn's Disease: What We Know](/articles/cbd-for-crohns-disease).\nThis study \"(2009). \"The Endocannabinoid-System of the skin in health and disease.\"\" was cited in CBD Portal articles and has been imported for reference.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 70/100\n\n[Studienzusammenfassung ansehen](/research/study/2009-the-endocannabinoid-system-bíró-2009)\n\n## Wie CBD bei Crohn's Disease & IBD\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für crohn's disease & ibd noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin) receptors (5-HT1A):** Mai influence [mood](/conditions/mood) and perception\n- **TRPV1-Rezeptoren:** Involved in [pain](/conditions/pain) perception and inflammation\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit crohn's disease & ibd zusammenhängen.\n\n## Welche Dosierungen wurden untersucht\n\n**Wichtig:** Dies ist KEINE medizinische Beratung. Ich teile mit, was Forscher in Studien verwendet haben, nicht empfohlene Dosierungen.\n\nIn den von mir überprüften Studien variierten die Dosierungen stark — typischerweise von 25mg bis 600mg täglich, abhängig vom Studiendesign und den spezifisch gemessenen Ergebnissen. Einige wichtige Muster:\n\n- Niedrigere Dosen (25-50mg) wurden in ersten Verträglichkeitsstudien verwendet\n- Moderat doses (100-300mg) appeared in many clinical trials\n- Höhere Dosen (400-600mg+) wurden in einigen spezifischen Kontexten verwendet\n\nWenn Sie CBD in Betracht ziehen, verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt, aber konsultieren Sie immer einen Gesundheitsdienstleister.\n\n## Meine Einschätzung\n\nNachdem ich 101 Studien zu CBD und crohn's disease & ibd — und über 12 Jahre in der CBD-Branche gearbeitet habe — hier ist meine ehrliche Einschätzung:\n\nDie Forschung ist vielversprechend, aber nicht schlüssig. Ich habe genügend positive Ergebnisse gesehen, um zu denken, dass CBD für crohn's disease & ibd eine Überlegung wert ist, aber ich möchte größere Studien sehen, bevor ich vollkommen überzeugt bin. Wenn Sie es ausprobieren, halten Sie Ihre Erwartungen realistisch und verfolgen Sie Ihre Ergebnisse.\n\nWorauf ich achte: Mehr randomisierte kontrollierte Studien mit größeren Stichprobengrößen.\n\n## Häufig gestellte Fragen\n\n### Kann CBD crohn's disease & ibd?\n\nNein. CBD ist kein Heilmittel für crohn's disease & ibd. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für crohn's disease & ibd?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei crohn's disease & ibd?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). If you're taking any medications, especially [blood thinners](/conditions/blood-thinners), anti-seizure drugs, or [antidepressants](/conditions/antidepressants), consult your doctor before using CBD.\n\n### Welche Art von CBD ist am besten für crohn's disease & ibd?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 101 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Authors** (2024). A Phase 2a, Randomized, Double-blind, Placebo-controlled, Crossover, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients. *ClinicalTrials.gov*.\n   [Zusammenfassung](/research/study/cbd-arthritis-research-2024)\n\n2. **Maureen Leehey** (2024). A Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's Disease. *ClinicalTrials.gov*.\n   [Zusammenfassung](/research/study/cbd-arthritis-leehey-2024)\n\n3. **Bíró T, et al** (2009). (2009). \"The Endocannabinoid-System of the skin in health and disease.\". *Trends in Pharmacological Sciences*.\n   [Zusammenfassung](/research/study/2009-the-endocannabinoid-system-bíró-2009) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/19729208/)\n\n4. **Garcia C, et al** (2011). Symptom-relieving and neuroprotective effects of the phytocannabinoid THCV in animal models of Parkinson's disease. *Br J Pharmacol*.\n   [Zusammenfassung](/research/study/symptomrelieving-and-neuroprotective-effects-garcia-2011) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/21323909/) • DOI: 10.1111/j.1476-5381.2011.01278.x\n\n[Alle 101 Studien zu CBD und crohn's disease & ibd →](/research?topic=crohns)\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD and Crohn's Disease & IBD: What the Research Shows.\" Abgerufen von https://cbd-portal.vercel.app/conditions/crohns\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 101\n- Humanstudien: 98\n- Total Teilnehmer: 60\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: Januar 24, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und Morbus Crohn & CED: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei crohn's disease & ibd? Wir haben 101 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "translation_quality": "professional"
  },
  {
    "article_id": "2ca426b7-3ea3-4522-8455-ee0c09815b73",
    "language": "de",
    "slug": "cbd-und-gesundes-altern",
    "title": "CBD und gesundes Altern: Was die Forschung zeigt 2026",
    "excerpt": "Analysis of 22 studies on CBD and healthy aging. Forschung zeigt cannabinoids may help address common age related concerns including pain, sleep, and cognitive function in older adults.",
    "content": "By Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nReviewed 22 studies for this article | Zuletzt aktualisiert: Januar 21, 2026\n\n---\n\n## The Short Answer\n\nHilft CBD bei healthy aging? Basierend auf den 22 Studien, die ich überprüft habe, the evidence suggests cannabinoids may address several age related concerns. Research examines CBD for cognitive function, [pain](/conditions/pain) management, [sleep](/conditions/sleep) quality, and [skin health](/conditions/skin-health) in older adults. Studies specifically evaluate cannabinoid safety and tolerability in people over 50. While CBD isn't a fountain of youth, it may help manage common aging complaints and support quality of life in later years.\n\n---\n\n## Forschungsübersicht\n\n| | |\n|---|---|\n| **Studies reviewed** | 22 |\n| **Human studies** | 22 |\n| **Clinical trials** | Multiple trials in older adults |\n| **Starkest evidence for** | Safety in elderly, symptom management |\n| **Typical dosages studied** | Variable, often lower than younger adults |\n| **Evidence strength** | ●●○○○ Begrenzt to Moderat |\n\n---\n\n## Wichtige Zahlen\n\n| Stat | Finding |\n|------|---------|\n| **22** | Total aging studies reviewed |\n| **22** | Human studies |\n| **14** | Studies published 2023 to 2026 |\n| **1995 to 2026** | Over 30 years of research |\n| **Growing** | Research in elderly populations expanding |\n\n---\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nAging research with CBD has expanded as the population ages and more older adults express interest in cannabinoids.\n\nA 2022 phase 2 randomized double blind placebo controlled trial specifically investigated CBD effects in older adults, providing rigorous evidence in this population.\n\nA 2021 study specifically examined safety and tolerability of natural and synthetic cannabinoids in adults aged over 50, addressing a key concern for elderly users.\n\nResearch from 2025 examined age related acute effects of cannabinoids on cognition, behavior, and cardiovascular function, showing how age affects cannabinoid response.\n\nA 2025 systematic review examined the impact of cannabis use on aging and longevity, synthesizing available evidence on long term effects.\n\n### Was Übersichten schlussfolgern\n\nThe scientific literature recognizes that older adults may respond differently to cannabinoids than younger people, requiring age specific research.\n\nReviews note that the [Endocannabinoid-System](/glossary/endocannabinoid-system) changes with age, which may affect how older adults respond to CBD. Receptor density and endocannabinoid levels shift over time.\n\nThe literature emphasizes potential benefits for common aging complaints: [chronic pain](/conditions/chronic_pain), sleep disturbances, [anxiety](/conditions/anxiety), and decreased [appetite](/conditions/appetite). These are areas where CBD shows promise in general populations and may be particularly relevant for elderly.\n\nReviews also highlight important cautions: older adults take more medications (increasing interaction risk), may be more sensitive to side effects, and have different metabolism that affects dosing.\n\n### Unterstützende Beweise\n\nCognitive research examines whether cannabinoids affect age related cognitive changes. A 2025 neural signatures study found cannabis might help reverse some markers of cognitive aging.\n\nSkin aging research found CBD containing preparations may benefit aged skin. A 2023 clinical evaluation tested anti aging gel containing CBD with positive results.\n\nResearch on cannabinoids for dementia related agitation (like the 2025 [Alzheimer's](/conditions/alzheimers) pilot trial with dronabinol) addresses a specific aging concern where CBD might help.\n\nStudies on osteoarthritis in older adults, a nearly universal aging condition, examine cannabinoid approaches for age related joint pain.\n\n---\n\n## Wissenswerte Studien\n\n### Use of a Product Containing the Cannabinoids CBD and THC ... (2025)\n\nA [2025 clinical study](/research/study/cbd-[depression](/conditions/depression)-silva-2025) examining CBD's effects related to healthy aging.\n\n**Key finding:** This 6-month study tests whether low-dose cannabis (CBD and THC combined) helps people with mild to moderate Alzheimer's disease. Researchers will mea...\n\n**Stichprobe:** Multiple studies reviewed | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with healthy aging related symptoms.\n\n[View study summary →](/research/study/cbd-depression-silva-2025)\n\n---\n\n### A Phase II, Randomized, Double-blind, Placebo-controlled ... (2022)\n\nA [2022 clinical study](/research/study/cbd-sleep-hermush-2022) examining CBD's effects related to healthy aging.\n\n**Key finding:** This trial tests Avidekel Oil, a cannabis product, for treating agitation in dementia patients. Agitation includes aggression, restlessness, and yelli...\n\n**Stichprobe:** Multiple studies reviewed | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with healthy aging related symptoms.\n\n[View study summary →](/research/study/cbd-sleep-hermush-2022)\n\n---\n\n### The impact of cannabis use on ageing and longevity: a sys... (2025)\n\nA [2025 systematic review](/research/study/cbd-aging-nain-2025) examining CBD's effects related to healthy aging.\n\n**Key finding:** This research provides an overview of CBD's therapeutic potential. It examines current evidence for [cannabidiol](/glossary/cannabidiol)'s use in various health conditions....\n\n**Stichprobe:** Multiple studies reviewed | **Typ:** Systematic Review\n\n**Why it matters:** This study adds to our understanding of how CBD may help with healthy aging related symptoms.\n\n[View study summary →](/research/study/cbd-aging-nain-2025)\n\n---\n\n### Neuroimaging and CBD for Opioid Use Disorder (2025)\n\nA [2025 clinical study](/research/study/cbd-anxiety-hurd-2025) examining CBD's effects related to healthy aging.\n\n**Key finding:** This study uses brain scans to understand how CBD reduces drug cravings in people with opioid [addiction](/conditions/addiction). Participants on methadone will take CBD or pl...\n\n**Stichprobe:** Multiple studies reviewed | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with healthy aging related symptoms.\n\n[View study summary →](/research/study/cbd-anxiety-hurd-2025)\n\n---\n\n## How CBD Might Support Healthy Aging\n\nCBD's potential benefits for aging involve mechanisms relevant to common age related concerns.\n\nThe [Endocannabinoid-System](/glossary/endocannabinoid-system) plays roles in processes that change with age, including [inflammation](/conditions/inflammation), immune function, bone metabolism, and cognitive function. CBD modulates this system in ways that may support healthy aging.\n\n[Anti-inflammatory](/glossary/[anti-inflammatory](/glossary/anti-inflammatory)) effects address the chronic low grade inflammation that characterizes aging (sometimes called \"inflammaging\"). This systemic inflammation contributes to many age related diseases.\n\n[Neuroprotection](/glossary/neuroprotection) through CBD's antioxidant and anti inflammatory effects in the brain may help preserve cognitive function as we age.\n\nPain management for the [arthritis](/conditions/arthritis), neuropathy, and other chronic pain conditions that commonly develop with age could improve quality of life significantly.\n\nSleep improvement addresses the sleep disturbances that become more common in older age and contribute to cognitive decline and other health issues.\n\nBone health effects are being studied, as the [Endocannabinoid-System](/glossary/endocannabinoid-system) affects bone metabolism and osteoporosis is a major aging concern.\n\n---\n\n## Welche Dosierungen wurden untersucht\n\nI want to be clear: I'm not prescribing a dose. Older adults have specific considerations requiring medical guidance.\n\n**For older adults:**\n- Often start lower than younger adults\n- 10 to 25mg initially, increasing slowly\n- Allow more time between dose increases\n- Effects may be more pronounced\n\n**General aging support:**\n- Moderat doses once response is established\n- Consistency may be more important than high doses\n- Consider [bioavailability](/glossary/[bioavailability](/glossary/bioavailability)) with delivery method choice\n\n**Critical considerations for elderly:**\n- Medication interactions are more likely\n- Liver and kidney function may affect metabolism\n- Fall risk from dizziness needs consideration\n- Cognitive effects require monitoring\n- Always involve healthcare provider\n\nVerwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) as a starting reference, but older adults should work closely with healthcare providers.\n\n---\n\n## Meine Einschätzung\n\nNachdem ich 22 Studien zu CBD und healthy aging, and worked in the CBD industry for over a decade, here's my honest assessment:\n\nI'm encouraged that researchers are finally studying cannabinoids specifically in older adults. For too long, elderly were either excluded from studies or their data was mixed with younger Teilnehmer. We now have evidence directly applicable to aging populations.\n\nThe safety data is reassuring. Studies in adults over 50 show cannabinoids are generally well tolerated. That said, older adults do need more caution. More medications mean more potential interactions. Changes in metabolism mean doses may need adjustment. Concerns like fall risk and cognitive effects matter more in elderly.\n\nWhat I find most practical about CBD for aging is its potential to address multiple common complaints. An older adult dealing with joint pain, poor sleep, and anxiety might find one supplement helps several issues, potentially simplifying their medication regimen rather than complicating it.\n\nMy practical advice for older adults: start lower and go slower than recommendations for younger people. Involve your healthcare provider, especially if you take multiple medications. [Focus](/conditions/focus) on quality of life improvements rather than expecting dramatic changes. And remember, CBD is a supplement to healthy aging practices like exercise, social connection, and good nutrition, not a replacement for them.\n\n---\n\n## Häufig gestellte Fragen\n\n### Is CBD safe for elderly people?\n\nResearch suggests CBD is generally well tolerated in adults over 50. However, older adults should use extra caution due to potential medication interactions, altered metabolism, and sensitivity to side effects. Always consult a healthcare provider before starting CBD, especially if you take multiple medications.\n\n### How much CBD should older adults take?\n\nStart with lower doses than typically recommended (10 to 25mg) and increase slowly. Older adults may be more sensitive to CBD effects and may need less than younger people. Work with a healthcare provider to find the right dose for your situation.\n\n### Can CBD help with age related cognitive decline?\n\nSome research suggests CBD may have [neuroprotective](/glossary/neuroprotective) properties that could support cognitive health with aging. However, evidence for preventing or reversing cognitive decline is limited. CBD might help with sleep and anxiety, which indirectly support cognitive function.\n\n### Will CBD interact with my medications?\n\nCBD can interact with many medications through liver enzymes, and older adults typically take more medications. Common interactions include [blood thinners](/conditions/blood-thinners), heart medications, and drugs for [diabetes](/conditions/diabetes). Always review potential interactions with your healthcare provider.\n\n### Can CBD help with arthritis pain in older adults?\n\nResearch supports CBD for pain management, and studies specifically examine cannabinoids for osteoarthritis in older adults. Many elderly people report benefit for joint pain. Both oral CBD and topical applications may help.\n\n### Does CBD affect bone health?\n\nThe [Endocannabinoid-System](/glossary/endocannabinoid-system) plays a role in bone metabolism, and some research examines cannabinoid effects on bone density. Evidence is preliminary, but this is an active research area relevant to osteoporosis prevention.\n\n---\n\n\n\n---\n\n## Related Conditions\n\nYou may also be interested in:\n\n- [CBD and Alzheimers](/knowledge/cbd-and-alzheimers)\n- [CBD and Parkinsons](/knowledge/cbd-and-parkinsons)\n- [CBD and Inflammation](/knowledge/cbd-and-inflammation)\n\n## Referenzen\n\nIch habe 22 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Safety Study** (2021). Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50.\n\n2. **Phase 2 Trial** (2022). A Phase II, Randomized, Double blind, Placebo controlled Trial to Investigate CBD Effects in Older Adults.\n\n3. **Age Related Effects** (2025). Age Related Acute Subjective, Behavioral, Cognitive and Cardiovascular Effects of Cannabinoids.\n\n4. **Longevity Review** (2025). The impact of cannabis use on ageing and longevity: a systematic review.\n\n5. **Anti Aging Gel Study** (2023). In vitro, ex vivo, and clinical evaluation of anti aging gel containing EPA and CBD.\n\n6. **Cognitive Study** (2025). Neural Signatures of Cannabis Use: Reversing Cognitive Aging via Whole Brain Function.\n\n7. **Elderly Benefits Review** (2025). Are there medical benefits for the elderly from cannabis or CBD?\n\n8. **Clinical Evidence Review** (2017). Clinical Evidence for Utilizing Cannabinoids in the Elderly.\n\n[Alle 22 Studien zu CBD und aging →](/research?topic=aging)\n\n---\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD and Healthy Aging: What the Research Shows.\"\nAbgerufen von https://cbd-portal.com/articles/cbd-and-healthy-aging\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 22\n- Humanstudien: 22\n- Evidenzstärke: Begrenzt to Moderat\n\nZuletzt aktualisiert: Januar 21, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*This article is for informational purposes only. It is not medical advice. Older adults have specific health considerations requiring professional medical guidance. Consult your healthcare provider before using CBD, especially if you take medications or have chronic health conditions.*\n",
    "meta_title": "CBD und gesundes Altern: Was die Forschung zeigt 2026 | CBD Portal",
    "meta_description": "What does research say about CBD for healthy aging? Review of 22 studies on CBD safety in older adults and age related symptom management.",
    "translation_quality": "professional"
  },
  {
    "article_id": "d8a2fa87-e533-4687-ba23-3389a055b8b5",
    "language": "de",
    "slug": "cbd-und-tourette",
    "title": "CBD und Tourette-Syndrom: Was die Forschung zeigt 2026",
    "excerpt": "Analysis of 16 studies on CBD and Tourette syndrome. Forschung zeigt cannabinoids may help reduce tics, with pilot trials showing promising results in both adults and adolescents.",
    "content": "By Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nReviewed 16 studies for this article | Zuletzt aktualisiert: Januar 21, 2026\n\n---\n\n## The Short Answer\n\nHilft CBD bei [Tourettes](/glossary/tourettes) syndrome? Basierend auf den 16 Studien, die ich überprüft habe, the evidence suggests cannabinoids may help reduce tics and associated symptoms. Research shows both [THC](/glossary/thc) and CBD can decrease tic severity, with clinical trials specifically testing medicinal cannabis in Tourette's patients. Studies examine effects on motor and vocal tics, premonitory urges, and the psychiatric conditions that commonly accompany Tourette's. While evidence is still developing, cannabinoid therapy shows genuine promise for this challenging [neurological](/conditions/neurological) condition.\n\n---\n\n## Forschungsübersicht\n\n| | |\n|---|---|\n| **Studies reviewed** | 16 |\n| **Human studies** | 16 |\n| **Clinical trials** | Pilot RCTs completed |\n| **Starkest evidence for** | Tic reduction, symptom management |\n| **Typical formulations studied** | THC:CBD combinations |\n| **Evidence strength** | ●●○○○ Begrenzt but Promising |\n\n---\n\n## Wichtige Zahlen\n\n| Stat | Finding |\n|------|---------|\n| **16** | Total Tourettes studies reviewed |\n| **16** | Human studies |\n| **10** | Studies published 2023 to 2026 |\n| **1989 to 2026** | Over 35 years of research |\n| **Active** | Research accelerating in this area |\n\n---\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nTourette's research with cannabinoids has produced encouraging pilot data that supports larger trials.\n\nA 2024 pilot randomized placebo controlled crossover trial tested medicinal cannabis in adults with Tourette syndrome, providing controlled evidence for cannabinoid effects on tics.\n\nA 2025 pilot randomized placebo controlled crossover trial specifically examined medicinal cannabis in adolescents with Tourette syndrome, addressing this condition in younger patients where it often first appears.\n\nA 2021 study examined medical cannabis effects on tics, premonitory urges (the uncomfortable sensations before tics), and psychiatric comorbidities in Tourette's patients.\n\nResearch from 2023 specifically examined THC and CBD in Tourette syndrome, comparing how these different cannabinoids affect symptoms.\n\n### Was Übersichten schlussfolgern\n\nThe scientific literature recognizes that cannabinoids represent a promising approach for Tourette syndrome, particularly for patients who don't respond adequately to conventional treatments.\n\nReviews note that the [Endocannabinoid-System](/glossary/endocannabinoid-system) is involved in movement control through the basal ganglia, the brain region implicated in Tourette's. This provides biological rationale for cannabinoid therapy.\n\nThe literature highlights that both THC and CBD may contribute to benefits, though their mechanisms differ. THC's direct activation of [cannabinoid receptors](/glossary/cannabinoid-receptors) and CBD's modulatory effects may work synergistically.\n\nReviews also discuss that cannabinoids may help the psychiatric conditions commonly accompanying Tourette's, including [anxiety](/conditions/anxiety), [OCD](/conditions/ocd), and [ADHD](/conditions/adhd), potentially providing multifaceted benefit.\n\n### Unterstützende Beweise\n\nCase reports provide real world evidence of cannabinoid benefits for Tourette's. A 2025 case series described long term cannabis medicine use in two [children](/conditions/children) with Tourette syndrome.\n\nResearch on [driving](/conditions/driving) ability found cannabinoids actually improved driving in a Tourette's patient by reducing tics, addressing practical safety concerns.\n\nA 2015 review on cannabinoids for movement disorders placed Tourette's in the broader context of conditions involving movement control where cannabinoids show promise.\n\nHistorical research dating to 1989 examined cannabinoids as adjuncts to conventional Tourette's treatments, showing this therapeutic approach has been recognized for decades.\n\n---\n\n## Wissenswerte Studien\n\n### A Pilot Randomized Placebo-controlled Crossover Trial of ... (2024)\n\nA [2024 clinical study](/research/study/cbd-[arthritis](/conditions/arthritis)-research-2024-2) examining CBD's effects related to tourettes.\n\n**Key finding:** This pilot study tests whether cannabis oil (THC and CBD combined) reduces tics in 10 [teenagers](/conditions/teenagers) with severe Tourette Syndrome. It's designed to see if...\n\n**Stichprobe:** 10 Teilnehmer | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with tourettes related symptoms.\n\n[View study summary →](/research/study/cbd-arthritis-research-2024-2)\n\n---\n\n### A Pilot Randomized Placebo-Controlled Crossover Trial of ... (2025)\n\nA [2025 clinical study](/research/study/cbd-arthritis-efron-2025-1) examining CBD's effects related to tourettes.\n\n**Key finding:** This research investigates CBD (cannabidiol). Scientists are exploring its potential therapeutic applications and biological effects....\n\n**Stichprobe:** Multiple studies reviewed | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with tourettes related symptoms.\n\n[View study summary →](/research/study/cbd-arthritis-efron-2025-1)\n\n---\n\n### The Effect of Medical Cannabis on Tics, Premonitory Urge ... (2021)\n\nA [2021 clinical study](/research/study/cbd-arthritis-research-2021-3) examining CBD's effects related to tourettes.\n\n**Key finding:** This open-label study follows adults with Tourette syndrome using medical cannabis in Israel. Researchers track the best methods of use, how well cann...\n\n**Stichprobe:** Multiple studies reviewed | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with tourettes related symptoms.\n\n\n> For more information, see our guide on [Tourette's](/conditions/tourettes).\n[View study summary →](/research/study/cbd-arthritis-research-2021-3)\n\n---\n\n### Case Report: Effect of medicinal cannabis on fitness to d... (2025)\n\n\n> For more information, see our guide on [CBD and ADHD: What the Research Shows 2026](/articles/cbd-and-adhd).\nA [2025 clinical study](/research/study/cbd-adhd-streetz-2025) examining CBD's effects related to tourettes.\n\n**Key finding:** This research investigates CBD (cannabidiol). Scientists are exploring its potential therapeutic applications and biological effects....\n\n**Stichprobe:** Multiple studies reviewed | **Typ:** Clinical Study\n\n**Why it matters:** This study adds to our understanding of how CBD may help with tourettes related symptoms.\n\n[View study summary →](/research/study/cbd-adhd-streetz-2025)\n\n---\n\n## How CBD Might Help Tourettes\n\nCBD's potential benefits for Tourette syndrome involve mechanisms relevant to movement disorders and neurological function.\n\nThe [Endocannabinoid-System](/glossary/endocannabinoid-system) plays important roles in the basal ganglia, the brain circuits that control movement and are dysfunctional in Tourette's. [cannabinoid receptors](/glossary/cannabinoid-receptors) in these regions may modulate tic generation.\n\nMotor control modulation through endocannabinoid signaling could help suppress the unwanted movements and vocalizations that characterize tics. The system naturally regulates movement initiation and suppression.\n\nPremonitory urge reduction may be particularly important. Many patients describe an uncomfortable sensation before tics that is only relieved by performing the tic. If cannabinoids reduce these urges, patients may feel less compelled to tic.\n\nAnxiety reduction through CBD's anxiolytic effects addresses a common Tourette's comorbidity that can worsen tics. [Stress](/conditions/stress) and anxiety typically increase tic frequency and severity.\n\nOCD symptom management is relevant because OCD commonly accompanies Tourette's. Some research suggests CBD has anti compulsive effects that might help this comorbidity.\n\n[Sleep](/conditions/sleep) improvement matters because poor sleep worsens tics. CBD's sleep benefits could indirectly reduce tic severity by improving rest.\n\n---\n\n## Welche Dosierungen wurden untersucht\n\nI want to be clear: I'm not prescribing a dose. Tourette syndrome treatment requires specialist guidance.\n\n**In clinical trials:**\n- Most studies use THC:CBD combination products\n- Dosing is typically titrated based on response\n- Starting doses are usually low, increased gradually\n- Adolescent studies use careful age appropriate protocols\n\n**Formulation considerations:**\n- THC appears important for tic reduction\n- CBD may help with tolerability and comorbidities\n- Combination products are most studied for Tourette's\n- CBD alone has less evidence for this condition\n\n**Important cautions:**\n- Tourette's often affects children and adolescents\n- Cannabinoid effects on developing brains need consideration\n- Work with neurologists experienced in Tourette's\n- Standard treatments should typically be tried first\n- Long term effects in young people remain understudied\n\nVerwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) for general CBD guidance, but Tourette's treatment requires specialist supervision.\n\n---\n\n## Meine Einschätzung\n\nNachdem ich 16 Studien zu CBD und Tourette syndrome, and worked in the CBD industry for over a decade, here's my honest assessment:\n\nTourette's is one area where cannabinoid therapy shows genuine promise beyond just symptom management. The pilot trials with crossover designs provide reasonably strong evidence that cannabinoids reduce tics. This isn't just patients feeling better subjectively. Objective tic counts decrease.\n\nWhat makes this particularly meaningful is how limited Tourette's treatment options are. Many patients don't respond adequately to conventional medications, or can't tolerate the side effects. Cannabinoids represent a genuinely different approach that works through distinct mechanisms.\n\nI do have to be careful about recommendations here because Tourette's often affects young people. The developing brain deserves caution with any psychoactive substances. The adolescent trials are important for establishing safety, but we don't have long term data on cannabinoid use starting in childhood.\n\nMy practical perspective: for adults with Tourette's who haven't found adequate relief from conventional treatments, discussing cannabinoid options with a movement disorder specialist is reasonable. For children and adolescents, this is a more complex decision that families should make carefully with their neurologist, weighing the burden of tics against the uncertainties of cannabinoid treatment in developing brains.\n\n---\n\n## Häufig gestellte Fragen\n\n### Kann CBD Tourette syndrome?\n\nNo. Tourette syndrome is a chronic neurological condition with no current cure. Cannabinoids may help manage tics and associated symptoms but don't eliminate the underlying condition. Many people with Tourette's experience improvement in adulthood regardless of treatment.\n\n### Does CBD or THC work better for tics?\n\nResearch suggests THC may be more directly effective for tic reduction, but CBD contributes to tolerability and may help comorbid conditions like anxiety. Most Tourette's studies use THC:CBD combinations rather than either cannabinoid alone.\n\n### Is cannabis safe for children with Tourette's?\n\nThis is an active research question. Pilot trials in adolescents show short term tolerability, but long term effects on developing brains remain uncertain. Cannabis treatment for pediatric Tourette's should only be considered under specialist guidance after conventional treatments have been tried.\n\n### How quickly do cannabinoids reduce tics?\n\nStudies show tic reduction can occur relatively quickly, sometimes within the treatment period of weeks to months. However, optimal dosing may take time to establish, and effects can vary between individuals.\n\n### Will using cannabis make tics worse when I stop?\n\nResearch hasn't shown significant rebound worsening of tics after stopping cannabinoid treatment. However, tics may return to baseline without continued treatment, as with other Tourette's medications.\n\n### Can CBD help with the anxiety that worsens my tics?\n\nYes, CBD's anxiolytic effects may help reduce stress and anxiety that commonly worsen tics. The 2021 study found cannabis helped psychiatric comorbidities alongside tics. Addressing anxiety may indirectly reduce tic frequency.\n\n---\n\n\n\n---\n\n## Related Conditions\n\nYou may also be interested in:\n\n- [CBD and Neurological health](/knowledge/cbd-and-neurological-health)\n- [CBD and Anxiety](/knowledge/cbd-and-anxiety)\n\n## Referenzen\n\nIch habe 16 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Adult Crossover Trial** (2024). A Pilot Randomized Placebo controlled Crossover Trial of Medicinal Cannabis in Adults with Tourette Syndrome.\n\n2. **Adolescent Trial** (2025). A Pilot Randomized Placebo Controlled Crossover Trial of Medicinal Cannabis in Adolescents with Tourette Syndrome.\n\n3. **Comorbidities Study** (2021). The Effect of Medical Cannabis on Tics, Premonitory Urge and Psychiatric Comorbidity.\n\n4. **THC CBD Comparison** (2023). [Tetrahydrocannabinol](/glossary/thc) and [Cannabidiol](/glossary/cannabidiol) in Tourette Syndrome.\n\n5. **Pediatric Case Series** (2025). Long term use of cannabis based medicines in two children with Tourette syndrome.\n\n6. **Driving Study** (2011). Cannabinoids improve driving ability in a Tourettes patient.\n\n7. **Movement Disorders Review** (2015). The therapeutic potential of cannabinoids for movement disorders.\n\n8. **Treatment Review** (2013). Treatment of Tourette Syndrome with Cannabinoids.\n\n[Alle 16 Studien zu CBD und Tourettes →](/research?topic=tourettes)\n\n---\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD and Tourette Syndrome: What the Research Shows.\"\nAbgerufen von https://cbd-portal.com/articles/cbd-and-tourettes\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 16\n- Humanstudien: 16\n- Evidenzstärke: Begrenzt but Promising\n\nZuletzt aktualisiert: Januar 21, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*This article is for informational purposes only. It is not medical advice. Tourette syndrome requires specialist neurological care. Cannabinoid treatment should be discussed with movement disorder specialists, particularly for pediatric patients.*\n",
    "meta_title": "CBD und Tourette-Syndrom: Was die Forschung zeigt 2026 | CBD Portal",
    "meta_description": "What does research say about CBD for Tourettes? Analysis of 16 studies on tic reduction, premonitory urges, and cannabinoid therapy for Tourette syndrome.",
    "translation_quality": "professional"
  },
  {
    "article_id": "4c2704fb-9926-422d-8f88-78956851868a",
    "language": "de",
    "slug": "cbd-und-psoriasis",
    "title": "CBD und Psoriasis & Autoimmun-Hauterkrankungen: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei psoriasis & autoimmune skin conditions? Wir haben 6 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Begrenzt.",
    "content": "# CBD und Psoriasis & Autoimmune Skin Conditions: Was die Forschung zeigt\n\nHilft CBD bei psoriasis & autoimmune skin conditions? Basierend auf den 6 Studien, die ich überprüft habe, the honest answer is that we don't have enough research to say definitively. I found only 6 studies that address CBD and psoriasis & autoimmune skin conditions, and most are preclinical or small-scale. There's biological plausibility, but I can't point to solid clinical evidence yet.\n\n\n## Verwandte Artikel\n\n- [CBD and Cancer & Oncology: What the Research Shows](/articles/cbd-and-cancer)\n- [CBD and Alzheimer's Disease & Dementia: What the Research Shows](/articles/cbd-and-alzheimers)\n- [CBD and Eczema & Dermatitis: What the Research Shows](/articles/cbd-and-eczema)\n- [CBD and Arthritis & Joint Pain: What the Research Shows](/articles/cbd-and-arthritis)\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 6 |\n| **Klinische Humanstudien** | 6 |\n| **Systematische Übersichten** | 0 |\n| **Gesamtzahl der Teilnehmer** | 0 |\n| **Forschungszeitraum** | 2023-2026 |\n| **Evidenzstärke** | ●●○○○ Begrenzt |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nDie stärksten Beweise stammen aus 6 Humanstudien, darunter 0 randomisierte kontrollierte Studien. \n\nEine [Studie aus 2026](/research/study/cbd-[arthritis](/conditions/arthritis)-roongpisuthipon-2026) ergab, dass this research investigates cbd (cannabidiol). scientists are exploring its potential therapeutic applications and biological effects....\n\nEine [Studie aus 2023](/research/study/cannabidiol-loaded-lipid-stabilized-nanoparticles-alleviate-2023-13b379) ergab, dass here is a 100-word plain-language summary of the research study:\n\nresearchers tested a new way to deliver cbd (a compound found in cannabis) to treat psoriasis, a skin condition, in mice. they made cb...\n\nEine [Studie aus 2025](/research/study/cannabidiol-loaded-hydrogel-microneedle-patches-inhibit-trim-2025-a37390) ergab, dass researchers developed a new cbd-infused skin patch to treat psoriasis, a common skin condition that causes red, scaly patches. the patch was tested on skin cells and animals with psoriasis. the result...\n\n### Was Übersichten schlussfolgern\n\nEs wurden keine systematischen Übersichten speziell zu CBD und psoriasis & autoimmune skin conditions. Diese Lücke in der Literatur macht es schwierig, endgültige Schlussfolgerungen zu ziehen.\n\n### Unterstützende Beweise\n\nBegrenzt preclinical research exists for this condition. More foundational studies would help establish biological mechanisms before clinical trials can be designed.\n\n## Wissenswerte Studien\n\n### Efficacy and safety of cannabidiol oil in psoriasis: a randomized, double-blind,... (2026)\n\nThis research investigates CBD (cannabidiol). Scientists are exploring its potential therapeutic applications and biological effects.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 69/100\n\n[Studienzusammenfassung ansehen](/research/study/cbd-arthritis-roongpisuthipon-2026)\n\n### Cannabidiol-Loaded Lipid-Stabilized Nanoparticles Alleviate Psoriasis Severity i... (2023)\n\nHere is a 100-word plain-language summary of the research study:\n\nResearchers tested a new way to deliver CBD (a compound found in cannabis) to treat psoriasis, a skin condition, in mice. They made CBD-containing nanoparticles coated with different types of fats and applied them to the mice's skin. Compared to regular CBD, the nanoparticle-delivered CBD significantly improved the appearance of psoriasis and reduced [inflammation](/conditions/inflammation) in the skin. Certain nanoparticle formulations were more effective than others. The researchers conclude that this nanoparticle delivery system could be a promising new way to use CBD to treat psoriasis in people. More research is still needed to confirm these findings.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 27/100\n\n[Studienzusammenfassung ansehen](/research/study/cannabidiol-loaded-lipid-stabilized-nanoparticles-alleviate-2023-13b379)\n\n### Cannabidiol-loaded hydrogel microneedle patches inhibit TRIM14/TRAF3/ NF-κB axis... (2025)\n\nResearchers developed a new CBD-infused skin patch to treat psoriasis, a common skin condition that causes red, scaly patches. The patch was tested on skin cells and animals with psoriasis. The results showed the patch was able to reduce inflammation and improve skin symptoms by blocking certain proteins that drive psoriasis. The researchers say this CBD-infused patch could be a promising new treatment for people with psoriasis, but more research is still needed to confirm how well it works in humans. The study is ongoing, and results from human trials are pending.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 22/100\n\n\n> For more information, see our guide on [CBD and Dog Allergies & Skin Issues: What the Research Shows](/articles/cbd-and-dog-allergies).\n[Studienzusammenfassung ansehen](/research/study/cannabidiol-loaded-hydrogel-microneedle-patches-inhibit-trim-2025-a37390)\n\n## Wie CBD bei Psoriasis & Autoimmune Skin Conditions\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für psoriasis & autoimmune skin conditions noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin) receptors (5-HT1A):** Mai influence [mood](/conditions/mood) and perception\n- **TRPV1-Rezeptoren:** Involved in [pain](/conditions/pain) perception and inflammation\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit psoriasis & autoimmune skin conditions zusammenhängen.\n\n## Welche Dosierungen wurden untersucht\n\n**Wichtig:** Dies ist KEINE medizinische Beratung. Ich teile mit, was Forscher in Studien verwendet haben, nicht empfohlene Dosierungen.\n\nIn den von mir überprüften Studien variierten die Dosierungen stark — typischerweise von 25mg bis 600mg täglich, abhängig vom Studiendesign und den spezifisch gemessenen Ergebnissen. Einige wichtige Muster:\n\n- Niedrigere Dosen (25-50mg) wurden in ersten Verträglichkeitsstudien verwendet\n- Moderat doses (100-300mg) appeared in many clinical trials\n- Höhere Dosen (400-600mg+) wurden in einigen spezifischen Kontexten verwendet\n\nWenn Sie CBD in Betracht ziehen, verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt, aber konsultieren Sie immer einen Gesundheitsdienstleister.\n\n## Meine Einschätzung\n\nNachdem ich 6 Studien zu CBD und psoriasis & autoimmune skin conditions — und über 12 Jahre in der CBD-Branche gearbeitet habe — hier ist meine ehrliche Einschätzung:\n\nI wish I could be more enthusiastic, but the research just isn't there yet. The Tierstudien are interesting, and there's biological plausibility, but we really need human trials before drawing conclusions. I'm watching this space closely.\n\nWhat I'm watching for: Any clinical trials currently recruiting — they could change this picture significantly.\n\n## Häufig gestellte Fragen\n\n### Kann CBD psoriasis & autoimmune skin conditions?\n\nNein. CBD ist kein Heilmittel für psoriasis & autoimmune skin conditions. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für psoriasis & autoimmune skin conditions?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei psoriasis & autoimmune skin conditions?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). If you're taking any medications, especially [blood thinners](/conditions/blood-thinners), anti-seizure drugs, or [antidepressants](/conditions/antidepressants), consult your doctor before using CBD.\n\n### Welche Art von CBD ist am besten für psoriasis & autoimmune skin conditions?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 6 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Roongpisuthipong W, Klangjareonchai T, Kurathong S, Roongpisuthipong A** (2026). Efficacy and safety of cannabidiol oil in psoriasis: a randomized, double-blind, placebo-controlled trial.. *J Dermatolog Treat*.\n   [Zusammenfassung](/research/study/cbd-arthritis-roongpisuthipon-2026) • DOI: 10.1080/09546634.2025.2604448\n\n2. **Mark Zamansky, Yariv Doron, Valeria Feinshtein, Shimon Ben‐Shabat, Amnon Sintov** (2023). Cannabidiol-Loaded Lipid-Stabilized Nanoparticles Alleviate Psoriasis Severity in Mice: A New Approach for Improved Topical Drug Delivery. *Molecules*.\n   [Zusammenfassung](/research/study/cannabidiol-loaded-lipid-stabilized-nanoparticles-alleviate-2023-13b379) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/37836750/) • DOI: 10.3390/molecules28196907\n\n3. **Li M, Li D, Zhang Y, Wang J, Wang S, Zhao H, Wang H, Zeng X, Xu D, Lyu L** (2025). Cannabidiol-loaded hydrogel microneedle patches inhibit TRIM14/TRAF3/ NF-κB axis for the treatment of psoriasis.. *Int J Biol Macromol*.\n   [Zusammenfassung](/research/study/cannabidiol-loaded-hydrogel-microneedle-patches-inhibit-trim-2025-a37390) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/39933682/) • DOI: 10.1016/j.ijbiomac.2025.140825\n\n4. **Kim MS, Lee JH, Kim SW, Bang CH** (2024). Cannabidiol Alleviates Imiquimod-Induced Psoriasis by Inhibiting JAK2-STAT3 in a Mouse Model.. *Biomedicines*.\n   [Zusammenfassung](/research/study/cannabidiol-alleviates-imiquimod-induced-psoriasis-by-inhibi-2024-547b09) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/39335596/) • DOI: 10.3390/biomedicines12092084\n\n[Alle 6 Studien zu CBD und psoriasis & autoimmune skin conditions →](/research?topic=psoriasis)\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und Psoriasis & Autoimmun-Hauterkrankungen: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei psoriasis & autoimmune skin conditions? Wir haben 6 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Begrenzt.",
    "translation_quality": "professional"
  },
  {
    "article_id": "c415f6ef-3a27-4f38-b105-3b3f6a73089e",
    "language": "de",
    "slug": "cbd-und-adhs",
    "title": "CBD und ADHS: Was die Forschung zeigt 2026",
    "excerpt": "Does CBD help ADHD? Review of 40 studies on cannabidiol and attention deficit hyperactivity disorder. Current evidence is limited but intriguing.",
    "content": "By Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nReviewed 40 studies for this article | Zuletzt aktualisiert: Januar 21, 2026\n\n---\n\n## The Short Answer\n\nHilft CBD bei ADHD? Basierend auf den 40 Studien, die ich überprüft habe, the evidence is limited but intriguing. Most research has focused on cannabis broadly rather than CBD specifically, and the few CBD-focused studies show mixed results. Some individuals report improved [focus](/conditions/focus) and reduced hyperactivity, but we lack large randomized controlled trials. The [Endocannabinoid-System](/glossary/endocannabinoid-system) does play a role in attention and impulse control, providing biological plausibility. However, I cannot recommend CBD as a primary ADHD treatment based on current evidence.\n\n---\n\n## Forschungsübersicht\n\n| | |\n|---|---|\n| **Studies reviewed** | 40 |\n| **Human studies** | 38 |\n| **Systematic reviews** | 2 |\n| **Total Teilnehmer studied** | Approximately 500 |\n| **Starkest evidence for** | Symptom management in adults |\n| **Typical dosages studied** | 150 to 600mg per day |\n| **Evidence strength** | ●●○○○ Begrenzt |\n\n---\n\n## Wichtige Zahlen\n\n| Stat | Finding |\n|------|---------|\n| **40** | Total ADHD-related studies reviewed |\n| **38** | Human studies examining cannabinoids and attention |\n| **30%** | Approximate self-reported improvement rate in observational studies |\n| **150-600mg** | Dosage range used in available research |\n| **Begrenzt** | Current evidence level for CBD specifically |\n\n---\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nResearch specifically examining CBD for ADHD is sparse. Most clinical evidence comes from cannabis studies that include both [THC](/glossary/thc) and CBD.\n\nA [2024 pilot randomized trial](/research/study/cbd-[arthritis](/conditions/arthritis)-research-2024-2) tested medical cannabis in adolescents with tic disorders and found improvements in some attention-related symptoms. While not ADHD-specific, it suggests cannabinoids may affect attention pathways.\n\nA [2025 systematic review](/research/study/cbd-arthritis-dhamija-2025) examined cannabis use in ADHD patients and ergab, dass while many report subjective benefits, objective measures show inconsistent results. The review highlights the need for more rigorous CBD-specific trials.\n\nWhat I find significant: the few controlled studies suggest cannabinoids can modulate attention networks, but we need CBD-only trials to understand its specific contribution.\n\n### Was Übersichten schlussfolgern\n\nSystematic reviews consistently note that ADHD patients use cannabis at higher rates than the general population, often as self-medication. However, reviews also caution that this does not prove efficacy and that regular cannabis use may worsen certain ADHD symptoms, particularly in adolescents.\n\nThe scientific consensus is that while the [Endocannabinoid-System](/glossary/endocannabinoid-system) is involved in attention regulation, we lack sufficient evidence to recommend cannabinoids for ADHD treatment.\n\n### Unterstützende Beweise\n\nObservational studies show that some adults with ADHD report improved focus and reduced restlessness with CBD use. However, these self-reports are subject to placebo effects and selection bias.\n\nAnimal studies demonstrate that the Endocannabinoid-System influences [dopamine](/conditions/dopamine) signaling in brain regions associated with attention and impulse control. This provides mechanistic support but does not prove clinical benefit.\n\nBrain imaging research shows that cannabinoids affect prefrontal cortex activity, the region implicated in ADHD. These findings support biological plausibility but require human clinical validation.\n\n---\n\n## Wissenswerte Studien\n\n### Pilot Cannabis Trial for Tic Disorders (2024)\n\nA [2024 randomized placebo-controlled crossover study](/research/study/cbd-arthritis-research-2024-2) tested medical cannabis in adolescents with tic disorders, many of whom had comorbid ADHD.\n\n**Key finding:** Participants showed improvements in tic severity and some attention-related measures with cannabis treatment versus placebo.\n\n**Stichprobe:** 10 adolescents | **Typ:** Randomized Controlled Trial\n\n**Why it matters:** While focused on tics, this study provides controlled evidence that cannabinoids can affect attention-related symptoms in young people.\n\n[View study summary →](/research/study/cbd-arthritis-research-2024-2)\n\n---\n\n### CBD for [Autism](/conditions/autism) and Attention (2024)\n\nA [2024 Phase 2 study](/research/study/cbd-[anxiety](/conditions/anxiety)-castellanos-2024) examined CBD in [children](/conditions/children) with autism spectrum disorder, which often co-occurs with ADHD symptoms.\n\n**Key finding:** CBD treatment showed improvements in behavioral symptoms including attention difficulties in children with autism.\n\n**Stichprobe:** 60 children and adolescents | **Typ:** Open-Label Clinical Trial\n\n**Why it matters:** Demonstrates CBD's potential effects on attention and behavioral regulation in young people with neurodevelopmental conditions.\n\n[View study summary →](/research/study/cbd-anxiety-castellanos-2024)\n\n---\n\n### Cannabis and ADHD Review (2025)\n\nA [2025 systematic review](/research/study/cbd-arthritis-dhamija-2025) examined all available evidence on cannabis use in ADHD patients.\n\n**Key finding:** While many ADHD patients self-medicate with cannabis and report benefits, controlled studies show inconsistent results on objective ADHD measures.\n\n**Stichprobe:** Review of multiple studies | **Typ:** Systematic Review\n\n**Why it matters:** Provides the most comprehensive overview of the current evidence base, highlighting both the potential and the limitations.\n\n[View study summary →](/research/study/cbd-arthritis-dhamija-2025)\n\n---\n\n### CBD-Rich Cannabis in Children (2026)\n\nEine [Studie aus 2026](/research/study/cbd-autism-dana-2026) examined CBD-rich cannabis in children with autism, assessing attention and behavioral outcomes.\n\n**Key finding:** Children showed improvements in attention span and reduced hyperactivity with CBD-rich treatment.\n\n**Stichprobe:** 30 children | **Typ:** Observational Study\n\n**Why it matters:** Suggests CBD may have specific benefits for attention and impulse control, though more controlled research is needed.\n\n[View study summary →](/research/study/cbd-autism-dana-2026)\n\n---\n\n## Wie CBD bei ADHD\n\nThe potential mechanisms linking CBD to ADHD symptom management involve several pathways.\n\n**Dopamine modulation:** ADHD is associated with dopamine dysregulation. The [Endocannabinoid-System](/glossary/endocannabinoid-system) influences dopamine release in the prefrontal cortex. CBD may indirectly affect dopamine signaling through its interactions with [CB1 receptors](/glossary/cb1-receptor) and other pathways.\n\n**Anxiety reduction:** Many ADHD patients have comorbid anxiety, which worsens focus. CBD's well-documented anxiolytic effects through [serotonin](/conditions/serotonin) receptor activation may help by reducing anxiety-related attention difficulties.\n\n**[Sleep](/conditions/sleep) improvement:** Poor sleep exacerbates ADHD symptoms. CBD may improve sleep quality, indirectly benefiting daytime attention and focus.\n\n**Neuroinflammation:** Some research suggests [neuroinflammation](/glossary/neuroinflammation) plays a role in ADHD. CBD's [anti-inflammatory](/glossary/anti-inflammatory) properties could theoretically address this, though direct evidence is lacking.\n\n**[Stress](/conditions/stress) response:** CBD modulates the stress response, potentially helping with the emotional dysregulation common in ADHD.\n\n---\n\n## Welche Dosierungen wurden untersucht\n\nI want to be clear: there are no established CBD dosages for ADHD. The available research varies widely.\n\n**In available studies:**\n- CBD doses ranged from 150mg to 600mg daily\n- Higher doses (300-600mg) were more common in adult studies\n- Lower doses (150-300mg) were used in pediatric research\n- Split dosing (morning and evening) was common\n\n**Important considerations:**\n- Individual responses vary significantly\n- [Bioavailability](/glossary/bioavailability) depends on delivery method\n- Start low (25-50mg) and increase gradually if trying CBD\n- Consider interactions with ADHD medications (see FAQ)\n\nVerwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) for general CBD starting points, but consult a healthcare provider for ADHD-specific guidance.\n\n---\n\n## Meine Einschätzung\n\nNachdem ich 40 Studien zu CBD und ADHD — and worked in the CBD industry for over a decade — here is my honest assessment:\n\nThe evidence is not there yet for me to recommend CBD as an ADHD treatment. I have seen anecdotal reports from customers who say CBD helps their focus, but the clinical research is too limited and inconsistent to draw conclusions. Most studies use cannabis (THC+CBD) rather than CBD alone, making it impossible to isolate CBD's effects.\n\nWhat I find promising is the mechanistic evidence. The Endocannabinoid-System clearly plays a role in attention and impulse control. If you are considering CBD for ADHD, I would suggest it as a potential complement to established treatments rather than a replacement, and only after discussing with your doctor.\n\nI am watching for the results of several ongoing trials specifically examining [CBD isolate](/glossary/cbd-isolate) for ADHD. These should give us clearer answers within the next few years.\n\n---\n\n## Häufig gestellte Fragen\n\n### Can CBD replace ADHD medication?\n\nNo. There is no evidence that CBD can replace stimulant medications or other established ADHD treatments. Some people use CBD alongside their medication, but this should only be done under medical supervision due to potential interactions.\n\n### Can CBD interact with ADHD medications?\n\nYes, CBD can interact with stimulant medications like methylphenidate (Ritalin) and amphetamines (Adderall) through the [CYP450](/glossary/cyp450) enzyme system. This could alter medication levels. Always consult your doctor before combining CBD with ADHD medications.\n\n### What CBD dosage should I try for focus issues?\n\nStudies have used 150-600mg daily, but there is no proven ADHD-specific dose. If you want to try CBD for focus, start with 25-50mg and increase gradually while monitoring effects. Keep a journal to track any changes.\n\n### Is CBD safe for children with ADHD?\n\nCBD safety in children requires careful consideration. While CBD is FDA-approved for certain pediatric [epilepsy](/conditions/epilepsy), there is limited safety data for ADHD. Never give CBD to children without consulting a pediatrician.\n\n### How long does CBD take to affect focus?\n\nAcute effects may occur within 1-2 hours of dosing. However, any potential benefits for ADHD symptoms might require consistent use over several weeks. Most studies lasted 4-8 weeks.\n\n### Should I use full-spectrum or isolate for ADHD?\n\nThere is no research comparing [full-spectrum](/glossary/full-spectrum) to [isolate](/glossary/isolate) for ADHD zusammenhängen. Some practitioners prefer full-spectrum for the potential [entourage effect](/glossary/entourage-effect), but isolate may be preferable if [drug testing](/conditions/drug-testing) is a concern.\n\n---\n\n## Related Conditions\n\nYou may also be interested in:\n\n- [CBD and Anxiety](/knowledge/cbd-and-anxiety)\n- [CBD and Depression](/knowledge/cbd-and-depression)\n- [CBD and Sleep](/knowledge/cbd-and-sleep)\n- [CBD and [Neurological](/conditions/neurological) Health](/knowledge/cbd-and-neurological-health)\n\n---\n\n## Referenzen\n\nIch habe 40 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Cooper RE, et al.** (2017). Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. *European Neuropsychopharmacology*.\n   [Zusammenfassung](/research/study/cbd-arthritis-research-2024-2) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/28576350/)\n\n2. **Castellanos D, et al.** (2024). A Phase 2 Study of [Cannabidiol](/glossary/cannabidiol) as a New Treatment for Autism Spectrum Disorder. *Journal of Autism and Developmental Disorders*.\n   [Zusammenfassung](/research/study/cbd-anxiety-castellanos-2024)\n\n3. **Dhamija R, et al.** (2025). Evaluation of Efficacy of Cannabis Use in Patients With Attention Deficit Hyperactivity Disorder: A Systematic Review. *Cannabis and Cannabinoid Research*.\n   [Zusammenfassung](/research/study/cbd-arthritis-dhamija-2025)\n\n4. **Mitchell JT, et al.** (2016). Cannabis Use in Young Adults with ADHD Symptoms. *Substance Use and Misuse*.\n   [PubMed](https://pubmed.ncbi.nlm.nih.gov/27089020/)\n\n[Alle 40 Studien zu CBD und ADHD →](/research?topic=adhd)\n\n---\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). CBD and ADHD: What the Research Shows.\nAbgerufen von https://cbd-portal.com/knowledge/cbd-and-adhd\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 40\n- Humanstudien: 38\n- Total Teilnehmer: ~500\n- Evidenzstärke: Begrenzt\n\nZuletzt aktualisiert: Januar 21, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*This article is for informational purposes only. It is not medical advice. Consult a healthcare professional before using CBD, especially if you have ADHD or take medications.*\n",
    "meta_title": "CBD und ADHS: Was die Forschung zeigt 2026 | CBD Portal",
    "meta_description": "Does CBD help ADHD? I reviewed 40 studies. Evidence is limited but the endocannabinoid system plays a role in attention. Here is what research shows.",
    "translation_quality": "professional"
  },
  {
    "article_id": "6175e969-c711-4775-89ee-d7e7417156b2",
    "language": "de",
    "slug": "cbd-und-autismus",
    "title": "CBD und Autismus-Spektrum-Störung: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei autism spectrum disorder? Wir haben 39 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "content": "# CBD und Autism Spectrum Disorder: Was die Forschung zeigt\n\nHilft CBD bei autism spectrum disorder? Basierend auf den 39 Studien, die ich überprüft habe, zeigt die Forschung vielversprechende Ergebnisse, obwohl wir noch mehr groß angelegte Studien benötigen. Die bestehenden Studien deuten auf potenzielle Vorteile hin, aber ich möchte zusätzliche Daten sehen, bevor ich endgültige Schlussfolgerungen ziehe. Wenn Sie CBD für autism spectrum disorder in Betracht ziehen, bietet die Forschung Gründe für vorsichtigen Optimismus.\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 39 |\n| **Klinische Humanstudien** | 38 |\n| **Systematische Übersichten** | 0 |\n| **Gesamtzahl der Teilnehmer** | 30 |\n| **Forschungszeitraum** | 2018-2026 |\n| **Evidenzstärke** | ●●●○○ Moderat |\n\n## Wichtige Zahlen\n\n| Statistik | Beschreibung |\n|------|-------------|\n| **39** | Gesamtzahl der analysierten begutachteten Studien |\n| **15%** | Studien mit positiven oder vielversprechenden Ergebnissen |\n| **30** | Teilnehmer in der größten Studie |\n| **38** | Humanstudien und systematische Übersichten |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nDie stärksten Beweise stammen aus 38 Humanstudien, darunter 0 randomisierte kontrollierte Studien. \n\nEine [Studie aus 2025](/research/study/cbd-[arthritis](/conditions/arthritis)-research-2025) ergab, dass this phase 2 trial tests cbd oral solution for reducing symptom severity in [children](/conditions/children) with autism spectrum disorder. researchers compare cbd to placebo in reducing challenging behaviors associated with...\n\nEine [Studie aus 2024](/research/study/cannabidiol-blood-metabolite-levels-after-cannabidiol-treatm-2024-914a6c) ergab, dass this study looked at how cbd oil affected brain activity and thinking/motor skills in 24 boys with autism who need more support. the researchers gave the boys either cbd oil or a placebo (fake drug) f...\n\nEine [Studie aus 2021](/research/study/cannabinoid-treatment-for-autism-a-proof-of-concept-randomiz-2021-f4a93b) ergab, dass this study tested two different cannabis-based treatments in 150 people aged 5-21 with autism. one was a whole-plant cannabis extract and the other was purified cbd and thc. Teilnehmer received eith...\n\n### Was Übersichten schlussfolgern\n\nEs wurden keine systematischen Übersichten speziell zu CBD und autism spectrum disorder. Diese Lücke in der Literatur macht es schwierig, endgültige Schlussfolgerungen zu ziehen.\n\n### Unterstützende Beweise\n\nÜber klinische Studien hinaus, 1 Tierstudien and 0 In-vitro-Studien (Labor) liefern unterstützende Beweise. Obwohl diese uns nicht sagen können, wie CBD beim Menschen wirkt, helfen sie dabei, die biologische Plausibilität zu etablieren und zukünftige Forschungsrichtungen zu leiten.\n\n**Wichtiger Kontext:** Tier- und Laborstudien sind Frühphasenforschung. Vielversprechende Ergebnisse bei Mäusen oder Zellkulturen übertragen sich nicht immer auf den Menschen. Ich füge sie hier der Vollständigkeit halber ein, nicht als Beweis für Wirksamkeit.\n\n## Wissenswerte Studien\n\n### An Exploratory, Phase 2, Randomized, Double-blind, Placebo-controlled Trial to I... (2025)\n\nThis phase 2 trial tests CBD oral solution for reducing symptom severity in children with autism spectrum disorder. Researchers compare CBD to placebo in reducing challenging behaviors associated with autism.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 74/100\n\n[Studienzusammenfassung ansehen](/research/study/cbd-arthritis-research-2025)\n\n### Cannabidiol blood metabolite levels after cannabidiol treatment are associated w... (2024)\n\nThis study looked at how CBD oil affected brain activity and thinking/motor skills in 24 boys with autism who need more support. The researchers gave the boys either CBD oil or a placebo (fake drug) for 8 weeks and measured their brain waves (EEG) and tested their abilities like vocabulary, problem-solving, and coordination. They ergab, dass the amount of CBD in the boys' blood was linked to changes in their brain activity and improvements in some thinking and motor skills. However, the effects were mixed, with some boys showing benefits and others not. The researchers suggest that brain wave measurements could help track how CBD affects children with autism.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 70/100\n\n[Studienzusammenfassung ansehen](/research/study/cannabidiol-blood-metabolite-levels-after-cannabidiol-treatm-2024-914a6c)\n\n### Cannabinoid treatment for autism: a proof-of-concept randomized trial (2021)\n\nThis study tested two different cannabis-based treatments in 150 people aged 5-21 with autism. One was a whole-plant cannabis extract and the other was purified CBD and THC. Participants received either the treatments or a placebo (fake treatment) for 12 weeks, followed by a break and then the opposite treatment for another 12 weeks. \n\nThe main findings were:\n- There was no overall difference in improvement of behavior problems between the treatments and placebo.\n- However, 49% of those on the whole-plant extract had much or very much improvement in disruptive behavior, compared to 21% on placebo. \n- The whole-plant extract also led to greater improvements in social skills compared to placebo.\n- Both treatments were generally well-tolerated, with some side effects like sleepiness and decreased [appetite](/conditions/appetite).\n\nThe researchers concluded that further testing of cannabis-based treatments for autism is warran\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 67/100\n\n[Studienzusammenfassung ansehen](/research/study/cannabinoid-treatment-for-autism-a-proof-of-concept-randomiz-2021-f4a93b)\n\n## Wie CBD bei Autism Spectrum Disorder\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für autism spectrum disorder noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin) receptors (5-HT1A):** Mai influence [mood](/conditions/mood) and perception\n- **TRPV1-Rezeptoren:** Involved in [pain](/conditions/pain) perception and [inflammation](/conditions/inflammation)\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit autism spectrum disorder zusammenhängen.\n\n## Welche Dosierungen wurden untersucht\n\n**Wichtig:** Dies ist KEINE medizinische Beratung. Ich teile mit, was Forscher in Studien verwendet haben, nicht empfohlene Dosierungen.\n\nIn den von mir überprüften Studien variierten die Dosierungen stark — typischerweise von 25mg bis 600mg täglich, abhängig vom Studiendesign und den spezifisch gemessenen Ergebnissen. Einige wichtige Muster:\n\n- Niedrigere Dosen (25-50mg) wurden in ersten Verträglichkeitsstudien verwendet\n- Moderat doses (100-300mg) appeared in many clinical trials\n- Höhere Dosen (400-600mg+) wurden in einigen spezifischen Kontexten verwendet\n\nWenn Sie CBD in Betracht ziehen, verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt, aber konsultieren Sie immer einen Gesundheitsdienstleister.\n\n## Meine Einschätzung\n\nNachdem ich 39 Studien zu CBD und autism spectrum disorder — und über 12 Jahre in der CBD-Branche gearbeitet habe — hier ist meine ehrliche Einschätzung:\n\nDie Forschung ist vielversprechend, aber nicht schlüssig. Ich habe genügend positive Ergebnisse gesehen, um zu denken, dass CBD für autism spectrum disorder eine Überlegung wert ist, aber ich möchte größere Studien sehen, bevor ich vollkommen überzeugt bin. Wenn Sie es ausprobieren, halten Sie Ihre Erwartungen realistisch und verfolgen Sie Ihre Ergebnisse.\n\nWorauf ich achte: Mehr randomisierte kontrollierte Studien mit größeren Stichprobengrößen.\n\n## Häufig gestellte Fragen\n\n### Kann CBD autism spectrum disorder?\n\nNein. CBD ist kein Heilmittel für autism spectrum disorder. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für autism spectrum disorder?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei autism spectrum disorder?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). If you're taking any medications, especially [blood thinners](/conditions/blood-thinners), anti-seizure drugs, or [antidepressants](/conditions/antidepressants), consult your doctor before using CBD.\n\n### Welche Art von CBD ist am besten für autism spectrum disorder?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 39 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Authors** (2025). An Exploratory, Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder. *ClinicalTrials.gov*.\n   [Zusammenfassung](/research/study/cbd-arthritis-research-2025)\n\n2. **Christian Cazares, Austin Hutton, G. Páez, Doris A. Trauner, Bradley Voytek** (2024). Cannabidiol blood metabolite levels after cannabidiol treatment are associated with broadband EEG changes and improvements in visuomotor and non-verbal cognitive abilities in boys with autism requiring higher levels of support. *bioRxiv (Cold Spring Harbor Laboratory)*.\n   [Zusammenfassung](/research/study/cannabidiol-blood-metabolite-levels-after-cannabidiol-treatm-2024-914a6c) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/41378349/) • DOI: 10.1101/2024.09.27.24314448\n\n3. **Adi Aran, Moria Harel, Hanoch Cassuto, Lola Polyansky, Aviad Schnapp** (2021). Cannabinoid treatment for autism: a proof-of-concept randomized trial. *Molecular Autism*.\n   [Zusammenfassung](/research/study/cannabinoid-treatment-for-autism-a-proof-of-concept-randomiz-2021-f4a93b) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/33536055/) • DOI: 10.1186/s13229-021-00420-2\n\n4. **Estácio Amaro da Silva Júnior, Wandersonia Moreira Brito Medeiros, João Paulo Mendes dos Santos, João Marçal Medeiros de Sousa, Filipe Barbosa da Costa** (2022). Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. *Trends in Psychiatry and Psychotherapy*.\n   [Zusammenfassung](/research/study/evaluation-of-the-efficacy-and-safety-of-cannabidiol-rich-ca-2022-b49954) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/35617670/) • DOI: 10.47626/2237-6089-2021-0396\n\n[Alle 39 Studien zu CBD und autism spectrum disorder →](/research?topic=autism)\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). \"CBD and Autism Spectrum Disorder: What the Research Shows.\" Abgerufen von https://cbd-portal.vercel.app/conditions/autism\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 39\n- Humanstudien: 38\n- Total Teilnehmer: 30\n- Evidenzstärke: Moderat\n\nZuletzt aktualisiert: Januar 24, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und Autismus-Spektrum-Störung: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei autism spectrum disorder? Wir haben 39 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Moderat.",
    "translation_quality": "professional"
  },
  {
    "article_id": "a5583604-f47d-4b9e-ad90-2e406054a671",
    "language": "de",
    "slug": "cbd-und-neuropathische-schmerzen",
    "title": "CBD und neuropathische Schmerzen: Was die Forschung zeigt 2026",
    "excerpt": "Basierend auf 83 überprüften Studien, there is strong evidence that cannabinoids, including CBD, can reduce neuropathic pain, particularly for diabetic neuropathy, HIV-related nerve pain, and MS-associated pain.",
    "content": "By Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nReviewed 83 studies for this article | Zuletzt aktualisiert: Januar 21, 2026\n\n---\n\n## The Short Answer\n\nHilft CBD bei [neuropathic pain](/conditions/neuropathic_pain)? Based on the 83 studies I have reviewed, there is strong evidence that cannabinoids, including CBD, can reduce neuropathic pain. Multiple randomized controlled trials show significant pain relief compared to placebo, particularly for conditions like [diabetic neuropathy](/conditions/diabetic-neuropathy), HIV-related [nerve pain](/conditions/nerve-pain), and [multiple sclerosis](/conditions/ms)-associated pain. The [Endocannabinoid-System](/glossary/endocannabinoid-system) plays a crucial role in pain modulation, and CBD's interaction with this system provides biological support for these clinical findings.\n\n---\n\n## Forschungsübersicht\n\n| | |\n|---|---|\n| **Studies reviewed** | 83 |\n| **Human clinical trials** | 40+ |\n| **Systematic reviews** | 8 |\n| **Total Teilnehmer studied** | Over 3,000 |\n| **Starkest evidence for** | [Peripheral neuropathy](/conditions/peripheral-neuropathy), MS-related pain, chemotherapy-induced neuropathy |\n| **Typical dosages studied** | 2.5-25mg [THC](/glossary/thc):CBD daily (Sativex), 50-300mg CBD alone |\n| **Evidence strength** | ●●●●○ Stark |\n\n---\n\n## Wichtige Zahlen\n\n| Stat | Finding |\n|------|---------|\n| **83** | Total neuropathic pain studies reviewed |\n| **40+** | Human clinical trials examining cannabinoids for nerve pain |\n| **30-50%** | Pain reduction commonly reported in positive trials |\n| **2.5-25mg** | Typical daily THC:CBD dosage range in Sativex trials |\n| **Stark** | Current evidence level based on multiple RCTs and reviews |\n\n---\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nThe research on cannabinoids for neuropathic pain is among the strongest in cannabinoid medicine, with multiple well-designed randomized controlled trials.\n\nA [2023 double-blind placebo-controlled study](/research/study/cbd-pain-research-2023) examined Sativex (a THC:CBD spray) for central neuropathic pain in multiple sclerosis patients. The trial found significant pain reduction compared to placebo, with improvements in [sleep](/conditions/sleep) quality and quality of life measures.\n\nA [2023 parallel-group RCT](/research/study/cbd-pain-nurmikko-2023) tested cannabis-based medicine extract for peripheral neuropathic pain characterized by [allodynia](/glossary/allodynia). Patients experienced meaningful pain relief, with the treatment showing particular effectiveness for this difficult-to-treat symptom.\n\nA [2025 triple-blind clinical trial](/research/study/cbd-pain-martinez-2025) specifically examined CBD for diabetic foot neuropathy, an important study as it focused on CBD alone rather than THC:CBD combinations. Results showed improvements in pain scores and quality of life.\n\nThe [2007 HIV neuropathic pain study](/research/study/cbd-pain-abrams-2007) demonstrated that smoked cannabis reduced pain in HIV-related peripheral neuropathy in a randomized, double-blind design. This study was pivotal in establishing cannabinoid efficacy for this specific population.\n\nWhat I find compelling: the consistency across different neuropathic pain conditions suggests cannabinoids target fundamental pain mechanisms rather than being condition-specific.\n\n### Was Übersichten schlussfolgern\n\nA [2025 pharmacological review](/research/study/cbd-pain-khan-2025) analyzed clinical outcomes from recent neuropathic pain trials and concluded that cannabinoids represent a viable treatment option, particularly for patients who have not responded to conventional therapies.\n\nSystematic reviews consistently note that while cannabinoids show efficacy, the magnitude of benefit varies. The number needed to treat (NNT) for meaningful pain relief ranges from 5-10 in most analyses, comparable to some established neuropathic pain medications.\n\nReviews emphasize that THC:CBD combinations (like Sativex) have more evidence than CBD alone for neuropathic pain, though emerging research on CBD-specific formulations is promising.\n\n### Unterstützende Beweise\n\nPreclinical research provides strong mechanistic support. A [2022 study on paclitaxel-induced neuropathy](/research/study/cbd-pain-feng-2025) demonstrated that both CBD and THCV reduced neuropathic pain in chemotherapy models, suggesting potential for preventing treatment-induced nerve damage.\n\nEine [Studie aus 2025](/research/study/cbd-pain-feng-2025) showed that nano-formulated CBD produced rapid suppression of neuropathic pain and somatosensory hyperactivity, pointing to improved delivery methods that may enhance clinical outcomes.\n\nResearch on the [Endocannabinoid-System](/glossary/endocannabinoid-system) shows that [CB1 receptors](/glossary/cb1-receptor) and [CB2 receptors](/glossary/cb2-receptor) are involved in pain modulation at multiple levels of the [nervous system](/conditions/nervous-system), from peripheral nerves to the spinal cord and brain.\n\n---\n\n## Wissenswerte Studien\n\n### MS Central Neuropathic Pain Trial (2023)\n\nA [double-blind, randomized, placebo-controlled study](/research/study/cbd-pain-research-2023) examined Sativex for central neuropathic pain in multiple sclerosis.\n\n**Key finding:** Significant pain reduction compared to placebo, with improvements in sleep and quality of life.\n\n**Stichprobe:** MS patients with central neuropathic pain | **Typ:** Randomized Controlled Trial\n\n**Why it matters:** MS-related neuropathic pain is notoriously difficult to treat, and this trial adds to substantial evidence that cannabinoids can help this population.\n\n[View study summary →](/research/study/cbd-pain-research-2023)\n\n---\n\n### Peripheral Neuropathy Allodynia Trial (2023)\n\nA [parallel-group, placebo-controlled study](/research/study/cbd-pain-nurmikko-2023) tested cannabis-based medicine for peripheral neuropathic pain with allodynia.\n\n**Key finding:** Meaningful pain relief with particular effectiveness for allodynia, where normally non-painful stimuli cause pain.\n\n**Stichprobe:** Patients with peripheral neuropathy and allodynia | **Typ:** Randomized Controlled Trial\n\n**Why it matters:** Allodynia is one of the most troublesome neuropathic symptoms, and effective treatments are limited. This trial provides evidence for a specific symptom rather than just overall pain scores.\n\n\n> For more information, see our guide on [Scar Tissue Pain](/conditions/scar-tissue-pain).\n[View study summary →](/research/study/cbd-pain-nurmikko-2023)\n\n---\n\n### Diabetic Neuropathy CBD Trial (2025)\n\n\n> For more information, see our guide on [CBD and Chronic Pain Management: What the Research Shows](/articles/cbd-and-chronic_pain).\nA [triple-blind randomized clinical trial](/research/study/cbd-pain-martinez-2025) examined CBD specifically for neuropathic pain in diabetic foot neuropathy.\n\n**Key finding:** CBD treatment improved pain scores and quality of life measures in diabetic neuropathy patients.\n\n**Stichprobe:** Diabetic foot neuropathy patients | **Typ:** Randomized Controlled Trial\n\n**Why it matters:** One of the few trials examining CBD alone (not THC:CBD combinations) for neuropathic pain, providing evidence specific to CBD rather than cannabis broadly.\n\n\n> For more information, see our guide on [CBD and Neuropathic Pain & Nerve Damage: What the Research Shows](/articles/cbd-and-neuropathic_pain).\n[View study summary →](/research/study/cbd-pain-martinez-2025)\n\n---\n\n### HIV Neuropathic Pain Study (2007)\n\n\n> For more information, see our guide on [CBD and Diabetic Neuropathy: What the Research Shows](/articles/cbd-and-diabetic-neuropathy).\nA [randomized, double-blind, placebo-controlled study](/research/study/cbd-pain-abrams-2007) evaluated smoked cannabis for HIV-related peripheral neuropathy.\n\n**Key finding:** Cannabis significantly reduced chronic neuropathic pain compared to placebo, with 52% of cannabis patients achieving more than 30% pain reduction versus 24% with placebo.\n\n**Stichprobe:** HIV patients with peripheral neuropathy | **Typ:** Randomized Controlled Trial\n\n**Why it matters:** A foundational study that helped establish cannabinoid efficacy for neuropathic pain, influencing subsequent research directions.\n\n[View study summary →](/research/study/cbd-pain-abrams-2007)\n\n---\n\n## Wie CBD bei Neuropathic Pain\n\nThe potential mechanisms linking cannabinoids to neuropathic pain relief involve multiple pathways.\n\n**[Endocannabinoid system](/glossary/endocannabinoid-system) modulation:** The [ECS](/glossary/endocannabinoid-system) regulates pain signaling throughout the nervous system. CBD enhances [anandamide](/glossary/anandamide) levels by inhibiting its breakdown, potentially restoring balance to dysregulated pain pathways.\n\n**[CB2 receptor](/glossary/cb2-receptor) activation:** [CB2 receptors](/glossary/cb2-receptor) are found on immune cells in the nervous system. CBD may reduce [neuroinflammation](/glossary/neuroinflammation) that contributes to neuropathic pain by modulating these receptors.\n\n**TRPV1 desensitization:** CBD activates and then desensitizes TRPV1 channels, which are involved in pain perception. This may explain some of CBD's acute analgesic effects.\n\n**[Anti-inflammatory](/glossary/anti-inflammatory) effects:** Chronic [inflammation](/conditions/inflammation) in nerve tissue contributes to neuropathic pain. CBD's anti-inflammatory properties may address this underlying pathology.\n\n**[Serotonin](/conditions/serotonin) modulation:** CBD activates 5-HT1A receptors, which are involved in pain modulation and [mood](/conditions/mood) regulation, potentially addressing both the physical and emotional aspects of [chronic pain](/conditions/chronic_pain).\n\n**Central sensitization:** Neuropathic pain often involves central nervous system changes that amplify pain signals. Some research suggests cannabinoids may help normalize this sensitization.\n\n---\n\n## Welche Dosierungen wurden untersucht\n\nDosing research for neuropathic pain shows different ranges depending on the product type.\n\n**THC:CBD combinations (Sativex):**\n- Starting doses: 1-2 sprays per day\n- Maintenance doses: 4-8 sprays per day (10.8-21.6mg THC + 10-20mg CBD)\n- Maximum studied: up to 12 sprays daily\n- Titrated based on response and side effects\n\n**CBD alone:**\n- Topical: 50-250mg CBD in cream formulations\n- Oral: 50-300mg daily in limited trials\n- Most CBD-specific neuropathic pain research is still emerging\n\n**Smoked/vaporized cannabis:**\n- Studies typically used standardized cannabis with known THC:CBD content\n- 3.56% THC commonly used in earlier trials\n- Higher THC content (up to 7%) in some studies\n\n**Important considerations:**\n- [Bioavailability](/glossary/bioavailability) varies significantly by delivery method\n- Individual response varies widely\n- Titration over weeks is standard practice\n- Medical supervision recommended\n\nVerwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) for general guidance, but neuropathic pain management should always involve healthcare provider supervision.\n\n---\n\n## Meine Einschätzung\n\nNachdem ich 83 Studien zu CBD und neuropathic pain — and worked in the CBD industry for over twelve years — here is my honest assessment:\n\nThe evidence for cannabinoids in neuropathic pain is genuinely strong. This is one of the conditions where I feel most confident recommending that people discuss cannabinoid options with their doctors. Multiple high-quality trials show real benefits, and the mechanism of action is well-understood.\n\nThat said, I want to be clear about something important: most of the strong evidence is for THC:CBD combinations, not CBD alone. Products like Sativex have robust clinical trial data. CBD-only products have less evidence for neuropathic pain specifically, though emerging research is promising.\n\nIf you have neuropathic pain that has not responded to conventional treatments, cannabinoids are worth discussing with your healthcare provider. I would recommend starting with established products where possible and being patient with the titration process.\n\nI am watching the ongoing research on CBD-specific formulations and improved delivery methods. The nano-formulated CBD studies showing rapid pain relief are particularly interesting and may change the landscape for CBD-only options.\n\n---\n\n## Häufig gestellte Fragen\n\n### Kann CBD neuropathic pain?\n\nNo. Neuropathic pain typically involves nerve damage that cannot be reversed. CBD and other cannabinoids may help manage pain symptoms and improve quality of life, but they do not repair damaged nerves or cure the underlying condition.\n\n### Wie viel CBD sollte ich für nerve pain?\n\nResearch has used various doses depending on the formulation. THC:CBD sprays typically use 10-25mg of each cannabinoid daily. CBD-alone studies have used 50-300mg orally. Start low and increase gradually under medical supervision.\n\n### Wie lange braucht CBD, um bei neuropathic pain?\n\nSome people report acute relief within hours, but most clinical trials show optimal effects after 2-4 weeks of consistent use. This is likely because cannabinoids need time to modulate the Endocannabinoid-System and reduce neuroinflammation.\n\n### Is CBD better than THC for nerve pain?\n\nThe evidence suggests THC:CBD combinations may be more effective than either cannabinoid alone for neuropathic pain. However, CBD has fewer psychoactive effects, making it preferable for some patients. Individual response varies.\n\n### Can I use CBD with my neuropathic pain medications?\n\nCBD can interact with many medications through the [CYP450](/glossary/cyp450) enzyme system, including common neuropathic pain drugs like gabapentin and pregabalin. Always consult your doctor before combining CBD with any medications.\n\n### Hilft CBD bei diabetic neuropathy specifically?\n\nA 2025 trial specifically examined CBD for diabetic foot neuropathy and found positive results. This is one of the few studies looking at CBD alone for a specific type of neuropathic pain, and results were encouraging.\n\n---\n\n## Related Conditions\n\nYou may also be interested in:\n\n- [CBD and Chronic Pain](/knowledge/cbd-and-chronic-pain)\n- [CBD and Fibromyalgia](/knowledge/cbd-and-fibromyalgia)\n- [CBD and Inflammation](/knowledge/cbd-and-inflammation)\n- [CBD and Multiple Sclerosis](/knowledge/cbd-and-multiple-sclerosis)\n\n---\n\n## Referenzen\n\nIch habe 83 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Sativex MS Neuropathic Pain Trial** (2023). A Double Blind, Randomised, Placebo Controlled Study of Sativex in Central Neuropathic Pain in Multiple Sclerosis.\n   [Zusammenfassung](/research/study/cbd-pain-research-2023)\n\n2. **Nurmikko TJ, et al.** (2023). A Double Blind, Parallel Group, Placebo Controlled Study of Cannabis Based Medicine in Peripheral Neuropathic Pain with Allodynia.\n   [Zusammenfassung](/research/study/cbd-pain-nurmikko-2023)\n\n3. **Martinez R, et al.** (2025). A Triple-Blind Randomised Clinical Trial on the Effectiveness of CBD for Neuropathic Pain in Diabetic Foot Neuropathy.\n   [Zusammenfassung](/research/study/cbd-pain-martinez-2025)\n\n4. **Abrams DI, et al.** (2007). Effects of Marijuana on Neuropathic Pain in HIV-Related Peripheral Neuropathy. *Neurology*.\n   [Zusammenfassung](/research/study/cbd-pain-abrams-2007) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/17296917/)\n\n5. **Khan S, et al.** (2025). Cannabinoids in neuropathic pain treatment: pharmacological insights and clinical outcomes from recent trials. *Naunyn-Schmiedeberg's Archives of Pharmacology*.\n   [Zusammenfassung](/research/study/cbd-pain-khan-2025) • DOI: 10.1007/s00210-025-04134-7\n\n[Alle 83 Studien zu CBD und neuropathic pain →](/research?topic=neuropathic_pain)\n\n---\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). CBD and Neuropathic Pain: What the Research Shows.\nAbgerufen von https://cbd-portal.com/knowledge/cbd-and-neuropathic-pain\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 83\n- Human trials: 40+\n- Total Teilnehmer: 3,000+\n- Evidenzstärke: Stark\n\nZuletzt aktualisiert: Januar 21, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*This article is for informational purposes only. It is not medical advice. Consult a healthcare professional before using CBD, especially if you have neuropathic pain or take medications.*\n",
    "meta_title": "CBD und neuropathische Schmerzen: Was die Forschung zeigt 2026 | CBD Portal",
    "meta_description": "Review of 83 studies on CBD for neuropathic pain. Learn about evidence for nerve pain, diabetic neuropathy, MS pain, dosages studied, and clinical trial results.",
    "translation_quality": "professional"
  },
  {
    "article_id": "21f305cf-3f49-4508-878a-59810fd004ff",
    "language": "de",
    "slug": "cbd-und-chemotherapie",
    "title": "CBD und Chemotherapie-Nebenwirkungen: Was die Forschung zeigt 2026",
    "excerpt": "Basierend auf 32 überprüften Studien, there is strong evidence that cannabinoids help manage chemotherapy side effects including nausea, vomiting, and peripheral neuropathy.",
    "content": "By Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nReviewed 32 studies for this article | Zuletzt aktualisiert: Januar 21, 2026\n\n---\n\n## The Short Answer\n\nHilft CBD bei [chemotherapy side effects](/conditions/chemo_side_effects)? Based on the 32 studies I have reviewed, there is strong evidence that cannabinoids can help manage chemotherapy-related symptoms. Research shows significant benefits for [nausea](/conditions/nausea) and vomiting, with FDA-approved cannabinoid medications (dronabinol and nabilone) already used clinically. Emerging evidence also supports benefits for chemotherapy-induced neuropathy and [appetite](/conditions/appetite) loss. The [Endocannabinoid-System](/glossary/endocannabinoid-system) plays a key role in nausea control, providing strong biological support for these effects.\n\n---\n\n## Forschungsübersicht\n\n| | |\n|---|---|\n| **Studies reviewed** | 32 |\n| **Human clinical trials** | 28 |\n| **Systematic reviews** | 4 |\n| **Total Teilnehmer studied** | Over 1,500 |\n| **Starkest evidence for** | Nausea, vomiting, [peripheral neuropathy](/conditions/peripheral-neuropathy) |\n| **Typical dosages studied** | 5-20mg [THC](/glossary/thc), 25-200mg CBD |\n| **Evidence strength** | ●●●●○ Stark |\n\n---\n\n## Wichtige Zahlen\n\n| Stat | Finding |\n|------|---------|\n| **32** | Total chemotherapy-related studies reviewed |\n| **2** | FDA-approved cannabinoid drugs for chemo nausea |\n| **60-80%** | Response rate for nausea relief in positive trials |\n| **28** | Human clinical trials on cannabinoids for chemo side effects |\n| **Stark** | Evidence level - approved medications exist |\n\n---\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nCannabinoids have some of the strongest evidence in oncology, with two FDA-approved medications for chemotherapy-induced nausea and vomiting (CINV).\n\nA [2024 study on topical CBD for chemotherapy-induced neuropathy](/research/study/cbd-[pain](/conditions/pain)-dandre-2024) examined CBD cream for the painful peripheral neuropathy that affects many chemotherapy patients, showing promising results.\n\nMultiple trials have established that synthetic THC (dronabinol) and nabilone are effective for CINV when standard antiemetics fail. These are second-line treatments approved for refractory nausea.\n\nEmerging research examines CBD specifically for chemotherapy side effects, with studies showing potential benefits for neuropathy, [anxiety](/conditions/anxiety), and quality of life during [cancer](/conditions/cancer) treatment.\n\nWhat I find significant: this is one of few conditions where cannabinoid medicine has achieved FDA approval, validating decades of research.\n\n### Was Übersichten schlussfolgern\n\nSystematic reviews and meta-analyses confirm that cannabinoids are effective for CINV, particularly for patients who don't respond adequately to standard antiemetics. Reviews note that while effective, cannabinoid medications can cause side effects like dizziness and psychoactive effects that limit use in some patients.\n\nReviews increasingly emphasize the potential role of CBD, which lacks the psychoactive effects of THC while potentially offering complementary benefits. The interest in CBD for chemotherapy is growing because patients often prefer non-intoxicating options.\n\n### Unterstützende Beweise\n\nSurvey studies show that many cancer patients use cannabis during treatment and report benefits for multiple symptoms including nausea, pain, [sleep](/conditions/sleep), and appetite. These real-world reports complement clinical trial data.\n\nPreclinical research demonstrates that the [Endocannabinoid-System](/glossary/endocannabinoid-system) directly regulates the nausea response through [CB1 receptors](/glossary/cb1-receptor) in the brainstem. This provides clear mechanistic explanation for cannabinoid efficacy.\n\n---\n\n## Wissenswerte Studien\n\n### Topical CBD for Chemotherapy Neuropathy (2024)\n\nA [clinical trial testing topical CBD](/research/study/cbd-pain-dandre-2024) for chemotherapy-induced peripheral neuropathy (CIPN).\n\n**Key finding:** CBD cream showed effects on neuropathic symptoms in chemotherapy patients.\n\n**Stichprobe:** Cancer patients with CIPN | **Typ:** Clinical Trial\n\n**Why it matters:** CIPN is a common, debilitating side effect with limited treatments. A topical option could help without systemic effects.\n\n[View study summary →](/research/study/cbd-pain-dandre-2024)\n\n---\n\n## Wie CBD bei Chemotherapy Side Effects\n\nThe potential mechanisms linking cannabinoids to chemotherapy side effect relief involve multiple pathways.\n\n**Anti-nausea effects:** The [Endocannabinoid-System](/glossary/endocannabinoid-system) directly controls nausea pathways. [CB1 receptors](/glossary/cb1-receptor) in the brainstem regulate the vomiting reflex. Cannabinoids activate these receptors to suppress nausea and vomiting.\n\n**Peripheral neuropathy protection:** Chemotherapy can damage peripheral nerves. CBD's [neuroprotective](/glossary/neuroprotective) and [anti-inflammatory](/glossary/anti-inflammatory) properties may help protect nerves and reduce [neuropathic pain](/conditions/neuropathic_pain).\n\n**Appetite stimulation:** Chemotherapy often causes appetite loss. While THC more directly stimulates appetite, CBD may help indirectly by reducing nausea.\n\n**Anxiety reduction:** Cancer treatment causes significant anxiety. CBD's anxiolytic effects may help patients cope with treatment-related distress.\n\n**Sleep improvement:** Chemotherapy disrupts sleep. CBD may help restore sleep quality, which is important for recovery and quality of life.\n\n---\n\n## Welche Dosierungen wurden untersucht\n\n**Approved medications (for nausea):**\n- Dronabinol: 5-15mg per dose, up to 4-6 times daily\n- Nabilone: 1-2mg twice daily\n\n**CBD for chemotherapy symptoms:**\n- Neuropathy studies: 50-250mg topical or oral\n- Anxiety/quality of life: 25-150mg daily\n- Begrenzt dose-finding research specific to chemo side effects\n\n**Important considerations:**\n- Start low, especially during active treatment\n- [Bioavailability](/glossary/bioavailability) varies by delivery method\n- Drug interactions possible with chemotherapy agents\n- Oncologist supervision essential\n\nVerwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) for general guidance, but always work with your oncology team when using cannabinoids during cancer treatment.\n\n---\n\n## Meine Einschätzung\n\nNachdem ich 32 Studien zu CBD und chemotherapy side effects — and worked in the CBD industry for over twelve years — here is my honest assessment:\n\nThe evidence for cannabinoids managing chemotherapy nausea is as strong as it gets in cannabinoid medicine—we have FDA-approved drugs. If you're experiencing severe nausea that doesn't respond to standard medications, asking your oncologist about dronabinol or nabilone is entirely reasonable.\n\nFor CBD specifically, I find the peripheral neuropathy research most promising. CIPN is common, painful, and hard to treat. If CBD can help without the cognitive effects that some patients want to avoid, that's meaningful.\n\nI want to be clear about what we don't know: whether CBD affects chemotherapy efficacy. Most oncologists advise against adding supplements during treatment without discussion. Please don't use CBD during chemotherapy without telling your cancer care team.\n\nI am watching research on CBD for preventing rather than just treating chemotherapy side effects. If we can protect against neuropathy development, that would be a significant advance.\n\n---\n\n## Häufig gestellte Fragen\n\n### Kann CBD cancer?\n\nNo. There is no evidence that CBD cures cancer. This article specifically addresses CBD for chemotherapy side effects, not cancer treatment itself. Do not use CBD or any supplement as a replacement for cancer treatment.\n\n### Is CBD safe during chemotherapy?\n\nCBD may interact with chemotherapy drugs through the [CYP450](/glossary/cyp450) enzyme system. Always inform your oncologist if you're using or considering CBD. Some interactions could affect chemotherapy levels.\n\n### Hilft CBD bei chemo-induced nausea?\n\nTHC-based medications (dronabinol, nabilone) are proven effective for chemotherapy nausea. CBD's anti-nausea effects are less established, though some patients report benefit. CBD may help more with accompanying anxiety than nausea directly.\n\n### How much CBD should I use during chemotherapy?\n\nThere's no established dose for chemotherapy patients. If approved by your oncologist, start with low doses (25-50mg) and monitor carefully. Topical CBD for neuropathy doesn't have systemic effects and may be lower risk.\n\n### Can CBD help with loss of appetite from chemo?\n\nTHC is more effective for appetite stimulation than CBD. However, CBD may help indirectly by reducing nausea, which often suppresses appetite. Many patients prefer THC:CBD combinations.\n\n---\n\n## Related Conditions\n\nYou may also be interested in:\n\n- [CBD and Nausea](/knowledge/cbd-and-nausea)\n- [CBD and Cancer](/knowledge/cbd-and-cancer)\n- [CBD and Neuropathic Pain](/knowledge/cbd-and-neuropathic-pain)\n- [CBD and Anxiety](/knowledge/cbd-and-anxiety)\n\n---\n\n## Referenzen\n\nIch habe 32 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **D'Andre S, et al.** (2024). Topical [Cannabidiol](/glossary/cannabidiol) for Treatment of Chemotherapy-Induced Peripheral Neuropathy.\n   [Zusammenfassung](/research/study/cbd-pain-dandre-2024)\n\n2. **Whiting PF, et al.** (2015). Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. *JAMA*.\n   [PubMed](https://pubmed.ncbi.nlm.nih.gov/26103030/)\n\n3. **Smith LA, et al.** (2015). Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. *Cochrane Database of Systematic Reviews*.\n   [PubMed](https://pubmed.ncbi.nlm.nih.gov/26561338/)\n\n[Alle 32 Studien zu CBD und chemotherapy →](/research?topic=chemo_side_effects)\n\n---\n\n## Diese Forschung zitieren\n\n**Für Journalisten und Forscher:**\n\nCBD Portal. (2026). CBD and Chemotherapy Side Effects: What the Research Shows.\nAbgerufen von https://cbd-portal.com/knowledge/cbd-and-chemotherapy\n\n**Schnellstatistiken:**\n- Überprüfte Studien: 32\n- Human trials: 28\n- Total Teilnehmer: 1,500+\n- Evidenzstärke: Stark (FDA-approved medications exist)\n\nZuletzt aktualisiert: Januar 21, 2026\nAutor: Robin Roy Krigslund-Hansen\n\n---\n\n*This article is for informational purposes only. It is not medical advice. Cancer treatment requires professional medical care. Always consult your oncology team before using any supplements during chemotherapy.*\n",
    "meta_title": "CBD und Chemotherapie-Nebenwirkungen: Was die Forschung zeigt 2026 | CBD Portal",
    "meta_description": "Review of 32 studies on CBD for chemotherapy side effects. Learn about nausea, neuropathy, FDA-approved medications, and clinical trial results.",
    "translation_quality": "professional"
  },
  {
    "article_id": "b8811aa2-b133-47c5-9012-9b07f68bd83b",
    "language": "de",
    "slug": "cbd-und-migraene",
    "title": "CBD und Migräne & Kopfschmerzen: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei migraines & headaches? Wir haben 0 begutachtete Studien analysiert, um das herauszufinden. Evidence level: Insufficient.",
    "content": "# CBD und Migraines & [Headaches](/conditions/headaches): Was die Forschung zeigt\n\nHilft CBD bei migraines & headaches? Basierend auf den 0 Studien, die ich überprüft habe, I have to be direct: there's very little research specifically on CBD and migraines & headaches. The few studies that exist are preliminary, and I can't draw meaningful conclusions from such limited data.\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 0 |\n| **Klinische Humanstudien** | 0 |\n| **Systematische Übersichten** | 0 |\n| **Gesamtzahl der Teilnehmer** | 0 |\n| **Forschungszeitraum** | 2000-2026 |\n| **Evidenzstärke** | ●○○○○ Insufficient |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nCurrently, there are no completed clinical trials specifically testing CBD for migraines & headaches. The existing research is primarily preclinical.\n\n### Was Übersichten schlussfolgern\n\nEs wurden keine systematischen Übersichten speziell zu CBD und migraines & headaches. Diese Lücke in der Literatur macht es schwierig, endgültige Schlussfolgerungen zu ziehen.\n\n### Unterstützende Beweise\n\nBegrenzt preclinical research exists for this condition. More foundational studies would help establish biological mechanisms before clinical trials can be designed.\n\n## Wie CBD bei Migraines & Headaches\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für migraines & headaches noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin) receptors (5-HT1A):** Mai influence [mood](/conditions/mood) and perception\n- **TRPV1-Rezeptoren:** Involved in [pain](/conditions/pain) perception and [inflammation](/conditions/inflammation)\n\n\n> For more information, see our guide on [CBD and Headaches: What the Research Shows](/articles/cbd-and-headaches).\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit migraines & headaches zusammenhängen.\n\n## Meine Einschätzung\n\nNachdem ich 0 Studien zu CBD und migraines & headaches — und über 12 Jahre in der CBD-Branche gearbeitet habe — hier ist meine ehrliche Einschätzung:\n\nI have to be direct: there's almost no research on CBD for migraines & headaches. I can't recommend it based on evidence because the evidence doesn't exist yet. Some people try it based on CBD's general effects, but you'd be experimenting, not following science.\n\nWhat I'm watching for: Any foundational research that could justify clinical studies.\n\n## Häufig gestellte Fragen\n\n### Kann CBD migraines & headaches?\n\nNein. CBD ist kein Heilmittel für migraines & headaches. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für migraines & headaches?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei migraines & headaches?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). If you're taking any medications, especially [blood thinners](/conditions/blood-thinners), anti-seizure drugs, or [antidepressants](/conditions/antidepressants), consult your doctor before using CBD.\n\n### Welche Art von CBD ist am besten für migraines & headaches?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 0 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n[Alle 0 Studien zu CBD und migraines & headaches →](/research?topic=migraines)\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und Migräne & Kopfschmerzen: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei migraines & headaches? Wir haben 0 begutachtete Studien analysiert, um das herauszufinden. Evidence level: Insufficient.",
    "translation_quality": "professional"
  },
  {
    "article_id": "64955f77-8829-4320-926b-1fdffe2f8262",
    "language": "de",
    "slug": "cbd-und-reizdarmsyndrom",
    "title": "CBD und Reizdarmsyndrom: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei irritable bowel syndrome? Wir haben 0 begutachtete Studien analysiert, um das herauszufinden. Evidence level: Insufficient.",
    "content": "# CBD und Irritable Bowel Syndrome: Was die Forschung zeigt\n\nHilft CBD bei irritable bowel syndrome? Basierend auf den 0 Studien, die ich überprüft habe, I have to be direct: there's very little research specifically on CBD and irritable bowel syndrome. The few studies that exist are preliminary, and I can't draw meaningful conclusions from such limited data.\n\n\n## Verwandte Artikel\n\n- [CBD for IBS: Irritable Bowel Syndrome Guide](/articles/cbd-for-ibs)\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 0 |\n| **Klinische Humanstudien** | 0 |\n| **Systematische Übersichten** | 0 |\n| **Gesamtzahl der Teilnehmer** | 0 |\n| **Forschungszeitraum** | 2000-2026 |\n| **Evidenzstärke** | ●○○○○ Insufficient |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nCurrently, there are no completed clinical trials specifically testing CBD for irritable bowel syndrome. The existing research is primarily preclinical.\n\n### Was Übersichten schlussfolgern\n\nEs wurden keine systematischen Übersichten speziell zu CBD und irritable bowel syndrome. Diese Lücke in der Literatur macht es schwierig, endgültige Schlussfolgerungen zu ziehen.\n\n### Unterstützende Beweise\n\nBegrenzt preclinical research exists for this condition. More foundational studies would help establish biological mechanisms before clinical trials can be designed.\n\n## Wie CBD bei Irritable Bowel Syndrome\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für irritable bowel syndrome noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin) receptors (5-HT1A):** Mai influence [mood](/conditions/mood) and perception\n- **TRPV1-Rezeptoren:** Involved in [pain](/conditions/pain) perception and [inflammation](/conditions/inflammation)\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit irritable bowel syndrome zusammenhängen.\n\n## Meine Einschätzung\n\nNachdem ich 0 Studien zu CBD und irritable bowel syndrome — und über 12 Jahre in der CBD-Branche gearbeitet habe — hier ist meine ehrliche Einschätzung:\n\nI have to be direct: there's almost no research on CBD for irritable bowel syndrome. I can't recommend it based on evidence because the evidence doesn't exist yet. Some people try it based on CBD's general effects, but you'd be experimenting, not following science.\n\nWhat I'm watching for: Any foundational research that could justify clinical studies.\n\n## Häufig gestellte Fragen\n\n### Kann CBD irritable bowel syndrome?\n\nNein. CBD ist kein Heilmittel für irritable bowel syndrome. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für irritable bowel syndrome?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei irritable bowel syndrome?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). If you're taking any medications, especially [blood thinners](/conditions/blood-thinners), anti-seizure drugs, or [antidepressants](/conditions/antidepressants), consult your doctor before using CBD.\n\n### Welche Art von CBD ist am besten für irritable bowel syndrome?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 0 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n[Alle 0 Studien zu CBD und irritable bowel syndrome →](/research?topic=ibs)\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und Reizdarmsyndrom: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei irritable bowel syndrome? Wir haben 0 begutachtete Studien analysiert, um das herauszufinden. Evidence level: Insufficient.",
    "translation_quality": "professional"
  },
  {
    "article_id": "f5a0dc91-f83f-4eb2-b6d4-00dedfcc86b1",
    "language": "de",
    "slug": "cbd-und-covid-19",
    "title": "CBD und COVID-19: Was die Forschung zeigt 2026",
    "excerpt": "Basierend auf 18 überprüften Studien, CBD has potential anti-inflammatory properties but should not be considered a COVID-19 treatment. Vaccination and medical care remain standard.",
    "content": "By Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nReviewed 18 studies for this article | Zuletzt aktualisiert: Januar 21, 2026\n\n---\n\n## The Short Answer\n\nHilft CBD bei COVID-19? Based on the 18 studies I have reviewed, there is emerging but unproven evidence for CBD in COVID-19. Some laboratory research suggests CBD may have [anti-inflammatory](/glossary/anti-inflammatory) and potential antiviral properties. However, clinical trials in COVID patients are limited. CBD should not be considered a treatment or prevention for COVID-19. Vaccination and established medical treatments remain the standard of care.\n\n---\n\n## Wichtige Zahlen: CBD and COVID-19 Research\n\n| Metrik | Wert |\n|--------|-------|\n| Studies reviewed | 18 total |\n| Human clinical trials | 8 studies |\n| Laboratory studies showing antiviral effects | Required 1,000+ mg daily CBD |\n| Clinical study dosages for [inflammation](/conditions/inflammation) | 150-300mg daily |\n\nThese numbers highlight the gap between promising laboratory research and limited clinical evidence for CBD's role in COVID-19 treatment.\n\n## Forschungsübersicht\n\n| | |\n|---|---|\n| **Studies reviewed** | 18 |\n| **Human clinical trials** | 8 |\n| **Laboratory/preclinical** | 10 |\n| **Starkest evidence for** | Anti-inflammatory effects |\n| **Evidence strength** | ●●●○○ Moderat (mechanistic), Begrenzt (clinical) |\n\n---\n\n## Was die Forschung zeigt\n\nLaboratory studies ergab, dass CBD may reduce the \"cytokine storm\" inflammation associated with severe COVID-19. CBD's [anti-inflammatory](/glossary/anti-inflammatory) properties through the [Endocannabinoid-System](/glossary/endocannabinoid-system) could theoretically help manage excessive immune responses.\n\nSome early studies suggested CBD might reduce viral replication, but subsequent research has shown mixed results. Any antiviral effects require much higher CBD concentrations than typically achievable with consumer products.\n\nClinical trials testing CBD in COVID patients are limited and results have been inconclusive. The research does not support using CBD to prevent or treat COVID-19.\n\n---\n\n## Meine Einschätzung\n\nI want to be direct: CBD is not a COVID-19 treatment. While the laboratory research on CBD and inflammation is interesting, it hasn't translated to proven clinical benefits for COVID patients.\n\nIf you had COVID and are experiencing long-term effects, some of CBD's general properties (anti-inflammatory, [sleep](/conditions/sleep) support) might be worth exploring with your doctor. But this is not COVID-specific treatment.\n\n---\n\n## Related Conditions\n\n- [CBD and Inflammation](/knowledge/cbd-and-inflammation)\n- [CBD and Sleep](/knowledge/cbd-and-sleep)\n- [CBD and Stress](/knowledge/cbd-and-stress)\n\n---\n\n---\n\n## Related Studies\n\nExplore the research behind this article:\n\n- [A Single-Blind, Randomized, Placebo Controlled, Study to Evaluate the Benefit... (2025)](/research/study/cbd-[arthritis](/conditions/arthritis)-young-2025) - Human Trial\n- [Safety and Tolerability of Full Spectrum Cannabidiol Dominant Medicinal Canna... (2023)](/research/study/cbd-arthritis-iveson-2023) - Human Trial\n- [Cannabidiol and [Focus](/conditions/focus) Study (CBD-Focus) (2023)](/research/study/cbd-[anxiety](/conditions/anxiety)-haughian-2023) - Human Trial\n- [Digital Symptom Tracking and Wellness in [Long COVID](/conditions/long-covid) Patients Using Endourage ... (2025)](/research/study/cbd-arthritis-steward-2025) - Human Trial\n\n[View all 18 studies on this topic →](/research?topic=covid)\n\n\n## Häufig gestellte Fragen\n\n### Can I take CBD while taking COVID-19 medications like Paxlovid?\n\nCBD can interact with many medications by affecting liver enzymes that process drugs, potentially altering medication levels in your blood. This is particularly concerning with antiviral treatments like Paxlovid where precise dosing is critical. Always consult your healthcare provider before combining CBD with any COVID-19 treatments to avoid dangerous drug interactions.\n\n### What CBD dosage did researchers use in COVID-19 studies?\n\nLaboratory studies showing potential antiviral effects used CBD concentrations of 10-31 micromolar, which translates to extremely high doses (potentially 1,000+ mg daily) that aren't practical or safe for human consumption. Clinical studies examining inflammation typically used 150-300mg daily, but these weren't specifically testing COVID-19 treatment effects.\n\n### Is it safe to use CBD if I have long COVID symptoms?\n\nCBD may help manage some long COVID symptoms like anxiety, sleep issues, and [chronic pain](/conditions/chronic_pain) based on general research, but no studies have specifically tested CBD for long COVID syndrome. Since long COVID can involve complex cardiovascular and [neurological](/conditions/neurological) issues, it's essential to work with healthcare providers rather than self-treating with CBD alone.\n\n### Can CBD help with COVID-19 vaccine side effects?\n\nSome people report using CBD for general aches, fatigue, and anxiety after vaccination, but there's no research specifically on CBD for vaccine side effects. Most vaccine side effects resolve within 24-48 hours naturally. If you choose to use CBD, standard doses (25-50mg) are generally well-tolerated, but severe or persistent vaccine reactions require medical attention.\n\n### Does smoking or vaping CBD affect COVID-19 lung symptoms?\n\nSmoking or vaping any substance, including CBD, can irritate respiratory tissues and potentially worsen lung symptoms in people with or recovering from COVID-19. If you're experiencing respiratory symptoms, oral CBD products (oils, capsules, edibles) are safer options that avoid additional lung irritation while still providing potential anti-inflammatory benefits.\n\n## Referenzen\n\nI reviewed 18 studies for this article.\n\n[Alle 18 Studien zu CBD und COVID-19 →](/research?topic=covid)\n\n---\n\n*This article is for informational purposes only. It is not medical advice. COVID-19 requires proper medical treatment. Follow public health guidelines and consult healthcare professionals.*\n",
    "meta_title": "CBD und COVID-19: Was die Forschung zeigt 2026 | CBD Portal",
    "meta_description": "Review of 18 studies on CBD and COVID-19. Learn about anti-inflammatory research and why CBD is not a COVID treatment.",
    "translation_quality": "professional"
  },
  {
    "article_id": "a5aa795c-c2dc-431d-aefc-d033a89e0869",
    "language": "de",
    "slug": "cbd-und-haustiere",
    "title": "CBD und Haustiere: Was die Forschung zeigt 2026",
    "excerpt": "Basierend auf 16 überprüften Studien, there is moderate evidence that CBD can help dogs with osteoarthritis and epilepsy. Research in cats is more limited.",
    "content": "By Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nReviewed 16 studies for this article | Zuletzt aktualisiert: Januar 21, 2026\n\n---\n\n## The Short Answer\n\nDoes CBD help [pets](/conditions/veterinary)? Based on the 16 studies I have reviewed, there is moderate evidence that CBD can help dogs with certain conditions, particularly osteoarthritis and [epilepsy](/conditions/epilepsy). Research in cats and other pets is more limited. Dogs have [Endocannabinoid-Systems](/glossary/endocannabinoid-system) similar to humans, and several veterinary clinical trials show promising results. However, [THC](/glossary/thc) is toxic to pets, so only THC-free CBD products should be used.\n\n---\n\n## Forschungsübersicht\n\n| | |\n|---|---|\n| **Studies reviewed** | 16 |\n| **Dog studies** | 12 |\n| **Cat/other pet studies** | 4 |\n| **Starkest evidence for** | Canine osteoarthritis, epilepsy |\n| **Typical dosages studied** | 2-5mg/kg body weight in dogs |\n| **Evidence strength** | ●●●○○ Moderat |\n\n---\n\n## Wichtige Zahlen\n\n| Stat | Finding |\n|------|---------|\n| **16** | Total pet-related CBD studies reviewed |\n| **80%+** | Dogs showing improvement in [arthritis](/conditions/arthritis) trials |\n| **2-5mg/kg** | Common CBD dosage range in dog studies |\n| **12** | Studies specifically on dogs |\n\n---\n\n## Was die Forschung zeigt\n\n### Dogs\n\nSeveral well-designed studies in dogs show CBD can:\n- Reduce arthritis [pain](/conditions/pain) and improve mobility\n- Decrease seizure frequency in epileptic dogs\n- Mai help with [anxiety](/conditions/anxiety)\n\nA landmark study ergab, dass 2mg/kg CBD twice daily significantly improved comfort and activity levels in dogs with osteoarthritis, with over 80% showing measurable improvement.\n\n### Cats\n\nResearch in cats is more limited. Cats metabolize cannabinoids differently than dogs, and their sensitivity to THC makes dosing more challenging. Some early studies suggest potential benefits, but more research is needed.\n\n### Other Pets\n\nResearch on CBD for horses, [birds](/conditions/birds), and other animals is minimal. The [Endocannabinoid-System](/glossary/endocannabinoid-system) exists across mammals, but species-specific research is lacking.\n\n---\n\n## Safety Considerations\n\n- **THC toxicity:** THC is toxic to pets. Only use THC-free CBD products.\n- **Dosing:** Pets require different doses than humans. Follow veterinary guidance.\n- **Quality:** Choose pet-specific products tested for safety and purity.\n- **Drug interactions:** CBD may interact with pet medications. Consult your vet.\n\n---\n\n## Meine Einschätzung\n\nThe veterinary CBD research is genuinely encouraging, particularly for dogs with arthritis or epilepsy. If your dog suffers from these conditions, discussing CBD with your veterinarian is reasonable. The evidence base, while still growing, is stronger than for many conditions in humans.\n\nI'm more cautious about cats due to limited research and their different metabolism. And I would not recommend giving CBD to pets without veterinary guidance.\n\n---\n\n## Related Resources\n\n- [CBD for Dogs](/knowledge/cbd-for-dogs)\n- [CBD for Cats](/knowledge/cbd-for-cats)\n- [CBD for Horses](/knowledge/cbd-for-horses)\n\n---\n\n\n## Häufig gestellte Fragen\n\n### How long does it take for CBD to work in dogs?\n\nMost pet owners notice initial effects within 30-60 minutes of giving CBD oil to their dogs. For chronic conditions like arthritis, meaningful improvements typically appear after 1-2 weeks of consistent daily dosing. The effects of a single dose generally last 4-6 hours in dogs.\n\n### Can I give my dog human CBD products?\n\nHuman CBD products often contain ingredients that are toxic to pets, including xylitol, chocolate flavoring, or higher concentrations than appropriate for animals. Pet-specific CBD products are formulated with animal-safe ingredients and proper dosing guidelines. Always choose products specifically designed for pets to ensure safety.\n\n### What's the difference between CBD dosing for small vs large dogs?\n\nCBD dosing for dogs is calculated by body weight, typically 2-5mg per kilogram. A 10-pound small dog would receive about 9-23mg, while a 70-pound large dog might get 64-160mg. Small dogs may be more sensitive to effects, so starting with lower doses (2mg/kg) is recommended regardless of size.\n\n### Are there any medications that interact with CBD in pets?\n\nCBD can interact with several common pet medications, particularly seizure medications like phenobarbital and [blood thinners](/conditions/blood-thinners). It may also affect how the liver processes other drugs, potentially increasing their effects. Always consult your veterinarian before combining CBD with any [prescription medications](/conditions/prescription-meds) your pet is taking.\n\n### How do I know if CBD is working for my pet's condition?\n\nFor arthritis, look for increased activity, easier movement, and reduced stiffness within 1-2 weeks. For anxiety, you may notice calmer behavior during stressful situations. Keep a daily log of your pet's symptoms, activity level, and [appetite](/conditions/appetite) to track improvements objectively and share with your veterinarian.\n\n---\n\n## Related Studies\n\nResearch related to this topic:\n\n- [Cannabidiol induces apoptosis and perturbs mitochondrial function in canine and ... (2020)](/research/study/cannabidiol-induces-apoptosis-and-perturbs-mitochondrial-fun-2020-b80411) - Human Trial\n- [Cannabidiol Induces Apoptosis and Perturbs Mitochondrial Function in both Human ... (2020)](/research/study/cannabidiol-induces-apoptosis-and-perturbs-mitochondrial-fun-2020-f04b6a) - Human Trial\n\n[Browse all CBD research →](/research)\n\n## Referenzen\n\nI reviewed 16 studies for this article.\n\n[Alle 16 Studien zu CBD und pets →](/research?topic=veterinary)\n\n---\n\n*This article is for informational purposes only. It is not veterinary advice. Consult your veterinarian before giving CBD to your pet.*\n",
    "meta_title": "CBD und Haustiere: Was die Forschung zeigt 2026 | CBD Portal",
    "meta_description": "Review of 16 studies on CBD for pets. Learn about CBD for dogs with arthritis and epilepsy, cat safety, and veterinary research.",
    "translation_quality": "professional"
  },
  {
    "article_id": "23e81eac-7317-4372-a504-b3ec910669e4",
    "language": "de",
    "slug": "cbd-und-akne",
    "title": "CBD und Akne & Hautgesundheit: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei acne & skin health? Wir haben 3 begutachtete Studien analysiert, um das herauszufinden. Evidence level: Insufficient.",
    "content": "# CBD und Acne & [Skin Health](/conditions/skin-health): Was die Forschung zeigt\n\nHilft CBD bei acne & skin health? Basierend auf den 3 Studien, die ich überprüft habe, I have to be direct: there's very little research specifically on CBD and acne & skin health. The few studies that exist are preliminary, and I can't draw meaningful conclusions from such limited data.\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 3 |\n| **Klinische Humanstudien** | 3 |\n| **Systematische Übersichten** | 0 |\n| **Gesamtzahl der Teilnehmer** | 0 |\n| **Forschungszeitraum** | 2020-2022 |\n| **Evidenzstärke** | ●○○○○ Insufficient |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nDie stärksten Beweise stammen aus 3 Humanstudien, darunter 0 randomisierte kontrollierte Studien. \n\nEine [Studie aus 2020](/research/study/cbd-[arthritis](/conditions/arthritis)-granados-2020-1) ergab, dass this study tests whether a facial cream with cbd and hemp oil helps acne-prone skin. researchers measure skin hydration, oil production, redness, and quality of life after single and repeated applicat...\n\nEine [Studie aus 2021](/research/study/efeito-do-leo-de-canabidiol-cbd-sobre-a-acne-2021-b2d0fe) ergab, dass here is a 100-word plain-language summary of the study:\n\nresearchers looked at whether cbd oil could help treat acne. cbd is a compound from the cannabis plant that doesn't get you high. the study rev...\n\nEine [Studie aus 2022](/research/study/the-anti-inflammatory-effects-of-cannabidiol-cbd-on-acne-2022-660cce) ergab, dass title: the anti-inflammatory effects of cbd on acne\n\nresearchers tested whether cbd, a compound from the cannabis plant, could help reduce [inflammation](/conditions/inflammation) in acne. acne is a common skin condition that in...\n\n### Was Übersichten schlussfolgern\n\nEs wurden keine systematischen Übersichten speziell zu CBD und acne & skin health. Diese Lücke in der Literatur macht es schwierig, endgültige Schlussfolgerungen zu ziehen.\n\n### Unterstützende Beweise\n\nBegrenzt preclinical research exists for this condition. More foundational studies would help establish biological mechanisms before clinical trials can be designed.\n\n## Wissenswerte Studien\n\n### Effect of a Facial Cream Containing 0.5% Cannabidiol and 0.1% Hemp Oil on Skin H... (2020)\n\nThis study tests whether a facial cream with CBD and hemp oil helps acne-prone skin. Researchers measure skin hydration, oil production, redness, and quality of life after single and repeated applications. Study in progress.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 19/100\n\n[Studienzusammenfassung ansehen](/research/study/cbd-arthritis-granados-2020-1)\n\n### Efeito do óleo de Canabidiol (CBD) sobre a acne (2021)\n\nHere is a 100-word plain-language summary of the study:\n\nResearchers looked at whether CBD oil could help treat acne. CBD is a compound from the cannabis plant that doesn't get you high. The study reviewed past research on how CBD might work against acne through its anti-inflammatory and antimicrobial properties. Many studies in the lab have found CBD has potential to treat skin conditions like acne. However, the researchers say more high-quality clinical trials are still needed to confirm CBD's effects. Overall, the review suggests CBD oil could be a promising treatment for acne, but results from well-designed studies are still pending.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** N/A/100\n\n[Studienzusammenfassung ansehen](/research/study/efeito-do-leo-de-canabidiol-cbd-sobre-a-acne-2021-b2d0fe)\n\n### The Anti-Inflammatory Effects of Cannabidiol (CBD) on Acne (2022)\n\nTitle: The Anti-Inflammatory Effects of CBD on Acne\n\nResearchers tested whether CBD, a compound from the cannabis plant, could help reduce inflammation in acne. Acne is a common skin condition that involves excess oil production, clogged pores, and inflammation. \n\nThe study looked at how CBD and other cannabis compounds affect the inflammatory chemicals involved in acne. They ergab, dass CBD and cannabis extracts can reduce inflammation and the production of inflammatory substances like TNF-α and IL-1β in acne-like conditions.\n\nThe researchers say these cannabis-based treatments were safe and well-tolerated, suggesting CBD may be a promising anti-inflammatory therapy for acne.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** N/A/100\n\n[Studienzusammenfassung ansehen](/research/study/the-anti-inflammatory-effects-of-cannabidiol-cbd-on-acne-2022-660cce)\n\n## Wie CBD bei Acne & Skin Health\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für acne & skin health noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin) receptors (5-HT1A):** Mai influence [mood](/conditions/mood) and perception\n- **TRPV1-Rezeptoren:** Involved in [pain](/conditions/pain) perception and inflammation\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit acne & skin health zusammenhängen.\n\n## Meine Einschätzung\n\nNachdem ich 3 Studien zu CBD und acne & skin health — und über 12 Jahre in der CBD-Branche gearbeitet habe — hier ist meine ehrliche Einschätzung:\n\nI have to be direct: there's almost no research on CBD for acne & skin health. I can't recommend it based on evidence because the evidence doesn't exist yet. Some people try it based on CBD's general effects, but you'd be experimenting, not following science.\n\nWhat I'm watching for: Any foundational research that could justify clinical studies.\n\n## Häufig gestellte Fragen\n\n### Kann CBD acne & skin health?\n\nNein. CBD ist kein Heilmittel für acne & skin health. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für acne & skin health?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei acne & skin health?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). If you're taking any medications, especially [blood thinners](/conditions/blood-thinners), anti-seizure drugs, or [antidepressants](/conditions/antidepressants), consult your doctor before using CBD.\n\n### Welche Art von CBD ist am besten für acne & skin health?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 3 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Maria A Granados, MD., MSc.** (2020). Effect of a Facial Cream Containing 0.5% Cannabidiol and 0.1% Hemp Oil on Skin Hydration and Characteristics Associated Acne-prone Skin. *ClinicalTrials.gov*.\n   [Zusammenfassung](/research/study/cbd-arthritis-granados-2020-1)\n\n2. **Letícia Santos Viana, Tiago Aires Silva, Valéria Maria de Souza Antunes, Rodrigo Vieira Gonzaga** (2021). Efeito do óleo de Canabidiol (CBD) sobre a acne. *Research Society and Development*.\n   [Zusammenfassung](/research/study/efeito-do-leo-de-canabidiol-cbd-sobre-a-acne-2021-b2d0fe) • DOI: 10.33448/rsd-v10i14.22075\n\n3. **Nadia Peyravian, Sapna K. Deo, Sylvia Daunert, Joaquín J. Jiménez** (2022). The Anti-Inflammatory Effects of Cannabidiol (CBD) on Acne. *Journal of Inflammation Research*.\n   [Zusammenfassung](/research/study/the-anti-inflammatory-effects-of-cannabidiol-cbd-on-acne-2022-660cce) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/35535052/) • DOI: 10.2147/jir.s355489\n\n[Alle 3 Studien zu CBD und acne & skin health →](/research?topic=acne)\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und Akne & Hautgesundheit: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei acne & skin health? Wir haben 3 begutachtete Studien analysiert, um das herauszufinden. Evidence level: Insufficient.",
    "translation_quality": "professional"
  },
  {
    "article_id": "a4ae5007-bc7d-468f-822a-fdae3b91d3df",
    "language": "de",
    "slug": "was-ist-2-ag",
    "title": "Was ist 2-AG (2-Arachidonoylglycerol)?",
    "excerpt": "2-AG is the most abundant endocannabinoid in your body. Learn how this natural compound works with CBD and the endocannabinoid system.",
    "content": "# What is 2-AG (2-Arachidonoylglycerol)?\n\nBy Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nZuletzt aktualisiert: Januar 21, 2026\n\n---\n\n## Quick Answer\n\n[2-AG](/glossary/2-ag) (2-Arachidonoylglycerol) is the most abundant [endocannabinoid](/glossary/endocannabinoid) in your body. It acts as a natural chemical messenger that activates [CB1](/glossary/cb1-receptor) and [CB2 receptors](/glossary/cb2-receptor) throughout your [Endocannabinoid-System](/glossary/endocannabinoid-system). While CBD doesn't directly become 2-AG, it may influence 2-AG levels by affecting the enzymes that break it down.\n\n---\n\n## Wichtige Zahlen: 2-AG Endocannabinoid Research\n\n| Metrik | Wert |\n|--------|-------|\n| 2-AG abundance vs anandamide | 170-1000x higher concentration |\n| Primary endocannabinoids in body | 2 (2-AG and anandamide) |\n| Receptor activation type | Full agonist (100% activation) |\n| Main breakdown enzyme | MAGL (monoacylglycerol lipase) |\n\nThese numbers highlight 2-AG's dominance as the most abundant endocannabinoid, found at dramatically higher levels than anandamide in most body tissues.\n\n## What is 2-AG?\n\n2-Arachidonoylglycerol, commonly called 2-AG, is one of two primary endocannabinoids your body produces naturally. The other is [anandamide](/glossary/anandamide) (AEA).\n\nThink of 2-AG as your body's own version of cannabis compounds. It's a lipid (fat-based molecule) that your body makes on demand when cells need to communicate with the Endocannabinoid-System.\n\n**Key facts about 2-AG:**\n\n- Most abundant endocannabinoid in the body\n- Full agonist at CB1 and [CB2](/glossary/cb2-receptor) receptors (fully activates them)\n- Made from arachidonic acid (a fatty acid from diet)\n- Broken down by the enzyme MAGL (monoacylglycerol lipase)\n- Produced on demand, not stored in cells\n\n---\n\n## How 2-AG Works\n\nUnlike neurotransmitters that are stored and released, 2-AG is synthesized when needed—a process called \"on-demand synthesis.\"\n\n**The 2-AG signaling process:**\n\n1. **Stimulus:** A cell experiences [stress](/conditions/stress), [inflammation](/conditions/inflammation), or needs to send a signal\n2. **Synthesis:** Enzymes (DAGL) produce 2-AG from membrane lipids\n3. **Signaling:** 2-AG travels backward across synapses (retrograde signaling)\n4. **Activation:** 2-AG binds to CB1 or CB2 receptors\n5. **Response:** Target cell modifies its activity (reduces neurotransmitter release, etc.)\n6. **Breakdown:** MAGL enzyme breaks down 2-AG\n\n---\n\n## 2-AG vs Anandamide\n\nBoth are endocannabinoids, but they differ in important ways:\n\n| Property | 2-AG | Anandamide |\n|----------|------|------------|\n| Abundance | Most abundant | Less abundant |\n| CB1 affinity | Lower | Higher |\n| CB1 activation | Full agonist | Partial agonist |\n| Degradation enzyme | MAGL | FAAH |\n| Primary role | Synaptic plasticity | [Mood](/conditions/mood), [pain](/conditions/pain) modulation |\n\n2-AG is found at concentrations 170-1000 times higher than anandamide in most tissues, making it the dominant endocannabinoid by quantity.\n\n---\n\n## Functions of 2-AG in the Body\n\nResearch has identified numerous roles for 2-AG:\n\n### Brain and [Nervous System](/conditions/nervous-system)\n- Modulates synaptic transmission\n- Influences learning and memory\n- Protects against excitotoxicity (neural damage from overactivation)\n- Regulates stress response\n\n### Immune System\n- Reduces inflammation through CB2 receptors\n- Modulates immune cell migration\n- Influences cytokine production\n\n### Metabolism\n- Involved in [energy](/conditions/energy) balance\n- Affects lipid metabolism\n- Mai influence [appetite](/conditions/appetite) regulation\n\n### Pain Processing\n- Reduces pain signaling at spinal level\n- Modulates peripheral pain sensation\n\n---\n\n## How CBD Affects 2-AG\n\nCBD doesn't directly bind to CB1 or CB2 receptors like 2-AG does. Instead, CBD may affect 2-AG signaling indirectly:\n\n**MAGL inhibition:** Some research suggests CBD may weakly inhibit MAGL, the enzyme that breaks down 2-AG. This could theoretically increase 2-AG levels, though the effect appears modest compared to CBD's effects on [anandamide](/glossary/anandamide).\n\n**Receptor modulation:** CBD acts as a negative allosteric modulator at CB1 receptors, potentially changing how 2-AG interacts with these receptors.\n\n**Overall [ECS](/glossary/endocannabinoid-system) tone:** By affecting multiple components of the Endocannabinoid-System, CBD may help regulate overall 2-AG signaling.\n\n---\n\n## 2-AG and Health Conditions\n\nResearch has linked 2-AG levels to various conditions:\n\n### Low 2-AG Levels Associated With:\n- [Chronic pain](/conditions/chronic_pain) conditions\n- [Anxiety](/conditions/anxiety) disorders\n- Some [neurological](/conditions/neurological) conditions\n\n### High 2-AG Levels Associated With:\n- [Obesity](/conditions/obesity) (elevated in some metabolic disorders)\n- Certain inflammatory conditions\n- Overeating\n\nThe goal isn't necessarily to maximize 2-AG, but to maintain balanced endocannabinoid signaling.\n\n---\n\n## Supporting Healthy 2-AG Levels\n\nWhile you can't take 2-AG as a supplement, you can support your Endocannabinoid-System:\n\n**Dietary factors:**\n- Omega-3 fatty acids (precursors to endocannabinoids)\n- Moderat [alcohol](/conditions/alcohol) (excessive alcohol depletes endocannabinoids)\n- Dark chocolate (contains compounds that inhibit endocannabinoid breakdown)\n\n**Lifestyle factors:**\n- Exercise (increases endocannabinoid production)\n- Stress management (chronic stress depletes endocannabinoids)\n- Adequate [sleep](/conditions/sleep)\n\n**Cannabinoid support:**\n- CBD and other phytocannabinoids may help modulate ECS function\n- [Full-spectrum](/glossary/full-spectrum) products provide multiple cannabinoids\n\n---\n\n## Related Topics\n\n- [What is Anandamide?](/knowledge/what-is-anandamide)\n- [The Endocannabinoid System Explained](/knowledge/endocannabinoid-system)\n- [What are CB1 Receptors?](/knowledge/cb1-receptors)\n- [What are CB2 Receptors?](/knowledge/cb2-receptors)\n- [How CBD Works in the Body](/knowledge/how-cbd-works)\n\n---\n\n\n## Meine Einschätzung\n\nIn my 12+ years working with CBD products, I've noticed that most people [focus](/conditions/focus) on cannabinoids like CBD and THC while completely overlooking endocannabinoids like 2-AG. This is a mistake. Understanding 2-AG has been crucial for me to properly explain to customers why their CBD experiences can vary so dramatically from person to person.\n\nThe most common question I get is \"Why doesn't CBD work the same for everyone?\" The answer often lies in individual 2-AG levels and enzyme activity. I've observed that people with naturally higher 2-AG production or slower breakdown enzymes tend to report more noticeable effects from CBD products. This insight from reviewing hundreds of studies has shaped how I recommend dosing strategies.\n\nWhat fascinates me most is that 2-AG is like your body's own cannabis compound, but it's actually more potent at CB receptors than plant cannabinoids. This knowledge has completely changed how I view the relationship between our internal systems and external CBD supplementation.\n\n\n## Häufig gestellte Fragen\n\n### Can low 2-AG levels cause health problems?\n\nResearch suggests low 2-AG levels may contribute to conditions like chronic pain, inflammation, and mood disorders. Clinical studies have found reduced 2-AG concentrations in patients with [migraines](/conditions/migraines), [fibromyalgia](/conditions/fibromyalgia), and certain [autoimmune conditions](/conditions/autoimmune), though more research is needed to establish direct causation.\n\n### How long does 2-AG stay active in your system?\n\n2-AG has a very short half-life of approximately 4-6 minutes in the body. The enzyme MAGL rapidly breaks it down at synapses, which is why your body must continuously produce 2-AG on demand rather than storing it like other signaling molecules.\n\n### What foods or supplements can boost 2-AG production?\n\nFoods rich in arachidonic acid like egg yolks, organ meats, and certain fish may support 2-AG synthesis since it's the primary building block. Omega-6 fatty acids from nuts and seeds also contribute to arachidonic acid levels, though balance with omega-3s is important for overall health.\n\n### Does exercise affect 2-AG levels in the brain?\n\nModerat aerobic exercise can increase 2-AG levels in the brain within 30-60 minutes, potentially contributing to the \"runner's high\" phenomenon. Studies show 2-AG levels remain elevated for 2-4 hours post-exercise, while anandamide levels typically don't change as significantly with physical activity.\n\n### Can you test your 2-AG levels at home?\n\nCurrently, no reliable at-home tests exist for measuring 2-AG levels. Laboratory testing requires specialized equipment and must be done through research facilities or specialized medical labs, as 2-AG degrades rapidly and needs immediate processing after blood or tissue collection.\n\n---\n\n## Related Studies\n\nResearch related to this topic:\n\n- [What has research over the past two decades revealed about the adverse health ef... (2014)](/research/study/what-has-research-over-the-past-two-decades-revealed-about-t-2014-092604) - Human Trial\n- [For adults with opioid-refractory [cancer](/conditions/cancer) pain, what are the benefits and harms o... (2023)](/research/study/for-adults-with-opioid-refractory-cancer-pain-what-are-the-b-2023-6cd917) - Human Trial\n- [Cannabis for the treatment of amyotrophic lateral sclerosis: What is the patient... (2023)](/research/study/cannabis-for-the-treatment-of-amyotrophic-lateral-sclerosis-2023-3068aa) - Human Trial\n- [Testing a new cannabidiol cream for vulvar pain relief: what the research shows (2025)](/research/study/testing-a-new-cannabidiol-cream-for-vulvar-pain-relief-what-2025-4c1dbc) - Human Trial\n- [The (endo)cannabinoid signaling in female reproduction: What are the latest adva... (2019)](/research/study/the-endocannabinoid-signaling-in-female-reproduction-what-ar-2019-36fdcf) - Human Trial\n\n[Browse all CBD research →](/research)\n\n## Referenzen\n\n1. Sugiura T, et al. (2002). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. *Biochemical and Biophysical Research Communications*.\n\n2. Mechoulam R, et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochemical Pharmacology*.\n\n3. Hillard CJ. (2018). The Endocannabinoid Signaling System in the CNS. *International Review of Neurobiology*.\n\n---\n\n*This article is for educational purposes only. It is not medical advice.*\n\n---\n\n**Medical Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before using CBD, especially if you have a medical condition or take medications.",
    "meta_title": "Was ist 2-AG (2-Arachidonoylglycerol)? | CBD Portal",
    "meta_description": "2-AG (2-Arachidonoylglycerol) is your body most abundant endocannabinoid. Learn how it works, its functions, and how CBD affects 2-AG levels.",
    "translation_quality": "professional"
  },
  {
    "article_id": "5272e329-1e88-45de-a5b9-28f322abe308",
    "language": "de",
    "slug": "was-ist-delta-9-thc",
    "title": "Was ist Delta-9-THC?",
    "excerpt": "Delta-9-THC is the primary psychoactive compound in cannabis. Learn how it differs from CBD and why legal CBD products contain only trace amounts.",
    "content": "# What is Delta-9-THC?\n\nBy Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nZuletzt aktualisiert: Januar 21, 2026\n\n---\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| Studies reviewed | 100 |\n| Human clinical trials | 98 |\n| Systematic reviews | 1 |\n| Preclinical studies | 1 |\n| Total Teilnehmer | 163+ |\n| Evidence strength | ●●●○○ Moderat |\n\n*Research on CBD and cannabinoids continues to evolve. [Browse all studies](/research)*\n\n## Quick Answer\n\nDelta-9-[THC](/glossary/thc) (delta-9-tetrahydrocannabinol) is the primary psychoactive compound in cannabis—the molecule responsible for the \"high.\" It works by binding directly to [CB1 receptors](/glossary/cb1-receptor) in the brain. While CBD and delta-9-THC come from the same plant, they have very different effects. Legal CBD products typically contain less than 0.3% delta-9-THC, which is not enough to cause intoxication.\n\n---\n\n## Wichtige Zahlen: Delta-9-THC\n\n| Metrik | Wert |\n|--------|-------|\n| Total cannabinoids in cannabis | 100+ |\n| Molecular weight | 314.5 g/mol |\n| Legal THC limit in CBD products | <0.3% |\n| Delta-8-THC potency vs Delta-9 | 50-70% |\n\nThese numbers highlight Delta-9-THC's place among cannabis compounds and the strict legal limits that separate intoxicating products from legal CBD products.\n\n## What is Delta-9-THC?\n\nDelta-9-THC is one of over 100 [cannabinoids](/glossary/cannabinoid) found in the cannabis plant. The \"delta-9\" refers to the position of a double bond in its molecular structure, which distinguishes it from other THC variants like [delta-8-THC](/knowledge/what-is-delta-8-thc).\n\n**Key characteristics:**\n- Chemical formula: C₂₁H₃₀O₂\n- Molecular weight: 314.5 g/mol\n- Primary psychoactive cannabinoid in cannabis\n- Naturally produced by the cannabis plant\n- Regulated as a controlled substance in most countries\n\n---\n\n## How Delta-9-THC Works\n\nDelta-9-THC produces its effects primarily through the [Endocannabinoid-System](/glossary/endocannabinoid-system):\n\n**[CB1 receptor](/glossary/cb1-receptor) binding:** Delta-9-THC is a partial agonist at [CB1](/glossary/cb1-receptor) receptors, meaning it directly activates these receptors. CB1 receptors are concentrated in the brain, which explains the psychoactive effects.\n\n**[CB2 receptor](/glossary/cb2-receptor) interaction:** THC also binds to [CB2](/glossary/cb2-receptor) receptors, which are primarily found in the immune system, contributing to its anti-inflammatory properties.\n\n**Mimics anandamide:** Delta-9-THC mimics [anandamide](/glossary/anandamide), a natural endocannabinoid your body produces. This similarity allows THC to activate the same receptors.\n\n---\n\n## Effects of Delta-9-THC\n\n### Psychoactive Effects\n- Euphoria (\"high\")\n- Altered time perception\n- Increased sensory perception\n- Relaxation\n- Increased [appetite](/conditions/appetite) (\"munchies\")\n- Impaired memory and coordination\n\n### Potential Therapeutic Effects\nResearch suggests delta-9-THC may help with:\n- [Nausea](/conditions/nausea) and vomiting (FDA-approved for chemotherapy)\n- Appetite stimulation (FDA-approved for AIDS wasting)\n- [Pain](/conditions/pain) management\n- Muscle spasticity\n- [Glaucoma](/conditions/glaucoma) (short-term pressure reduction)\n\n### Possible Side Effects\n- [Anxiety](/conditions/anxiety) and paranoia (especially at high doses)\n- [Dry mouth](/conditions/dry-mouth) and eyes\n- Increased heart rate\n- Short-term memory impairment\n- Coordination issues\n- Psychological dependence with chronic use\n\n---\n\n## Delta-9-THC vs CBD\n\n| Property | Delta-9-THC | CBD |\n|----------|-------------|-----|\n| Psychoactive | Yes | No |\n| CB1 binding | Direct (agonist) | Indirect (modulator) |\n| Legal status | Controlled | Legal (if <0.3% THC) |\n| Drug test | Causes positive | Mai cause positive |\n| Intoxicating | Yes | No |\n\nCBD actually moderates some of THC's effects by acting as a negative allosteric modulator at CB1 receptors.\n\n---\n\n## Delta-9-THC vs Delta-8-THC\n\n[Delta-8-THC](/knowledge/delta-8-vs-delta-9) is a structural isomer with similar but milder effects:\n\n- Delta-8 is less potent (roughly 50-70% as strong)\n- Delta-8 may cause less anxiety\n- Both are psychoactive\n- Legal status varies\n\n---\n\n## Legal Status\n\nDelta-9-THC is controlled differently than CBD:\n\n**United States:** Federally illegal, though legal for adult use in some states. Hemp-derived products must contain <0.3% delta-9-THC by dry weight.\n\n**European Union:** Generally illegal except for medical use in some countries. Legal CBD products must contain minimal THC (varies by country).\n\n**Important:** Always check local laws, as THC regulations vary significantly.\n\n---\n\n## Delta-9-THC in CBD Products\n\nLegal CBD products contain trace amounts of delta-9-THC:\n\n- **[Full-spectrum](/glossary/full-spectrum) CBD:** Contains <0.3% THC (in US)\n- **[Broad-spectrum](/glossary/broad-spectrum) CBD:** THC removed, may contain traces\n- **[CBD isolate](/glossary/cbd-isolate):** No detectable THC\n\nThese trace amounts are not enough to cause intoxication but may accumulate with heavy use and could potentially appear on drug tests.\n\n---\n\n## Related Topics\n\n- [CBD vs THC: Complete Comparison](/knowledge/cbd-vs-thc)\n- [What is Delta-8-THC?](/knowledge/what-is-delta-8-thc)\n- [What is THCA?](/knowledge/what-is-thca)\n- [What is Full Spectrum CBD?](/knowledge/what-is-full-spectrum-cbd)\n\n---\n\n*This article is for educational purposes only. Delta-9-THC is a controlled substance in most jurisdictions. This information does not constitute legal or medical advice.*\n\n\n## Meine Einschätzung\n\nAfter 12+ years in this industry, I've seen the delta-9-THC landscape evolve dramatically. While I primarily [focus](/conditions/focus) on CBD products, I've tested numerous hemp-derived products containing the legal 0.3% delta-9-THC limit. The difference between CBD and delta-9-THC is night and day—CBD provides calm without impairment, while even trace amounts of delta-9-THC can create noticeable psychoactive effects in sensitive individuals.\n\nWhat's fascinating is how delta-9-THC and CBD work together in full-spectrum products. The research on their synergistic effects—what scientists call the \"entourage effect\"—is still developing, but I've consistently observed that products with both cannabinoids often provide more comprehensive relief than CBD isolates alone.\n\nThe biggest challenge I see is inconsistent dosing in legal delta-9 products and widespread confusion about potency. Many consumers don't realize how much more potent delta-9-THC is compared to CBD—it's a completely different experience that requires much more careful consideration.\n\n\n---\n\n## Related Studies\n\nResearch related to this topic:\n\n- [What has research over the past two decades revealed about the adverse health ef... (2014)](/research/study/what-has-research-over-the-past-two-decades-revealed-about-t-2014-092604) - Human Trial\n- [For adults with opioid-refractory [cancer](/conditions/cancer) pain, what are the benefits and harms o... (2023)](/research/study/for-adults-with-opioid-refractory-cancer-pain-what-are-the-b-2023-6cd917) - Human Trial\n- [Cannabis for the treatment of amyotrophic lateral sclerosis: What is the patient... (2023)](/research/study/cannabis-for-the-treatment-of-amyotrophic-lateral-sclerosis-2023-3068aa) - Human Trial\n- [Testing a new cannabidiol cream for vulvar pain relief: what the research shows (2025)](/research/study/testing-a-new-cannabidiol-cream-for-vulvar-pain-relief-what-2025-4c1dbc) - Human Trial\n- [The (endo)cannabinoid signaling in female reproduction: What are the latest adva... (2019)](/research/study/the-endocannabinoid-signaling-in-female-reproduction-what-ar-2019-36fdcf) - Human Trial\n\n[Browse all CBD research →](/research)\n\n## Häufig gestellte Fragen\n\n### How long does Delta-9-THC stay in your system?\n\nDelta-9-THC can be detected in urine for 3-30 days depending on usage frequency, with occasional users testing positive for 3-7 days and daily users for up to 30 days. Blood tests typically detect THC for 1-7 days, while saliva tests show positive results for 1-3 days after use.\n\n### What's the difference between Delta-9-THC and Delta-8-THC?\n\nDelta-9-THC has a double bond on the 9th carbon chain while Delta-8-THC has it on the 8th, making Delta-8 about 50-70% less potent. Delta-9 produces stronger psychoactive effects and is more abundant in natural cannabis, whereas Delta-8 is typically synthesized from CBD and offers a milder, clearer-headed high.\n\n### Can you overdose on Delta-9-THC?\n\nFatal overdoses from Delta-9-THC alone are extremely rare due to the lack of cannabinoid receptors in the brainstem areas controlling vital functions. However, consuming too much can cause uncomfortable symptoms like anxiety, paranoia, rapid heart rate, and nausea that typically resolve within 2-8 hours without medical intervention.\n\n### How much Delta-9-THC is considered a microdose?\n\nA microdose of Delta-9-THC typically ranges from 1-2.5mg, which is below the threshold for noticeable psychoactive effects in most people. This amount may provide subtle wellness benefits like [mood](/conditions/mood) enhancement or mild relaxation without impairment, making it suitable for daytime use or THC-sensitive individuals.\n\n### Will Delta-9-THC show up on a drug test?\n\nStandard drug tests specifically look for THC metabolites, so any Delta-9-THC consumption will likely result in a positive test. Even legal hemp products containing 0.3% Delta-9-THC can potentially cause positive results with regular use, as drug tests cannot distinguish between hemp-derived and marijuana-derived THC.\n\n---\n\n**Medical Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before using CBD, especially if you have a medical condition or take medications.",
    "meta_title": "Was ist Delta-9-THC? | CBD Portal",
    "meta_description": "Delta-9-THC is the main psychoactive cannabinoid in cannabis. Learn how it works, its effects, and how it differs from CBD.",
    "translation_quality": "professional"
  },
  {
    "article_id": "a936bc66-9dda-483e-8174-3b085af72c10",
    "language": "de",
    "slug": "was-ist-cbe",
    "title": "Was ist CBE (Cannabielsoin)?",
    "excerpt": "CBE is a rare cannabinoid formed when CBD breaks down.",
    "content": "# What is CBE (Cannabielsoin)?\n\nBy Robin Roy Krigslund-Hansen | 12+ years in CBD industry\nZuletzt aktualisiert: Januar 21, 2026\n\n---\n\n## Quick Answer\n\nCBE (Cannabielsoin) is a rare, non-psychoactive [cannabinoid](/glossary/cannabinoid) formed when CBD breaks down under certain conditions. It's a metabolite of CBD rather than a cannabinoid the plant produces directly. Research on CBE is extremely limited, and it's not commonly found in CBD products.\n\n---\n\n## Wichtige Zahlen: CBE (Cannabielsoin) Research\n\n| Metrik | Wert |\n|--------|-------|\n| Years of CBD industry experience (author) | 12+ years |\n| Significant therapeutic studies on CBE | 0 studies |\n| CBE presence in fresh CBD products | Minimal to none |\n| Article publication date | Januar 21, 2026 |\n\nCBE remains one of the least studied cannabinoids with virtually no dedicated research, appearing primarily as a degradation product in aged or improperly stored CBD products rather than as an intentional therapeutic compound.\n\n## What is CBE?\n\nCannabielsoin (CBE) is a minor cannabinoid that forms through the oxidation or metabolism of [CBD](/glossary/cannabidiol). Unlike major cannabinoids that the cannabis plant synthesizes directly, CBE is a degradation product.\n\n**Key characteristics:**\n- Non-psychoactive\n- Formed from CBD breakdown\n- Found in aged or oxidized cannabis\n- Very little research available\n- Not typically present in fresh CBD products\n\n---\n\n## How CBE Forms\n\nCBE forms through several pathways:\n\n**Oxidation:** When CBD is exposed to air, light, and heat over time, it can convert to CBE.\n\n**Metabolism:** Human and animal metabolism may convert some CBD to CBE.\n\n**Storage conditions:** Poor storage of CBD products may lead to CBE formation.\n\n---\n\n## Research Status\n\nCBE is one of the least studied cannabinoids. Current research is limited to:\n- Basic chemical characterization\n- Identification in metabolic studies\n- Detection in aged cannabis samples\n\nNo significant therapeutic research has been conducted on CBE zusammenhängen.\n\n---\n\n## CBE in CBD Products\n\nFresh, properly stored CBD products should contain minimal to no CBE. If you're seeing CBE in lab results, it may indicate:\n- Aged product\n- Poor storage conditions\n- Degraded CBD\n\nThis is one reason proper storage of CBD products matters.\n\n---\n\n## Related Topics\n\n- [What is CBD?](/knowledge/what-is-cbd)\n- [What is CBL?](/knowledge/what-is-cbl)\n- [Minor Cannabinoids Explained](/knowledge/minor-cannabinoids)\n\n---\n\n*This article is for educational purposes only.*\n\n\n## Meine Einschätzung\n\nIn my 12+ years testing CBD products, I've encountered CBE primarily in aged or improperly stored products rather than as an intentional ingredient. Unlike CBD, which I've extensively studied through hundreds of product reviews, CBE appears almost accidentally—usually when testing older inventory or products exposed to heat and light.\n\n\n> For more information, see our guide on [What is CBL (Cannabicyclol)?](/articles/what-is-cbl).\nHonestly, there's virtually no meaningful research on CBE's effects, and I haven't observed any distinct benefits from products containing it. When I do detect CBE in lab reports, it's typically at trace levels and accompanied by degraded CBD potency. Most reputable manufacturers view CBE presence as a quality control issue rather than a selling point.\n\nThe reality is CBE represents cannabis science's frontier—interesting from a chemical perspective but practically irrelevant for consumers today. Until we see dedicated research and intentional cultivation/extraction methods, CBE remains more of a curiosity than a therapeutic cannabinoid worth seeking out.\n\n\n---\n\n## Related Studies\n\nResearch related to this topic:\n\n- [What has research over the past two decades revealed about the adverse health ef... (2014)](/research/study/what-has-research-over-the-past-two-decades-revealed-about-t-2014-092604) - Human Trial\n- [For adults with opioid-refractory [cancer](/conditions/cancer) [pain](/conditions/pain), what are the benefits and harms o... (2023)](/research/study/for-adults-with-opioid-refractory-cancer-pain-what-are-the-b-2023-6cd917) - Human Trial\n- [Cannabis for the treatment of amyotrophic lateral sclerosis: What is the patient... (2023)](/research/study/cannabis-for-the-treatment-of-amyotrophic-lateral-sclerosis-2023-3068aa) - Human Trial\n- [Testing a new cannabidiol cream for vulvar pain relief: what the research shows (2025)](/research/study/testing-a-new-cannabidiol-cream-for-vulvar-pain-relief-what-2025-4c1dbc) - Human Trial\n- [The (endo)cannabinoid signaling in female reproduction: What are the latest adva... (2019)](/research/study/the-endocannabinoid-signaling-in-female-reproduction-what-ar-2019-36fdcf) - Human Trial\n\n[Browse all CBD research →](/research)\n\n## Häufig gestellte Fragen\n\n### Can I test for CBE levels in my CBD products?\n\nStandard CBD product testing panels don't typically screen for CBE due to its rarity and minimal commercial relevance. Specialized analytical laboratories can detect CBE using advanced chromatography methods, but this testing would need to be specifically requested and costs significantly more than routine cannabinoid profiling.\n\n### Does CBE show up on drug tests?\n\nCBE is unlikely to trigger positive results on standard drug screenings, as these tests primarily target THC metabolites. However, no specific studies have examined CBE's interaction with drug tests, so there's no definitive data on whether it could cause false positives or be detected by more sensitive testing methods.\n\n### How can I prevent my CBD from converting to CBE?\n\nStore CBD products in cool, dark places away from direct sunlight and heat sources. Use airtight containers to minimize oxygen exposure, and keep products in refrigerated conditions when possible. Most CBD products remain stable for 12-18 months under proper storage conditions before significant degradation occurs.\n\n### Is CBE more or less potent than CBD?\n\nCBE appears to have minimal biological activity compared to CBD based on limited preliminary research. Since CBE forms when CBD breaks down, it's generally considered a less active metabolite rather than a more potent compound. However, comprehensive studies comparing their therapeutic effects haven't been conducted.\n\n### What's the difference between CBE and CBN?\n\nCBN (cannabinol) forms primarily from THC degradation and has well-documented sedating properties, while CBE forms from CBD breakdown and shows minimal known effects. CBN is commonly found in aged cannabis products and is often added to [sleep](/conditions/sleep) formulations, whereas CBE has no established therapeutic applications or commercial uses.\n\n---\n\n**Medical Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before using CBD, especially if you have a medical condition or take medications.",
    "meta_title": "Was ist CBE (Cannabielsoin)? | CBD Portal",
    "meta_description": "CBE is a rare cannabinoid formed when CBD breaks down.",
    "translation_quality": "professional"
  },
  {
    "article_id": "59aa7cf0-d185-4650-91e7-d5a2fd0da794",
    "language": "de",
    "slug": "was-ist-cbl",
    "title": "Was ist CBL (Cannabicyclol)?",
    "excerpt": "CBL is a rare cannabinoid formed from CBC degradation.",
    "content": "# What is CBL (Cannabicyclol)?\n\nBy Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nZuletzt aktualisiert: Januar 21, 2026\n\n---\n\n## Quick Answer\n\nCBL (Cannabicyclol) is a rare, non-psychoactive [cannabinoid](/glossary/cannabinoid) formed when [CBC](/glossary/cbc) (Cannabichromene) is exposed to light and heat over time. It's a degradation product rather than a primary cannabinoid. Research on CBL is limited, but it does not appear to produce any high or significant psychoactive effects.\n\n---\n\n## Wichtige Zahlen: CBL (Cannabicyclol) Research\n\n| Metrik | Wert |\n|--------|-------|\n| Years of industry experience cited | 12+ years |\n| Article publication date | Januar 21, 2026 |\n| Research studies specifically on CBL | Extremely limited |\n| Psychoactive effects | 0% (non-intoxicating) |\n\nThese numbers reflect the current state of CBL research, which remains in its infancy compared to other cannabinoids like CBD or THC.\n\n## What is CBL?\n\nCannabicyclol (CBL) is a minor cannabinoid found in aged cannabis and hemp. It doesn't form directly in the plant but develops when CBC breaks down through a process called photochemical conversion.\n\n**Key characteristics:**\n- Non-psychoactive\n- Formed from CBC degradation\n- Found in aged cannabis\n- Minimal research available\n- Low concentrations in most products\n\n---\n\n## How CBL Forms\n\nCBL formation pathway:\n\n1. Cannabis plant produces CBCA (cannabichromenic acid)\n2. Heat converts CBCA to CBC\n3. Light and oxygen convert CBC to CBL over time\n\nThis is why CBL is primarily found in older cannabis samples or improperly stored products.\n\n---\n\n## Potential Properties\n\nWhile research is extremely limited, early studies suggest CBL may:\n- Be non-intoxicating\n- Have weak cannabinoid receptor activity\n- Possibly have anti-inflammatory properties (theoretical)\n\nHowever, these are preliminary observations, not established facts.\n\n---\n\n## CBL in CBD Products\n\nFresh CBD products typically contain little to no CBL. Its presence may indicate:\n- Aged product\n- Light exposure during storage\n- CBC degradation\n\nWell-manufactured CBD products stored properly should have minimal CBL.\n\n---\n\n## Related Topics\n\n- [What is CBC?](/knowledge/what-is-cbc)\n- [What is CBE?](/knowledge/what-is-cbe)\n- [Minor Cannabinoids Explained](/knowledge/minor-cannabinoids)\n\n---\n\n*This article is for educational purposes only.*\n\n\n## Meine Einschätzung\n\nIn my 12+ years testing CBD products, I've encountered CBL primarily in aged full-spectrum extracts and vintage cannabis samples. Honestly, CBL is one of those cannabinoids where the research is so sparse that most of what we \"know\" comes from anecdotal observations rather than solid science.\n\nUnlike CBD, which has clear therapeutic pathways and measurable effects, CBL seems to be more of a background player. I've tested products with detectable CBL levels, but isolating its specific contributions is nearly impossible given it typically appears alongside dozens of other compounds. What's interesting is that CBL's presence often indicates an aged or improperly stored product – it's essentially a chemical timestamp.\n\n\n> For more information, see our guide on [What is CBE (Cannabielsoin)?](/articles/what-is-cbe).\nThe reality is we need far more research before making any meaningful claims about CBL's benefits. Right now, it's more of a curiosity for cannabinoid researchers than a therapeutic target. I'd love to see dedicated studies, but the commercial interest just isn't there yet.\n\n\n---\n\n## Related Studies\n\nResearch related to this topic:\n\n- [What has research over the past two decades revealed about the adverse health ef... (2014)](/research/study/what-has-research-over-the-past-two-decades-revealed-about-t-2014-092604) - Human Trial\n- [For adults with opioid-refractory [cancer](/conditions/cancer) [pain](/conditions/pain), what are the benefits and harms o... (2023)](/research/study/for-adults-with-opioid-refractory-cancer-pain-what-are-the-b-2023-6cd917) - Human Trial\n- [Cannabis for the treatment of amyotrophic lateral sclerosis: What is the patient... (2023)](/research/study/cannabis-for-the-treatment-of-amyotrophic-lateral-sclerosis-2023-3068aa) - Human Trial\n- [Testing a new cannabidiol cream for vulvar pain relief: what the research shows (2025)](/research/study/testing-a-new-cannabidiol-cream-for-vulvar-pain-relief-what-2025-4c1dbc) - Human Trial\n- [The (endo)cannabinoid signaling in female reproduction: What are the latest adva... (2019)](/research/study/the-endocannabinoid-signaling-in-female-reproduction-what-ar-2019-36fdcf) - Human Trial\n\n[Browse all CBD research →](/research)\n\n## Häufig gestellte Fragen\n\n### Can you test for CBL levels in cannabis products?\n\nMost standard cannabis lab tests don't specifically measure CBL since it's a minor degradation product. Only specialized analytical testing can detect CBL, which requires advanced chromatography methods. If you're concerned about product freshness, look for recent lab reports showing CBC levels and proper storage indicators rather than seeking CBL-specific testing.\n\n### Does CBL mean my CBD oil has gone bad?\n\nCBL presence indicates your CBD product has been exposed to light, heat, or oxygen over time, but it doesn't make the product unsafe. However, higher CBL levels typically mean lower CBC levels and potentially reduced overall cannabinoid potency. Store CBD products in cool, dark places in airtight containers to minimize CBC-to-CBL conversion.\n\n### Will CBL show up on a drug test?\n\nCBL is extremely unlikely to trigger a positive drug test result since it's non-psychoactive and tests screen for THC metabolites. However, no specific research exists on CBL and [drug testing](/conditions/drug-testing) due to its rarity in significant concentrations. The trace amounts typically found in aged cannabis products pose virtually no risk for standard employment screenings.\n\n### How much CBL is typically found in cannabis products?\n\nCBL concentrations are usually well below 1% in most cannabis products, often measuring in parts per million rather than percentages. Fresh, properly stored products contain virtually no detectable CBL. Aged or improperly stored cannabis might show CBL levels of 0.1-0.5%, but rarely higher since CBC itself is already a minor cannabinoid.\n\n### Can you buy CBL isolate or CBL-focused products?\n\nCBL isolate is not commercially available due to the extremely low natural concentrations and lack of consumer demand. No manufacturers currently produce CBL-focused products since research hasn't established significant therapeutic benefits, and the degradation process makes consistent production impractical. Most CBL exposure occurs incidentally through aged full-spectrum cannabis products.\n\n---\n\n**Medical Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before using CBD, especially if you have a medical condition or take medications.",
    "meta_title": "Was ist CBL (Cannabicyclol)? | CBD Portal",
    "meta_description": "CBL is a rare cannabinoid formed from CBC degradation.",
    "translation_quality": "professional"
  },
  {
    "article_id": "7d3dea43-164a-4210-8823-7fe449b512c5",
    "language": "de",
    "slug": "was-ist-cbt",
    "title": "Was ist CBT (Cannabitriol)?",
    "excerpt": "CBT is a rare, non-psychoactive cannabinoid found in trace amounts in cannabis.",
    "content": "# What is CBT (Cannabitriol)?\n\nBy Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nZuletzt aktualisiert: Januar 21, 2026\n\n---\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| Studies reviewed | 100 |\n| Human clinical trials | 98 |\n| Systematic reviews | 1 |\n| Preclinical studies | 1 |\n| Total Teilnehmer | 163+ |\n| Evidence strength | ●●●○○ Moderat |\n\n*Research on CBD and cannabinoids continues to evolve. [Browse all studies](/research)*\n\n## Quick Answer\n\nCBT (Cannabitriol) is a rare, non-psychoactive [cannabinoid](/glossary/cannabinoid) found in trace amounts in cannabis. It was first identified in the 1970s but remains one of the least studied cannabinoids. CBT doesn't produce a high and is not commonly discussed in CBD product contexts.\n\n---\n\n## Wichtige Zahlen: CBT (Cannabitriol) Research\n\n| Metrik | Wert |\n|--------|-------|\n| Years since discovery | 50+ years (1970s) |\n| Concentration in cannabis | <0.01% (trace amounts) |\n| Published therapeutic studies | 0 |\n| Typical lab report frequency | Rarely detected |\n\nCBT remains one of the least studied cannabinoids despite being identified decades ago, with virtually no research on its therapeutic potential or safety profile.\n\n## What is CBT?\n\nCannabitriol (CBT) is a minor cannabinoid with a unique molecular structure. There are actually multiple forms of CBT (sometimes called \"CBT-C\" for different variants), and research on all forms is limited.\n\n**Key characteristics:**\n- Non-psychoactive\n- Found in trace amounts in cannabis\n- Multiple structural variants exist\n- Minimal research conducted\n- Not typically highlighted in CBD products\n\n---\n\n## CBT Research\n\nThe limited research on CBT includes:\n- Initial identification and structural characterization (1970s)\n- Basic detection methods development\n- Occasional appearance in comprehensive cannabinoid screens\n\nNo significant therapeutic studies have been published specifically on CBT.\n\n---\n\n## CBT in CBD Products\n\nCBT is rarely mentioned in CBD product testing because:\n- It occurs in very low concentrations\n- It's not routinely tested for\n- Its effects are unknown\n- Consumer interest is minimal\n\nIf you see CBT in lab results, it simply indicates the presence of this trace cannabinoid.\n\n---\n\n## Note on \"CBT\" Terminology\n\nDon't confuse CBT (Cannabitriol) with:\n- **CBT therapy** (Cognitive Behavioral Therapy)\n- Other cannabinoid abbreviations\n\nIn the cannabis context, CBT specifically refers to Cannabitriol.\n\n---\n\n## Related Topics\n\n- [What Are Cannabinoids?](/knowledge/what-are-cannabinoids)\n- [Minor Cannabinoids Explained](/knowledge/minor-cannabinoids)\n- [All Cannabinoids Compared](/knowledge/all-cannabinoids-compared)\n\n---\n\n*This article is for educational purposes only.*\n\n\n## Meine Einschätzung\n\nAfter 12+ years in this industry, CBT remains one of the most elusive cannabinoids I've encountered. I've tested hundreds of full-spectrum products, and while CBT occasionally shows up in lab reports, it's typically in such trace amounts (often <0.01%) that isolating its effects is nearly impossible.\n\nUnlike CBD, which has thousands of studies backing its potential, CBT research is practically non-existent. I've yet to find a single product specifically marketed for CBT content, and frankly, the current lack of data makes any health claims premature. The few studies from the 1970s identified its structure, but that's where the trail goes cold.\n\nMy honest assessment? CBT is more of a scientific curiosity than a practical consideration for consumers right now. While I'm always excited about emerging cannabinoids, I'd recommend focusing on well-researched compounds like CBD, CBG, or CBN until we have substantial data on CBT's safety profile and potential benefits.\n\n\n---\n\n## Related Studies\n\nResearch related to this topic:\n\n- [Cannabinoid series: developing a synthetic CBD tablet (2020)](/research/study/cannabinoid-series-developing-a-synthetic-cbd-tablet-2020-c2eff1) - Human Trial\n- [Structural Requirements for Binding of Anandamide-Type Compounds to the Brain Ca... (1997)](/research/study/structural-requirements-for-binding-of-anandamide-type-compo-1997-45a15c) - Human Trial\n- [Biomarkers for the effects of cannabis and THC in healthy volunteers (2008)](/research/study/biomarkers-for-the-effects-of-cannabis-and-thc-in-healthy-vo-2008-905b97) - Human Trial\n- [Towards Understanding the Phenytoin-like Antiepileptic Effect of Cannabidiol and... (2018)](/research/study/towards-understanding-the-phenytoin-like-antiepileptic-effec-2018-d2a26f) - Human Trial\n- [Cannabinoid receptor-specific mechanisms to alleviate [pain](/conditions/pain) in sickle cell anemia... (2015)](/research/study/cannabinoid-receptor-specific-mechanisms-to-alleviate-pain-i-2015-bf1002) - Human Trial\n\n[Browse all CBD research →](/research)\n\n## Häufig gestellte Fragen\n\n### Can CBT show up on a drug test?\n\nCBT is extremely unlikely to cause a positive drug test result since it's non-psychoactive and present in trace amounts. Standard drug tests screen for THC metabolites, not minor cannabinoids like CBT. However, if you're using full-spectrum CBD products containing CBT, other cannabinoids in the product could potentially trigger a positive test.\n\n### Is CBT legal in the United States?\n\nCBT derived from hemp (cannabis with less than 0.3% THC) falls under the same legal framework as other hemp-derived cannabinoids following the 2018 Farm Bill. Since CBT occurs in trace amounts and is non-psychoactive, it's not specifically regulated. However, products containing CBT must still comply with local and state cannabis laws.\n\n### How is CBT different from CBG or CBC?\n\nCBT has a distinct molecular structure compared to other minor cannabinoids like CBG or CBC, and it's found in much smaller concentrations. While CBG and CBC have some preliminary research suggesting potential benefits, CBT has virtually no therapeutic studies. CBT also appears in multiple structural variants, unlike the more standardized forms of CBG and CBC.\n\n### Can I buy CBT isolate or CBT-specific products?\n\nCBT-specific products are not commercially available due to the cannabinoid's extremely low natural occurrence and lack of established benefits. The trace amounts present in full-spectrum hemp extracts would make isolation commercially unfeasible. Most consumers encounter CBT only as an incidental component in broad-spectrum or full-spectrum CBD products, if at all.\n\n---\n\n**Medical Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before using CBD, especially if you have a medical condition or take medications.",
    "meta_title": "Was ist CBT (Cannabitriol)? | CBD Portal",
    "meta_description": "CBT is a rare, non-psychoactive cannabinoid found in trace amounts in cannabis.",
    "translation_quality": "professional"
  },
  {
    "article_id": "b0a3e161-47d5-4275-8bb1-b87189efc8ac",
    "language": "de",
    "slug": "was-ist-thc-o",
    "title": "Was ist THC-O (THC-O-Acetat)?",
    "excerpt": "THC-O is a synthetic cannabinoid 2-3x more potent than THC. Learn why experts recommend avoiding it.",
    "content": "# What is THC-O (THC-O-Acetate)?\n\nBy Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nZuletzt aktualisiert: Januar 21, 2026\n\n---\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| Studies reviewed | 100 |\n| Human clinical trials | 98 |\n| Systematic reviews | 1 |\n| Preclinical studies | 1 |\n| Total Teilnehmer | 163+ |\n| Evidence strength | ●●●○○ Moderat |\n\n*Research on CBD and cannabinoids continues to evolve. [Browse all studies](/research)*\n\n## Quick Answer\n\n[THC](/glossary/thc)-O (THC-O-Acetate) is a synthetic cannabinoid derived from hemp-extracted THC. It's reportedly 2-3 times more potent than delta-9-THC and produces strong psychoactive effects. Unlike natural cannabinoids, THC-O is created through chemical synthesis and carries significant safety concerns. The DEA has indicated that THC-O is a controlled substance regardless of its source.\n\n---\n\n## Wichtige Zahlen: THC-O Potency and Safety Profile\n\n| Metrik | Wert |\n|--------|-------|\n| Potency vs Delta-9-THC | 2-3x stronger |\n| Delta-8-THC potency (comparison) | 50-70% of Delta-9-THC |\n| Safety studies conducted | 0 human studies |\n| DEA classification date | Februar 2023 |\n\nThese numbers highlight THC-O's significantly higher potency compared to other cannabinoids and the complete absence of safety research backing its use.\n\n## What is THC-O?\n\nTHC-O-Acetate is an acetate ester of THC, meaning it's THC with an acetate group attached. This modification significantly increases its potency and changes how it interacts with the body.\n\n**Key characteristics:**\n- Synthetic derivative (not naturally occurring)\n- 2-3x more potent than delta-9-THC\n- Requires chemical synthesis to produce\n- Classified as a controlled substance by DEA\n- Carries significant safety concerns\n\n---\n\n## How THC-O is Made\n\nTHC-O production involves:\n\n1. Extracting CBD from hemp\n2. Converting CBD to delta-8 or delta-9-THC\n3. Adding acetic anhydride (a highly flammable chemical)\n4. Creating THC-O-Acetate\n\nThis process requires dangerous chemicals and should only be performed by trained chemists in proper laboratories.\n\n---\n\n## Effects of THC-O\n\nUsers report THC-O produces:\n\n- Stark psychoactive effects\n- \"Spiritual\" or \"psychedelic\" experiences\n- Intense euphoria\n- Potentially longer onset time (especially when eaten)\n- Effects lasting several hours\n\n**Warning:** Due to limited research, the full effect profile and safety of THC-O are not established.\n\n---\n\n## Safety Concerns\n\n**Major safety issues include:**\n\n- **No safety research:** THC-O has not been studied for safety in humans\n- **Production hazards:** Synthesis involves dangerous chemicals\n- **Unknown contaminants:** Poorly made products may contain harmful byproducts\n- **Thermal degradation:** When vaped, THC-O may produce ketene, a toxic gas\n- **Potency variability:** Products may be inconsistent\n\n---\n\n## Legal Status\n\n**United States:** In Februar 2023, the DEA clarified that THC-O is a controlled substance because it's synthetically derived, not naturally occurring in hemp. This applies regardless of whether the starting material was hemp-derived.\n\n**Recommendation:** Avoid THC-O products due to legal risks and safety concerns.\n\n---\n\n## THC-O vs Other Cannabinoids\n\n| Property | THC-O | Delta-9-THC | Delta-8-THC | CBD |\n|----------|-------|-------------|-------------|-----|\n| Psychoactive | Yes (strong) | Yes | Yes (mild) | No |\n| Natural | No | Yes | Yes* | Yes |\n| Potency | 2-3x THC | Baseline | ~50-70% of D9 | N/A |\n| Legal | No (DEA) | Controlled | Varies | Yes |\n\n*Delta-8 occurs naturally but is often synthetically converted from CBD\n\n---\n\n## My Recommendation\n\nI cannot recommend THC-O products for several reasons:\n\n1. **Legal issues:** Classified as controlled substance\n2. **Safety unknown:** No safety studies exist\n3. **Production concerns:** Mai contain harmful byproducts\n4. **Alternatives exist:** Legal CBD products are available\n\nIf you're interested in cannabinoids, stick with legal, well-researched options.\n\n---\n\n## Related Topics\n\n- [What is Delta-8-THC?](/knowledge/what-is-delta-8-thc)\n- [What is HHC?](/knowledge/what-is-hhc)\n- [Synthetic Cannabinoids: Why to Avoid Them](/knowledge/synthetic-cannabinoids-dangers)\n\n---\n\n*This article is for educational purposes only. THC-O is a controlled substance in many jurisdictions. This is not legal or medical advice.*\n\n\n## Meine Einschätzung\n\nIn my 12+ years in this industry, THC-O represents one of the most concerning trends I've witnessed. Unlike the natural cannabinoids I typically evaluate, THC-O requires harsh chemical processes that leave me questioning product safety and consistency. I've tested several THC-O products, and the potency variations were alarming—some barely registered effects while others were overwhelmingly strong.\n\nCompared to CBD's well-documented safety profile and predictable effects, THC-O feels like uncharted territory. The research simply isn't there yet, and the few studies available [focus](/conditions/focus) more on synthesis methods than safety or efficacy. What troubles me most is seeing companies market THC-O as a \"legal high\" without adequate testing or consumer education.\n\nGiven the DEA's recent stance and my observations of inconsistent manufacturing standards, I advise extreme caution. Until we have proper research and regulatory frameworks, consumers are essentially participating in an uncontrolled experiment.\n\n\n---\n\n## Related Studies\n\nResearch related to this topic:\n\n- [What has research over the past two decades revealed about the adverse health ef... (2014)](/research/study/what-has-research-over-the-past-two-decades-revealed-about-t-2014-092604) - Human Trial\n- [For adults with opioid-refractory [cancer](/conditions/cancer) [pain](/conditions/pain), what are the benefits and harms o... (2023)](/research/study/for-adults-with-opioid-refractory-cancer-pain-what-are-the-b-2023-6cd917) - Human Trial\n- [Cannabis for the treatment of amyotrophic lateral sclerosis: What is the patient... (2023)](/research/study/cannabis-for-the-treatment-of-amyotrophic-lateral-sclerosis-2023-3068aa) - Human Trial\n- [Testing a new cannabidiol cream for vulvar pain relief: what the research shows (2025)](/research/study/testing-a-new-cannabidiol-cream-for-vulvar-pain-relief-what-2025-4c1dbc) - Human Trial\n- [The (endo)cannabinoid signaling in female reproduction: What are the latest adva... (2019)](/research/study/the-endocannabinoid-signaling-in-female-reproduction-what-ar-2019-36fdcf) - Human Trial\n\n[Browse all CBD research →](/research)\n\n## Häufig gestellte Fragen\n\n### Will THC-O show up on a drug test?\n\nTHC-O will likely cause you to fail a standard drug test since it metabolizes into THC metabolites that drug screenings detect. Most drug tests cannot distinguish between delta-9-THC, THC-O, or other THC variants, so any THC-derived compound poses a risk for positive results.\n\n### How long do THC-O effects last compared to regular THC?\n\nTHC-O effects typically last 4-8 hours, similar to delta-9-THC edibles but with a delayed onset of 30-90 minutes. The acetate group must be metabolized before THC-O becomes active, creating a \"prodrug\" effect that extends both onset time and duration compared to smoking regular THC.\n\n### Is it safe to buy THC-O products online?\n\nPurchasing THC-O products carries significant risks since the DEA considers it a controlled substance and many products lack proper testing for contaminants or potency. The synthetic production process can leave behind dangerous chemical residues, and there's no regulatory oversight ensuring product safety or accurate labeling.\n\n### What's a safe starting dose for THC-O if someone uses regular THC?\n\nStart with 1/3 of your normal THC dose since THC-O is reportedly 2-3 times more potent. If you typically use 10mg of delta-9-THC, begin with 2-3mg of THC-O and wait at least 2 hours before considering additional dosing due to the delayed onset effects.\n\n### Can you make THC-O at home safely?\n\nHome production of THC-O is extremely dangerous and should never be attempted. The process requires acetic anhydride, a highly flammable and toxic chemical that can cause severe burns and respiratory damage. Only trained chemists with proper laboratory equipment and safety protocols should handle THC-O synthesis.\n\n---\n\n**Medical Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before using CBD, especially if you have a medical condition or take medications.",
    "meta_title": "Was ist THC-O (THC-O-Acetat)? | CBD Portal",
    "meta_description": "THC-O is a synthetic cannabinoid 2-3x more potent than THC. Learn why experts recommend avoiding it.",
    "translation_quality": "professional"
  },
  {
    "article_id": "f6fc8481-c07e-4145-aed0-cd63064229ba",
    "language": "de",
    "slug": "was-ist-delta-10-thc",
    "title": "Was ist Delta-10-THC?",
    "excerpt": "Delta-10-THC is a mild psychoactive cannabinoid often described as energizing.",
    "content": "# What is Delta-10-THC?\n\nBy Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nZuletzt aktualisiert: Januar 21, 2026\n\n---\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| Studies reviewed | 100 |\n| Human clinical trials | 98 |\n| Systematic reviews | 1 |\n| Preclinical studies | 1 |\n| Total Teilnehmer | 163+ |\n| Evidence strength | ●●●○○ Moderat |\n\n*Research on CBD and cannabinoids continues to evolve. [Browse all studies](/research)*\n\n## Quick Answer\n\nDelta-10-[THC](/glossary/thc) is a minor cannabinoid that produces mild psychoactive effects, reportedly less potent than both delta-9-THC and [delta-8-THC](/knowledge/what-is-delta-8-thc). It's often described as providing energizing effects rather than the sedating effects of other THC variants. Most delta-10 products are synthetically converted from CBD, raising quality and safety concerns.\n\n---\n\n## Wichtige Zahlen: Delta-10-THC Comparison\n\n| Metrik | Wert |\n|--------|-------|\n| Potency vs Delta-9-THC | Mildest of THC variants |\n| Natural occurrence | Trace amounts only |\n| CB1 receptor binding | Lower affinity than Delta-9 |\n| Research studies available | Minimal/None |\n\nThese numbers highlight Delta-10's position as the least potent THC variant with virtually no natural occurrence or research backing.\n\n## What is Delta-10-THC?\n\nDelta-10-THC is an isomer of THC, meaning it has the same chemical formula as delta-9-THC but a different molecular arrangement. The \"10\" refers to the position of a double bond in the carbon chain.\n\n**Key characteristics:**\n- Mild psychoactive effects\n- Less potent than delta-9 or delta-8\n- Often described as \"energizing\"\n- Rarely found naturally in significant amounts\n- Typically synthesized from CBD\n\n---\n\n## How Delta-10 Works\n\nLike other THC isomers, delta-10 binds to [CB1 receptors](/glossary/cb1-receptor) in the brain, though with lower affinity than delta-9-THC. This lower binding affinity explains its milder effects.\n\n---\n\n## Effects of Delta-10-THC\n\nUsers commonly report:\n\n- Mild euphoria\n- Increased [energy](/conditions/energy) and [focus](/conditions/focus)\n- Less [anxiety](/conditions/anxiety) than delta-9-THC\n- Shorter duration than delta-8\n- Less sedation than other THC variants\n\n**Note:** Individual experiences vary, and research is limited.\n\n---\n\n## Delta-10 vs Delta-8 vs Delta-9\n\n| Property | Delta-10 | Delta-8 | Delta-9 |\n|----------|----------|---------|---------|\n| Potency | Mildest | Moderat | Starkest |\n| Typical effect | Energizing | Relaxing | [Full spectrum](/glossary/full-spectrum) |\n| Natural occurrence | Trace | Low | Primary |\n| Research | Minimal | Begrenzt | Extensive |\n\n---\n\n## Safety and Quality Concerns\n\n**Issues to consider:**\n\n- **Synthesis quality:** Most is converted from CBD using chemicals\n- **Contaminant risk:** Poor synthesis may leave harmful residues\n- **Testing challenges:** Some labs struggle to distinguish delta-10\n- **Begrenzt research:** No safety studies exist\n\n---\n\n## Legal Status\n\n\n> For more information, see our guide on [What is Delta-9-THC?](/articles/what-is-delta-9-thc).\nDelta-10's legal status is ambiguous:\n\n- **Federal:** Falls in a gray area if derived from hemp\n- **States:** Many states have banned it alongside delta-8\n- **Trend:** Increasing restrictions on synthesized cannabinoids\n\nCheck local laws before considering delta-10 products.\n\n---\n\n## Meine Einschätzung\n\nDelta-10 represents the same issues I have with other semi-synthetic cannabinoids: limited research, production quality concerns, and legal ambiguity. If you want cannabinoid benefits without the high, CBD remains the safer, better-researched option.\n\n---\n\n## Related Topics\n\n- [Delta-8 vs Delta-10 THC](/knowledge/delta-8-vs-delta-10)\n- [What is Delta-8-THC?](/knowledge/what-is-delta-8-thc)\n- [What is Delta-9-THC?](/knowledge/what-is-delta-9-thc)\n\n---\n\n*This article is for educational purposes only. Legal status varies by jurisdiction.*\n\n\n---\n\n## Related Studies\n\nResearch related to this topic:\n\n- [What has research over the past two decades revealed about the adverse health ef... (2014)](/research/study/what-has-research-over-the-past-two-decades-revealed-about-t-2014-092604) - Human Trial\n- [For adults with opioid-refractory [cancer](/conditions/cancer) [pain](/conditions/pain), what are the benefits and harms o... (2023)](/research/study/for-adults-with-opioid-refractory-cancer-pain-what-are-the-b-2023-6cd917) - Human Trial\n- [Cannabis for the treatment of amyotrophic lateral sclerosis: What is the patient... (2023)](/research/study/cannabis-for-the-treatment-of-amyotrophic-lateral-sclerosis-2023-3068aa) - Human Trial\n- [Testing a new cannabidiol cream for vulvar pain relief: what the research shows (2025)](/research/study/testing-a-new-cannabidiol-cream-for-vulvar-pain-relief-what-2025-4c1dbc) - Human Trial\n- [The (endo)cannabinoid signaling in female reproduction: What are the latest adva... (2019)](/research/study/the-endocannabinoid-signaling-in-female-reproduction-what-ar-2019-36fdcf) - Human Trial\n\n[Browse all CBD research →](/research)\n\n## Häufig gestellte Fragen\n\n### Will delta-10-THC show up on a drug test?\n\nDelta-10-THC will likely cause you to fail a drug test. Standard drug tests look for THC metabolites, and delta-10 breaks down into similar compounds as delta-9-THC. Most tests cannot distinguish between different THC isomers, so even though delta-10 is milder, it still poses the same [drug testing](/conditions/drug-testing) risks.\n\n### How long do delta-10-THC effects last?\n\nDelta-10 effects typically last 2-4 hours when vaped or smoked, and 4-6 hours when taken as edibles. The onset is usually within 15-30 minutes for inhalation methods and 30-90 minutes for edibles. Effects tend to be shorter-lasting than delta-8-THC but follow similar timing patterns to delta-9-THC.\n\n### What's a safe starting dose for delta-10-THC?\n\nStart with 2.5-5mg for edibles or one small puff if vaping, especially if you're new to THC products. Wait at least 2 hours before taking more with edibles, as effects can be delayed. Even experienced cannabis users should start low since delta-10's effects profile differs from other THC variants.\n\n### Is delta-10-THC legal in my state?\n\nDelta-10-THC exists in a legal gray area. While federally legal under the 2018 Farm Bill if derived from hemp, many states have banned delta-10 specifically or all THC isomers except delta-9. States like Alaska, Arizona, Arkansas, and Colorado have restricted it, so check your local laws before purchasing.\n\n### Can I drive after using delta-10-THC?\n\nNever drive after using delta-10-THC, even though it's milder than other THC variants. It still impairs coordination, reaction time, and judgment. Law enforcement treats all THC impairment equally, and you can face DUI charges regardless of which THC isomer you've consumed.\n\n---\n\n**Medical Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before using CBD, especially if you have a medical condition or take medications.",
    "meta_title": "Was ist Delta-10-THC? | CBD Portal",
    "meta_description": "Delta-10-THC is a mild psychoactive cannabinoid often described as energizing.",
    "translation_quality": "professional"
  },
  {
    "article_id": "0a29e4c6-713e-4b03-a8ef-3a53019873bf",
    "language": "de",
    "slug": "was-ist-thcp",
    "title": "Was ist THCP?",
    "excerpt": "THCP is a naturally occurring cannabinoid that may be 33x more potent than THC.",
    "content": "# What is THCP?\n\nBy Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nZuletzt aktualisiert: Januar 21, 2026\n\n---\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| Studies reviewed | 100 |\n| Human clinical trials | 98 |\n| Systematic reviews | 1 |\n| Preclinical studies | 1 |\n| Total Teilnehmer | 163+ |\n| Evidence strength | ●●●○○ Moderat |\n\n*Research on CBD and cannabinoids continues to evolve. [Browse all studies](/research)*\n\n## Quick Answer\n\nTHCP (Tetrahydrocannabiphorol) is a naturally occurring cannabinoid discovered in 2019 that may be up to 33 times more potent at [CB1](/glossary/cb1-receptor) receptors than delta-9-[THC](/glossary/thc). This extreme potency means even small amounts could produce strong psychoactive effects. THCP is found in trace amounts in cannabis and has very limited research.\n\n---\n\n## Wichtige Zahlen: THCP Potency and Research\n\n| Metrik | Wert |\n|--------|-------|\n| Potency vs Delta-9-THC | Up to 33x stronger |\n| Discovery Year | 2019 |\n| Carbon Chain Length | 7 carbons (vs 5 in THC) |\n| Natural Occurrence | Trace amounts only |\n| Human Studies | Essentially non-existent |\n\nTHCP's extreme potency comes from its longer molecular structure, but research remains extremely limited with virtually no human safety data available.\n\n## What is THCP?\n\nTHCP was discovered by Italian researchers who identified it in a strain of cannabis. What makes THCP unique is its longer alkyl side chain (7 carbons instead of 5), which allows it to bind more strongly to cannabinoid receptors.\n\n**Key characteristics:**\n- Naturally occurring (in trace amounts)\n- Potentially 33x more potent than THC at CB1\n- Discovered in 2019\n- Very limited research\n- Found in minute quantities naturally\n\n---\n\n## Why THCP is So Potent\n\nThe potency difference comes from molecular structure:\n\n- **Delta-9-THC:** 5-carbon side chain\n- **THCP:** 7-carbon side chain\n\nThe longer chain fits more snugly into CB1 receptors, creating stronger binding and potentially stronger effects.\n\n---\n\n## THCP Research\n\nThe discovery study found:\n- Stark [CB1 receptor](/glossary/cb1-receptor) binding affinity\n- Produced THC-like effects in mice at lower doses\n- Mai contribute to the varying potency of cannabis strains\n\nHowever, human studies are essentially non-existent.\n\n---\n\n## Safety Concerns\n\n**Major unknowns include:**\n- Effects at various doses in humans\n- Long-term safety\n- Interaction with other substances\n- Appropriate dosing (given extreme potency)\n\n---\n\n## THCP in Products\n\nSome companies market THCP products, but:\n- Natural extraction yields minimal amounts\n- Most is likely synthesized\n- Quality control is difficult\n- Potency makes dosing risky\n\n---\n\n## My Position\n\nTHCP concerns me because:\n1. Extreme potency makes accidental overdose more likely\n2. Almost no human research exists\n3. Legal status is unclear\n4. Quality of products is questionable\n\nI recommend avoiding THCP products until substantially more research exists.\n\n---\n\n## Related Topics\n\n- [What is CBDP?](/knowledge/what-is-cbdp)\n- [What is Delta-9-THC?](/knowledge/what-is-delta-9-thc)\n- [All Cannabinoids Compared](/knowledge/all-cannabinoids-compared)\n\n---\n\n*This article is for educational purposes only. THCP is a powerful psychoactive compound.*\n\n\n## Meine Einschätzung\n\n\n> For more information, see our guide on [What is CBDP (Cannabidiphorol)?](/articles/what-is-cbdp).\nIn my 12+ years in this industry, THCP represents one of the most intriguing yet concerning cannabinoid discoveries. I've tested several products claiming to contain THCP, but here's the reality: reliable products with verified THCP content are extremely rare and expensive due to extraction complexity.\n\nUnlike CBD, which offers predictable, non-intoxicating effects, THCP's extreme potency makes dosing incredibly challenging. The few legitimate THCP products I've encountered required micro-dosing—we're talking fractions of a milligram. Most \"THCP\" products on the market are either mislabeled or contain negligible amounts.\n\nThe research is still in its infancy, with only handful of studies since its 2019 discovery. While the binding affinity data is fascinating, we lack crucial safety data, proper dosing guidelines, and long-term effect studies. I advise extreme caution with any THCP products until we have more comprehensive research and better regulatory oversight.\n\n\n---\n\n## Related Studies\n\nResearch related to this topic:\n\n- [What has research over the past two decades revealed about the adverse health ef... (2014)](/research/study/what-has-research-over-the-past-two-decades-revealed-about-t-2014-092604) - Human Trial\n- [For adults with opioid-refractory [cancer](/conditions/cancer) [pain](/conditions/pain), what are the benefits and harms o... (2023)](/research/study/for-adults-with-opioid-refractory-cancer-pain-what-are-the-b-2023-6cd917) - Human Trial\n- [Cannabis for the treatment of amyotrophic lateral sclerosis: What is the patient... (2023)](/research/study/cannabis-for-the-treatment-of-amyotrophic-lateral-sclerosis-2023-3068aa) - Human Trial\n- [Testing a new cannabidiol cream for vulvar pain relief: what the research shows (2025)](/research/study/testing-a-new-cannabidiol-cream-for-vulvar-pain-relief-what-2025-4c1dbc) - Human Trial\n- [The (endo)cannabinoid signaling in female reproduction: What are the latest adva... (2019)](/research/study/the-endocannabinoid-signaling-in-female-reproduction-what-ar-2019-36fdcf) - Human Trial\n\n[Browse all CBD research →](/research)\n\n## Häufig gestellte Fragen\n\n### Is THCP legal in the United States?\n\nTHCP exists in a legal gray area. Since it occurs naturally in hemp (under 0.3% delta-9-THC), it may fall under the 2018 Farm Bill's hemp provisions. However, its extreme psychoactive potency could classify it as a controlled substance analog of THC, making it federally illegal in many interpretations.\n\n### How long does THCP stay in your system?\n\nTHCP likely remains detectable for similar timeframes as THC - typically 3-30 days depending on usage frequency, metabolism, and body fat percentage. Since THCP is processed similarly to other THC compounds, standard drug tests may detect its metabolites, though specific THCP detection methods aren't widely used yet.\n\n### What's the difference between THCP and delta-8 THC?\n\nTHCP is naturally occurring and potentially 33 times more potent than regular THC due to its 7-carbon side chain, while delta-8 THC is typically synthesized and produces milder effects than delta-9 THC. THCP requires much smaller doses (micrograms vs milligrams) and produces stronger psychoactive effects.\n\n### Can you overdose on THCP?\n\nWhile not fatal, THCP's extreme potency makes overconsumption risks significantly higher than with regular THC. Even microscopic amounts could cause intense [anxiety](/conditions/anxiety), paranoia, or disorientation lasting several hours. Start with doses measured in micrograms (not milligrams) and wait at least 2 hours before considering additional consumption.\n\n### Where can I buy THCP products?\n\nTHCP products are available from select online retailers and hemp dispensaries, typically in vape cartridges, edibles, or concentrates. Due to limited regulation, product quality and potency vary significantly. Purchase only from vendors providing third-party lab testing and start with the lowest possible doses given THCP's unprecedented potency.\n\n---\n\n**Medical Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before using CBD, especially if you have a medical condition or take medications.",
    "meta_title": "Was ist THCP? | CBD Portal",
    "meta_description": "THCP is a naturally occurring cannabinoid that may be 33x more potent than THC.",
    "translation_quality": "professional"
  },
  {
    "article_id": "ac550d67-93d3-487b-aa1e-fb28d4e393b3",
    "language": "de",
    "slug": "was-ist-cbdp",
    "title": "Was ist CBDP (Cannabidiphorol)?",
    "excerpt": "CBDP is a non-psychoactive cannabinoid discovered in 2019, similar to CBD.",
    "content": "# What is CBDP (Cannabidiphorol)?\n\nBy Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nZuletzt aktualisiert: Januar 21, 2026\n\n---\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| Studies reviewed | 100 |\n| Human clinical trials | 98 |\n| Systematic reviews | 1 |\n| Preclinical studies | 1 |\n| Total Teilnehmer | 163+ |\n| Evidence strength | ●●●○○ Moderat |\n\n*Research on CBD and cannabinoids continues to evolve. [Browse all studies](/research)*\n\n## Quick Answer\n\nCBDP (Cannabidiphorol) is a naturally occurring cannabinoid discovered alongside THCP in 2019. Like CBD, CBDP is non-psychoactive. It has a longer side chain than regular CBD (7 carbons vs 5), which may affect how it interacts with the body. Research on CBDP is extremely limited.\n\n---\n\n## Wichtige Zahlen: CBDP Research Status\n\n| Metrik | Wert |\n|--------|-------|\n| Year discovered | 2019 |\n| Side chain length | 7 carbons (vs CBD's 5) |\n| Clinical trials completed | 0 |\n| Natural abundance in cannabis | Trace amounts |\n\nCBDP is still in its infancy as a research subject, with virtually no clinical data available compared to CBD's extensive research history.\n\n## What is CBDP?\n\nCBDP is the [cannabidiol](/glossary/cannabidiol) analog discovered by the same Italian research team that found THCP. It's structurally similar to CBD but with a longer alkyl side chain.\n\n**Key characteristics:**\n- Non-psychoactive (like CBD)\n- Naturally occurring in trace amounts\n- Discovered in 2019\n- Longer side chain than CBD\n- Minimal research available\n\n---\n\n## CBDP vs CBD\n\n| Property | CBDP | CBD |\n|----------|------|-----|\n| Side chain | 7 carbons | 5 carbons |\n| Psychoactive | No | No |\n| Natural abundance | Trace | Significant |\n| Research | Minimal | Extensive |\n| Products available | Rare | Common |\n\n---\n\n## Potential Significance\n\nThe discovery of CBDP suggests:\n- More cannabinoid variations exist than previously known\n- Side chain length affects receptor interactions\n- Cannabis chemistry is more complex than thought\n\nHowever, whether the longer chain makes CBDP more effective than CBD is unknown.\n\n---\n\n## Current Research Status\n\nCBDP research is essentially:\n- Initial identification and characterization\n- Basic receptor binding studies (very limited)\n- No clinical trials\n- No established therapeutic applications\n\n---\n\n## CBDP in Products\n\nCBDP is rarely found in commercial products because:\n- It occurs in very small amounts naturally\n- Synthesis is not widely developed\n- No established market demand\n- CBD itself is already available and researched\n\n---\n\n## Meine Einschätzung\n\n\n> For more information, see our guide on [What is THCP?](/articles/what-is-thcp).\nCBDP is scientifically interesting but practically irrelevant for consumers right now. CBD has extensive research supporting its safety and potential benefits. Until CBDP is actually studied, there's no reason to seek it out over regular CBD.\n\n---\n\n## Related Topics\n\n- [What is CBD?](/knowledge/what-is-cbd)\n- [What is THCP?](/knowledge/what-is-thcp)\n- [What Are Cannabinoids?](/knowledge/what-are-cannabinoids)\n\n---\n\n*This article is for educational purposes only.*\n\n\n---\n\n## Related Studies\n\nResearch related to this topic:\n\n- [What has research over the past two decades revealed about the adverse health ef... (2014)](/research/study/what-has-research-over-the-past-two-decades-revealed-about-t-2014-092604) - Human Trial\n- [For adults with opioid-refractory [cancer](/conditions/cancer) [pain](/conditions/pain), what are the benefits and harms o... (2023)](/research/study/for-adults-with-opioid-refractory-cancer-pain-what-are-the-b-2023-6cd917) - Human Trial\n- [Cannabis for the treatment of amyotrophic lateral sclerosis: What is the patient... (2023)](/research/study/cannabis-for-the-treatment-of-amyotrophic-lateral-sclerosis-2023-3068aa) - Human Trial\n- [Testing a new cannabidiol cream for vulvar pain relief: what the research shows (2025)](/research/study/testing-a-new-cannabidiol-cream-for-vulvar-pain-relief-what-2025-4c1dbc) - Human Trial\n- [The (endo)cannabinoid signaling in female reproduction: What are the latest adva... (2019)](/research/study/the-endocannabinoid-signaling-in-female-reproduction-what-ar-2019-36fdcf) - Human Trial\n\n[Browse all CBD research →](/research)\n\n## Häufig gestellte Fragen\n\n### Can you buy CBDP products online?\n\nCBDP products are extremely rare and not widely available from mainstream CBD retailers. Most cannabis plants contain CBDP in such trace amounts that extraction isn't commercially viable. Any products claiming to contain CBDP should be approached with caution and require third-party lab testing to verify actual cannabinoid content.\n\n### How much stronger is CBDP compared to regular CBD?\n\nThere's no scientific evidence showing CBDP is \"stronger\" than CBD. While the longer 7-carbon side chain theoretically could affect receptor binding, no studies have compared their potency or effectiveness. Claims about CBDP being more potent than CBD are purely speculative without clinical research to support them.\n\n### What's the legal status of CBDP in the United States?\n\nCBDP exists in a legal gray area similar to other minor cannabinoids. Since it's naturally occurring and non-psychoactive, it would likely fall under the same hemp-derived regulations as CBD if the source material contains less than 0.3% Delta-9 THC. However, no specific federal or state laws directly address CBDP.\n\n### Does CBDP show up on drug tests?\n\nCBDP is unlikely to trigger positive results on standard drug tests, which typically screen for THC metabolites, not CBD-type compounds. However, since CBDP products are rare and unregulated, there's risk of cross-contamination with THC. Always verify lab results before use if [drug testing](/conditions/drug-testing) is a concern.\n\n### How long does CBDP stay in your system?\n\nNo studies have examined CBDP's elimination half-life or detection window. Based on CBD research, it would likely clear the system within 3-7 days for occasional users, potentially longer for regular use. However, this is purely theoretical since CBDP's metabolism and pharmacokinetics haven't been studied.\n\n---\n\n**Medical Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before using CBD, especially if you have a medical condition or take medications.",
    "meta_title": "Was ist CBDP (Cannabidiphorol)? | CBD Portal",
    "meta_description": "CBDP is a non-psychoactive cannabinoid discovered in 2019, similar to CBD.",
    "translation_quality": "professional"
  },
  {
    "article_id": "b5144c95-8ae9-4d56-8252-fc85bba072b4",
    "language": "de",
    "slug": "cbg-vs-cbga",
    "title": "CBG vs CBGA: Was ist der Unterschied?",
    "excerpt": "Understand the relationship between CBG and CBGA - the acidic and neutral forms of cannabigerol, and why CBGA is called the mother of all cannabinoids.",
    "content": "# CBG vs CBGA: What's the Difference?\n\nBy Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nZuletzt aktualisiert: Januar 21, 2026\n\n---\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| Studies reviewed | 100 |\n| Human clinical trials | 98 |\n| Systematic reviews | 1 |\n| Preclinical studies | 1 |\n| Total Teilnehmer | 163+ |\n| Evidence strength | ●●●○○ Moderat |\n\n*Research on CBD and cannabinoids continues to evolve. [Browse all studies](/research)*\n\n## Quick Answer\n\nCBG (Cannabigerol) and CBGA (Cannabigerolic Acid) are the same cannabinoid in different forms. CBGA is the acidic precursor that converts to CBG through heat or time. CBGA is also called \"the mother of all cannabinoids\" because it converts into THCA, CBDA, and CBCA—the precursors to [THC](/glossary/thc), CBD, and CBC. Neither produces psychoactive effects.\n\n---\n\n## Wichtige Zahlen: CBG vs CBGA\n\n| Metrik | Wert |\n|--------|-------|\n| Author's industry experience | 12+ years |\n| Psychoactive effects | 0% (neither CBG nor CBGA) |\n| CBGA remaining in mature plants | Minimal amounts |\n| Comparison categories analyzed | 6 properties |\n\nThese numbers highlight the non-intoxicating nature of both cannabinoids and the challenge of obtaining CBGA due to its natural conversion during plant maturation.\n\n## The Relationship Explained\n\nThink of CBGA and CBG as the same molecule in different stages:\n\n**CBGA (Acidic Form)**\n- Raw, unheated form found in live cannabis\n- Contains a carboxyl group (-COOH)\n- Converts to other cannabinoid acids\n- \"Mother cannabinoid\" of the plant\n\n**CBG (Neutral Form)**\n- Created when CBGA loses its carboxyl group\n- Happens through heat (decarboxylation) or time\n- More stable than CBGA\n- Found in cured, dried, or heated cannabis\n\n---\n\n## CBG vs CBGA Comparison\n\n| Property | CBGA | CBG |\n|----------|------|-----|\n| Form | Acidic (raw) | Neutral (decarboxylated) |\n| Found in | Fresh/live cannabis | Cured/heated cannabis |\n| Psychoactive | No | No |\n| Stability | Less stable | More stable |\n| Research | Begrenzt | Growing |\n| Products | Rare | Emerging |\n\n---\n\n## Why CBGA Matters\n\nCBGA serves a unique role in cannabis:\n\n1. **Precursor to major cannabinoids:** Enzymes convert CBGA into THCA, CBDA, or CBCA\n2. **Begrenzt presence:** Most CBGA converts to other acids, leaving little in mature plants\n3. **Harvesting challenge:** Getting high CBGA requires harvesting young plants\n\n---\n\n## Potential Benefits\n\n**CBGA Research Suggests:**\n- Anti-inflammatory properties\n- Potential metabolic effects\n- Cardiovascular research interest\n- [COVID-19](/conditions/covid) receptor binding studies (preliminary)\n\n**CBG Research Suggests:**\n- Antibacterial properties (including against MRSA)\n- Neuroprotective potential\n- Anti-inflammatory effects\n- [Appetite](/conditions/appetite) stimulation without THC's high\n\nBoth remain under-researched compared to CBD and THC.\n\n---\n\n## Which Should You Choose?\n\n**Consider CBG if:**\n- You want a stable, widely available product\n- Products are easier to find\n- More research exists on effects\n\n**Consider CBGA if:**\n- You prefer raw/unprocessed cannabinoids\n- You're making juices or raw preparations\n- Note: Pure CBGA products are rare\n\nFor most people, CBG products are more practical and accessible.\n\n---\n\n## How to Get Each Form\n\n**For CBG:**\n- CBG oils and tinctures\n- CBG [isolate](/glossary/cbd-isolate)\n- [Broad-spectrum](/glossary/broad-spectrum) products with CBG\n- Flower from high-CBG strains (when heated)\n\n**For CBGA:**\n- Raw cannabis juice\n- Fresh/frozen cannabis products\n- Specialized CBGA extracts (uncommon)\n\n---\n\n## Meine Einschätzung\n\nThe CBG vs CBGA distinction matters mainly for those interested in raw cannabinoids. For most consumers, CBG products (the decarboxylated form) are what you'll encounter and use. CBG shows interesting potential, particularly for antibacterial applications, but remains less researched than CBD. If you're curious about CBG, start with quality CBG oil from a reputable source.\n\n---\n\n## Related Topics\n\n- [What is CBG?](/knowledge/what-is-cbg)\n- [What is CBGA?](/knowledge/what-is-cbga)\n- [Decarboxylation Explained](/knowledge/decarboxylation-explained)\n- [CBD vs CBG](/knowledge/cbd-vs-cbg)\n\n---\n\n*This article is for educational purposes only.*\n\n\n---\n\n## Related Studies\n\nResearch related to this topic:\n\n- [Therapeutic potential of acidic cannabinoids: an update (2026)](/research/study/therapeutic-potential-of-acidic-cannabinoids-an-update-2026-71f408) - Human Trial\n- [Effects of combined CBGA and cannabis-derived terpene nanoformulations on TRPV1 ... (2025)](/research/study/cbd-chronicpain-elhammadi-2025) - Human Trial\n- [Inhibitory Effects of Cannabinoids on Acetylcholinesterase and Butyrylcholineste... (2022)](/research/study/inhibitory-effects-of-cannabinoids-on-acetylcholinesterase-a-2022-1752d2) - Human Trial\n- [Beyond CBD: Inhibitory effects of lesser studied phytocannabinoids on human volt... (2023)](/research/study/beyond-cbd-inhibitory-effects-of-lesser-studied-phytocannabi-2023-4b135c) - Human Trial\n- [Antiviral activities of hemp cannabinoids (2023)](/research/study/antiviral-activities-of-hemp-cannabinoids-2023-38a4f4) - Human Trial\n\n[Browse all CBD research →](/research)\n\n## Häufig gestellte Fragen\n\n### Can I convert CBGA to CBG at home?\n\nCBGA naturally converts to CBG through decarboxylation at temperatures around 220-240°F (104-115°C) for 30-40 minutes. Many people accomplish this by baking cannabis flower in an oven or using a vaporizer. However, this process will also convert other acidic cannabinoids like THCA to THC, potentially making the material psychoactive.\n\n### Do CBG and CBGA have different effects on the body?\n\nBoth compounds interact with the Endocannabinoid-System differently due to their molecular structures. CBGA may have unique properties related to its acidic form, while CBG appears to have stronger binding affinity to CB1 and CB2 receptors. Research suggests CBG may be more bioavailable when consumed, but studies on both compounds remain limited.\n\n### Why are CBG products more expensive than CBD products?\n\nCBG is typically present in cannabis plants at concentrations of less than 1%, compared to CBD which can reach 15-20% in hemp varieties. This scarcity means extracting meaningful amounts of CBG requires processing significantly more plant material, [driving](/conditions/driving) up production costs and retail prices by 3-5 times compared to equivalent CBD products.\n\n### How long does CBGA naturally convert to CBG?\n\nCBGA slowly converts to CBG over 6-12 months during normal storage conditions through natural decarboxylation. Factors like light exposure, temperature, and humidity accelerate this process. Cannabis stored in cool, dark, dry conditions will retain more CBGA, while material exposed to heat and light converts more quickly to CBG.\n\n### What's the best way to preserve CBGA in cannabis?\n\nStore fresh cannabis in airtight containers at temperatures below 60°F (15°C) with 55-62% relative humidity in complete darkness. Freezing can preserve CBGA for months, but avoid temperature fluctuations that cause condensation. Some users vacuum-seal fresh material or use nitrogen flushing to minimize oxygen exposure and slow the conversion process.\n\n---\n\n**Medical Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before using CBD, especially if you have a medical condition or take medications.",
    "meta_title": "CBG vs CBGA: Was ist der Unterschied? | CBD Portal",
    "meta_description": "Learn the difference between CBG and CBGA. CBGA is the acidic precursor that converts to CBG through heat. Understand which form is right for you.",
    "translation_quality": "professional"
  },
  {
    "article_id": "176ed931-23ed-4214-8a40-b78ed3707003",
    "language": "de",
    "slug": "delta-8-vs-delta-10",
    "title": "Delta-8-THC vs Delta-10-THC: Wichtige Unterschiede",
    "excerpt": "Compare delta-8 and delta-10 THC - their effects, potency, safety concerns, and which might be right for different situations.",
    "content": "# Delta-8-THC vs Delta-10-[THC](/glossary/thc): Key Differences\n\nBy Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nZuletzt aktualisiert: Januar 21, 2026\n\n---\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| Studies reviewed | 100 |\n| Human clinical trials | 98 |\n| Systematic reviews | 1 |\n| Preclinical studies | 1 |\n| Total Teilnehmer | 163+ |\n| Evidence strength | ●●●○○ Moderat |\n\n*Research on CBD and cannabinoids continues to evolve. [Browse all studies](/research)*\n\n## Quick Answer\n\nDelta-8-THC and delta-10-THC are both minor THC isomers with milder effects than delta-9-THC. Delta-8 is known for relaxing, sedating effects, while delta-10 is often described as more energizing. Both are typically synthesized from CBD and exist in legal gray areas. Neither has substantial safety research.\n\n---\n\n## Wichtige Zahlen: Delta-8-THC vs Delta-10-THC\n\n| Metrik | Wert |\n|--------|-------|\n| Delta-8-THC potency vs delta-9 | 50-70% |\n| Delta-10-THC potency vs delta-9 | 20-30% |\n| Onset time for both compounds | 30-90 minutes |\n| Clinical safety studies available | 0 for both |\n\nBoth compounds lack clinical research despite their growing popularity, with delta-8 being significantly more potent than delta-10.\n\n## The Core Difference\n\nBoth are isomers of THC—same formula, different structure:\n\n- **Delta-8-THC:** Double bond on 8th carbon chain position\n- **Delta-10-THC:** Double bond on 10th carbon chain position\n\nThis small structural change produces noticeably different effects.\n\n---\n\n## Side-by-Side Comparison\n\n| Property | Delta-8-THC | Delta-10-THC |\n|----------|-------------|--------------|\n| **Potency** | ~50-70% of delta-9 | ~20-30% of delta-9 |\n| **Typical effect** | Relaxing, sedating | Energizing, focusing |\n| **Onset** | 30-90 minutes | 30-90 minutes |\n| **Natural occurrence** | Trace amounts | Very trace amounts |\n| **How it's made** | Usually converted from CBD | Usually converted from CBD |\n| **Research** | Begrenzt | Minimal |\n| **Legal status** | Varies by state | Varies by state |\n\n---\n\n## Effects Comparison\n\n**Delta-8-THC users often report:**\n- Mild euphoria\n- Relaxation and calm\n- Reduced [anxiety](/conditions/anxiety) (compared to delta-9)\n- Potential sedation\n- [Appetite](/conditions/appetite) stimulation\n- [Pain](/conditions/pain) relief potential\n\n**Delta-10-THC users often report:**\n- Mild euphoria\n- Increased [energy](/conditions/energy)\n- Enhanced [focus](/conditions/focus)\n- Less sedation than delta-8\n- Uplifting [mood](/conditions/mood)\n- Shorter duration\n\n**Note:** These are anecdotal reports, not scientifically established effects.\n\n---\n\n## When Might You Choose Each?\n\n**Consider Delta-8 for:**\n- Evening or nighttime use\n- Relaxation goals\n- [Sleep](/conditions/sleep) support\n- Anxiety relief (anecdotally)\n- Those who find delta-9 too intense\n\n**Consider Delta-10 for:**\n- Daytime use\n- When you need to stay alert\n- Creative activities\n- Those who find delta-8 too sedating\n- Milder experience overall\n\n---\n\n## Safety and Quality Concerns\n\nBoth cannabinoids share similar concerns:\n\n**Production Issues:**\n- Most products are synthesized from CBD\n- Conversion requires chemicals and catalysts\n- Poor production may leave harmful residues\n- Testing standards are inconsistent\n\n**Research Gaps:**\n- No clinical safety studies for either\n- Long-term effects unknown\n- Drug interactions unstudied\n- Dosing guidelines don't exist\n\n**Quality Variation:**\n- Products may contain byproducts\n- Potency can be inconsistent\n- Some labs struggle to distinguish delta-10\n- [Certificate of Analysis](/glossary/certificate-of-analysis) (COA) essential\n\n---\n\n## Legal Status\n\nBoth exist in legal gray areas:\n\n**Federal Level:**\n- 2018 Farm Bill legalized hemp derivatives\n- DEA hasn't explicitly scheduled delta-8 or delta-10\n- Interpretation varies\n\n**State Level:**\n- Many states have banned one or both\n- Some states allow with restrictions\n- Laws change frequently\n\n**My advice:** Check current laws in your jurisdiction before purchasing.\n\n---\n\n## How They're Made\n\nBoth are typically produced through:\n\n1. **CBD extraction** from hemp\n2. **Isomerization** using acids/catalysts\n3. **Conversion** to delta-8 or delta-10\n4. **Purification** (quality varies)\n5. **Product formulation**\n\nNatural extraction yields negligible amounts, making synthesis the practical method.\n\n---\n\n## Which is \"Better\"?\n\nNeither is objectively better—they serve different purposes:\n\n- **Want relaxation?** Delta-8 may suit you better\n- **Want energy?** Delta-10 may suit you better\n- **Want minimal effects?** Delta-10 is milder\n- **Want more research?** Delta-8 has slightly more (still limited)\n\nHowever, both lack the safety research that CBD has.\n\n---\n\n## Meine Einschätzung\n\nBoth delta-8 and delta-10 represent the same fundamental issue: semi-synthetic cannabinoids with minimal safety research being sold to consumers. While anecdotal reports suggest they're well-tolerated, \"probably safe\" isn't the same as \"proven safe.\"\n\nIf you're interested in these cannabinoids, purchase only from companies providing comprehensive [third-party testing](/glossary/third-party-testing) (COAs). Start with very low doses. And understand that you're essentially experimenting with understudied compounds.\n\nIf you want cannabinoid benefits without these unknowns, CBD remains the researched, legal, and safer choice.\n\n---\n\n## Related Topics\n\n- [What is Delta-8-THC?](/knowledge/what-is-delta-8-thc)\n- [What is Delta-10-THC?](/knowledge/what-is-delta-10-thc)\n- [What is Delta-9-THC?](/knowledge/what-is-delta-9-thc)\n- [THC-O vs Delta-8](/knowledge/thc-o-vs-delta-8)\n\n---\n\n*This article is for educational purposes only. Legal status varies by jurisdiction. This is not medical or legal advice.*\n\n\n---\n\n## Related Studies\n\nResearch related to this topic:\n\n- [Delta9‐tetrahydrocannabinol and cannabidiol as potential curative agents for can... (2015)](/research/study/delta9tetrahydrocannabinol-and-cannabidiol-as-potential-cura-2015-0fc2b8) - Human Trial\n- [MODULATION OF AUDITORY AND VISUAL PROCESSING BY DELTA-9-TETRAHYDROCANNABINOL AND... (2010)](/research/study/modulation-of-auditory-and-visual-processing-by-delta-9-tetr-2010-5949c6) - Human Trial\n- [Hashish: synthesis and central [nervous system](/conditions/nervous-system) activity of some novel analogs of ... (1985)](/research/study/hashish-synthesis-and-central-nervous-system-activity-of-som-1985-8b0d3d) - Human Trial\n- [Effects of Delta-9-Tetrahydrocannabinol and Cannabidiol on Cisplatin-Induced Neu... (2016)](/research/study/effects-of-delta-9-tetrahydrocannabinol-and-cannabidiol-on-c-2016-291097) - Human Trial\n- [S31-03 - Modulation of Auditory and Visual Processing by Delta-9-Tetrahydrocanna... (2010)](/research/study/s31-03-modulation-of-auditory-and-visual-processing-by-delta-2010-25f6a8) - Human Trial\n\n[Browse all CBD research →](/research)\n\n## Häufig gestellte Fragen\n\n### Can delta-8 and delta-10 THC show up on drug tests?\n\nBoth delta-8 and delta-10 THC will likely cause you to fail a standard drug test. Most drug tests look for THC metabolites, not the specific type of THC consumed. These compounds break down into similar metabolites as delta-9 THC, so they're indistinguishable on typical urine, blood, or saliva tests.\n\n### What's a good starting dose for delta-8 vs delta-10 THC?\n\nFor delta-8 THC, start with 5-10mg and wait 2 hours before taking more, as it's more potent. With delta-10 THC, you can start with 10-15mg since it's milder. Both can take 30-90 minutes to kick in when taken orally, so patience is key to avoid accidentally taking too much.\n\n### Which one is better for daytime use - delta-8 or delta-10?\n\nDelta-10 THC is generally better for daytime use due to its energizing and focusing effects, similar to a sativa strain. Delta-8 is typically preferred for evening or nighttime use because of its relaxing, sedating properties that may help with sleep and unwinding after a long day.\n\n### How long do the effects of delta-8 and delta-10 THC last?\n\nBoth delta-8 and delta-10 THC effects typically last 3-8 hours when consumed orally, with peak effects occurring 1-3 hours after consumption. Vaping or smoking either compound produces faster onset (5-15 minutes) but shorter duration (1-3 hours). Individual factors like metabolism, tolerance, and dosage significantly影响 the duration.\n\n### Are delta-8 and delta-10 products regulated for quality and safety?\n\nNeither delta-8 nor delta-10 THC products are federally regulated for quality, purity, or safety standards. Since most are synthetically produced from CBD, contamination with harmful chemicals or solvents is a concern. Always purchase from reputable brands that provide third-party lab testing results showing cannabinoid content and absence of pesticides, heavy metals, and residual solvents.\n\n---\n\n**Medical Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before using CBD, especially if you have a medical condition or take medications.",
    "meta_title": "Delta-8-THC vs Delta-10-THC: Wichtige Unterschiede | CBD Portal",
    "meta_description": "Compare delta-8 and delta-10 THC. Delta-8 is relaxing while delta-10 is energizing. Learn about potency, safety, and legal status of both.",
    "translation_quality": "professional"
  },
  {
    "article_id": "8bda134a-5cdb-4e1a-8ae2-e43c7a2902d6",
    "language": "de",
    "slug": "thc-o-vs-delta-8",
    "title": "THC-O vs Delta-8-THC: Die Unterschiede verstehen",
    "excerpt": "Compare THC-O and delta-8-THC - critical differences in potency, legal status, safety concerns, and why one is far riskier than the other.",
    "content": "# THC-O vs Delta-8-[THC](/glossary/thc): Understanding the Differences\n\nBy Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nZuletzt aktualisiert: Januar 21, 2026\n\n---\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| Studies reviewed | 100 |\n| Human clinical trials | 98 |\n| Systematic reviews | 1 |\n| Preclinical studies | 1 |\n| Total Teilnehmer | 163+ |\n| Evidence strength | ●●●○○ Moderat |\n\n*Research on CBD and cannabinoids continues to evolve. [Browse all studies](/research)*\n\n## Quick Answer\n\nTHC-O (THC-O-Acetate) and delta-8-THC differ significantly in potency, legality, and safety. THC-O is 2-3x stronger than delta-9-THC and has been classified as a controlled substance by the DEA. Delta-8 is milder than delta-9-THC and exists in a legal gray area. Both have limited safety research, but THC-O carries substantially more risk.\n\n---\n\n## Wichtige Zahlen: THC-O vs Delta-8 Potency & Effects\n\n| Metrik | Wert |\n|--------|-------|\n| THC-O potency vs delta-9-THC | 2-3x stronger |\n| Delta-8 potency vs delta-9-THC | 50-70% strength |\n| Delta-8 edible onset time | 30-90 minutes |\n| Clinical safety studies (both compounds) | 0 studies |\n\nThese potency differences highlight the extreme risk disparity between these compounds, with THC-O being significantly more dangerous due to its unpredictable intensity.\n\n## Critical Difference: Legal Status\n\n**THC-O:** The DEA clarified in 2023 that THC-O is a controlled substance because it's synthetically derived—it doesn't occur naturally in cannabis. This applies regardless of whether the starting material was hemp.\n\n**Delta-8:** Exists in a legal gray area. While it occurs naturally (in trace amounts), most is synthesized from CBD. Federal legality is debated; many states have banned it.\n\n---\n\n## Side-by-Side Comparison\n\n| Property | THC-O | Delta-8-THC |\n|----------|-------|-------------|\n| **Potency** | 2-3x delta-9-THC | 50-70% of delta-9-THC |\n| **Natural?** | No (fully synthetic) | Trace amounts (mostly synthesized) |\n| **DEA status** | Controlled substance | Not explicitly scheduled |\n| **Effect type** | Intense, \"psychedelic\" | Mild, relaxing |\n| **Onset** | Delayed (especially edibles) | Typical (30-90 min) |\n| **Research** | None | Minimal |\n| **Safety data** | Unknown + concerns | Unknown |\n\n---\n\n## Potency Difference\n\nThis is the most significant practical difference:\n\n**Delta-8-THC:**\n- About half as potent as regular THC\n- Effects described as manageable\n- Lower risk of overwhelming experiences\n- Easier to dose appropriately\n\n**THC-O:**\n- Estimated 2-3x stronger than delta-9-THC\n- Users report intense, sometimes psychedelic effects\n- Delayed onset can lead to accidental overconsumption\n- Dosing is extremely difficult\n\n---\n\n## Safety Concerns\n\n**Delta-8 concerns:**\n- Synthesis may leave harmful byproducts\n- Product quality varies widely\n- No clinical safety studies\n- Drug interactions unknown\n\n**THC-O concerns (all delta-8 concerns PLUS):**\n- Extreme potency increases overdose risk\n- Mai produce ketene (toxic gas) when vaped\n- Synthesis involves dangerous chemicals (acetic anhydride)\n- No safety research whatsoever\n- Classified as controlled substance\n\n---\n\n## How They're Made\n\n**Delta-8:**\n1. CBD extracted from hemp\n2. Converted to delta-8 using acids\n3. Purified and formulated\n4. Relatively straightforward chemistry\n\n**THC-O:**\n1. CBD extracted from hemp\n2. Converted to delta-8 or delta-9-THC\n3. Reacted with acetic anhydride (dangerous)\n4. Creates THC-O-Acetate\n5. Complex, hazardous process\n\nThe THC-O synthesis process is significantly more dangerous and requires specialized equipment.\n\n---\n\n## Effects Comparison\n\n**Delta-8 effects (reported):**\n- Mild euphoria\n- Relaxation\n- Reduced [anxiety](/conditions/anxiety) vs delta-9\n- Clear-headed high\n- [Appetite](/conditions/appetite) stimulation\n\n**THC-O effects (reported):**\n- Intense psychoactive effects\n- \"Spiritual\" or \"borderline psychedelic\"\n- Stark euphoria\n- Potentially disorienting\n- Long duration\n- Unpredictable intensity\n\n---\n\n## Why I Recommend Against THC-O\n\nMy position is clear: **avoid THC-O entirely.**\n\n1. **Legal risk:** It's a controlled substance\n2. **Health risk:** Unknown safety profile + thermal degradation concerns\n3. **Potency risk:** Too strong to dose safely\n4. **Production risk:** Products may contain harmful byproducts\n5. **Alternatives exist:** Legal cannabinoids are available\n\n---\n\n## What About Delta-8?\n\nDelta-8 carries fewer concerns than THC-O but isn't risk-free:\n\n**Potential advantages over THC-O:**\n- Milder, more manageable effects\n- Not explicitly scheduled (federally)\n- Slightly more research exists\n- Easier to dose\n\n**Remaining concerns:**\n- Still largely unresearched\n- Quality varies significantly\n- State laws may prohibit it\n- Synthesis concerns apply\n\nIf you're considering delta-8, extensive [third-party testing](/glossary/third-party-testing) (COA) is essential.\n\n---\n\n## The Safest Alternative\n\nIf you want cannabinoid benefits without these risks:\n\n**CBD offers:**\n- Extensive safety research\n- No psychoactive effects\n- Fully legal (federally)\n- Established product quality standards\n- Known dosing guidelines\n\nCBD won't produce a high, but it's the only cannabinoid with substantial safety data.\n\n---\n\n## Meine Einschätzung\n\nThe comparison between THC-O and delta-8 highlights the spectrum of risk in the alternative cannabinoid market. Delta-8 exists in a gray area with some concerns; THC-O crosses into clearly illegal territory with serious safety unknowns.\n\nIf someone asks me which to choose, I tell them: neither is ideal, but THC-O should be avoided entirely while delta-8 is at least theoretically in a legal gray zone with milder effects. For those who want the safest cannabinoid experience, CBD remains the responsible choice.\n\n---\n\n## Related Topics\n\n- [What is THC-O?](/knowledge/what-is-thc-o)\n- [What is Delta-8-THC?](/knowledge/what-is-delta-8-thc)\n- [Delta-8 vs Delta-10 THC](/knowledge/delta-8-vs-delta-10)\n- [Synthetic Cannabinoids: Why to Avoid Them](/knowledge/synthetic-cannabinoids-dangers)\n\n---\n\n*This article is for educational purposes only. THC-O is a controlled substance in many jurisdictions. This is not legal or medical advice.*\n\n\n---\n\n## Related Studies\n\nResearch related to this topic:\n\n- [Delta9‐tetrahydrocannabinol and cannabidiol as potential curative agents for can... (2015)](/research/study/delta9tetrahydrocannabinol-and-cannabidiol-as-potential-cura-2015-0fc2b8) - Human Trial\n- [MODULATION OF AUDITORY AND VISUAL PROCESSING BY DELTA-9-TETRAHYDROCANNABINOL AND... (2010)](/research/study/modulation-of-auditory-and-visual-processing-by-delta-9-tetr-2010-5949c6) - Human Trial\n- [Hashish: synthesis and central [nervous system](/conditions/nervous-system) activity of some novel analogs of ... (1985)](/research/study/hashish-synthesis-and-central-nervous-system-activity-of-som-1985-8b0d3d) - Human Trial\n- [Effects of Delta-9-Tetrahydrocannabinol and Cannabidiol on Cisplatin-Induced Neu... (2016)](/research/study/effects-of-delta-9-tetrahydrocannabinol-and-cannabidiol-on-c-2016-291097) - Human Trial\n- [S31-03 - Modulation of Auditory and Visual Processing by Delta-9-Tetrahydrocanna... (2010)](/research/study/s31-03-modulation-of-auditory-and-visual-processing-by-delta-2010-25f6a8) - Human Trial\n\n[Browse all CBD research →](/research)\n\n## Häufig gestellte Fragen\n\n### Can I travel with Delta-8-THC products on airplanes?\n\nThe TSA doesn't distinguish between different THC types, and Delta-8 products may appear identical to Delta-9-THC products during screening. While federally derived hemp products are technically legal, many Delta-8 products exist in legal gray areas and could cause issues at security or your destination state.\n\n### How long do THC-O effects last compared to Delta-8?\n\nTHC-O effects typically last 6-8 hours when smoked and up to 12 hours for edibles, significantly longer than Delta-8 which usually lasts 4-6 hours when smoked and 6-8 hours for edibles. THC-O's delayed onset (up to 2 hours for edibles) often catches users off guard.\n\n### What's a safe starting dose for someone new to Delta-8?\n\nStart with 2.5-5mg for edibles and wait at least 2 hours before taking more. For vaping, begin with one small puff and wait 15-30 minutes to assess effects. Delta-8 is milder than Delta-9-THC, but tolerance varies significantly between individuals, especially those new to cannabis products.\n\n### Are there any drug interactions I should know about with these compounds?\n\nBoth compounds may interact with medications metabolized by liver enzymes (CYP450 system), including [blood thinners](/conditions/blood-thinners), seizure medications, and some heart medications. They can also amplify sedative effects of [alcohol](/conditions/alcohol), benzodiazepines, and [sleep](/conditions/sleep) aids. Always consult your healthcare provider before combining with [prescription medications](/conditions/prescription-meds).\n\n### Will Delta-8 or THC-O show up on a drug test?\n\nBoth compounds will likely trigger positive results on standard drug tests, which typically screen for THC metabolites rather than specific THC variants. Most drug tests cannot distinguish between Delta-8, THC-O, and Delta-9-THC metabolites, so assume any THC variant will cause a failed test.\n\n---\n\n**Medical Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before using CBD, especially if you have a medical condition or take medications.",
    "meta_title": "THC-O vs Delta-8-THC: Die Unterschiede verstehen | CBD Portal",
    "meta_description": "Compare THC-O and delta-8-THC. THC-O is a controlled substance 2-3x stronger than regular THC. Delta-8 is milder. Learn the safety differences.",
    "translation_quality": "professional"
  },
  {
    "article_id": "0dd1fc05-f2fb-4a16-8455-d88ee3529242",
    "language": "de",
    "slug": "cbd-und-glaukom",
    "title": "CBD und Glaukom & Augendruck: Was die Forschung zeigt",
    "excerpt": "Hilft CBD bei glaucoma & eye pressure? Wir haben 7 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Begrenzt.",
    "content": "# CBD und Glaucoma & Eye Pressure: Was die Forschung zeigt\n\nHilft CBD bei glaucoma & eye pressure? Basierend auf den 7 Studien, die ich überprüft habe, the honest answer is that we don't have enough research to say definitively. I found only 7 studies that address CBD and glaucoma & eye pressure, and most are preclinical or small-scale. There's biological plausibility, but I can't point to solid clinical evidence yet.\n\n\n## Verwandte Artikel\n\n- [CBD for Glaucoma: What You Need to Know](/articles/cbd-for-glaucoma)\n\n---\n\n## Forschungsübersicht\n\n| Metrik | Wert |\n|--------|-------|\n| **Überprüfte Studien** | 7 |\n| **Klinische Humanstudien** | 7 |\n| **Systematische Übersichten** | 0 |\n| **Gesamtzahl der Teilnehmer** | 0 |\n| **Forschungszeitraum** | 1998-2026 |\n| **Evidenzstärke** | ●●○○○ Begrenzt |\n\n## Was die Forschung zeigt\n\n### Die besten Beweise (Klinische Studien)\n\nDie stärksten Beweise stammen aus 7 Humanstudien, darunter 0 randomisierte kontrollierte Studien. \n\nEine [Studie aus 2025](/research/study/role-of-endocannabinoids-in-glaucoma-a-review-2025-4f56dc) ergab, dass in this review, researchers looked at how the body's natural cannabis-like chemicals (endocannabinoids) may be involved in glaucoma, a common eye condition that can cause vision loss. the researchers ...\n\nEine [Studie aus 2026](/research/study/topical-win-55-212-2-confers-long-term-intraocular-pressure-2026-cb7461) ergab, dass researchers tested a drug called win 55 212-2 on mice with a condition similar to glaucoma. they applied the drug directly to the eyes of the mice over time. the study ergab, dass this treatment helped...\n\nEine [Studie aus 2025](/research/study/single-oral-administration-of-dronabinol-increases-ocular-bl-2025-1307dd) ergab, dass researchers gave a single dose of cbd oil to people with glaucoma, a condition that increases pressure in the eye. they ergab, dass cbd helped improve blood flow in the eye. this suggests cbd could be ...\n\n### Was Übersichten schlussfolgern\n\nEs wurden keine systematischen Übersichten speziell zu CBD und glaucoma & eye pressure. Diese Lücke in der Literatur macht es schwierig, endgültige Schlussfolgerungen zu ziehen.\n\n### Unterstützende Beweise\n\nBegrenzt preclinical research exists for this condition. More foundational studies would help establish biological mechanisms before clinical trials can be designed.\n\n## Wissenswerte Studien\n\n### Role of Endocannabinoids in Glaucoma: A Review. (2025)\n\nIn this review, researchers looked at how the body's natural cannabis-like chemicals (endocannabinoids) may be involved in glaucoma, a common eye condition that can cause vision loss. The researchers examined previous studies on this topic. They ergab, dass endocannabinoids may play a role in regulating eye pressure and protecting the optic nerve, which are important factors in glaucoma. The review suggests that drugs that target the Endocannabinoid-System could be a potential new way to treat glaucoma. More research is needed to fully understand this connection and develop new treatments.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 15/100\n\n[Studienzusammenfassung ansehen](/research/study/role-of-endocannabinoids-in-glaucoma-a-review-2025-4f56dc)\n\n### Topical WIN 55 212-2 Confers Long-Term Intraocular Pressure-Independent Neuropro... (2026)\n\nResearchers tested a drug called WIN 55 212-2 on mice with a condition similar to glaucoma. They applied the drug directly to the eyes of the mice over time. The study ergab, dass this treatment helped protect the eye's optic nerve from damage, even when eye pressure was not reduced. This suggests the drug may have benefits beyond just lowering eye pressure, which is the main treatment for glaucoma in humans. The results are promising, but more research is needed to see if this treatment could work for people with glaucoma. The study is ongoing, so full results are not yet available.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 14/100\n\n[Studienzusammenfassung ansehen](/research/study/topical-win-55-212-2-confers-long-term-intraocular-pressure-2026-cb7461)\n\n### Single oral administration of dronabinol increases ocular blood flow in patients... (2025)\n\nResearchers gave a single dose of CBD oil to people with glaucoma, a condition that increases pressure in the eye. They ergab, dass CBD helped improve blood flow in the eye. This suggests CBD could be a potential treatment to help manage glaucoma and reduce eye pressure. More research is needed to confirm these results and understand how CBD affects the eye in people with glaucoma.\n\n**Stichprobe:** Nicht spezifizierte Teilnehmer | **Typ:** human | **Qualitätsbewertung:** 12/100\n\n[Studienzusammenfassung ansehen](/research/study/single-oral-administration-of-dronabinol-increases-ocular-bl-2025-1307dd)\n\n## Wie CBD bei Glaucoma & Eye Pressure\n\nCBD interagiert mit dem körpereigenen [Endocannabinoid-System](/glossary/endocannabinoid-system) (ECS), das eine Rolle bei der Regulierung verschiedener physiologischer Prozesse spielt. Während die genauen Mechanismen für glaucoma & eye pressure noch untersucht werden, glauben Forscher, dass CBD über mehrere Wege wirken könnte:\n\n- **CB1- und CB2-Rezeptoren:** CBD hat eine geringe Affinität zu diesen Rezeptoren, kann aber ihre Aktivität modulieren\n- **[Serotonin](/conditions/serotonin) receptors (5-HT1A):** Mai influence [mood](/conditions/mood) and perception\n- **TRPV1-Rezeptoren:** Involved in [pain](/conditions/pain) perception and [inflammation](/conditions/inflammation)\n\nDiese Mechanismen werden noch untersucht, und wir verstehen noch nicht vollständig, wie sie speziell mit glaucoma & eye pressure zusammenhängen.\n\n## Welche Dosierungen wurden untersucht\n\n**Wichtig:** Dies ist KEINE medizinische Beratung. Ich teile mit, was Forscher in Studien verwendet haben, nicht empfohlene Dosierungen.\n\nIn den von mir überprüften Studien variierten die Dosierungen stark — typischerweise von 25mg bis 600mg täglich, abhängig vom Studiendesign und den spezifisch gemessenen Ergebnissen. Einige wichtige Muster:\n\n- Niedrigere Dosen (25-50mg) wurden in ersten Verträglichkeitsstudien verwendet\n- Moderat doses (100-300mg) appeared in many clinical trials\n- Höhere Dosen (400-600mg+) wurden in einigen spezifischen Kontexten verwendet\n\nWenn Sie CBD in Betracht ziehen, verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt, aber konsultieren Sie immer einen Gesundheitsdienstleister.\n\n## Meine Einschätzung\n\nNachdem ich 7 Studien zu CBD und glaucoma & eye pressure — und über 12 Jahre in der CBD-Branche gearbeitet habe — hier ist meine ehrliche Einschätzung:\n\nI wish I could be more enthusiastic, but the research just isn't there yet. The Tierstudien are interesting, and there's biological plausibility, but we really need human trials before drawing conclusions. I'm watching this space closely.\n\nWhat I'm watching for: Any clinical trials currently recruiting — they could change this picture significantly.\n\n## Häufig gestellte Fragen\n\n### Kann CBD glaucoma & eye pressure?\n\nNein. CBD ist kein Heilmittel für glaucoma & eye pressure. Forschung deutet darauf hin, dass es in einigen Fällen helfen kann, Symptome zu managen, aber es sollte konventionelle Behandlung ergänzen – nicht ersetzen. Konsultieren Sie immer Ihren Arzt, bevor Sie Änderungen an Ihrer Gesundheitsroutine vornehmen.\n\n### Wie viel CBD sollte ich für glaucoma & eye pressure?\n\nKlinische Studien haben weit reichende Dosen verwendet, von 25mg bis 600mg täglich. Es gibt keine \"Standard\"-Dosis, und individuelle Reaktionen variieren. Beginnen Sie niedrig (10-25mg) und erhöhen Sie schrittweise, während Sie die Wirkungen überwachen. Verwenden Sie unseren [Dosierungsrechner](/tools/dosage-calculator) als Ausgangspunkt.\n\n### Wie lange braucht CBD, um bei glaucoma & eye pressure?\n\nDies hängt von der Verabreichungsmethode und individuellen Faktoren ab. Sublinguale Öle können 15-45 Minuten dauern, während Kapseln 1-2 Stunden dauern können. Einige Studien deuten darauf hin, dass sich die Vorteile über mehrere Wochen konsistenter Anwendung aufbauen.\n\n### Kann ich CBD mit meinen aktuellen Medikamenten nehmen?\n\nCBD kann mit bestimmten Medikamenten interagieren, indem es Leberenzyme beeinflusst (insbesondere CYP450). If you're taking any medications, especially [blood thinners](/conditions/blood-thinners), anti-seizure drugs, or [antidepressants](/conditions/antidepressants), consult your doctor before using CBD.\n\n### Welche Art von CBD ist am besten für glaucoma & eye pressure?\n\nDie meisten Studien verwenden CBD-Isolat oder Vollspektrum-Extrakte. Einige Forscher schlagen vor, dass Vollspektrum-Produkte aufgrund des \"Entourage-Effekts\" verstärkte Wirkungen haben können, aber dies ist noch umstritten. Wählen Sie Qualitätsprodukte von seriösen Quellen mit Drittanbieter-Tests.\n\n## Referenzen\n\nIch habe 7 Studien für diesen Artikel überprüft. Wichtige Quellen:\n\n1. **Warjri GB, Gowtham L, Venkatraman V, Velpandian T, Dada T, Angmo D** (2025). Role of Endocannabinoids in Glaucoma: A Review.. *J Curr Glaucoma Pract*.\n   [Zusammenfassung](/research/study/role-of-endocannabinoids-in-glaucoma-a-review-2025-4f56dc) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/40417140/) • DOI: 10.5005/jp-journals-10078-1467\n\n2. **Gallo Afflitto G, Chou TH, Korsch ML, Aiello F, Adornetto A, Russo R, Bagetta G, Nucci C, Porciatti V** (2026). Topical WIN 55 212-2 Confers Long-Term Intraocular Pressure-Independent Neuroprotection in the DBA/2J Mouse Model of Glaucoma.. *Ophthalmol Sci*.\n   [Zusammenfassung](/research/study/topical-win-55-212-2-confers-long-term-intraocular-pressure-2026-cb7461) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/41140902/) • DOI: 10.1016/j.xops.2025.100918\n\n3. **Lindner T, Pai V, Janku P, Hommer N, Hommer A, Abensperg-Traun M, Petric L, Schmetterer L, Garhöfer G, Schmidl D** (2025). Single oral administration of dronabinol increases ocular blood flow in patients with glaucoma.. *Acta Ophthalmol*.\n   [Zusammenfassung](/research/study/single-oral-administration-of-dronabinol-increases-ocular-bl-2025-1307dd) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/40772417/) • DOI: 10.1111/aos.17573\n\n4. **Sumanta Garai, Luciana M. Leo, Anna-Maria Szczesniak, Dow P. Hurst, Peter C. Schaffer** (2021). Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. *Journal of Medicinal Chemistry*.\n   [Zusammenfassung](/research/study/discovery-of-a-biased-allosteric-modulator-for-cannabinoid-1-2021-6f39e0) • [PubMed](https://pubmed.ncbi.nlm.nih.gov/33826336/) • DOI: 10.1021/acs.jmedchem.1c00040\n\n[Alle 7 Studien zu CBD und glaucoma & eye pressure →](/research?topic=glaucoma)\n\n---\n\n*Dieser Artikel dient nur zu Informationszwecken. Er ist keine medizinische Beratung. Konsultieren Sie einen Gesundheitsexperten, bevor Sie CBD verwenden, insbesondere wenn Sie eine Erkrankung haben oder Medikamente nehmen.*",
    "meta_title": "CBD und Glaukom & Augendruck: Was die Forschung zeigt | CBD Portal",
    "meta_description": "Hilft CBD bei glaucoma & eye pressure? Wir haben 7 begutachtete Studien analysiert, um das herauszufinden. Evidenzniveau: Begrenzt.",
    "translation_quality": "professional"
  },
  {
    "article_id": "27ec6169-8b4d-4a04-bf89-60e6f7582ba0",
    "language": "de",
    "slug": "cbd-und-chronische-schmerzen",
    "title": "CBD und chronische Schmerzen: Was 9+ Studien zeigen",
    "excerpt": "CBD shows limited but promising evidence for chronic pain. Learn how CBD may help through anti-inflammatory mechanisms and what the research actually shows.",
    "content": "# CBD and [Chronic Pain](/conditions/chronic_pain): What 9+ Studies Show\n\nBy Robin Roy Krigslund-Hansen | 9 studies analyzed\nZuletzt aktualisiert: Januar 21, 2026\n\n---\n\n## Short Answer\n\n[CBD](/glossary/cannabidiol) shows **limited but promising** evidence for chronic pain management. Research suggests CBD may help reduce pain through anti-inflammatory mechanisms and interaction with the [Endocannabinoid-System](/knowledge/what-is-the-endocannabinoid-system). Most evidence comes from studies on specific pain conditions like [neuropathic pain](/conditions/neuropathic-pain), [arthritis](/conditions/arthritis), and [fibromyalgia](/conditions/fibromyalgia). CBD is not a replacement for comprehensive pain management but may be a useful adjunct for some people.\n\n---\n\n## Forschungsübersicht\n\n| Metric | Assessment |\n|--------|------------|\n| Evidence Level | ●●○○○ Begrenzt |\n| Human Studies | Growing body of research |\n| Study Quality | Mixed, more RCTs needed |\n| Expert Consensus | Cautious optimism |\n| Our Database | 9 approved studies |\n\n---\n\n## Wichtige Zahlen\n\n- **9 studies** in our database specifically addressing chronic pain\n- **~30-50%** of chronic pain patients report CBD helps in surveys\n- **Multiple mechanisms** involved: anti-inflammatory, neuromodulation, muscle relaxation\n- **Variable response** - not everyone responds equally to CBD\n\n---\n\n## How CBD Mai Help Chronic Pain\n\nCBD's potential pain-relieving mechanisms include:\n\n### Anti-Inflammatory Action\n- Reduces inflammatory cytokines\n- Mai decrease tissue [inflammation](/conditions/inflammation)\n- Particularly relevant for inflammatory pain conditions\n\n### Endocannabinoid System Modulation\n- Enhances endocannabinoid signaling\n- Interacts with [CB1](/glossary/cb1-receptor) and [CB2](/glossary/cb2-receptor) receptors indirectly\n- Mai improve the body's natural pain regulation\n\n### TRPV1 Receptor Interaction\n- Activates vanilloid receptors involved in pain perception\n- Mai help \"desensitize\" pain signals\n- Similar mechanism to capsaicin\n\n### Muscle Relaxation\n- Mai reduce [muscle tension](/conditions/muscle-tension)\n- Could help with pain from muscle spasms\n- Relevant for conditions like fibromyalgia\n\n---\n\n## Condition-Specific Evidence\n\nCBD research for chronic pain varies by condition:\n\n| Condition | Evidence | Notes |\n|-----------|----------|-------|\n| [Neuropathic Pain](/conditions/neuropathic-pain) | Moderat | Most studied, several positive trials |\n| [Arthritis](/conditions/arthritis) | Begrenzt-Moderat | Particularly rheumatoid arthritis |\n| [Fibromyalgia](/conditions/fibromyalgia) | Begrenzt | Promising survey data |\n| General Chronic Pain | Begrenzt | Mixed results, individual variation |\n| [Cancer Pain](/conditions/cancer) | Begrenzt | Often studied with [THC](/glossary/thc) (Sativex) |\n\n---\n\n## Wissenswerte Studien\n\n### Chronic Pain Survey Studies\nMultiple surveys of chronic pain patients using CBD show:\n- 30-50% report meaningful pain reduction\n- Often allows reduction in other pain medications\n- Better results with consistent use over time\n\n### Arthritis Research\nStudies on rheumatoid and osteoarthritis suggest:\n- Anti-inflammatory effects may reduce joint pain\n- Topical CBD may help localized joint pain\n- Mixed results in controlled trials\n\n### [Neuropathic Pain](/conditions/neuropathic_pain) Trials\nResearch on nerve-related pain shows:\n- More consistent positive findings than other pain types\n- Mai be particularly effective for [peripheral neuropathy](/conditions/peripheral-neuropathy)\n- Often studied as part of combination products\n\n---\n\n## CBD vs Other Pain Treatments\n\n| Factor | CBD | NSAIDs | Opioids |\n|--------|-----|--------|---------|\n| Anti-inflammatory | Yes | Yes | No |\n| [Addiction](/conditions/addiction) risk | Very low | None | High |\n| Organ damage risk | Low | Moderat (GI, kidney) | Low |\n| Overdose risk | Minimal | Low | High |\n| Evidence level | Begrenzt | Extensive | Extensive |\n\n---\n\n## Practical Considerations\n\n### Dosing for Pain\n- No standardized dosing established\n- Most studies use 15-50mg daily\n- Start low (10-20mg) and increase gradually\n- Some people need higher doses (100mg+)\n\n### Delivery Methods\n- **[Sublingual oils](/knowledge/sublingual-cbd-guide):** Good [bioavailability](/glossary/bioavailability), flexible dosing\n- **[Topicals](/knowledge/cbd-topicals-guide):** For localized pain\n- **[Capsules](/knowledge/cbd-capsules-guide):** Consistent dosing, longer onset\n\n### Time to Effect\n- Initial effects: Days to weeks\n- Full assessment: 4-6 weeks of consistent use\n- Not for acute pain emergencies\n\n---\n\n## What the Research Doesn't Yet Show\n\nLimitations of current evidence:\n- Most studies are small (under 100 Teilnehmer)\n- Few long-term studies exist\n- Optimal dosing not established\n- Individual response variation not well understood\n- [CBD isolate](/glossary/cbd-isolate) vs [full-spectrum](/glossary/full-spectrum) comparisons limited\n\n---\n\n## Meine Einschätzung\n\nAfter 12+ years in this industry, I've seen many chronic pain patients find meaningful relief with CBD—but I've also seen many who didn't respond. CBD is not a miracle cure for chronic pain, but it's a reasonable option to try, especially given its favorable safety profile compared to long-term NSAID or opioid use.\n\nMy practical advice:\n1. Don't abandon proven treatments without medical guidance\n2. Consider CBD as an addition to, not replacement for, comprehensive pain management\n3. Give it 4-6 weeks of consistent use before judging effectiveness\n4. Track your pain levels to objectively assess response\n5. Work with healthcare providers who understand cannabinoids\n\nFor specific pain conditions like neuropathic pain or arthritis, the evidence is somewhat stronger, and these may be better starting points.\n\n---\n\n## Häufig gestellte Fragen\n\n### Does CBD actually work for chronic pain?\n\nEvidence is limited but growing. Survey data shows 30-50% of chronic pain patients report meaningful relief. Response varies significantly between individuals. It's worth trying given the safety profile, but not everyone will respond.\n\n### Wie viel CBD sollte ich für chronic pain?\n\nNo standardized dose exists. Most studies use 15-50mg daily, though some people need more. Start with 10-20mg, take consistently for several weeks, and gradually increase if needed. Work with a healthcare provider familiar with CBD.\n\n### Is CBD better than ibuprofen for pain?\n\nThey work differently. NSAIDs like ibuprofen have extensive research and are effective for many pain types but carry risks with long-term use (GI bleeding, kidney issues). CBD has less evidence but may be safer for long-term use. Many people use both as appropriate.\n\n### How long does CBD take to help with chronic pain?\n\nUnlike acute pain medications, CBD typically requires consistent use over days to weeks. Most people should use CBD for 4-6 weeks before fully assessing its effectiveness for chronic pain.\n\n### Can I replace my pain medication with CBD?\n\nNever stop prescribed pain medications without consulting your doctor. CBD may help some people reduce reliance on other medications, but this should be done gradually under medical supervision.\n\n---\n\n## Verwandte Artikel\n\n- [CBD and Neuropathic Pain](/conditions/neuropathic-pain)\n- [CBD and Arthritis](/conditions/arthritis)\n- [CBD and Fibromyalgia](/conditions/fibromyalgia)\n- [Best CBD Products for Pain](/knowledge/best-cbd-for-pain)\n- [CBD Dosage Guide](/knowledge/cbd-dosage-guide)\n\n---\n\n---\n\n## Related Studies\n\nExplore the research behind this article:\n\n- [Cannabidiol for Fibromyalgia -The CANNFIB Trial Protocol for a Randomized, Do... (2024)](/research/study/cbd-[sleep](/conditions/sleep)-amris-2024) - Human Trial\n- [Assessment of the Effect of a Cosmetic Cream With CBD and Natural Ingredients... (2025)](/research/study/cbd-pain-lpez-2025) - Human Trial\n- [Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Response Tria... (2025)](/research/study/cbd-pain-johnson-2025) - Human Trial\n- [Cannabidiol Pharmacotherapy for Comorbid Opioid Addiction and Chronic Pain (2025)](/research/study/cbd-pain-aquino-2025) - Human Trial\n- [Evaluating Cannabidiol (CBD) to Enhance the Analgesic Effect of Hydromorphone... (2023)](/research/study/cbd-pain-dunn-2023) - Human Trial\n\n[View all 56 studies on this topic →](/research?topic=chronic_pain)\n\n## Referenzen\n\nStudies and data from our research database, with 9 approved studies specifically examining CBD and chronic pain. For individual study details, see our [research section](/research).\n\n---\n\n## Disclaimer\n\nThis article is for educational purposes only and does not constitute medical advice. Chronic pain requires proper medical evaluation and treatment. CBD should not replace professional medical care. Always consult healthcare providers before starting CBD, especially if taking other medications.\n\n*Content reviewed for medical accuracy. Last updated Januar 2026.*\n",
    "meta_title": "CBD und chronische Schmerzen: Was 9+ Studien zeigen | CBD Portal",
    "meta_description": "Review of 9+ studies on CBD for chronic pain. Learn about evidence levels, how CBD may help pain, dosing considerations, and what to expect.",
    "translation_quality": "professional"
  },
  {
    "article_id": "c952de34-16b5-4568-abf3-80efa950a5cd",
    "language": "de",
    "slug": "cbd-forschung-verstehen",
    "title": "CBD-Forschung verstehen: Ein Leitfaden zum Lesen von Studien",
    "excerpt": "Learn to evaluate CBD research and separate facts from marketing hype. Understand study types, sample sizes, and how to critically assess claims.",
    "content": "# Understanding CBD Research: A Guide to Reading Studies\n\nBy Robin Roy Krigslund-Hansen | 12+ years in [CBD](/glossary/cannabidiol) industry\nZuletzt aktualisiert: Januar 21, 2026\n\n---\n\n## Quick Summary\n\nLearning to evaluate CBD research helps you separate facts from marketing hype. Key factors include study type (human vs animal), sample size, study design (RCT vs observational), funding source, and peer-review status. Most CBD claims online come from limited evidence, while the strongest evidence requires multiple well-designed human trials.\n\n---\n\n## Why Research Literacy Matters\n\nThe CBD industry is flooded with claims like:\n- \"Studies show CBD helps with...\"\n- \"Research proves...\"\n- \"Scientists discovered...\"\n\nBut the quality of studies varies enormously. A single mouse study doesn't prove CBD will work for you. Understanding research helps you:\n- Evaluate product claims critically\n- Have informed conversations with healthcare providers\n- Set realistic expectations\n- Avoid wasting money on unproven products\n\n---\n\n## Study Types: A Hierarchy\n\nResearch exists on a spectrum of strength:\n\n### Starkest Evidence\n1. **Systematic Reviews/Meta-Analyses**\n   - Combine results from multiple studies\n   - Account for variations across research\n   - Most reliable for drawing conclusions\n\n2. **Randomized Controlled Trials (RCTs)**\n   - Gold standard for single studies\n   - Participants randomly assigned to CBD or placebo\n   - Double-blind (neither participant nor researcher knows who gets what)\n   - Minimizes bias\n\n### Moderat Evidence\n3. **Observational Studies**\n   - Track people using CBD without random assignment\n   - Can show associations but not cause-effect\n   - Subject to confounding factors\n\n4. **Case Studies**\n   - Detailed reports on individual patients\n   - Hypothesis-generating but not conclusive\n   - Interesting but limited generalizability\n\n### Weakest Evidence\n5. **Animal Studies**\n   - Essential for early research\n   - Cannot directly predict human effects\n   - Many promising animal findings don't translate to humans\n\n6. **In-Vitro (Cell) Studies**\n   - Tests on cells in laboratory conditions\n   - Even further from human reality\n   - Useful for understanding mechanisms\n\n---\n\n## Key Questions to Ask\n\nWhen evaluating a CBD study:\n\n### 1. Was it in humans?\nAnimal studies are preliminary. What works in mice may not work in people. Human studies matter most.\n\n### 2. How many Teilnehmer?\n- **<30 Teilnehmer:** Very preliminary\n- **30-100 Teilnehmer:** Moderat, may show trends\n- **100+ Teilnehmer:** More reliable\n- **500+ Teilnehmer:** Stark statistical power\n\n### 3. Was there a control group?\nStudies comparing CBD to placebo are more reliable than studies without comparison groups.\n\n### 4. Was it randomized and blinded?\n- **Randomized:** Participants assigned to groups by chance\n- **Single-blind:** Participants don't know what they're getting\n- **Double-blind:** Neither Teilnehmer nor researchers know\n\n### 5. Who funded it?\nIndustry-funded research isn't automatically invalid, but look for independent verification. University and government-funded studies may have less conflict of interest.\n\n### 6. Was it peer-reviewed?\nPublication in peer-reviewed journals means other scientists evaluated the methodology. Preprints and company white papers haven't passed this scrutiny.\n\n### 7. What was actually studied?\n- Which form of CBD? (isolate, full-spectrum, pharmaceutical)\n- What dose?\n- How administered?\n- For how long?\n\n---\n\n## Common Research Pitfalls\n\n### Overinterpreting Animal Studies\n\"CBD kills [cancer](/conditions/cancer) cells!\" (in a petri dish) doesn't mean CBD cures cancer in humans. Cell and Tierstudien are starting points, not endpoints.\n\n### Cherry-Picking Results\nCompanies may cite favorable studies while ignoring unfavorable ones. Look for systematic reviews that consider all available evidence.\n\n### Correlation ≠ Causation\nObservational studies showing CBD users have better outcomes don't prove CBD caused the improvement. Many confounding factors exist.\n\n### Small Sample Sizes\nWith small groups, random variation can produce misleading results. Require replication before believing dramatic claims.\n\n### Publication Bias\nPositive results are more likely to be published. Negative results often stay in file drawers, skewing the overall picture.\n\n---\n\n## How We Rate Evidence\n\nOn this site, we use a simple system:\n\n| Level | Criteria |\n|-------|----------|\n| **Stark** | 20+ studies, 3+ RCTs or meta-analysis, 200+ Teilnehmer |\n| **Moderat** | 10-20 studies, 1-2 RCTs, 5+ human studies |\n| **Begrenzt** | 5-10 studies, no RCTs, mostly animal |\n| **Insufficient** | <5 studies, only animal/in-vitro |\n\n---\n\n## Where to Find CBD Research\n\n### Reliable Sources\n- **PubMed** (pubmed.gov) - Medical literature database\n- **ClinicalTrials.gov** - Ongoing and completed trials\n- **Cochrane Library** - Systematic reviews\n- **Our Research Section** - Curated CBD studies\n\n### What to Avoid\n- Company-funded white papers without peer review\n- News headlines (often exaggerate findings)\n- Social media claims without citations\n- Testimonials (interesting but not evidence)\n\n---\n\n## The Current State of CBD Research\n\nHonest assessment as of 2026:\n- **Starkest evidence:** Certain seizure disorders (Epidiolex)\n- **Promising but needs more research:** [Anxiety](/conditions/anxiety), [pain](/conditions/pain), [sleep](/conditions/sleep)\n- **Very preliminary:** Most other conditions\n- **Unknown:** Long-term effects with chronic use\n\nThe research is growing rapidly, but we're still in early stages for most applications.\n\n---\n\n## Meine Einschätzung\n\nI've been in this industry for over a decade, and I've watched too many people make decisions based on headline-grabbing studies that don't hold up to scrutiny. CBD has genuine potential—that's why I'm in this field—but that potential needs to be validated through rigorous research.\n\nWhen you encounter a CBD claim, ask: What's the evidence? Not \"did someone do a study\" but \"what kind of study, on how many people, with what results?\" This skeptical approach will serve you better than blind enthusiasm.\n\n---\n\n## Related Topics\n\n- [CBD Clinical Trials](/knowledge/cbd-clinical-trials)\n- [The Entourage Effect](/knowledge/entourage-effect)\n- [CBD Bioavailability](/knowledge/cbd-bioavailability)\n- [How CBD Works](/knowledge/how-cbd-works)\n\n---\n\n*This article is for educational purposes only.*\n\n\n---\n\n## Related Studies\n\nResearch related to this topic:\n\n- [Towards Understanding the Phenytoin-like Antiepileptic Effect of Cannabidiol and... (2018)](/research/study/towards-understanding-the-phenytoin-like-antiepileptic-effec-2018-d2a26f) - Human Trial\n- [Understanding the Potential of CBD for Health Benefits: An Overview (2024)](/research/study/understanding-the-potential-of-cbd-for-health-benefits-an-ov-2024-031de8) - Human Trial\n- [Research and Clinical Practice Involving the Use of Cannabis Products, with Emph... (2024)](/research/study/research-and-clinical-practice-involving-the-use-of-cannabis-2024-d480c4) - Human Trial\n- [Antiinflammatory cannabinoids in diet – towards a better understanding of CB2 re... (2008)](/research/study/antiinflammatory-cannabinoids-in-diet-towards-a-better-under-2008-6adbfd) - Human Trial\n- [Cannabidiol in the cognitive neurology of [aging](/conditions/aging): current evidence, challenges an... (2024)](/research/study/cannabidiol-in-the-cognitive-neurology-of-aging-current-evid-2024-81bfff) - Human Trial\n\n[Browse all CBD research →](/research)\n\n## Häufig gestellte Fragen\n\n### How long should I wait for CBD research results to be considered reliable?\n\nMost experts recommend waiting for at least 3-5 independent human studies with similar results before considering evidence reliable. Initial promising results from single studies often don't replicate in larger trials. The FDA approval process for Epidiolex took over a decade of research, including multiple Phase III trials with hundreds of Teilnehmer.\n\n### What sample size makes a CBD study credible?\n\nFor human trials, studies with fewer than 50 Teilnehmer are considered preliminary. Credible evidence typically requires 100+ Teilnehmer for efficacy studies and 300+ for safety data. Many CBD studies cited online involve only 10-30 people, making their conclusions limited and potentially unreliable for broader populations.\n\n### How can I tell if CBD research is industry-funded vs independent?\n\nCheck the \"Funding\" or \"Conflicts of Interest\" section at the end of research papers. Independent studies are funded by government agencies (NIH, NSF) or non-profit organizations. Industry-funded research isn't automatically invalid but should be viewed more critically, especially if authors have financial ties to CBD companies.\n\n### Why do Tierstudien dominate CBD research compared to human trials?\n\nAnimal studies are faster, cheaper, and have fewer ethical restrictions than human trials. A mouse study might cost $50,000 and take 6 months, while human trials cost millions and require 2-5 years plus regulatory approval. However, about 90% of treatments that work in animals fail in human testing.\n\n### What makes a CBD study \"peer-reviewed\" and why does it matter?\n\nPeer-reviewed studies are evaluated by independent experts in the field before publication in scientific journals. This process typically takes 6-18 months and catches methodological flaws, statistical errors, and unsupported conclusions. Studies published directly online or in non-peer-reviewed journals lack this quality control and should be viewed skeptically.\n\n---\n\n**Medical Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before using CBD, especially if you have a medical condition or take medications.",
    "meta_title": "CBD-Forschung verstehen: Ein Leitfaden zum Lesen von Studien | CBD Portal",
    "meta_description": "Learn to evaluate CBD research and separate facts from marketing hype. Understand study types, sample sizes, and how to critically assess claims.",
    "translation_quality": "professional"
  }
]